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Abstract 
Background: Lung cancer is one of the most commonly reported cancers, and is known to be 
associated with a poor prognosis. The role of macrophages in lung cancer, including alveolar 
macrophages (AMs), tumour-associated macrophages (TAMs) and monocytes, is 
multifaceted and the literature shows conflicting roles. In the lungs, macrophages are termed 
AMs and are located both in the air spaces of the lungs and in the lower airways. AMs play a 
vital role in the lung microenvironment and have been used to investigate cellular changes 
within the lung environment in different pulmonary diseases, including lung cancer. Similar 
to TAMs, two distinct phenotypes of AMs have been identified within the lungs, the M1 
(classically activated) and M2 (alternatively activated) macrophage subsets. TAMs are a cell 
type belonging to the macrophage lineage and are known to be located near or within tumour 
masses. They have been considered to be a better macrophage type to study in cancer 
research, because of their location within tumour microenvironment and interaction with 
cancer cells. Similarly, monocytes play an essential role in the immune response against 
tumour cells in the systemic environment. Monocytes have been shown to have similar 
phenotypes to those seen in the M1 and M2 TAMs population in tumour microenvironments. 
Although macrophage subsets have been well characterised in many cancers, their phenotype 
and function in lung cancer still needs further investigation. Aims: (I) To characterise the M1 
and M2 macrophage populations within the AM population using flow cytometry and real-
time quantitative polymerase chain reaction (RT-PCR) in patients with non-small lung 
carcinoma (NSCLC) compared to non-cancer controls; (II) To evaluate the M1 and M2 
monocyte populations (macrophage precursors) in patients with NSCLC compared to non-
cancer controls using flow cytometry. In addition, Th1 and Th2 cytokine levels that 
contribute to the differentiation of these populations will be analysed in the serum of patients 
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with NSCLC versus non-cancer controls; (III) To use quantitative proteomics to investigate 
the up-regulation of novel proteins in bronchoalveolar lavage (BAL) fluid from patients with 
primary lung adenocarcinoma to potentially identify new potential biomarkers expressed by 
AMs; and (IV) To characterise the M1 and M2 macrophage populations within TAMs in 
different subtypes of NSCLC compared to non-cancer lung tissue. Methods and materials: 
AMs were obtained from patients with NSCLC and non-cancer control subjects and analysed 
for surface marker differences using flow cytometry. The mRNA expression of IL-6, IL-12, 
IL-10 and MMP-9 cytokines was measured using RT-PCR. Freshly prepared peripheral blood 
mononuclear cell (PBMC) samples were also obtained from patients with NSCLC and from 
non-cancer controls. Flow cytometry was performed to investigate the expression of M1 and 
M2 markers on peripheral monocytes (classical monocytes CD14
++
, CD45
+
 and CD16
-
). The 
Th1 and Th2 cytokine levels were analysed in serum samples using the cytometric bead array 
(CBA) and the Bio-Plex, MAGPIC-Luminex system, respectively. In addition, BAL fluid 
samples from subjects with and without primary lung adenocarcinoma were analysed using 
quantitative proteomics. Finally, TAMs subsets from non-tumour and tumour tissues were 
analysed using immunohistochemistry (IHC). Results: The expression of M2 marker CD163 
as well as CD71 and CD44 was greater on AMs from patients with NSCLC compared to non-
cancer controls. However, there were no significant differences in the surface expression 
(%SE) of M1 marker HLA-DR (Human leukocyte antigen-D related) and myeloid marker 
CD11b in NSCLC patients compared to non-cancer controls. The mRNA expression levels of 
IL-10 and MMP-9 were increased in AMs from NSCLC patients compared to non-cancer 
controls. In contrast, the expression of IL-6 and IL-12 was not significantly different in 
NSCLC patients compared to non-cancer controls. There were no significant differences in 
the expression of M1 (HLA-DR) and/or M2 markers (CD163 and CD36) on classical 
monocytes in patients with NSCLC compared to non-cancer controls. The expression of 
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CD11b, CD11c, CD71 and CD44 were also shown to be similar in patients with NSCLC 
compared to non-cancer controls. The Th1 and Th2 cytokines levels in serum revealed no 
significant difference between patients with NSCLC (undifferentiated NSCLC, lung 
adenocarcinoma and squamous cell lung carcinoma) and non-cancer controls. However, the 
expression of IL-1β, IL-4, IL-6 and IL-8 was found to be significantly increased in serum of 
patients with large cell lung carcinoma but not in other lung cancer subtypes compared to 
non-cancer controls using the Bio-Plex, MAGPIC-Luminex assay. For proteomic analysis, 
1,100 proteins were identified and 33 of these were found to be consistently over-expressed 
in the BAL fluid of adenocarcinoma samples compared to non-cancer controls. These 
proteins included S100-A8, annexin A1, annexin A2, thymidine phosphorylase (TP) and 
transglutaminase 2 (TG2) which have been shown previously to be related to cancer 
progression. Other over-expressed identified proteins such as chloride intracellular channel 
protein 1, transgelin-2, catalase, carbonic anhydrase II, galectin-1, and Lamin-B1 have been 
shown to be promising new lung cancer biomarkers. For the TAMs investigation, the 
expression of CD68 and M2 marker CD163 was found to be significantly increased in all 
NSCLC subtypes (adenocarcinoma, squamous cell lung carcinoma and large cell lung 
carcinoma) compared to non-tumour tissues. In contrast, the expression of iNOS (M1 marker) 
was significantly decreased in the tumour tissue of patients with adenocarcinoma and 
squamous cell lung carcinoma but not in large cell lung carcinoma compared to non-tumour 
tissue. Conclusion: The results of the AM study (aim I) suggested that NSCLC has the ability 
to alter AMs function and play a role in changing their phenotype. Different markers and 
cytokines such as CD163, CD71, CD44, IL-10 and MMP-9 were found to be altered in 
patients with NSCLC compared to non-cancer controls. It also indicated that AMs express 
more M2 phenotype in NSCLC patients compared to non-cancer controls. Moreover, the 
result of the monocyte study (aim II) showed no alteration in classical peripheral blood 
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monocyte phenotype and function in patients with NSCLC compared to non-cancer controls. 
Therefore, these results suggested that there is no systemic impairment in monocyte 
phenotype and function in patients with NSCLC compared to non-cancer controls. The 
Th1/Th2 cytokine levels were also found to not be affected by the presence of NSCLC 
(except large cell lung carcinoma) compared to non-cancer controls. The expression of some 
Th1 and Th2 cytokines (IL-1β, IL-4, IL-6 and IL-8) were altered in patients with large cell 
lung carcinoma, which indicates the ability of this lung cancer subtype to manipulate 
cytokine expression in the systemic environment. In addition, the results of the proteomics 
study (aim III) demonstrated an overexpression of a number of novel proteins in BAL fluid of 
adenocarcinoma patients may be utilised as potential biomarkers. These proteins included 
S100-A8, annexin A1, annexin A2, thymidine phosphorylase (TP) and transglutaminase 2 
(TG2) which are known to be related to cancer progression. The last aim results (TAM study) 
suggested that NSCLC has the ability to alter TAMs phenotype. The expression of M2 
marker CD163 was found to be significantly increased in all NSCLC subtypes compared to 
non-tumour tissues. In contrast, the expression of iNOS (M1 marker) was significantly 
decreased in the tumour tissue of patients with adenocarcinoma and squamous cell lung 
carcinoma but not in large cell lung carcinoma compared to non-tumour tissues. These results 
indicated that TAMs express more M2 phenotype in NSCLC patients compared to non-
tumour tissues. Taken together, the results of this thesis indicate that NSCLC might have the 
ability to alter phenotype and function within the lung tumour areas in the local environment 
(AMs and TAMs) but not in the bloodstream in the systemic environment (monocytes and 
serum). The thesis outcomes support the previous suggestion regarding the importance of 
potentially targeting M2 macrophages for future therapeutic agents and aim to skew 
macrophage populations back to M1 subsets to stimulate anti-tumour effects within the 
tumour microenvironment.  
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Chapter 1 Literature Review 
1.1. Introduction 
The human lungs are highly vascularised in order to facilitate their main role of gas exchange 
(1). They are exposed to numerous substances from the external environment, which can 
cause lung injury and eventually may lead to lung tumour initiation (2, 3). Lung cancer is a 
malignant tumour that generally initiates in the tissue of the lungs. It arises when lung cells 
convert from a normal to an abnormal state and then start to grow leading to the tumour mass 
origination (4). Lung cancer is one of the most common cancers worldwide and in the 
Western World particularly it has a high incidence (Fig. 1) (5). It has also been recognised to 
be the leading cause of cancer mortality worldwide with approximately 1 million deaths 
annually (6-8). In Australia, males with lung cancer have a worse prognosis than patients 
with other frequently diagnosed cancers. In particular, the 5-year relative survival for male 
lung cancer patients is shown to be 6 to 8 times lower than males with melanoma, prostate 
cancer, bowel cancer and lymphoid cancers. In addition, the 5-year relative survival for 
females diagnosed with lung cancer was about 4 to 6 times worse than for female patients 
who were diagnosed with melanoma, breast cancer, lymphoid cancers and bowel cancer (Fig. 
2) (5). Despite the development of new treatments, lung cancer still has, in general, a poor 
prognosis and short patient survival time (9). 
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Figure 1: International comparison of estimated incidence of lung cancer, males and females, 
2008. The incidence rate of lung cancer is high in developed regions including Australia, 
Europe and North America (5).  
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Figure 2: Five-year relative survival for most commonly diagnosed cancers in Australia from 
2000 to 2007. This graph indicates that lung cancer patients, both males and females, have a 
poor prognosis in comparison to people with other frequently diagnosed cancers (5).  
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The human immune system is known to play a role in local and systemic defence that 
eventually inhibits tumour growth in most scenarios. Human immune system components 
such as macrophages are essential to control and prevent the initiation of cancer. They are 
also involved in cancer immunoediting through the innate and adaptive immune systems (10, 
11). However, it has been shown that the human immune system may play a dual role in both 
eliminating and promoting human tumours. Thus, the human immune system has been 
described as a double-edged sword in regard to its interaction with tumour 
microenvironments (12). In particular, the role of macrophages in lung cancer is multifaceted 
and conflicting. They have the ability to produce pro-inflammatory factors that have been 
found to enhance anti-tumour functions. In contrast, pro-tumour functions of macrophages in 
lung cancer have also been reported. Thus, a dual role of macrophages is suggested in the 
lung cancer microenvironment (13). 
 Monocytes are a macrophage precursor and identified to be the leading source of 
recruited tissue macrophages (12). Macrophages can then migrate to local sites of injury, 
disorder and infection, where their presence leads to acute and chronic inflammation either in 
the local or systemic environment (14). In human lungs, alveolar macrophages (AMs) are 
located in the air spaces of the lungs and in the lower airways (15). AMs perform a vital role 
in the lung microenvironment and have been used to investigate cellular changes within the 
lung environment in a variety of pulmonary diseases, including lung cancer (16). Two 
distinct phenotypes of tumour-associated macrophages (TAMs) have been identified within 
the lungs; the classically activated macrophages (M1) and the alternatively activated 
macrophages (M2). Similar to macrophages, monocytes (macrophage precursors) play a vital 
role in the immune response against tumour cells. Monocytes have also been shown to have 
similar phenotypes (M1 and M2) in the blood stream to those shown by TAMs in the tumour 
microenvironments (17). The M1 macrophages are activated by IFN-with or without LPS 
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and TNF-α. They are generally suggested to be associated with anti-tumour functions and 
extended survival time in patients with non-small cell lung carcinoma (NSCLC) (18, 19). In 
contrast, the M2 macrophages have three well-defined forms: M2a which are induced by IL-4 
or IL-13; M2b which are initiated by exposure to immune complexes and agonists of toll-like 
receptor (TLRs); and M2c which are induced by IL-10 and glucocorticoids. M2 are known to 
be related to tumour initiation, tumour growth, poor prognosis and tumour metastasis (18, 
19).  
It has been shown previously that there are many differences between polarised 
subsets of macrophages (M1 and M2) in terms of cytokine and chemokine secretion, cytokine 
and chemokine receptor, expression of surface markers and effector molecules (20). Each 
macrophage subset expresses distinct molecules under the influence of various macrophage 
activators (19). For instance, the cytokines and enzymes that have been described as 
inhibitors of tumour cell proliferation, such as IL-1, TNF-α (tumour necrosis factor alpha), 
ROS (reactive oxygen species) and NOS (nitric oxide synthase), are associated with the M1 
subset. Conversely, M2 are associated with a low expression of such tumour inhibitor 
enzymes (e.g. iNOS) and produce factors such as IL-10 that are associated with tumour cell 
proliferation (19, 20). It has also been hypothesised that changes in the tumour 
microenvironment such as alterations in glucose levels and pH as well as the development of 
hypoxia may arise in the transition from an early to an advanced tumour stage (21). These 
factors could mediate macrophage phenotype alteration within the local or systemic 
environment.  
Studies that have examined the role of macrophages in lung cancer have provided 
inconsistent results. Although some studies report increased cytotoxic activity and anti-
tumour effects of these immune effector cells, others have reported decreased cytotoxic 
activity and pro-tumour effects (13, 22-27). A dual role for macrophages in lung cancer has 
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therefore been suggested, with the idea that they may both inhibit and/or promote tumour 
progression (13). Further investigation of macrophages is highly desirable in order to advance 
our understanding of these important components of the human immune system and their 
connection to the lung cancer microenvironment. This thesis aims to determine the influence 
of NSCLC on the phenotype and function of macrophages in their local (AMs and TAMs) 
and systemic (circulating classical blood monocytes and serum) environments. Samples used 
in this study were collected from patients with NSCLC and then compared to non-cancer 
controls. The resident AMs, circulating classical blood monocytes and serum were collected 
from bronchoalveolar lavage (BAL) fluid and blood, respectively. Various indicators and 
techniques were used in this study to illuminate the impact of NSCLC on macrophage (AMs, 
TAMs and monocytes) phenotype and function including flow cytometry, real-time 
quantitative polymerase chain reaction (RT-PCR), quantitative proteomics, cytometric bead 
array (CBA), Bio-Plex assay and immunohistochemistry (IHC). 
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1.2. The human lungs 
The human lungs are surrounded by visceral pleura and they fill the pleural cavities. The 
lungs comprise approximately 80% air, 10% blood, 3% conductive airways and blood 
vessels, and only 3% is alveolar tissue. The lungs are divided into upper and lower lobes by 
oblique fissures and five lobar bronchi are divided from the main bronchi (Fig. 3) (28). The 
human lungs are highly vascularised to facilitate their main function of gas exchange. The 
adult human lungs have a surface area of approximately 150 m
2 
that enables inhalation of 
about 10,000 – 15,000 litres of air every day (1). This exposes the lung to numerous toxic 
substances from the external environment with possible resulting lung injury. However, the 
respiratory tract has various defence mechanisms to overcome the inhalation of some external 
particles such as chemicals and microorganisms (2, 3). These mechanisms include coughing 
and sneezing when particles lodge and irritate the upper respiratory tract. In the lower 
respiratory tract, there are two main clearance methods, the mucociliary and phagocytic 
systems. The mucociliary system clears larger particles (<5 m) from the trachea-bronchial 
airway while smaller particles (<0.1 m) are removed by the phagocytic system, which is 
mainly mediated by resident AMs (2). However, repeated chronic lung injury can result in 
lung cancer initiation, which stimulates the creation of reactive oxygen and nitrogen species 
(ROS and RNS) and other pro-inflammatory chemokines and cytokines through the 
involvement of different inflammatory cells in the lung including macrophages (3, 29).   
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Figure 3: The normal structure of the human lungs. This image shows the structure of the normal 
human lungs. They are divided into upper and lower lobes by oblique fissures (28). 
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1.3. Histology of the normal human lungs and airways 
The bronchial wall contains a thin mucosa and a large submucosal layer. The mucosa has 
respiratory epithelium lying on a basement membrane and under that a supportive connective 
tissue. Between the mucosa and the submucosa, there is no clear boundary. The submucosal 
coat is known to contain muscle, glands and cartilage (28, 30). The basement membrane 
consists of three layers: a lamina lucida, which makes contact with epithelial cells, a lamina 
densa and a lamina reticularis, the latter only present in adults. Epithelial cells overlay the 
basement membrane and are held together by desmosomes, gap junctions and terminal bars 
that block excessive fluid movement across the epithelium (30). The morphology and 
function of the individual epithelial cells will not be discussed here, except to mention that 
the main epithelial cells include ciliated cells, mucous cells, submucosal glands, 
neuroendocrine cells and basal cells (28, 31). Alveoli are present in large numbers and in 
diverse arrangement on respiratory bronchioles and alveolar ducts. In the alveolar duct 
system, alveoli are arranged to facilitate their functions in expiration and inspiration. In the 
human adult lungs, there are around 300-500 million alveoli (28, 32). Each alveolus measures 
about 250μm in diameter when expanded, although sizes vary with those in the upper parts of 
the lung described as being larger than those in the lower parts of the lung as a result of 
gravitational forces (28, 33). Alveolar tissue contains different types of cells that are known 
to assist various functions in the lung. The alveolar epithelium is one example, which consists 
of two cell types, the alveolar epithelial type I and II cells. The alveolar epithelial type I cells 
have limited cytoplasmic organelles, but are significant for their attenuated cytoplasm. As a 
result they extend long distances from the nuclear zone of the cell, and have been described 
as covering up to 5,000 μm2 of the alveolar surface (32, 34). These cells function to provide a 
comprehensive thin covering and prevent fluid loss, however they also enable rapid gas 
exchange. The alveolar epithelial type II cell is taller compared to the type I cell. However, it 
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only covers 7% of the alveolar surface. It is often present in the corners of alveoli and is 
covered with the type I cell. The function of alveolar epithelial type II cell is to differentiate 
into a type I cell and to remodel the alveolar wall in the case of injury. The alveolar epithelial 
type I cells are connected together and also to type II epithelial cells via tight junctions (32). 
Other cells including interstitial cells and the immune effector cells considered in this study 
will be discussed in detail later.  
1.4. Lung cancer 
Lung cancer is a malignant tumour, which originates in lung tissue. It can arise anywhere in 
the lungs, including the trachea, bronchi, bronchioles and alveoli. It grows when the lung 
cells become abnormal and ultimately lead to the development of a tumour mass (4). Lung 
cancer is one of the most common cancers in the Western World and is the primary source of 
cancer mortality with approximately 1 million deaths annually (6-8). It is associated with a 
short survival time (10-15% of patients survive 5 years or longer) and an ineffective 
treatment strategy (9). It is well known that the survival rate of lung cancer is related to the 
age of diagnosis (Fig. 4 and Fig. 5). In Australia, more than 9,000 people are diagnosed with 
lung cancer every year. The incidence rate of lung cancer in Australia has decreased by 32% 
in men (from 85 to 58 cases per 100,000), but in women it is rising by 72% (from 18 to 31 
cases per 100,000); a phenomenon which has been explained as being due to women taking 
up smoking later than men (Fig. 6) (35). Lung cancer was the leading cause of cancer deaths 
in both men and women in Australia in 2007. On average, 13 men and eight women die from 
lung cancer every day in Australia (with a total of 7626 deaths from lung cancer in 2007) (5).  
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Figure 4: Relative survival for lung cancer per 100,000, for males and females in Australia. 
The graph shows that the relative survival rates are different depending on the age of 
diagnosis and these results confirm the importance of early diagnosis (5).  
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Figure 5: Incidence and death rates for lung cancer per 100,000, for males and females in 
Australia. The graph displays the incidence and death rate of lung cancer in Australian males 
and females in 2007 (5).  
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Figure 6: Incidence and death rates for lung cancer per 100,000, for males and females in 
Australia. The graph exhibits the incidence and death rates of lung cancer from 1982 to 2007 
in Australia (5). 
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It is well established that smoking is the leading cause (80-90%) of lung cancer cases 
(36, 37). However, accumulating evidence strongly suggests that there are other factors that 
might increase the susceptibility of humans to lung cancer. These include air pollution, a 
family history of lung tumours, chronic lung disorders, gender and race (Fig. 7). An example 
of the influence of gender is that female smokers are found to be more vulnerable to 
developing lung cancer than men, and this is believed to be a result of the higher level of 
aromatic DNA adducts (deoxyribonucleic acid) (indicating DNA damage) in females. 
Another example where race appears to be a factor is that African Americans are found to be 
at higher risk of lung cancer, with a 1.8 times greater risk than that of their Caucasian 
counterparts (38, 39).  
The majority of lung cancer is primary lung cancer, which initiates from the lung. The 
main subtypes of primary lung cancer are small cell lung carcinoma and non-small cell lung 
carcinoma (NSCLC). The progression of primary lung cancer is based on clinical stages and 
lung cancer subtypes. Approximately 85-90% of diagnosed lung cancers are NSCLC. 
NSCLC is differentiated into squamous cell lung carcinoma, adenocarcinoma and large cell 
lung carcinoma mainly based on their histological features (40). These NSCLC subclasses 
have different tumour cell size and shape, but they were grouped together because of their 
approach to treatment and the prognosis is very similar. However, recently it has been 
recognised that different lung cancer subtypes respond differently to treatment. For example, 
metastatic lung adenocarcinoma that expresses epidermal growth factor receptor (EGFR) or 
KRAS (kirsten rat sarcoma viral oncogene homolog) can be treated with biological agents 
that are not helpful as yet for other subtypes, e.g. squamous cell lung carcinoma (41, 42). 
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Figure 7: This diagram summarises the main risk factors of lung cancer. Cigarette smoking 
has been confirmed to be the leading cause of lung cancer. Other factors have also been 
suggested to be associated with lung cancer occurrence, in particular air pollution and chronic 
lung diseases (5).  
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1.5. Classification of lung cancer 
The classification of lung cancers has been updated and adjusted several times. The lung 
cancer typing is mainly based on histological features. Thus, lung cancer types are named 
depending on the initial tumour cell type (43). In some lung tumour environments, there are 
mixed cell types or the cell might change during the cancer progression and treatment (44-
46). This has led some researchers to suggest that all pulmonary carcinomas arise from a 
common stem cell that has the ability to display various pathways (47). However, the 
different tumour subtypes can be clearly differentiated based on their clinical behaviour and 
the way they respond to treatment. Lung cancer typing is negatively impacted by the small 
size of fibreoptic bronchoscopic biopsy specimens, the reliability of pathologist identification 
of histology and methodological limitations. A study on pathologists’ examination and 
classification showed that they agreed on the classification of 72% of small cell lung 
carcinomas, 56% of adenocarcinomas, 48% of squamous cell lung carcinomas and only 5% 
of large cell lung carcinomas (48). This study has shown that there is considerable variability 
in the classification of the lung cancer subtypes (47). However, the World Health 
Organisation (WHO) classified lung cancer into (I) NSCLC and (II) small cell lung 
carcinoma. NSCLC is categorised into squamous cell lung carcinoma, adenocarcinoma and 
large cell lung carcinoma and a few other less common subtypes e.g. adenosquamous 
carcinoma and sarcomatoid carcinoma. NSCLC is known to be the most common lung cancer 
and accounts for 85% of all lung cancer cases (5, 47). In Australia, approximately 64% of 
lung cancers in males and 61% in females were reported to be NSCLC (Fig. 8). For males 
and females, adenocarcinoma was the most reported type of NSCLC, though the 
adenocarcinoma incidence rate was lower in males than females (26% vs. 34%). However, 
the incidence rate of squamous cell lung carcinoma was higher in males than in females, 
being 20% versus 10%, respectively. The percentage of lung cancers that were classified as 
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large cell lung carcinoma was around 17% for both males and females. Moreover, the 
percentage of lung cancers that were categorised as small cell lung carcinoma was 11% for 
males and 13% for females. Finally, other specified carcinoma types and unspecified 
malignant neoplasms accounted for 25% of lung cancers in males and 26% in females (Fig. 
8) (5). This statistical fact was the main factor that led us to concentrate on NSCLC and try to 
add additional knowledge to this field. The following paragraphs will briefly discuss the three 
NSCLC subtypes, including squamous cell lung carcinoma, adenocarcinoma and large cell 
lung carcinoma.  
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Figure 8: The percentage of lung cancer incidence by type in Australia, 2007. This graph 
displays that NSCLC is the most common lung cancer (5). 
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Firstly, squamous cell lung carcinoma has typically been considered as a tumour of the 
central bronchi but recently there has been a decrease in the number of central tumours and 
an increase in tumours initiated from peripheral areas (49). Squamous cell lung carcinoma 
was known to be the most common type in many countries but adenocarcinoma is increasing 
and is now the commonest NSCLC type (50, 51). The decline in squamous cell lung 
carcinoma incidence might be because of the decrease in the percentage of smokers since the 
1950s and the skew to low-tar filter cigarettes. Squamous cell lung carcinoma accounts for 
25–30% of all lung cancer (52). It can be diagnosed histologically from uneven nests and 
tumour cells separated by varying amounts of fibrous stroma. This kind of tumour cell has 
large irregular nuclei, clumped chromatin and nucleoli of varying size and differentiated 
squamous cell lung carcinomas show noticeable keratinization (47). The WHO classification 
describes four different subtypes of squamous cell lung carcinoma: papillary, clear cell, small 
cell and basaloid (47).  
Next, adenocarcinoma incidence shows an increase in many countries
 
and
 
is
 
now the 
most frequent NSCLC and it accounts for 35–40% of lung cancers overall (47, 50, 53). The 
reason behind the increase in the number of patients with adenocarcinoma is believed to be 
the growing popularity of filter-tipped cigarettes. The majority of patients with pulmonary 
adenocarcinoma are elderly smokers, but there is a high number of adenocarcinoma in non-
smokers and the young (54, 55). Most of the adenocarcinomas arise from the periphery of the 
lung or what has been called the terminal respiratory unit. The WHO classification of lung 
tumours names five different subtypes of adenocarcinoma (acinar, papillary, bronchiolo-
alveolar, solid with mucin production and mixed). Recently several researchers have 
suggested the existence of other growth patterns; papillary with a prominent “morular” 
component, micropapillary, secretory endometrioid-like, adenocarcinoma with massive 
lymphocyte infiltration, basaloid and those showing enteric differentiation (56, 57). These 
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classification changes have guided the International Association for the Study of Lung 
Cancer (IASLC), the American Thoracic Society (ATS) and European Respiratory Society 
(ERS) to suggest adjustments to the WHO classification (47).   
Finally, large cell lung carcinoma subtype is a less common lung cancer in comparison 
to other NSCLC subtypes; it accounts for 10–15% of lung cancers (47). This subtype is an 
aggressive tumour and is usually centrally located and frequently displays an exophytic, 
endobronchial pattern of growth and a well-defined edge (52, 58). The large lung carcinoma 
cells are arranged in monotonous fields and can be distinguished from small cell carcinoma 
through cytological features. The features of this cancer are the large size of the tumour cell 
and the nuclear detail; they also have a moderate amount of cytoplasm, chromatin that is 
clumped at the periphery of the nucleus and a prominent nucleolus (59, 60). Five subtypes of 
large cell lung carcinomas have been documented: clear cell, neuroendocrine (the tumour of 
middle-aged or elderly cigarette smokers that arises in central bronchi) basaloid, 
lymphoepithelioma-like and rhabdoid (47). 
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1.6. Cancer immunoediting and lung stromal cells    
The term “immunoediting” is used to describe the changes in immunogenicity of tumours due 
to the anti-tumour response of the immune system. It contains three phases: elimination, 
equilibrium, and escape. The elimination phase contains four different phases, including (I) 
the initiation of the anti-tumour immune response, (II) tumour death induced through 
interferon gamma (IFN-γ), (III) more tumour killing by natural killer cells (NK) and 
macrophages, and (IV) the specific anti-tumour function via CD4
+
 and CD8
+
 T cells. The 
tumour cells that successfully survive the elimination phase might proceed to the equilibrium 
phase where the immune system is able to control their growth but cannot completely destroy 
them. The tumour cells may overcome all these phases and enter the escape phase where they 
start to progress and metastasise to other organs (61).  
The human immune system exhibits local and systemic functions that ultimately inhibit 
tumour growth. Several studies have shown that the components of the immune system are 
not just important in controlling and preventing the initiation of cancer, but that they are 
involved in cancer immunoediting through the innate and adaptive immune systems (10, 11). 
Such immunoediting can occur through a number of different mechanisms, including via the 
presence of inflammatory cells (macrophages, NK, dendritic cells and lymphocytes) and their 
secretion of various immunological factors such as chemokines and cytokines that are known 
to increase the host’s defence against tumours (e.g. IFN-γ, IL-12 and IL-1) (12).   
However, the immune system has been shown to exhibit a dual role in both eliminating 
and promoting human tumours, thus sometimes being described as a double-edged sword in 
the way it interacts in tumour microenvironments (12). A number of studies have shown that 
components of the immune system (innate and adaptive) are associated with tumour growth 
and poor prognosis in cancer patients (62-64). In particular, macrophages have been 
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suggested to promote tumour growth, invasion and metastasis through the secretion of 
different chemokines, cytokines and other factors such as IL-10, matrix metalloproteinases 
(MMPs), vascular endothelial growth factor (VEGF) and transforming growth factor- (TGF-
. Macrophages are known to be the first cells to arrive at the tumour site and perform 
various functions that can inhibit tumour growth, while other macrophages may encourage 
tumour cell survival and escape (Fig. 9) (12, 65). All these reasons make macrophages (AMs, 
TAMs and monocytes) crucial fundamental cells to be intensely investigated in order to 
understand the association between these cells and tumour initiation, growth and metastasis.  
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Figure 9: The process of cancer immunoediting. (A) This figure shows how the elimination 
process begins with the recognition of transformed cells through lymphocytes, which is then 
stimulated to produce IFN-γ. (B) The expression of IFN-γ leads to stimulation of the innate 
immune system response and then recruitment of NK, DC and macrophages. (C) NK cells 
and macrophages attack tumour cells while CD4
+
 and CD8
+
 T cells develop in the lymph 
node. (D) Tumour-specific T cells (CD4
+
 and CD8
+
) then migrate into the tumour site where 
they start recognising and destroying tumour cells. Blue: Tumour cells; grey: non-
transformed cells; white surrounded by a dashed black line: dead tumour cells; DC: dendritic 
cells; NK: natural killer cells and Mac: macrophages (12). 
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Lung tumours are composed of tumour cells and surrounding connective tissue and 
cells, which make up the tumour stroma (Fig. 10). The interaction between tumour cells and 
stromal cells as well as the extracellular matrix (ECM) plays a vital role in tumour growth 
and progression (66). Tumour cells have the ability to interact and alter the function of 
surrounding connective tissue to support and maintain their proliferation and progression 
(67). The tumour stroma possesses several cellular compartments, including 
fibroblasts/myofibroblasts, smooth muscle cells, endothelial cells, dendritic cells, 
macrophages and other inflammatory cells. They can interact with each other through the 
secretion of growth factors, chemokines, proteases and ECM components (67-69). 
Macrophages are one of the most important types of stromal cells that have been shown to be 
associated with both tumour progression and tumour regression. Macrophages (AMs and 
TAMs) and their precursor cell, monocytes, will be studied in detail here in order to examine 
their potential role in patients with NSCLC. AMs, TAMs and monocytes are attractive cells 
to be targeted to find new biomarkers, treatment targets, prognostic and diagnostic indicators. 
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Figure 10: The interaction between tumour cells and tumour stroma. The tumour cells are 
able to alter the function of stromal cells and utilise their expression to survive, grow, invade 
and migrate. Stromal cells, including macrophages, endothelial cells, neutrophils, 
lymphocytes and fibroblasts, as well as the extracellular matrix compartment, surround and 
interact with the tumour cells. This drawing shows the vital location and the significant role 
of macrophages, which allows them to be active in controlling tumour cell growth and/or 
support tumour growth and metastasis (70).  
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1.7. Macrophage phenotype and function 
Macrophages and monocytes both have similar features to granulocytes, in particular with 
neutrophils. They both have the ability to migrate through several body compartments, 
including bone marrow, blood, lymphoid, and all non-hematopoietic tissues (Fig. 11) (14, 
71). Monocytes are the main source of recruited tissue macrophages in several conditions 
such as infection, granulomata, atherosclerosis and tumours. Macrophages then migrate to 
sites of injury and infection, where their presence leads to acute and chronic inflammation 
either in the local or systemic environment (14).  
Monocytes are an important part of the innate immune response to cancer. The notion 
that the immune system has a protective role in tumour development is well established (12), 
with recent work also suggesting a converse role in promoting tumour initiation and 
progression (72). Previous studies looking at monocytes in a range of different cancer types 
have demonstrated conflicting results regarding monocyte phenotype and function in 
different cancer microenvironments. Studies in patients with lung, breast and other cancers 
have described inhibited monocytes function (73-77), whereas Mariotta et al. (2002) 
suggested that NSCLC does not affect monocyte adherence and phagocytosis before 
chemotherapy in lung cancer patients compared to healthy controls (17). Other studies have 
demonstrated monocytes capable of both inhibiting and stimulating tumour growth at the 
same time (78).  
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Figure 11: Monocyte and macrophage differentiation. Immature monocytes released from 
bone marrow migrate through the bloodstream under the influence of different cytokines and 
chemokines (e.g. M-CSF and GM-CSF) into tissues (lung, liver, spleen, peritoneal cavity and 
brain) where they differentiate into resident macrophages under the influence of IFN-γ and 
LPS. 
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Monocytes can be characterised into classical monocyte (CD14
++
/CD16
-
), 
intermediate monocyte (CD14
+
/CD16
+
) and non-classical monocyte (CD14
+
/CD16
++
) 
phenotypes, and all of these have been detected in circulating peripheral blood mononuclear 
cells (PBMC) (Fig. 12) (79, 80). Monocytes are known to differentiate into tissue 
macrophages. Classical monocytes (CD14
++
/CD16
-
) differentiate into M1 macrophages, while 
non-classical monocytes (CD14
+
/CD16
++
) differentiate into M2 macrophages (81). M1 cells 
function as antigen-presenting cells and have a vital role in immune activation and function 
(82). In contrast, M2 are known to be associated with poor antigen presentation and the 
production of factors that suppress T cell proliferation and activity (82). The major source of 
macrophage migration to the tumour site is from classical monocytes. In spite of this, the 
majority of macrophages within the tumour area have been identified as M2 macrophages 
(81). However, it has been reported that classical monocytes can differentiate into M2 
macrophages (83).  
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Figure 12: Monocyte classification. Monocytes have been categorised based on their CD14 
and CD16 expression into classical monocytes (CD14
++
/CD16
-
), intermediate monocytes 
(CD14
++
/CD16
+
) and non-classical monocytes (CD14
+
/CD16
++
). 
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Macrophages are mononuclear phagocyte cells that reside in different compartments 
within the body (lung, liver, spleen, peritoneal cavity and brain). They are crucial to the innate 
and adaptive immune system. Macrophages are released from bone marrow as immature 
monocytes and then migrate through the bloodstream into tissue sites where they can 
differentiate into resident macrophages (84). Thus, macrophages arise originally from 
haemopoietic progenitors (71), and then differentiate into subpopulations of tissue 
macrophages directly or via circulating monocytes (85). Resident macrophages are present in 
different organs under stressful conditions as well as in the absence of inflammation. Tissue 
macrophages can also be replicated and differentiated locally, depending on the stimulus and 
tissue environment (14). Macrophages are highly active cells and have been shown to express 
various receptors, cytokines and chemokines in normal and abnormal cells in different sites. 
They can perform endocytosis, phagocytosis, and secrete various products, including 
cytokines (TNF, IL-1, IL-6, IL-4, IL-13, IL-10), growth factors (transforming growth factor-
beta (TGF-), platelet derived growth factor (PDGF) and VEGF). They also demonstrate 
trophic and toxic functions, contribute to tissue remodelling and host defence in innate and 
adaptive immunity (14).  
In the lung, macrophages termed AMs are localised in the air spaces and also exist in 
the lower airways in the presence or absence of infection (15) where they play a crucial part in 
immunity and inflammation (Fig. 13) (16). Macrophages in other sites of the human body are 
similar to AMs in the lungs, although their functions may differ according to the requirements 
of the tissue in which they reside. The main difference between AMs and peritoneal 
macrophages is their mode of metabolism as AMs use aerobic rather than anaerobic 
metabolism (28). AMs like other macrophage subtypes have diverse functions in the 
regulation of adaptive immunity, including the production of reactive oxygen and nitrogen 
species and antigen presentation (86). AMs and other macrophage subtypes regulate local 
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inflammatory reactions via the release of cytokines and provide primary defence by 
phagocytosis of foreign particles (87).  
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Figure 13: The alveolar structure and anatomical location of AMs. The main components of 
the alveolus are shown in this figure including AMs (88).  
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 Cytokines are involved in numerous immune reactions, including tumouricidal 
activity (22). Upon stimulation, AMs secrete pro-inflammatory cytokines such as TNF-α, IL-
1, IL-6 and IL-12 (24, 89) and anti-inflammatory cytokines such as IL-10, TGF-β and IL-13 
(13, 90). Also AMs exert direct cytotoxic effects by phagocytosis or indirect anti-tumour 
effects via cytokine release and natural killer cell activation (23). AMs therefore play a critical 
role in lung immune regulation and the prevention of lung diseases, including lung cancer 
(91). 
As mentioned before, the ultimate source of AM is the bone marrow, but under 
special circumstances the pulmonary interstitial cells is considered to be the immediate 
source. It has been demonstrated that most monocytes migrated to become AMs by passing 
into alveoli but a few of them differentiate in the interstitium (92, 93). The differentiation 
process of monocytes into AMs involves cytoplasmic enlargement, loss of myeloperoxidase 
and the development of lysosomes more characteristic of mature macrophages. Hence, the 
number of AMs might increase by enhanced migration from the interstitium and then division 
of cells (28, 92). AMs stay in the alveolus for 7 days, then the majority of the cells move to 
the terminal bronchiole and subsequently to the pharynx where AMs are eventually discarded 
(94). Respiratory movements stimulate AMs transport and this translocation of AMs is 
assumed to be important to antigen presentation and the induction of lung immunity (28).  
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1.8. Macrophages in lung cancer 
The work of Coley William (1891) on sarcomas was the first to demonstrate that the 
immune system is involved in the regression of cancers (95). This work has led many 
scientists to start working on cancer immunology in order to find a better treatment for 
cancers. In regards to our study, the connection between lung cancer and macrophages 
especially TAMs has been widely reviewed (20, 96). However, less is known about AMs and 
monocytes compared to TAMs in lung cancer. Thus, this literature review will concentrate 
more on AM phenotype and function in lung cancer. Immature monocytes derived from bone 
marrow migrate through the bloodstream into tissues where they differentiate into resident 
macrophages (e.g. AMs) in the lungs through the influence of IFN- and lipopolysaccharide 
(LPS) (16). AMs are localised in the airspaces of the lungs (97) and exist in the lower airways 
in the presence or absence of infection (15), where they play a crucial part in immunity and 
inflammation of the lungs (16). The main role of AMs in the lung is to eliminate foreign 
substances (98).  
Macrophages (AMs and TAMs) are known to be crucial cells in lung cancer as they 
are in close proximity to tumour cells compared to other stromal cells. Similar to TAMs, the 
enrichment of AMs (M2 phenotype) favours tumour growth and correlates with poor 
prognosis in lung cancer. AMs and TAMs are known to be responsible for releasing several 
growth factors, cytokines, chemokines, inflammatory mediators and other molecules (20). 
Many of these factors are well known and have been associated with tumour growth, poor 
prognosis and metastasis including VEGF, PDGF and IL-10. For instance, AMs and TAMs 
secrete high amounts of pro-angiogenic factors such as VEGF, which stimulate tumour 
vascularisation and metastasis. Another potential pathogenic activity of these cells is the 
suppression of anticancer immune responses (e.g. induce the secretion of IL-10) (99).  
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Complement receptors and toll-like receptors are important in the contribution of 
AMs to the initial defence in inflammation, infection and tumour via the production of 
cytokines and chemokines secretion (e.g. IFN-and IL-8), monocyte chemoattractant protein-
1 (MCP-1) and growth factors. They also function diversely in the regulation of adaptive 
immunity, including via the production of ROS, NOS and metalloproteinases as well as 
through antigen presentation (86, 100).   
AMs regulate local inflammatory reactions via the release of cytokines and provide a 
primary defence mechanism against foreign particles by phagocytosis (87). Cytokines are 
involved in numerous immune reactions, including tumouricidal activity (22). AMs secrete 
both pro-inflammatory cytokines such as TNF-α, IL-1, IL-6 and IL-12 (24, 89) and anti-
inflammatory cytokines such as IL-10, TGF-β and IL-13 (13, 90). Upon stimulation, AMs 
may exert direct cytotoxic effects by phagocytosis, or anti-tumour effects via cytokine release 
and natural killer cell activation (23). Therefore, AMs appear to play a critical role in lung 
immunoregulation and potentially in the prevention of lung diseases, including lung cancer 
(91). Studies investigating the role of AMs in lung cancer have provided inconsistent results. 
Whilst some studies report increased cytotoxic activity and anti-tumour effects after AMs 
activation, others have reported decreased cytotoxic activity and pro-tumour effects (13, 22-
27). A dual role for macrophages in lung cancer has therefore been suggested with the idea 
that AMs may both inhibit and/or promote tumour progression (13). The anti-tumour 
functions of AMs need further investigation in order to enable lung tumour to be treated with 
M1 macrophage-activating drugs. Similar to TAMs, AMs are attractive targets of lung cancer 
immunotherapy if M1 macrophage-activating drugs can be delivered to the lungs. 
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1.9. Macrophage polarisation and tumour progression 
The role of macrophages (AMs, TAMs and monocytes) in the tumour environment has been 
widely reviewed (17, 20, 23, 27). TAMs have been suggested to be the most important 
macrophage subtype and immune cells in NSCLC, because the amount of TAMs in the 
tumour islets or stroma can be independently utilised to predict patient's survival time (101). 
There are two major phenotypes of macrophages that perform different functions: M1 and 
M2. The M1 macrophages inhibit cell proliferation, promote inflammation and tissue damage 
while M2 inhibit inflammation, promote cell proliferation and tissue remodelling and repair 
(102). The M1 macrophages are activated by IFN-with or without LPS and TNF-α (18-20, 
103). M1 secret different pro-inflammatory cytokines such as IL-1, IL-12, TNF-α, and 
inducible nitric oxide synthase (iNOS) (Fig. 14) (20). A study has shown the presence of both 
M1 and M2 phenotypes within NSCLC tumour islets (18). In addition, the M1 macrophage 
subset appeared more frequently within tumour islets and was associated with extended 
survival time in patients with NSCLC (18). In contrast, the M2 phenotype has three well-
defined forms: M2a which are induced by IL-4 or IL-13; M2b which are initiated by 
exposure to immune complexes and agonists of toll-like receptor (TLRs); and M2c which are 
induced by IL-10 and glucocorticoids (Fig. 14) (19). Macrophages have been shown to 
exhibit several phenotypes (e.g. M1, M2a, M2b, etc.) mainly depending on the environment 
in which they are found. There are many examples of macrophage-polarising events during 
tumour progression, including the secretion of tumour-derived mediators and hypoxic tissue 
damage, as well as influences from other immune cells and stromal components (18, 104-
106). The exact characterisation of macrophage populations within M1 and M2 subtypes can 
perhaps be overgeneralised, as macrophages have been described as highly plastic cells that 
can demonstrate a variety of phenotypes (104). However, the markers of M1 and M2 
phenotype can still be used to categorise the phenotype and function of macrophages (104). A 
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small number of macrophages express both M1 and M2 markers and this leads to the 
suggestion that a mixed phenotype occurs (106). A study previously verified that the M1 and 
M2 markers differentiate macrophage populations, although about 5% of the cells stained for 
both M1 and M2 markers using immunohistochemistry (IHC) (18).  
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Figure 14: Macrophage subsets have distinctive inducers and multiple functions. 
Macrophages polarise into the M1 subset under the influence of IFN-γ and LPS and have 
anti-tumour functions via the secretion of effector molecules such as iNOS, IL-1 TNF and IL-
6. In contrast, IL-4 and IL-13 stimulate M2a polarisation; M2b is induced by exposure to 
TLR and IL-1R, and IL-10 is described as an inducer of M2c. The three M2 subtypes are 
described as tumour promoters; they induce tumour growth through the inhibition of anti-
tumour factors and/or over-expression of tumour progression factors such as IL-10, TGF-β 
and angiogenesis mediators.      
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The M2 macrophages have been associated with tumour initiation and progression 
and have also been described as an inhibitor of inflammatory responses and adaptive Th1 
immunity (18, 103). The M2 macrophages produce anti-inflammatory cytokines such as IL-
10 and stimulate the expression of the mannose receptor and arginase I, while simultaneously 
reducing iNOS and arginine (107). Other than their ability to reduce the amount of NO, 
which is significant for the elimination of tumour cells (108), M2 can inhibit antigen 
presentation (19) and T-cell proliferation (109). The cytokines that regulate M2 activation 
have been associated with NSCLC and other types of tumours (110). A recent study showed 
that early lung neoplasia in vivo is associated with increased numbers of M2 macrophages 
regardless of whether the model of carcinogenesis is genetically- or chemically-induced 
(107). Also in vitro, the M2 macrophages have been found to encourage the growth of 
various tumour cells (111) and to increase tumour cell survival (112). The M2 macrophages 
also play a vital role in promoting angiogenesis via VEGF, which is a prominent mediator of 
angiogenesis (18, 113).  
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1.10. The potential role of alveolar macrophages in tumour regression 
1.10.1. The role of pro-inflammatory cytokines: TNF-α, IL-1 and lL-6 
AMs derived from patients with lung cancer have been shown to function efficiently against 
tumour cell growth in vitro (Table 1) (22-25, 114). Increased TNF-α and IL-1 secretion from 
AMs of patients with lung cancer after stimulation with IFN-γ and granulocyte macrophage 
colony stimulating factor (GM-CSF) has been demonstrated when compared to AMs from 
patients with non-malignant disorders (24). IL-1 mediates cytotoxicity and suppression of 
tumour growth (115, 116) and TNF-α inhibits angiogenesis to prevent tumour growth. TNF-α 
can therefore act as an anti-tumour monokine and be responsible for spontaneous (without 
external activation) cytotoxic effects of AMs (117). Hence, AMs from patients with lung 
cancer may be able to secrete normal amounts of pro-inflammatory cytokines, suggesting that 
AMs function normally in patients with lung cancer. Despite these findings, decreased TNF-α 
secretion by AMs has also been reported in patients with lung cancer (13, 27, 116). However, 
Lentsch et al. (1996) showed that the reduction in TNF- did not impair cytotoxic activity of 
AMs against lung cancer in vivo (116). Overall, the secretion of TNF-α by AM appears to 
have an important anti-tumour role, however, there may be other mechanisms that contribute 
to AMs anti-tumour effects in the absence of TNF-α.  
Numerous studies have isolated AMs from BAL fluid to assess their function in the 
presence of known macrophage-activating agents such as IFN-γ and GM-CSF (25, 27, 89, 
115, 118). IFN-γ stimulates IFN-γ inducible protein (IP-10), an anti-tumour molecule that 
impairs tumour angiogenesis, whereas GM-CSF promotes the proliferation of haematopoietic 
progenitor cells and influences the anti-tumour function of AMs (118). After IFN-γ 
stimulation, the cytotoxic effects of AMs in patients with lung cancer are enhanced even from 
a depressed baseline level (23, 115). Stimulation with GM-CSF enhanced expression of 
mRNA coding for TNF-α, IL-1 and IL-6 in AMs and monocytes from patients with lung 
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cancer in a time-dependent manner, and isolation of AMs from patients with lung cancer 
receiving GM-CSF therapy and cultured with LPS showed enhanced IL-6 secretion (89, 118). 
These findings suggest GM-CSF therapy may enhance tumouricidal activity of AMs in 
patients with lung cancer.  
The ability of IL-6 to inhibit tumour cell growth has also been suggested (22). The 
elevation of IL-6 level has been detected in BAL cell culture and blood from patients with 
lung cancer compared to those with benign diseases (22). Upon LPS stimulation, IL-6 
secretion was increased in AMs from patients with lung cancer (22). IL-6 functions 
synchronously with IL-1 and TNF-α in order to support anti-tumour immunity (118). A 
recent study investigated IL-6 levels in BAL fluid and serum from patients with lung cancer 
before and during radiotherapy (RT). The IL-6 level in BAL fluid was higher compared to 
controls and was further elevated during RT, potentially confirming the role of IL-6 in 
mediating an inflammatory response. However, the study did not specify the source of IL-6 
secretion (119). However, other studies have demonstrated the ability of IL-6 to promote lung 
tumour growth and it has an association with a poor prognosis (120-122). A study has shown 
that tumour growth caused by tobacco smoke was mediated by IL-6 and TNF-α (120). Also 
the deficiency of IL-6 and TNF-α has led to decreased lung tumour cell proliferation (120). 
Similarly, another study has shown that IL-6 plays a vital role in promoting cancer stem cells 
derived from the NSCLC cell line H460 (121). Therefore, it was suggested that targeting IL-6 
could potentially improve lung cancer therapeutic techniques (121). An interesting clinical 
study demonstrated that NSCLC patients with high plasma levels of IL-6 responded poorly to 
chemotherapy. Additionally, it was suggested that IL-6 level could be used as a prognostic 
marker for lung cancer survival among those patients who have received chemotherapy 
(123).   
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1.11. The potential role of AMs in tumour progression 
1.11.1. The role of anti-inflammatory cytokines: TGF-β and IL-10 
AMs in lung cancer have been shown to exert pro-tumour effects via their secretion of anti-
inflammatory/immunosuppressive cytokines such as TGF-β and IL-10 (Table 1) (13, 25).  
TGF-β has been shown to enhance tumour cell proliferation in vitro and in vivo. (13). In vitro 
stimulation of AMs with LPS induced TGF-β secretion in patients with lung cancer (22). 
Also, increased TGF-β secretion has been reported in the serum of lung cancer patients 
compared to healthy controls (124). However, the mechanism underlying the increased 
production of TGF- and its role in AMs regulation and lung cancer growth is unclear (124).  
IL-10 is a potent tumour angiogenesis inhibitor released by AMs with or without LPS 
stimulation in vitro. Following LPS stimulation, Yanagawa et al. (1999) found no significant 
differences in IL-10 production by AMs from patients with lung cancer in comparison with 
control patients (13, 25). Conversely, IL-10 has been identified as a potential inhibitor of pro-
inflammatory cytokines and other cytotoxic molecules that mediate the killing of tumour 
cells. Therefore, IL-10 has been found to inhibit the anti-tumour activities of AMs and may 
thus contribute to tumour progression (125).     
1.11.2. Altered AMs function via inhibition of anti-tumour effects  
AMs have also been shown to function inefficiently and to promote tumour growth in 
patients with lung cancer (23, 26, 27, 116, 125). Inhibition of pro-inflammatory cytokine 
secretion by AMs has been reported in the presence of elevated levels of serum IL-10 (116, 
125). In murine peritoneal macrophages, LPS-induced TNF- release was inhibited by IL-10 
(126). The suppression of TNF- function favours tumour proliferation and differentiation 
through the activation of IL-10. This is consistent with the suppression of AMs anti-tumour 
function in advanced-stage lung cancer (91).      
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The IL-10 secretion by AMs has also been found to inhibit the cytokine secretion of 
other T cell proliferation inducers, such as IL-2 (116). Although the anti-tumour effect of IL-
2 is not completely understood, it has the capacity to mediate cytotoxicity and induce 
synthesis of IL-1 and TNF-α (127). In addition, IL-10 decreased Golgi apparatus (GA) and 
rough endoplasmic reticulum (RER) function in AMs from patients with lung cancer (116). 
The reduction of GA and RER negatively impact the synthesis and secretion of cytokines 
such as TNF-α, leading to dysfunction and down-regulation of AMs function. A reduction in 
TNF- could also lead to a reduction in cytostatic activity of AMs and may promote tumour 
growth and proliferation (116). The cytostatic activity of AMs has been shown to be 
compromised in patients with lung cancer (23, 128-130). In some studies, the reduction in 
cytostatic activity is greater in AMs from tumour-bearing segments compared to non-tumour 
bearing segments (129), whereas in others the defect appears more generalised (23).   
1.11.3. Altered cytotoxicity and cytokine release  
Altered cytotoxic activity of AMs from patients with lung cancer has been demonstrated (13, 
24, 26, 27) with both increased (24, 131) and decreased (13, 27) cytotoxic function described. 
Impaired cytotoxic ability of AMs from patients with lung cancer has been shown along with 
increased TNF-α and IL-1 production in the same patients (24). This revealed an obvious 
discrepancy in the correlation between cytokine release and cytotoxicity. Increased cytotoxic 
activity by AMs from lung cancer patients was discovered, however, with no reported 
alteration in cytokine release (131). These results suggest increased cytokine release or 
cytotoxicity may be a reaction to the presence of the tumour, rather than a primary 
mechanism preventing its occurrence. However, altered cytotoxic activity in AMs and TAMs 
has been shown to be mediated via decreased secretion of cytokines (IL-1, IL-6 and TNF-α) 
in patients with lung cancer (13, 27). Decreased TNF-α and IL-1 secretion has been 
demonstrated in AMs from patients with both NSCLC (squamous cell lung carcinoma and 
 44 Chapter 2: Literature Review 
large cell lung carcinoma subtypes) and small cell lung cancer, and reduced IL-6 secretion 
has been demonstrated from AMs derived from patients with large cell undifferentiated and 
small cell subtypes (27). TNF-α, IL-1 and IL-6 promote the induction of Th1 cells, which 
enable macrophage-mediated killing. Reduced Th1 mediated cytokines may consequently 
limit the cytotoxic potential of AMs or TAMs and enable tumour progression (13). Whilst IL-
6 release can contribute to the anti-tumour function of AM, a pro-tumour function has also 
been proposed. Even with IFN-γ and LPS stimulation, IL-6 inhibited the development of 
tumouricidal function in AMs of patients with lung cancer (26). Therefore, overproduction or 
dysregulation of IL-6 by macrophages can contribute to the growth and metastasis of many 
carcinomas, including lung cancer (132). 
1.11.4. Altered phagocytic capacity and receptor expression  
Decreased antibody-mediated cytotoxicity in AMs from lung cancer patients has been 
reported. AMs normally take up antigens for processing and present them on major 
histocompatibility complex (MHC) class I and II molecules. This activates T cells and in turn 
stimulates phagocytosis (macrophage-mediated killing) and the release of pro-inflammatory 
cytokines (TNFα and IL-1) (87). A study has confirmed that AMs from patients with small 
cell and squamous cell lung carcinoma were impaired in their ability to uptake 40nm 
fluorescent polystyrene beads, in comparison with controls, while AMs from patients with 
small cell, squamous and large undifferentiated carcinoma showed decreased uptake of 
1000nm beads (27). Impairment of uptake ability may highlight impairment in the phagocytic 
capability of AMs in lung cancer. The same study suggested differences in the phagocytic 
ability of AMs depending upon the histological subtype of lung cancer. Reduced 
functionality of AMs may thus promote tumour growth and differentiation.   
Altered cell surface expression of MHC molecules on AMs has been found in patients 
with lung cancer. Decreased MHC class II expression on AMs from patients with small cell 
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carcinoma and decreased intracellular adhesion molecule (ICAM-1) and CD83 expression 
from patients with small, large and squamous cell lung carcinoma after IFN-γ stimulation has 
been demonstrated by flow cytometry (27). Conversely, McDonald et al. (1990) found no 
difference in the expression of ICAM-1 with or without IFN-γ stimulation (23). ICAM-1 
plays an essential role in the early stages of T-cell activation. Reduced expression of ICAM-1 
therefore impairs AMs-mediated cytotoxicity (87). In addition, reduced expression of 
mannose receptor by AMs in lung cancer patients has also been shown (27). The mannose 
receptor is a transmembrane glycoprotein that binds and internalises carbohydrate ligands 
such as mannose and fructose. Mannose receptor is expressed on AM and plays a role in host 
defence and immune regulation. Therefore, reduced receptor expression may impair anti-
tumour function by AMs and favour tumour progression (133).  
Alterations in the functional status of AMs vary with the stage of lung cancer (91, 
129, 131). A decline in cytostatic and cytotoxic activity of AMs from patients with advanced 
stages of primary lung cancer has been observed (91, 129, 130), suggesting a growth-
promoting effect of lung tumours on AMs function. In contrast, increased cytotoxicity in 
advanced stages of lung cancer has also been documented (131).         
The underlying demographic and clinical characteristics of a patient may also 
influence AMs function. Such characteristics include age, smoking status, tumour histology, 
tumour stage and the presence of underlying comorbidities such as chronic obstructive 
pulmonary disease (COPD). BAL and whole blood cells from patients with small cell lung 
carcinoma and NSCLC cancer were compared in their secretion of IL-1, IL-6 and TNF-α. It 
was suggested that BAL and blood cells from patients with small cell lung carcinoma 
secreted significantly less cytokines (IL-1, IL-6 and TNF-α) than BAL and blood cells from 
patients with NSCLC (22). Although Pouniotis et al. (2006) noted differences in function 
between AMs from patients with different histological subtypes of lung cancer (27), the 
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majority of studies do not differentiate further than comparing between the two major 
categories of small cell lung carcinoma or NSCLC (13, 24, 25, 134).  
1.12. Role of alveolar macrophages in angiogenesis 
AMs have the ability to promote tumour progression by facilitating angiogenesis. 
Angiogenesis plays an important role in tumour growth, invasion and metastasis (132). It 
involves degradation of extracellular matrix and stromal invasion by endothelial cells (132). 
The proliferation, migration, and differentiation of endothelial cells into functional capillaries 
initiates the development of vasculature in the tumour (87). AMs are known to release growth 
factors, cytokines and inflammatory mediators in lung cancer. These factors and mediators 
include IL-8, VEGF, PDGF, basic fibroblast growth factor (bFGF) and MMPs, which are 
known to regulate angiogenesis (135).  
Increased secretion of IL-8 by AMs has been reported in patients with lung cancer and 
increased gene expression of IL-8 in lung cancer cell lines after co-culture with TAMs has 
also been found (135). The IL-8 is a potent angiogenic factor that is released from AMs and 
has been identified as favouring tumour growth and metastasis (118). The IL-8 in serum and 
BAL fluid has been shown to be higher in patients with lung cancer than in non-cancer 
controls and the level of IL-8 in BAL fluid can be considered as a prognostic factor for 
decreased survival (119). Lung cancer cells from patients with NSCLC demonstrated 
increased IL-8 mRNA expression after interaction with tumour infiltrating macrophages in 
vitro, suggesting that tumour cells may be activated by macrophages and secrete angiogenic 
factors (such as IL-8) which then enable tumour progression (135). Tumour progression 
associated with reduced survival rates has also been found in patients with NSCLC whose 
tumour cell lines demonstrated increased IL-8 mRNA expression compared to those with 
reduced expression (135).     
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VEGF also plays an important role in angiogenesis (113). It has been reported that the 
transcription and protein production of VEGF is increased in multinuclear cells of pulmonary 
sarcoid granulomas (136). VEGF may have a chemotactic effect on TAMs and increased 
expression may guide migration to avascular areas, increasing blood vessel development in 
tumours (87). The expression of VEGF-C, a member of the VEGF family, has been shown in 
tumour cells and stromal macrophages of patients with NSCLC using the IHC technique. 
However, VEGF-C expression in tumour cells and stromal macrophages did not correlate 
with nodal metastasis or angiogenesis (137). The underlying mechanisms involved in VEGF 
expression in AMs and their functional significance in lung cancer remain incompletely 
determined (138). 
Increased PDGF production by TAMs in tumour stroma has been reported (13, 134). 
Tumour stroma is specialised peritumoral and intratumoral connective tissue comprised of 
endothelial, mesenchymal, and inflammatory cells and sometimes described as a tumour 
microenvironment (13). It is suggested that elevated PDGF in the tumour stroma favours 
tumour progression and angiogenesis via the migration of endothelial and mesenchymal cells 
(13). This is supported by studies showing that PDGF stimulates cell migration in human 
lung carcinoma cells (139). Cell migration plays an important role in metastasis and can be 
promoted via the release of cytokines from AMs.   
MMPs are matrix degrading enzymes that facilitate tumour growth and metastasis 
through the breakdown of extracellular matrix and in particular basement membranes (87). In 
patients with lung cancer, matrix metalloproteinase-12 (MMP-12) and matrix 
metalloproteinase-9 (MMP-9) have been shown to promote lung tumour growth (140, 141). 
MMP-12 is released by AMs and favours tumour progression by enhancing angiogenesis and 
the breakdown of elastin. Interestingly, an association between increased VEGF and MMP-
12 gene expression and tumour vascularity has been demonstrated (140). MMPs are an 
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attractive target for therapeutic purposes because of their involvement in tumour progression. 
However, a recent trial has suggested that some MMPs might play a crucial role in host 
resistance against tumour progression. An increase in Lewis lung carcinoma pulmonary 
metastasis was shown in MMP12-deficient mice while normal MMP12 expression was 
associated with reduced tumour-associated microvessel density in vivo (142). Collectively, 
these results suggest an important role for MMP12 in inhibiting lung metastasis and indicate 
that specific MMP inhibitors could be designed to target tumour-promoting MMPs in order to 
inhibit tumour growth (142).  
Increased MMP-9 levels and significant correlations between tumour stage and both 
BAL fluid and plasma MMP9 levels have been demonstrated in patients with NSCLC (143). 
It has also been suggested that serum MMP-9 levels (but not BAL fluid MMP-9 levels) can 
be useful in distinguishing between malignant and benign lung diseases. The same study also 
demonstrated that serum MMP-9 levels relate to both disease stage and general clinical status 
of patients with NSCLC (144). This study did not, however, specify which cells 
(macrophages or cancer cells) was the source of MMP-9. Further investigation is clearly 
required into the relationship between macrophage, MMPs and lung cancer.     
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Table 1: Summary of pro- and anti-tumour roles of alveolar macrophages in lung 
cancer 
Primary lung 
cancer subtype 
Type of 
macrophage 
Anti-tumour 
role 
Pro-tumour 
role 
 
Clinical 
parameters 
 
Reference 
Small cell lung 
carcinoma 
AMs 
 
 
 
AMs 
 
 
 
 
 
 
Decreased IL-6, 
TNFα and IL-1 
production 
 
Decreased IL-6, 
TNFα, IL-1, 
MHC class II 
surface expression 
 
Further reductions 
seen in phase IV 
 
 
Inability to 
stimulate anti-
tumour immunity 
 
(22) 
 
 
 
(27) 
 
Non-small cell 
lung carcinoma 
(NSCLC) 
AMs 
 
 
 
 
 
TIM 
 
 
 
 
TAMs 
 
 
 
 
AMs 
 
 
 
 
 
TAMs 
 
 
 
TAMs 
 
 
 
 
AMs 
 
 
 
 
AMs, Monocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increased AM 
count and IL-6 
secretion with 
GM/CSF 
 
 
Decreased TGF 
 
 
 
VEGF-C not 
correlated to 
angiogenesis 
 
 
Increased TNFα 
and IL-1 
 
 
Increased TNFα, 
IL-1, IL-6 mRNA 
expression with 
GS/CSF, 
 
IL-6 found to 
inhibit the 
development of 
tumouricidal 
activity 
 
Increased 
expression of IL-8 
mRNA 
 
 
Gene expression 
of IL-8 and 
MMP-9 
 
 
Increased 
secretion of IL-8 
 
 
 
 
Decreased IL-1, 
TNFα, IL-6   and 
increased PDGF 
 
Expression of 
VEGF-C 
 
 
 
 
 
 
 
Impaired 
cytotoxic ability 
 
Correlate to 
metastatic 
potential of 
cancer cells 
 
 
Interaction with 
NSLC may 
promote 
invasiveness 
 
GM/CSF induces 
a cellular 
expansion in the 
lung 
 
Limit possible 
cytotoxicity and 
promote 
angiogenesis 
 
 
 
 
 
 
Lower 5-year 
survival rate with 
high expression of 
VEGF in cancer 
cells 
 
 
 
 
GS/CSF therapy 
enhanced 
cytotoxic activity 
(26) 
 
 
 
 
 
(135) 
 
 
 
 
(132) 
 
 
 
 
(118) 
 
 
 
 
 
(13) 
 
 
 
(137) 
 
 
 
 
(24) 
 
 
 
 
(89) 
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Adenocarcinoma TIM 
 
 
 
AMs 
 
 
 
 
Increased IL-6 
and IL-1β 
 
High density 
(microvessel 
counts) 
Short relapse-free 
survival of 
patients 
(132) 
 
 
(22) 
Squamous cell 
lung carcinoma 
AMs  Decreased TNFα, 
IL-1 and mannose 
receptor 
 
 (27) 
Large cell lung 
carcinoma 
AMs  Decreased TNFα, 
IL-1, IL-6 
 (27) 
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1.13. Altered alveolar macrophages function: the role of smoking and lung 
cancer 
Smoking increases the risk of lung cancer. Many studies have looked at the impact of 
smoking on AM functionality (131, 138, 145-148). Some have shown suppressed anti-tumour 
activity of AMs from smokers with lung cancer compared to non-smokers with the same 
disease (91). Using LPS and IFN-γ stimulation, cytotoxicity levels were reduced in AMs 
from current smoking patients with lung cancer, compared to non-smokers and ex-smokers. 
Cigarette smoke contains approximately 4,000 components, 55 of which are described as 
carcinogenic. One of the most important nicotine derivatives is the nitrosamine 4 
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). NNK has been found to down- 
regulate cytokine production by AMs. NNK activation inhibits TNF and IL-12, while 
increasing IL-10 and PGD2 release. These results suggest that NNK favours the 
differentiation of AMs from M1 to M2 phenotype, which is known to induce tumour growth, 
angiogenesis and progression (146).  
The impact of smoking on AM recognition molecules and phagocytic capacity in a 
non-cancer context was investigated in another study which found decreased phagocytic 
ability of AMs in both smokers and ex-smokers with COPD and healthy smokers when 
matched to non-smoking control participants. However, phagocytic ability was greater in 
COPD patients who had stopped smoking when compared to COPD patients who currently 
smoke. It has also been demonstrated that smoking impacts AMs recognition molecules and 
is associated with cyclic adenosine monophosphate (cAMP) increase (147).  
 A recent study showed that cigarette smoke is able to induce AMs polarisation 
towards M2 phenotype in patients with COPD by deactivating M1 macrophage. Researchers 
found that cigarette smoke was able to down-regulate M1-related genes such as CXCL9, 
CXCL10, CXCL11 and CCL5, while up-regulating M2-related genes such as MMP-2 and 
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MMP-7 (149). However, further investigation is required to determine the polarisation status 
of AMs within the tumour microenvironment of patients with lung cancer, the factors that 
favour AMs polarisation and whether alterations in polarisation modulate tumour growth and 
prognosis.        
Down-regulation of IFN-γ signalling has been demonstrated in AMs from smokers. 
IFN-γ is an important cytokine, which can perform several functions important for the 
development of activated macrophages during inflammation. Dhillon et al. (2009) found that 
chronic exposure of the alveolar space to cigarette smoke could result in a loss of IFN-γR α- 
chain expression on AMs, followed by a down regulation of IFN-γ signalling. The function of 
IFN-γ in immune surveillance may thus be deficient in the lungs of smokers and could lead to 
both infection and the development of cancer (148). Many of the studies examining smoking 
and its effect on AMs have utilised different animal models of smoking. Although the 
translation from animal to human studies is still not clear, animal studies are able to provide 
greater focus on the interaction between cigarette smoking and AMs function. One study has 
shown that the release of MMP-12 and TNF-α by AMs was altered in mice exposed to 
cigarette smoke. MMP-12 secretion from mouse AMs was increased after cigarette smoke 
exposure, whereas TNF-α secretion showed an initial time-dependent increase and 
subsequent decrease over ten days (145). Cigarette smoke may thus progressively 
compromise AMs functionality, particularly in terms of TNF-α secretion. However, more 
research is required to investigate the role of cigarette smoking on pro-inflammatory and 
MMP secretion from AMs and its association with lung cancer. 
 Chapter 2: Literature Review 53 
1.14. Alveolar macrophages: roles of reactive nitrogen/oxygen species (ROS 
and NOS) 
AMs release large amounts of toxic molecules such as ROS and NOS (150). Overproduction 
of ROS/NOS has been described as a potential factor leading to cancer through mechanisms 
such as inhibition of apoptosis, DNA damage and P53 mutation (3). The AMs taken from 
tumour-bearing lobes of patients with lung cancer were demonstrated in a study by Sharma et 
al. (1997) to produce significantly higher quantities of oxygen radicals compared with those 
from disease-free lobes (151).  
The AMs are one of the main producers of cytokines and their production may be 
modified in response to alterations in NOS concentration. In studies which have investigated 
the role of NOS in human lung cancer (152-154), increasing NOS levels in BAL fluid were 
associated with squamous cell lung carcinoma compared to control subjects (153). 
Additionally, the generation of NOS was higher in cultured AMs from patients with lung 
cancer in comparison to controls (154). The NOS is able to regulate VEGF expression in 
mouse lung tumours as well as other systems, demonstrating NOS ability to modulate 
angiogenesis in lung tumours in vivo. Kisley et al. (2002) suggested that the absence of iNOS 
or inhibitors of its activity reduced mouse lung cancer development (155). The same results 
have also been achieved in studies of rodent cancer models (156). Most of the studies 
showing a clear role of macrophage-mediated NOS secretion in tumour inhibition have been 
in murine models and its role in human macrophages requires further investigation (157).  
1.14.1. Therapeutic modulation and future directions  
For many years, immunologists have considered that the presence of inflammatory cells such 
as macrophages is a sign of an effective host immune response against tumour growth (158). 
Contrary to this theory, various studies have now demonstrated that the recruitment to and 
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presence of macrophages in the tumour microenvironment can be associated with increased 
tumour growth and metastasis, poor prognosis and decreased patient survival (72, 159). A 
recent study showed that knocking down macrophages with clodronate-encapsulated 
liposomes reduced angiogenesis and tumour growth in mouse and in xenograft models of 
teratocarcinoma and rhabdomyosarcoma (160). These studies suggest that the mechanism 
reducing angiogenesis was mediated by the M2 macrophage subset, which has been shown to 
promote angiogenesis in these tumour models.  
The M1 macrophages are able to kill and inhibit the growth of tumour cells when they 
are activated with LPS and IFN-γ. However, in tumour sites M1 macrophages are present in 
lower numbers and they are likely to polarise towards M2 phenotype under the influence of 
several factors such as IL-10 and the inhibition of NF-кB (96, 161). Recent evidence suggests 
that new therapeutic strategies should be targeting the ‘switch’ from M1 to M2 macrophage 
subsets in the early stages of tumour progression. Also re-adjusting M2 and skewing it to M1 
subsets would be a possible therapeutic strategy to reduce already established tumours (20, 
158). Recent studies have suggested that the use of CpG (C-phosphate-G) and anti-IL-10 
receptor antibodies is able to switch M2 subsets back to M1 subsets with establishment of full 
anti-tumour activity (162). Another study revealed that the inhibition of STAT3 activity, 
which is known to mediate IL-10 function, resulted in restored pro-inflammatory M1 
macrophage function (161). A DNA vaccine targeting legumain, which is a specific stress 
protein overexpressed by M2 macrophages, resulted in a robust immune response that 
decreased the number of legumain-expressing TAMs and increased survival rates in mouse 
models of metastatic breast, colon and non-small lung cancer (163). Interestingly, a recent 
study investigating the role of hypoxia and macrophage subsets showed that hypoxia-
inducible factor 1-alpha (HIF-1 knockout (HIF-1-/-) macrophages were still able to 
infiltrate hypoxic tumour regions and skew towards M2 phenotype with reduced cytotoxicity. 
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However, the HIF-1-/- macrophages were not able to display the same angiogenesis-
promoting properties as wildtype (Wt) macrophages (164). Taken together, reducing or 
preventing M2 phenotype polarisation in tumour microenvironments may be a promising 
therapeutic strategy to reduce the pro-tumour effects of M2 macrophages. 
1.15. Bronchoalveolar lavage (BAL) and flow cytometry  
1.15.1. Bronchoalveolar lavage (BAL) as a research tool 
Fibreoptic bronchoscopy was developed for clinical practice and it is commonly used for 
diagnostic and therapeutic purposes. Ikeda introduced the flexible fibreoptic bronchoscope in 
1968 and from there a major development in this technique was made (165). The scope can 
be done using a flexible or rigid bronchoscope. A flexible scope is almost always used; 
however, in rare cases such as retrieving foreign objects a rigid bronchoscope might be used. 
Flexible bronchoscopy is the more common procedure because less discomfort is experienced 
for the patient compared to rigid bronchoscopy and it can also be performed easily and safely 
under moderate sedation (166, 167). This technique has some limitations that negatively 
impact its usage and outcomes such as the variation in the technical performance and 
application of bronchoscopy in clinical practice. Despite its limitations, bronchoscopy 
remains one of the most common clinical procedures for lung cancer diagnosis (166, 168).  
Fibreoptic bronchoscopy with bronchoalveolar lavage (BAL) using manual hand held 
suction in order to remove non-adherent cells and lung lining fluid from the mucosal surface 
is widely used in the research environment (169). The BAL provides access to lower 
respiratory tract cells (macrophage, B- and T- cells) and their products, so it can be used to 
obtain immune cells and in particular to investigate their condition in a normal or stressful 
environment (166, 168). BAL is performed using 50 ml syringes prefilled with warmed 
normal saline. Gentle hand suction is then performed and the BAL retrieved volume is 
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usually between 100 and 150 ml. The BAL fluid is collected on ice and transferred to 
polypropylene containers in order to minimise macrophage adherence. BAL fluid gained 
from healthy non-smokers should consist of a majority of AMs (80–90%), some lymphocytes 
(5–15%), and very few neutrophils (3%) or eosinophils (1%) (39). Freshly taken BAL fluid 
has a milky or light brown to cloudy appearance. For research purposes, BAL fluid and cells 
are commonly processed for further investigation using different techniques such as flow 
cytometry (39, 170).  
1.15.2. Flow cytometry  
Flow cytometry is a device that illuminates cells (particles) as they flow individually in front 
of a light source and then collects and presents the signals from those particles (171). The 
common term that has been used to describe anything that can be detected by the instrument 
is “event”. Flow cytometry has been widely used in laboratories for both research and 
diagnosis because it has the ability to process and detect various particles, including cells 
(128), cell lines (172), bacteria (173), sperm (174), latex beads (27) and DNA fragments 
(175). It also provides a large and diverse set of information about events as it can illuminate 
individual particles. The cell size, cytoplasmic complexity, DNA or RNA content, and a wide 
range of membrane-bound and intracellular proteins can be measured using flow cytometry 
(171). Flow cytometry is also increasingly being used in clinical applications because of the 
recent development of less-expensive, smaller, more user-friendly instruments (171). Several 
fluorescent dyes have been used to analyse particles by conjugating them to antibodies that 
bind either to the surface and/or intracellular compartments. A fluorescent dye absorbs light 
and then emits light of a different colour usually with longer wavelength. The light emitted 
from each event can be detected and stored for later analysis. Flow cytometry has been used 
to process and analyse BAL fluid samples from many conditions, including lung cancer and 
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other pulmonary disorders, and also to evaluate immune cell function in different diseases 
(27, 128, 149). 
1.16. Summary and Implications 
The role of macrophages in lung cancer appears paradoxical. Whilst macrophages are clearly 
implicated in inhibiting tumour growth with consequent tumour regression, they have also 
been demonstrated to have pro-tumour functions resulting in tumour onset and eventually 
tumour progression and metastasis. Differences between study outcomes may relate to the 
examination of different lung cancer histological subtypes, different tumour stages or 
examination of macrophages from different lung segments (i.e. tumour bearing or non-
tumour bearing lung segments). Patient demographics such as smoking status, and the 
presence or absence of comorbidities such as COPD, may also contribute to differences. A 
number of pro- and/or anti-inflammatory cytokines have been described as possessing dual 
roles in lung cancer including TNF-α, IL-6, IL-8, IL-10, VEGF and PDGF. However, their 
direct effect on the function of macrophages in patients with lung cancer is not completely 
understood. Smoking has also been associated with altered macrophage functionality in lung 
cancer patients. Further studies are encouraged to examine macrophages (AMs, TAMs and 
monocytes) phenotype and function in lung cancer under a range of different conditions 
including diverse histological subtypes to answer the questions about the link between lung 
tumour environment and macrophages phenotype and function. Thus, our study aims to 
assess the complex connection between NSCLC and macrophage phenotype and function. 
Various surface and intracellular markers, cytokines, proteins and genes were utilised in this 
study in order to investigate this issue. Several techniques including flow cytometry, RT-
PCR, quantities proteomics, CBA, Bio-Plex, MAGPIX-Luminex and IHC were also used in 
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this study to elucidate the relationship between lung cancer and macrophages function and 
phenotype.  
1.17. Aims and hypotheses 
Previous studies that examined the role of macrophages in lung cancer have provided 
inconsistent results. Some studies have shown alteration in macrophage phenotype and 
function in the presence of lung cancer while others show no effect. Macrophages (AMs, 
TAMs and monocytes) are part of the lung tumour microenvironment and have been 
suggested to play a major role in promoting and/or suppressing tumour growth and 
metastasis. The relationship between NSCLC and macrophage phenotype and function is 
controversial and still needs further intensive investigation. We hypothesise that macrophages 
in local and systemic environment (AMs, TAMs and monocytes) skew from the M1 to M2-
activated phenotype in NSCLC. We also believe that NSCLC has the ability to alter some 
macrophage functions, Th1 and Th2 cytokine levels in serum and proteins expression in BAL 
fluid.  
Here, we aim to assess this hypothesis by (I) characterising the M1 and M2 
macrophage populations within the AM population using flow cytometry and PCR in patients 
with NSCLC compared to non-cancer controls; (II) evaluating the M1 and M2 monocyte 
populations (macrophage precursors) in patients with NSCLC compared to non-cancer 
controls using flow cytometry. Furthermore, Th1 and Th2 cytokine levels that contribute to 
the differentiation of these populations will be analysed in the serum of patients with NSCLC 
versus non-cancer controls; (III) using quantitative proteomics to investigate the up-
regulation of novel proteins in BAL fluid from patients with primary lung adenocarcinoma to 
potentially identify new potential biomarkers expressed by alveolar macrophages; and (IV) 
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finally characterising the M1 and M2 macrophage populations within TAMs in different 
subtypes of NSCLC compared to non-tumour tissue. 
In other words this study aims to identify if NSCLC has the ability to affect the 
phenotype and function of macrophage populations in the local and systemic environment 
using three different macrophage subtypes (AMs, TAMs and monocytes). It also investigates 
the presence of biomarkers expressed in the BAL fluid that may be associated with NSCLC. 
This study characterises the presence of specific macrophage subset markers from the lungs 
(AMs and TAMs), blood (monocytes) and serum of patients with NSCLC. In particular, we 
will determine their phenotypic similarity with the classically-activated M1 macrophage 
subset and the alternatively-activated M2 macrophage subset by examining the expression of 
specific cell surface and intracellular markers (HLA-DR, iNOS, CD163 and CD36) and 
several other markers e.g. CD71, CD11b, CD11c, CD44, IL-10, MMP-9, IL-6, IL-12, tumour 
necrosis factor (TNF) and interferon gamma (IFN- γ). It also aims to help in the identification 
of new potential biomarkers for NSCLC, which might assist in the development of more 
effective anti-tumour treatments.  
1.18. Significance, Scope and Definitions 
This research focused on macrophages phenotype and function in patients with NSCLC 
compared to non-cancer controls. Some of the surface expression markers, cytokines, 
chemokines, proteins and genes that are known to be associated with macrophage subtypes 
(AMs, TAMs and monocytes) were investigated in this study. A number of techniques were 
used in order to evaluate our hypothesis including flow cytometry, RT-PCR, quantitative 
proteomics, cytometric bead array (CBA), Bio-Plex assay and immunohistochemistry (IHC). 
The outcomes of this research will be beneficial in understanding the impact of NSCLC on 
macrophage phenotype and function.  
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Chapter 2 Materials and Methods 
2.1. Sample collection 
In this thesis different samples were collected and utilised to meet the aims of this research, 
including BAL fluid (AMs, protein and RNA), blood (monocytes, serum) and lung tissue 
(TAMs). BAL fluid and blood samples were collected through the Department of Respiratory 
and Sleep Medicine, Austin Health, Heidelberg, VIC, Australia. Also, tissues and additional 
serum samples were obtained from the Victorian Cancer Bio-Bank, Melbourne, Australia. 
This chapter will describe in detail all the samples, materials and methods that were used in 
this thesis.  
2.2. Materials and methods for monocyte and serum Th1 and Th2 cytokine 
profile study 
2.2.1. Monocyte study participants 
Blood was obtained from patients undergoing diagnostic bronchoscopy for investigation of 
lung cancer or who were undergoing bronchoscopy for investigation of a non-cancer related 
symptom. Complete blood count (CBC) was completed for all blood samples using CELL-
DYN Emerald (Abbott Diagnostics, USA) at the RMIT Hematology Department, Melbourne. 
Patients were recruited through the Department of Respiratory and Sleep Medicine, Austin 
Health, Heidelberg, VIC, Australia. Human Ethics approval was received from HREC Austin 
Health H2007/02814 and RMIT University Human Research Ethics Committee ASEHAPP 
15-13 and the informed consent of all participants was obtained. Staging was applied in this 
study using the new TNM (tumour, node, metastases) staging system (seventh edition) for 
lung cancer (176). 
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2.2.2. Peripheral blood mononuclear cells (PBMC) 
Venous blood was collected in heparinised tubes and PBMC were isolated by Ficoll-Paque 
density gradient centrifugation (GE Healthcare Bio-sciences, Uppsala, Sweden) (177). PBMC 
are a population of immune cells that remain at the less dense (mononuclear cell layer), upper 
interface of the Ficoll layer (Fig. 15). PBMC isolated populations consist of lymphocytes (T 
cells, B cells, and NK cells) (70-80%), monocytes (10-30%), and dendritic cells (1-2%). The 
blood was diluted (1:2) in sterile Phosphate buffered saline (PBS) and then 25 ml of the 
diluted cell suspension was layered over 15 ml of Ficoll-Paque in a 50 ml conical tube. The 
tube was then centrifuged at 400xg for 30 minutes without brake. The mononuclear cell layer 
(white blood cell ring fraction) was transferred into a new 50 ml tube using sterile Pasteur’s 
pipette. The volume was then adjusted to 30 ml using sterile PBS and centrifuged at 300xg 
for 10 minutes. For removal of platelets, the cell pellet was resuspended in 30 ml of sterile 
PBS and centrifuged at 200xg for 10-15 minutes and the supernatant carefully removed 
completely. The pellet was resuspended in 10 ml PBS to be counted and freshly used or 
frozen down at -80°C in 90% fetal bovine serum (FBS) and 10% dimethyl sulfoxide 
(DMSO).  
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Figure 15: Ficoll-Paque density gradient centrifugation. Ficoll-Paque was used to isolate 
PBMC (mononuclear cell) from NSCLC patients and non-cancer controls. PBMC are the 
populations of immune cells (lymphocytes, monocyte and dendritic cells) that remain at the 
less dense, upper interface of the Ficoll layer.  
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2.2.3. Monocyte phenotype analysis by flow cytometry 
Flow cytometry was used to assess monocyte expression of CD14, CD45 CD71, CD11b, 
CD44, CD16 and CD11c (BD Pharmingen 
TM
, USA) as well as the M1 marker HLA-DR (BD 
Pharmingen 
TM
, USA) and the M2 markers CD163 and CD36 (BD Pharmingen 
TM
, USA) 
(Table 2).  
The cells were fixed with 2% paraformaldehyde (PFA)/PBS at room temperature for 
20 minutes. The cells were then centrifuged for 5 minutes at 604xg, washed in 0.5% (w/v) 
saponin/PBS and incubated at room temperature for another 15 minutes. The cells were 
stained with antibodies directly conjugated to fluorescent probes. All antibodies were diluted 
in 0.5% Bovine serum albumin (BSA)/PBS (w/v) based on cell numbers at the 
manufacturer’s recommended concentrations and added to cells for 40 minutes in the dark on 
ice. After incubation, the cells were washed with PBS and then centrifuged for 5 minutes at 
268xg. The pellet was then resuspended in FACS Fix buffer (1% BSA, 0.1% (w/v) sodium 
azide and 2% (w/v) paraformaldehyde (PFA) in 500l of PBS) and analysed using flow 
cytometry (BD FACS Canto BD Biosciences, San Jose, CA, USA). Approximately 10
6
 cells 
were stained with various combinations of antibodies. Purity of monocytes was assessed 
according to CD14
++
, CD45
+
 and CD16
-
 expression by flow cytometry. At least 5,000 cells 
were collected and analysed (BD FACS Canto BD Biosciences, San Jose, CA, USA). All 
analysis was completed using the BD FACSDiva
TM 
analysis software (BD Biosciences, USA) 
within the RMIT Flow Cytometry Facility, Bundoora, Melbourne. All quadrants were set up 
according to matched isotype control antibodies and all results are shown as % surface 
expression (%SE) and/or mean fluorescence intensity (MFI).  
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2.2.4. Cytometric bead array (CBA) 
The serum samples for the CBA assay were fractionated by leaving blood undisturbed for 15-
30 minutes at room temperature. The clot was then removed by centrifuging at 2,000xg for 10 
minutes. The blood samples were obtained from patients undergoing diagnostic 
bronchoscopy for investigation of lung cancer or who were undergoing bronchoscopy for 
investigation of a non-cancer related symptom. Patients were recruited through the 
Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, VIC, Australia. 
The Human Th1/Th2 11plex Ready-to-Use FlowCytomix Multiplex (eBiosciences, USA) 
was employed to detect the level (pg/ml) of Th1/ Th2 cytokines including IL-1β, IL-2, IL-4, 
IL-5, IL-8, IL-10, IL-12 (p70), TNF-α, tumour necrosis factor beta (TNF-β), and IFN-γ in 
serum samples of patients with primary lung cancer and non-cancer controls, according to the 
manufacturer’s instructions (Human Th1/Th2 11plex RTU FlowCytomix Kit). Fluorescence 
was analysed using flow cytometry (FACS Canto, BD Biosciences, San Jose, CA, USA) and 
cytokine levels were determined using the BMS FlowCytomix Software within the RMIT 
Flow Cytometry Facility, Bundoora, Melbourne. 
2.2.5. Cytokine and Chemokine Measurement by Bio-Plex multiplex system 
Different groups of ready to use serum samples were purchased from the Victorian Cancer 
Bio-Bank (Victoria, Australia) to analyse the Th1 and Th2 cytokines profile using the Bio-
Plex, MAGPIX-Luminex assay. The Bio-Plex assay kit from Bio-Rad was applied to detect 
the Th1/ Th2 cytokines including IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12 (p70), IP-10, TNF-α, 
MCP-1 and VEGF in serum samples of patients with NSCLC (adenocarcinoma, squamous 
cell lung carcinoma and large cell lung carcinoma) and non-cancer controls. The method was 
performed by the same operator according to manufacturers’ instructions. The kit supplied 
standards that were reconstituted and diluted at 7 serial concentrations following 
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manufacturer’s instructions (standard curves). Standards included all recombinant cytokines 
tested and were considered as positive controls for the procedure. Bead fluorescence readings 
were analysed using the Bio-Plex MAGPIX multiplex reader (Bio-Rad, USA) and cytokine 
levels were determined using the Bio-Plex Manager Software (Bio-Rad, USA) within RMIT 
University, Bundoora, Melbourne. 
2.2.6. Statistical analysis of monocyte and cytokine profiles studies  
Experiments were performed in triplicate. The results are shown as mean values ± standard 
error (SEM) as error bars. The statistical analysis was performed using GraphPad Prism-6. 
One-way ANOVA multiple comparison test (as a post-test analysis) was performed with the 
Tukey test (multiple comparison test comparing every group with every other group).  
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Table 2: Markers used to characterise the phenotype and function of monocytes in 
patients with NSCLC compared to non-cancer controls 
Cell types Markers Company References 
Monocyte / myeloid / 
macrophage markers 
 
CD14 
BD Pharmingen 
TM
, 
USA 
(76, 178) 
 
CD11b 
BD Pharmingen 
TM
, 
USA 
(179) 
CD44 
BD Pharmingen 
TM
, 
USA 
(180) 
CD16 
BD Pharmingen 
TM
, 
USA 
(178, 181) 
CD11c 
BD Pharmingen 
TM
, 
USA 
(182) 
CD71 
BD Pharmingen 
TM
, 
USA 
(183) 
M1 HLA-DR 
BD Pharmingen 
TM
, 
USA 
(76, 179) 
M2 
CD163 
BD Pharmingen 
TM
, 
USA 
(184) 
CD36 
BD Pharmingen 
TM
, 
USA 
(184) 
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2.3. Materials and methods for alveolar macrophages and proteomics 
studies  
2.3.1. BAL fluid participants 
BAL fluid samples were obtained from patients undergoing diagnostic bronchoscopy for 
investigation of lung cancer through the Department of Respiratory and Sleep Medicine, 
Austin Health, Heidelberg, VIC, Australia. Human Ethics approval was received from HREC 
Austin Health H2007/02814 and RMIT University Human Research Ethics Committee 
ASEHAPP 15-13 and the informed consent of all participants was obtained. Staging was 
applied in this study using the new TNM (tumour, node, metastases) staging system (seventh 
edition) for lung cancer (176). 
2.3.2. BAL fluid processing 
BAL fluid was sampled at the time of diagnostic fibreoptic bronchoscopy using instilled 
aliquots of normal saline pre-warmed to 37°C. In the case of patients with lung cancer, the 
samples were taken from an adjacent uninvolved lobe. In the case of non-cancer controls, the 
sample was from the right middle lobe or lingula lobe. The BAL fluid samples were collected 
in sterile centrifuge tubes, immediately placed on ice and stored at 4°C until collection (185). 
The BAL fluid samples were stained using a Rapid Diff Kit (Australian Biostain) in order to 
differentiate WBC counts. Differential cell counts were ascertained by light microscopy. 
Cells were collected by centrifuging the BAL fluid at 500xg for 6 minutes at 4°C. The cells 
were then washed twice in 0.1% BSA/PBS (w/v) at 4°C. The cell suspension containing 
trypan blue 0.2% (w/v) (Sigma, USA) was counted using haemocytometer. After counting, 
cells were either analysed immediately or frozen and stored in liquid nitrogen for future 
analysis. For storage, AMs pellet was resuspended in RPMI-1640 medium (Greiner, Bio-one, 
USA) containing 10% fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO) at a 
 Chapter 3: Materials and Methods 69 
concentration of 1-5 x 10
6 
cells/ml.   
2.3.3. Differentiation of AMs phenotype using flow cytometry  
Cell staining was carried out using antibodies directly conjugated to fluorescent probes. Flow 
cytometry was used to assess AMs expression of CD68 (macrophage marker) (Dako, 
Denmark), CD11b (macrophage-1 antigen), CD71 (transferrin receptor protein 1) and CD44 
(cell-surface glycoprotein involved in cell–cell interactions, cell adhesion and migration) (BD 
Pharmingen 
TM
, USA). The M1 conjugated marker HLA-DR (Human leukocyte antigen-D 
related) (BD Pharmingen
TM
, USA) and the M2 conjugated marker CD163 (BD 
Pharmingen
TM
, USA) were also investigated (Table 3). Crystal violet was used to overcome 
auto-fluorescence, and unstained and isotype controls were used to determine the quadrant 
positions. To overcome spectral overlapping between FITC (fluorescein isothiocyanate) and 
PE (phycoerythrin) fluorochrome emission spectra, compensation values were calculated and 
adjusted based on AMs FITC and PE fluorochromes. Each staining condition contained 10
6
 
cells/100μl.  
2.3.3.1. Surface staining  
AMs were washed with PBS and then centrifuged for 5 minutes at 268xg. All antibodies were 
diluted in 0.5% BSA/PBS (w/v) based on cell numbers at the manufacturer’s recommended 
concentrations and added to cells for 40 minutes in the dark on ice. After incubation, cells 
were washed twice with cold PBS and then resuspended with 0.4% crystal violet in order to 
minimise AM autofluorescence. AMs were then centrifuged and resuspended in FACS Fix 
buffer (1% BSA, 0.1% (w/v) sodium azide and 2% (w/v) paraformaldehyde (PFA) in 500l 
of PBS) and analysed using flow cytometry (BD FACS Canto BD Biosciences, San Jose, CA, 
USA).  
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2.3.3.2. Intracellular staining  
AMs were fixed with 2% paraformaldehyde (PFA) /PBS at room temperature for 20 minutes. 
Cells were then centrifuged for 5 minutes at 604xg, washed in 0.5% (w/v) saponin/PBS and 
incubated at room temperature for another 15 minutes. After incubation, AMs were 
centrifuged again for 5 minutes at 604xg and antibody staining was performed as outlined 
above for surface staining.  
The cells were analysed based on CD68
+
 expression and then further analysed for 
expression of defined M1 and M2 markers. At least 5,000 CD68
+
 cells were analysed for 
each experimental condition. All experiments were performed in triplicate and quadrants 
were set up according to matched isotype control antibodies and all results are shown as 
percentage surface expression (%SE). Gates, dot plots, compensations and mean values were 
calculated and analysed using the BD FACSDiva
TM 
analysis software (BD Biosciences, 
USA).  
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Table 3: Markers used to characterise the phenotype and function of alveolar 
macrophages (AMs) in patients with NSCLC compared to non-cancer controls  
Cell types Markers Company References 
 CD68 Dako, Denmark (27) 
Macrophage/ myeloid 
markers 
CD11b 
BD Pharmingen 
TM
, 
USA 
(179) 
CD44 
BD Pharmingen 
TM
, 
USA 
(180) 
CD71 
BD Pharmingen 
TM
, 
USA 
(183) 
M1 HLA-DR 
BD Pharmingen 
TM
, 
USA 
(76, 179) 
M2 CD163 
BD Pharmingen 
TM
, 
USA 
(184) 
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2.3.4. RNA sample isolation 
The RNA samples were isolated using a PARIS kit (Protein and RNA Isolation System) 
(Ambion, Life Technologies Australia, Mulgrave, VIC, Australia). The AMs were washed 
twice with PBS and cell disruption buffer added (at least 300μl) for ≥106 cells. The lysate was 
then incubated on ice for 5-10 minutes to ensure complete cell disruption before continuing 
processing. Once the lysate was homogenised, the sample was immediately mixed with an 
equal volume of 2X lysis/binding solution at room temperature. Absolute ethanol (150μl) was 
added to the mixture containing the sample, disruption buffer and 2X lysis/ binding solution. 
The sample mixture was then applied to a filter cartridge assembled in a collection tube. The 
mixture was centrifuged at 604xg for 0.5-1 minute or until the lysate/ethanol mixture was 
passed through the filter. The wash solution I was applied to the filter cartridge and 
centrifuged at 604xg for 15-60 seconds. Wash solution 2/3 was then applied twice to the filter 
cartridge and drawn through the filter at 604xg for 1 minute. After discarding the wash 
solutions, the filter was centrifuged for 10-30 seconds at 9660xg to remove the last traces of 
wash solutions. The filter cartridge was then transferred into a new collection tube and 200μl 
preheated elution solution (95-100°C) applied to the filter. This eluate containing the RNA 
was then recovered by centrifugation for 30 seconds at 4293xg. The RNA quantity was 
measured using UV spectrophotometer (Cintras GBC scientific instrument, Australia). RNA 
samples were then stored at -80°C and kept on ice when in use.  
2.3.5. Real-Time quantitative PCR Analysis  
Primers were designed for the following genes (IL-6, IL-12, IL-10 and MMP9). The 
quantitative PCR was performed using (Bio-Rad, MyiQ
TM 
single color, Real-Time PCR 
detection system, USA). All the primers were designed using primer design software 
(Invitrogen, Life Technologies, USA) and were then purchased from Invitrogen (Invitrogen, 
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Life Technologies Australia, Mulgrave, VIC, Australia) (Table 4). A post-run melting curve 
program was employed in each assay to confirm the presence of a single, specific amplicon 
of the predicted size (amplicon is a segment of DNA that is amplified using PCR). The 
standard curve method was used to determine the relative concentration of each gene of 
interest with the average of triplicate amplifications normalised to a housekeeping gene, 60S 
ribosomal protein L32 (RPL32) [accession number NM_000994]. All samples were run in 
triplicate and the mean values were calculated. The relative expression of target genes was 
calculated in relation to the mean values of target gene expression in the control group using 
the delta Ct method. 
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Table 4: The list of primers that were designed and performed using Bio-Rad, Real-
Time PCR detection system 
Genes Primer sequence 
Human RPL32 F: GGC AGC CAT CTC CTT CTC GGC 
R: TGC CTC TGG GTT TCC GCC AGT 
Human IL-6 F: GGA ACG CTC CTC TGC ATT GCC A 
R: ACA AGC ACT GGG GTG GGT CG 
Human IL-12 F: GGC CTG AAC CAG ACG TGG CA 
R: GCC CGG GCT GGC CAA TAC AT 
Human IL-10 F: GGA GGA GGT GAT GCC CCA AGC 
R: CGA TGA CAG CGC CGT AGC CTC 
Human MMP-9 F: ACC GCC AAC TAC GAC CGG GA 
R: GAA GAC GCA CAG CTC CCC CG 
F: forward primer sequence; R: reverse primer sequence  
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2.3.6. Statistical analysis of AM study results  
Experiments were performed in triplicate. The results are shown as mean values ± standard 
error (SEM) as error bars. The statistical analysis was performed using GraphPad Prism-6.  
One-way ANOVA multiple comparison test (as a post-test analysis) was performed with the 
Tukey test (multiple comparison test comparing every group with every other group).   
2.3.7. Protein sample isolation 
The protein samples were isolated using the PARIS kit (Protein and RNA Isolation System) 
(Ambion, Life Technologies Australia, Mulgrave, VIC, Australia). The AMs pellet was 
washed twice with PBS and cell disruption buffer added (at least 300μl) for ≥106 cells. The 
lysate was incubated on ice for 5-10 minutes to ensure complete cell disruption before 
continuing processing of the sample. Protein samples were then stored at -80°C and kept on 
ice when in use.  
2.3.8. Protein sample preparation  
The protein samples (150μl) were mixed and washed twice with 750μl of ice cold acetone 
(Merck Millipore, Darmstadt, Germany) and then incubated overnight at -20°C. They were 
then centrifuged at 13,148xg for 10 minutes at 4°C and the supernatant discarded. The pellets 
were carefully layered with ice cold acetone (750μl) and then centrifuged at 17,968xg for 10 
minutes at 4°C and the supernatant discarded. The resultant pellets were dissolved in 100µl of 
8 M urea (Merck Millipore, Darmstadt, Germany) and 50 mM TEAB (triethyl ammonium 
bicarbonate) (Sigma-Aldrich, St. Louis, MO, USA) with alternate sonication and vortexing. 
Protein concentration estimation was carried out using the micro BCA assay kit (Thermo 
Scientific, Rockford, IL, USA) and then micro-plate reader at 562nm (Biochrom ASYS 
UVM 340 micro-plate reader, UK). The concentration was adjusted to 100µg/100µL using 8 
M urea, 50 mM TEAB buffer. Reduction was carried out using TCEP (Tris2-carboxyethyl 
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phosphine) (Thermo Scientific, Rockford, IL, USA) to a final concentration of 10 mM and 
incubated at 37°C for 30 minutes. Alkylation was carried out with iodoacetamide (Sigma-
Aldrich, St. Louis, MO, USA) to a final concentration of 55 mM and incubated for 45 
minutes in the dark. The urea was diluted to a 1 M final concentration using 25 mM TEAB, 
prior to digestion. Digestion was then carried out using sequencing grade modified trypsin 
(Promega, Madison, WI, USA) based on a ratio of 1:40 (1μg trypsin: 40μg protein) overnight 
at 37°C.  
The peptide mixture samples were collected after overnight incubation and acidified 
using formic acid to a final concentration of 1% (v/v). Solid phase extraction clean-up of 
samples (to remove any traces of primary amine-containing molecules that could react with 
formaldehyde) was carried out using Oasis HLB cartridges based on the manufacturer’s 
instruction (Waters, Milford, MA, USA). The eluted samples were partially dried using 
CentriVap Centrifugal Vacuum Concentrators (Labconco, Kansas City, MO, USA) for 20 
minutes followed by overnight freeze drying (Virtis Benchtop SLC Freeze Dryer, SP 
Scientific, Warminster, PA, USA). 
2.3.9. 2-plex dimethylation labelling  
Dimethyl labelling was carried out as described previously (186). Peptide samples were first 
resuspended in 400μl of 100 mM TEAB. To 100 µl of the buffer, 4μl of 4% (v/v) CH2O and 
CD2O were added to the samples to be labelled with light and heavy dimethyl, respectively. 
This was followed by the addition of 4μl of 0.6 M NaBH3CN to both the light and 
intermediate label. The samples were incubated in a fume hood for one hour at room 
temperature (15-22°C) while mixing using a bench top test tube mixer. The labelling reaction 
was quenched by adding 16μl of 1% (v/v) ammonia solution then the samples were briefly 
mixed and centrifuged in a fume hood. For further reaction quenching, 8μl of formic acid was 
added to the samples on ice to acidify the samples. The differentially labelled samples were 
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then mixed at a 1:1 ratio and analysed using liquid chromatography–mass spectrometry (LC-
MS/MS).  
2.3.10. LC-MS/MS and data analysis 
The dimethyl-labelled samples were analysed on a LTQ Orbitrap Elite (Thermo Scientific, 
Rockford, IL, USA) instrument coupled to an Ultimate 3000 RSLC nanosystem (Dionex) 
(Thermo Scientific, Rockford, IL, USA). A nanoLC system was equipped with an Acclaim 
Pepmap nano-trap column (Dionex – C18, 100 Å, 75 µm×2 cm) and an Acclaim Pepmap 
analytical column (Dionex C18, 2µm, 100 Å, 75 µm×15 cm) running in 3-80% CH3CN 
containing 0.1% formic acid gradient over 25 minutes. The LTQ Orbitrap Elite mass 
spectrometer was operated in the data-dependent mode, whereby spectra were acquired first 
in positive mode at 240,000 resolution followed by high energy collisional dissociation at 
15,000 resolution. Ten of the most intense peptide ions with charge states ≥2 were isolated 
and fragmented using normalised collision energy of 35 and activation time of 0.1 ms (high 
energy collisional dissociation).  
The Orbitrap MS data were analysed using Proteome Discoverer (Thermo Scientific 
version 1.4, Rockford, IL, USA) with the Mascot search engine (Matrix Science version 2.4, 
Boston, MA, USA) against the Uniprot database maintained at the Bio21 Institute, University 
of Melbourne, Australia (currently containing 26,617,536 sequences). Search parameters 
were precursor mass tolerance of 10 ppm and fragment mass tolerance of 0.2 Da. 
Carbamidomethyl of cysteine was set as fixed modification and dimethyl labelling (light and 
medium at +28.0313 and +32.0564, respectively) at the peptide N-terminus and lysine set as 
variable modifications. Trypsin with a maximum of 0 missed cleavage was used as the 
cleavage enzyme. A false discovery rate threshold of 1% was applied and identification of 
two or more unique peptides and two or more peptides were required for positive 
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identification and quantification, respectively. A two-fold differential expression was chosen 
as being significant.   
2.4. Materials and methods for tumour-associated macrophage (TAM) 
study 
2.4.1. Lung specimen collection and sectioning 
All tissue samples were purchased from Victorian Cancer Bio-Bank (Victoria, Australia). All 
lung specimens were fixed with 4% formaldehyde, followed by dehydration through graded 
alcohols, paraffin embedding and preparation of 4-μm sections. For H&E staining, sections 
were rehydrated, stained with haematoxylin for 2 minutes and rinsed in running tap water for 
2 minutes. The sections were then blued in Scott’s tap water for 1 minute, rinsed with tap 
water for 2 minutes, stained with eosin for 2 minutes, dehydrated in alcohols cleared in 
xylene and coverslipped using DePeX mounting media. 
2.4.2. Immunohistochemical staining 
Lung sections were heated at 60
o
C for 1 hour, hydrated and rinsed in tap water for 2 minutes. 
The sections were then boiled in 10 mM citrate buffer, pH=6 for 10 minutes for antigen 
retrieval followed by cooling at room temperature for 20 minutes. The sections were then 
incubated with peroxidase incubator 0.3% H2O2 for 15 minutes at room temperature and then 
protein blocker (2% goat serum, 1% BSA, 0.1% cold fish gelatin, 0.1% Triton X-100, 0.05% 
Tween 20 and 0.05% sodium azide) to block nonspecific staining for 30 minutes at room 
temperature. Primary antibodies to CD68 (monoclonoal mouse anti-human CD68 Clone KP1, 
ready-to-use) (Dako, Carpinteria, CA, USA), NCL-CD163 (1:100; Novocastra
TM
 liquid 
mouse monoclonal antibody CD163 clone 10D6) (Leica Biosystems, UK) and iNOS 
(inducible nitric oxide synthase) (1:200; rabbit polyclonal anti-human iNOS, Abcam, UK) 
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were incubated for 1 hour at room temperature and then washed three times using washing 
buffer for 5 minutes. The CD68 sections were incubated with EnVision™+ FLEX+ mouse 
linker for 15 minutes and then washed three times using washing buffer for 5 minutes. All 
sections were then incubated with secondary antibody Dako EnVision™+ Dual Link system-
HRP) (Dako, Glostrup, Denmark). The sections were incubated at room temperature for 30 
minutes and washed with washing buffer three times for 5 minutes. The sections were then 
incubated with DAB solution (Dako, Glostrup, Denmark) for 1-3 minutes and washed in the 
washing buffer three times for 5 minutes. The sections counterstained with haematoxylin 
while being observed under a microscope, dehydrated, cleared and coverslipped using DePeX 
mounting media.  
2.4.3. Quantitative analysis of immunohistochemical staining 
All slides were scanned at an absolute magnification of 20x using the Aperio Scanscope XT 
pathology digital imaging systems at Austin Health, Heidelberg, VIC, Australia (Aperio 
Technologies, USA). The background illumination levels were calibrated using a prescan 
procedure. The acquired digital images representing whole tissue sections were evaluated for 
image quality. All acquired images were labeled, placed in dedicated project folders, and 
stored in a designated external hard drive. The slides were viewed and analysed using 
ImageScope analysis software (version 12; Aperio Technologies, USA). The colocalisation 
algorithm (version 11; Aperio Technologies, USA) were applied to quantify IHC staining. 
The algorithm calculated the percentage area of positive staining based on the deconvolution 
method to separate the stains and classify each pixel according to the number of stains 
present. The threshold for each stain was specified and the algorithm reports the percentage 
of area for which each stain combination is detected: 1, 2, 3, 1+2, 1+3, 2+3, 1+2+3 or none.  
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2.4.4. Statistical analysis of TAM study  
The results are shown as % of positive area ± standard error (SEM) as error bars. The 
statistical analysis was performed using GraphPad Prism-6. One-way ANOVA multiple 
comparison test (as a post-test analysis) was performed with the Tukey test (multiple 
comparison test comparing every group with every other group). 
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Chapter 3 Blood Monocyte Phenotype and Th1/Th2 Cytokine 
Profiles in NSCLC  
3.1. Introduction    
Monocytes are a type of white blood cell (leukocyte). They can be classified into classical 
monocyte (pro-inflammatory), intermediate monocyte and non-classical monocyte (anti-
inflammatory) phenotypes, all of which have been detected in circulating PBMC (79, 80).  
Monocytes are a macrophage precursor and are known to differentiate into macrophages after 
entering the tissue spaces. Classical monocytes (CD14
++
/CD16
-
) have been shown to 
differentiate into M1 macrophages, while non-classical monocytes (CD14
+
/CD16
++
) 
differentiate into M2 macrophages (81). 
Classical monocytes are used in this study as they are the main source of tissue 
macrophages and the majority of the macrophages within the tumour area have been 
identified as M2 macrophages (81). However, a recent study has reported that classical 
monocytes can differentiate into M2 macrophages (83). There is controversy regarding 
monocyte differentiation and their effect in the tumour microenvironment. Therefore, further 
understanding of the immunology of lung cancer may enable the development of immune-
modulatory strategies beyond those in current use, such as monoclonal antibodies targeted to 
specific cellular receptors. 
In this study, two different techniques (CBA and Bio-Plex, MAGPIX-Luminex) were 
used to study the Th1 and Th2 cytokine level in the serum of patients with NSCLC compared 
to non-cancer controls. Both techniques provide quantitative measurement of large numbers 
of analytes using an automated 96-well plate format. However, recent studies have 
questioned the sensitivity and reproducibility of the CBA assay and suggest the Luminex-
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based kit with magnetic beads to be a better technique (187-189). Therefore, the Bio-Plex, 
MAGPIX-Luminex was used here to analyse Th1 and Th2 cytokine levels. Also the serum 
samples for Bio-Plex assay were obtained from the Victorian Cancer Bio-Bank to include all 
NSCLC subtypes.  
Here, fresh un-stimulated classical monocytes were used to ascertain the phenotype 
and function changes in patients with NSCLC compared to non-cancer controls. Also, 
Th1/Th2 cytokine profiles were assessed to determine the possible impact of NSCLC 
compared to non-cancer controls. This part of the study is trying to give a better 
understanding of the effect of NSCLC on the macrophage precursor (monocytes) phenotype 
and function outside the lung (systemically) compared to non-cancer controls, as well as to 
identify if the presence of NSCLC would alter the cytokine profiles (Th1 and Th2) in serum 
samples compared to non-cancer controls. 
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3.2. Results 
The demographic details of all NSCLC and non-cancer control subjects are shown in Table 5. 
Blood samples were collected at Austin Health (Heidelberg, VIC, Australia) to gain PBMC 
(flow cytometry) and serum samples (used in CBA assay).  
Complete blood count (CBC) was investigated in all patients to verify if the patients 
had significant underlying medical conditions e.g. infection, which could result in monocyte 
phenotype alteration. The total mean number of WBC (white blood cells) in NSCLC patients 
was significantly higher than in non-cancer controls. The mean values of all WBC types 
(except basophil cells) and RBCs were tended to be higher in patients with NSCLC compared 
to non-cancer controls. However, there were no significant differences in the mean values of 
all WBC types and RBCs in NSCLC compared to non-cancer controls. Also the mean values 
of all WBC types and RBCs were within the normal range in both groups (Table 6).  
In flow cytometry results, there were no statistically significant differences in M1 
marker (HLA-DR), M2 markers (CD163 and CD36) or CD11c and CD44 in patients with 
NSCLC (undifferentiated NSCLC, adenocarcinoma and squamous cell lung carcinoma) 
compared to non-cancer controls. Both %SE (% surface expression) and MFI (mean 
fluorescence intensity) expression of surface markers showed similar values. The expression 
of CD11b and CD71 was also shown to be similar between patient groups (undifferentiated 
NSCLC, adenocarcinoma and squamous cell lung carcinoma) and non-cancer controls.  
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Table 5: Demographic details of NSCLC and non-cancer control subjects 
 n 
Age (years) 
Mean ± SD 
Gender 
Smoking 
status 
Stages Subtypes 
   M/F N/Ex/S I/II/III/IV N/A/S 
Control 20 60.45 ± 19.31 10/10 7/11/2   
Cancer 30 67.1 ± 10.68 17/13 3/16/11 8/3/7/12 9/11/10 
n: number; SD: standard deviation; M: male; F: female; N: non-smoker; Ex: ex-smoker; S: 
smoker; N: undifferentiated NSCLC; A: adenocarcinoma; S: squamous cell lung carcinoma. 
Demographic details of the participants and staging details of lung cancer patients. This Table 
shows the total number of patient samples, age, gender, smoking status and lung tumour 
subtypes and stages. Full samples detail (e.g. GOLD stages) are displayed in Appendix A - 
Tables 16 and 17. 
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Table 6: Complete blood count (CBC) details of NSCLC and non-cancer control patients 
Groups 
Total 
number 
 
WBC 
 
 
NE 
 
 
LY 
 
 
MO 
 
 
EO 
 
BA RBC 
Normal 
Value 
(x10
9
/L) 
 4 - 11 2 - 7.5 1.5 - 4 0.2 - 0.80 0.04 - 0.40 0.02 - 0.10 3.80 - 6.50 
Control 20 4.35 ± 1.82 2.11 ± 1.07 1.31 ± 0.47 0.23 ± 0.14 0.13 ± 0.06 0.38 ± 0.50 4.85 ± 0.91 
Cancer 30 6.76 ± 3.90 3.4095 ± 3.46 1.68 ± 1.31 0.34 ± 0.22 0.20 ± 0.17 0.29 ± 0.20 5.04 ± 1.08 
CBC analysis was performed on whole blood collected from patients with primary NSCLC and non-cancer controls using Beckman Coulter 
(AcT 5 blood differentiation) (Fullerton, CA, USA). WBC: white blood cell; NE: neutrophil; LY: lymphocyte; MO: monocyte; EO: 
eosinophil; BA: basophil; RBC: red blood cell.   
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3.2.1. No difference in HLA-DR, CD163 and CD36 expression in patients with NSCLC 
compared to non-cancer controls 
The impact of NSCLC on the classical monocytes expression of HLA-DR (M1 phenotypes), 
CD163 and CD36 (M2 phenotypes) was investigated in patients with NSCLC compared to 
non-cancer controls using flow cytometry. Classical monocytes were gated based on forward 
scatter (FSC) and side scatter (SSC) profiles within patient groups and based on the 
expression of CD14, CD45 and CD16 markers. Results show that there were no significant 
differences in %SE (P=0.155) and MFI (P=0.1048) of HLA-DR (M1 marker) expression in 
patients with NSCLC (undifferentiated NSCLC, adenocarcinoma and squamous cell lung 
carcinoma) compared to non-cancer controls (Figs. 16 and 17). In addition, flow cytometry 
analysis showed there were no significant differences in the %SE (P=0.505) and MFI 
(P=0.4582) of CD163 (M2 marker) in NSCLC patients (undifferentiated NSCLC, 
adenocarcinoma and squamous cell lung carcinoma) compared to non-cancer controls. We 
also showed that there were no significant differences in the %SE (P=0.160) and MFI 
(P=0.4018) of CD36 (M2 marker) staining between the NSCLC patient group and non-cancer 
controls (Figs. 16 and 17). The expression of HLA-DR, CD163 and CD36 were also 
examined between early and advanced lung cancer criteria and results showed no difference 
in patients with more advanced stages compared to early lung cancer.  
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Figure 16: HLA-DR, CD163 and CD36 surface expression on (CD14
++
/CD16
-
) blood 
monocytes in patients with primary NSCLC compared to non-cancer controls. (A-F) 
Representative flow cytometry dot plots from PBMC stained against CD14 and then co-
stained with HLA-DR, CD163 and CD36 on patients with NSCLC (red colour) and non-
cancer controls (green colour). All data was collected on a BD FACS Canto (BD Biosciences, 
San Jose, CA, USA) within the RMIT Flow Cytometry Facility (Bundoora, Melbourne).  
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Figure 17: HLA-DR, CD163 and CD36 expression on (CD14
++
/CD16
-
) blood monocytes in 
patients with NSCLC compared to non-cancer controls. Summary graphs show the mean 
values of MFI ± SEM of (A) HLA-DR, (B) CD163 and (C) CD36 markers from patients with 
NSCLC (n=9 undifferentiated NSCLC, 11 adenocarcinoma and 10 squamous cell lung 
carcinoma) versus non-cancer controls (n=20). One-way ANOVA multiple comparison test 
(as a post-test analysis) was performed.  
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3.2.2. No difference in CD11b, CD71, CD11c and CD44 expression 
The potential impact of NSCLC on the classical monocytes expression of CD11b, CD71 and 
CD44 was investigated in patients with NSCLC compared to non-cancer controls using flow 
cytometry. The %SE and MFI of CD11b, CD71, CD11c and CD44 were similar between 
patient groups (undifferentiated NSCLC, adenocarcinoma and squamous cell lung carcinoma) 
and non-cancer controls (Figs. 18, 19 and 20). The %SE and MFI of the myeloid marker 
CD11b was not different between cancer and non-cancer control subjects: %SE (P=0.58), 
MFI (P=0.5396). Also, CD71 results indicated that there were no significant differences in 
the %SE (P=0.97) and MFI (P=0.0558) of the transferrin receptor marker in patients with 
NSCLC compared to non-cancer controls. There was no significant difference in the %SE 
(P=0.93) or MFI (P=0.4313) of the CD11c in patients with NSCLC compared to non-cancer 
controls. In addition, CD44 results revealed that there were no significant differences in the 
%SE (P=0.50) or MFI (P=0.7495) of the CD44 marker in NSCLC patients compared to non-
cancer controls.  
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Figure 18: CD11b and CD11c surface expression in PBMC by flow cytometry. (A-D) 
Representative flow cytometry dot plots example from PBMC stained against CD14 and then 
co-stained with CD11b and CD11c on patients with NSCLC (red colour) and non-cancer 
controls (green colour). All data was collected on a BD FACS Canto (BD Biosciences, San 
Jose, CA, USA)within the RMIT Flow Cytometry Facility (Bundoora, Melbourne). 
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Figure 19: CD71 and CD44 surface expression in PBMC by flow cytometry. (A-D) 
Representative flow cytometry dot plots example from PBMC stained against CD14 and then 
co-stained with CD71 and CD44 on patients with NSCLC (red colour) and non-cancer 
controls (green colour). All data was collected on a BD FACS Canto (BD Biosciences, San 
Jose, CA, USA)within the RMIT Flow Cytometry Facility (Bundoora, Melbourne). 
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Figure 20: CD11b, CD11c, CD71 and CD44 expression on (CD14
++
/CD16
-
) blood 
monocytes in patients with NSCLC compared to non-cancer controls. Summary graphs show 
the mean values of MFI ± SEM of (A) CD11b, (B) CD11c, (D) CD71 and (D) CD44 markers 
from patients with NSCLC (n=9 undifferentiated NSCLC, 11 adenocarcinoma and 10 
squamous cell lung carcinoma) versus non-cancer controls (n=20). One-way ANOVA 
multiple comparison test (as a post-test analysis) was performed.  
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3.2.3. No significant difference in Th1/Th2 cytokines serum levels in patients with NSCLC 
compared to non-cancer controls using CBA assay  
The possible influence of NSCLC on the Th1/Th2 cytokines serum levels was investigated in 
patients with NSCLC compared to non-cancer controls using cytometric bead array (CBA) 
analysis. Cytokine analysis revealed no significant difference in Th1/Th2 cytokine serum 
levels in patients with NSCLC (undifferentiated NSCLC, adenocarcinoma and squamous cell 
lung carcinoma) compared to non-cancer controls (Figs. 21 and 22). Large cell lung 
carcinoma subtype was not included as only one sample was collected during two years of 
samples collection. This is predictable as large cell lung carcinoma is known to be a less 
common lung cancer in comparison to other NSCLC subtypes (47). Cytokines were analysed 
in patients with NSCLC and non-cancer controls by the CBA analysis.  
Cytokines that were detectable in patient serum samples included Th1 cytokines TNF-
, TNF-, IFN-, IL-2, IL-12 (p70), and IL-1and Th2 cytokines IL-4 and IL-5 showed no 
significant differences between patients with NSCLC compared to non-cancer controls. The 
quality and reproducibility of Th1 and Th2 cytokine results using the CBA assay was not 
sufficient as some cytokines such as IL-12 (p70), IL-8, IL-4 and IL-5 were barely identified. 
This proves the previous outcomes regarding the quality and reproducibility of the CBA 
assay technique (187-189). Therefore, this part of the study was repeated with a different 
group of serum samples using the most recommended technique the Bio-Plex, MAGPIX-
Luminex assay (188).  
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Figure 21: Th1 cytokine secretion profiles in serum of patients with NSCLC (undifferentiated 
NSCLC, adenocarcinoma and squamous cell lung carcinoma) compared to controls. Serum 
was analysed for (A) TNF-α, (B) TNF-β, (C) IFN-γ, (D) IL-2, (E) IL-12 (p70) and (F) IL-1β 
using the CBA assay. Data was analysed using the FCAP Array™ v3.0.1 Software (BD 
Biosciences, USA) and results are expressed as mean (pg/ml) ± SEM, (n=20 controls, 9 
undifferentiated NSCLC, 11 adenocarcinoma and 10 squamous cell lung carcinoma). One-
way ANOVA multiple comparison test (as a post-test analysis) was performed.  
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Figure 22: Th2 cytokine secretion profiles in serum of patients with NSCLC (undifferentiated 
NSCLC, lung adenocarcinoma and squamous cell lung carcinoma) compared to controls. 
Serum was analysed for (A) IL-8, (B) IL-10, (C) IL-5 and (D) IL-4 using the CBA assay. 
Data was analysed using the FCAP Array™ v3.0.1 Software (BD Biosciences, USA) and 
results are expressed as mean (pg/ml) ± SEM, (n=20 controls, 9 undifferentiated NSCLC, 11 
adenocarcinoma and 10 squamous cell lung carcinoma). One-way ANOVA multiple 
comparison test (as a post-test analysis) was performed.  
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3.2.4. Th1/Th2 cytokines level in serum of patients with NSCLC compared to non-cancer 
controls using Bio-Plex assay 
In this part of the study all serum samples were purchased from the Victorian Cancer Bio-
Bank (Victoria, Australia) to include all NSCLC subtypes (see Table 7). Unlike the CBA 
assay, 10 serum samples of patients with large cell lung carcinoma were added to be analysed 
using the Bio-Plex, MAGPIX-Luminex assay. Large cell lung carcinoma samples were 
ordered directly from the Bio-Bank as it is a less common subtype and there were not enough 
patients with this type of tumour during sample collection.   
The potential impact of NSCLC on the Th1/Th2 cytokines levels in serum was 
investigated in patients with NSCLC compared to non-cancer controls using Bio-Plex, 
MAGPIX-Luminex assay. Similar to CBA analysis, Th1/Th2 cytokine serum analysis using 
the Bio-Plex, MAGPIX-Luminex assay indicated no significant difference in patients with 
adenocarcinoma and squamous cell lung carcinoma compared to non-cancer controls. 
However, patients with large cell lung carcinoma showed significant increase in the level of 
IL-1β, IL-4, IL-6 and IL-8 in serum using the Bio-Plex, MAGPIX-Luminex assay (Figs. 23 
and 24). IL-1β level in serum was found to be significantly increased in patients with large 
cell lung carcinoma compared to non-cancer controls (P≤0.01) and to patients with squamous 
cell lung carcinoma (P≤0.05). Also the IL-4 and IL-8 level in serum was significantly 
increased in patients with large cell lung carcinoma compared to non-cancer controls 
(P≤0.01) and to patients with adenocarcinoma (P≤0.05) as well as squamous cell lung 
carcinoma (IL-4= P≤0.01 and IL-8= P≤0.05). Finally, large cell lung carcinoma was found to 
promote the level of IL-6 compared to non-cancer controls (P≤0.01) and adenocarcinoma 
patients (P≤0.05).  
 
 
 Chapter 4: Blood Monocyte Phenotype and Th1/Th2 Cytokine Profiles in NSCLC 97 
Table 7: Demographic details of lung cancer and non-cancer control subjects for serum 
samples using Bio-Plex assay 
 n 
Age (years) 
Mean ± SD 
Gender Subtypes 
Smoking 
status 
Subtypes 
   M/F I/II/III/IV N/Ex/S A/S/L 
Control 10 43.5 ± 17.69 0/10  4/4/2  
Cancer 30 66.83 ± 11.30 23/7 2/15/11/2 7/11/12 10/10/10 
n: number; SD: standard deviation; M: male; F: female; A: adenocarcinoma; S: squamous 
cell lung carcinoma; L: large cell lung carcinoma. Serum samples were obtained from 
patients with and without NSCLC.  Samples were obtained from the Victorian Cancer Bio-
Bank, Melbourne, Australia.  
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Figure 23: Th1 cytokine secretion profiles in serum of patients with NSCLC (lung 
adenocarcinoma, squamous cell lung carcinoma, large cell lung carcinoma) compared to non-
cancer controls. Serum was analysed for (A) IL-1β, (B) TNF-α, (C) MCP-1, (D) IP-10 and 
(E) IL-12 (p70) by Bio-Plex assay using the MAGPIX-Luminex instrument. Data was 
analysed using the Bio-Plex Manager Software (Bio-Rad) and results are expressed as 
median fluorescence intensity (FI) ± SEM, (n=10 controls, 10 adenocarcinoma, 10 squamous 
cell lung carcinoma and 10 large cell lung carcinoma). One-way ANOVA multiple 
comparison test (as a post-test analysis) was performed with the Tukey test (multiple 
comparison test comparing every group with every other group). *P≤0.05 and **P≤0.01 
indicates statistical significance.  
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Figure 24: Th2 cytokine secretion profiles in serum of patients with NSCLC 
(adenocarcinoma, squamous cell lung carcinoma, large cell lung carcinoma) compared to 
non-cancer controls. Serum was analysed for (A) IL-4, (B) IL-6, (C) IL-8, (D) IL-10 and (E) 
VEGF by Bio-Plex assay using the MAGPIX-Luminex instrument. Data was analysed using 
the Bio-Plex Manager Software (Bio-Rad) and results are expressed as median fluorescence 
intensity (FI) ± SEM, (n=10 controls, 10 adenocarcinoma, 10 squamous cell lung carcinoma 
and 10 large cell lung carcinoma). One-way ANOVA multiple comparison test (as a post-test 
analysis) was performed with the Tukey test (multiple comparison test comparing every 
group with every other group). *P≤0.05 and **P≤0.01 indicates statistical significance.  
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2.3. Discussion 
The concept that the immune system has a protective role in tumour development is well 
established (12). Recent work has demonstrated that the immune system can not only prevent 
tumour formation but potentially also function to promote tumour initiation and progression 
(72). In particular, immune cells such as blood monocytes can function differently depending 
on the cancer types (78). While some studies indicated that monocyte function in cancer 
patients is within the normal range (17, 190), another study has shown impairment in 
monocyte function (77). 
In this study we demonstrated that the phenotype of freshly isolated blood classical 
monocytes from patients with NSCLC is not altered and does not show clear skewing from 
an anti-tumour (M1) to a pro-tumour (M2) phenotype. There were no significant differences 
in expression of M1 marker (HLA-DR), M2 markers (CD163 and CD36), CD11c, CD44, 
CD11b and CD71 in patients with NSCLC compared to non-cancer controls. In addition, 
there were no significant differences in the secretion of Th1/Th2 cytokines measured in the 
serum of NSCLC patients compared to non-cancer controls.  
The M1 phenotype was assessed here using HLA-DR as a marker. The HLA-DR 
molecule plays a vital role in the immune response by regulating the interaction between 
antigen-presenting cells including monocytes (191, 192). It has been described as an M1 
marker in the monocyte-macrophage system (179). Some studies have reported reduced 
HLA-DR expression on blood monocytes in human cancers such as prostate and ovarian 
cancer (76, 193, 194). As well as examining M1 phenotype, M2 phenotype markers (CD163 
and CD36) were used to investigate skewing from M1 to M2 markers on classical monocytes 
in blood from patients with NSCLC. CD163 is a scavenger receptor that plays a major role in 
the anti-inflammatory response and has been identified as M2 marker (184, 195). CD36 is 
also expressed on monocytes and is involved mainly in phagocytosis (184, 196). Sugai et al. 
 Chapter 4: Blood Monocyte Phenotype and Th1/Th2 Cytokine Profiles in NSCLC 101 
(2004) studied the alteration of monocyte characteristics by examining the intracellular 
expression of IL-10 and IL-12 cytokines (197). They found that patients with advanced 
gastric cancer had different monocyte phenotypic characteristics compared to those with 
early stage cancer and non-cancer control subjects (197). In our study, there were no 
significant differences in expression of CD163 and CD36 between non-cancer controls and 
NSCLC patients. Additionally, there was no apparent influence of tumour stage upon 
expression of these markers, although it is acknowledged that the numbers are small. These 
results when viewed in the context of previous studies raise questions regarding the impact of 
experimental design such as culturing and the use of molecules like LPS on monocyte 
polarisation and function.  
CD11b and CD11c are myeloid cell markers that are expressed on monocytes and 
macrophages (198). CD11b plays a major role in many functions of myeloid cells including 
adhesion, migration, chemotaxis and phagocytosis (198-200). In this study we therefore 
investigated the effect of NSCLC on monocyte expression of CD11b and CD11c. There were 
no significant differences in expression of CD11b and CD11c in NSCLC patients compared 
to non-cancer controls. These results are consistent with those of Mariotta et al. (2002) who 
suggested NSCLC does not affect monocyte adherence and phagocytosis in patients with 
lung cancer when compared to healthy controls (17).  
Another marker that was examined was transferrin receptor (CD71). CD71 is known 
to be associated with rapidly proliferating cells such as cancer cells and plays a major role in 
cell growth and DNA synthesis, proliferation and cell survival (201, 202). Increased CD71 
expression has been demonstrated in cancer patients, including those with lung cancer, in 
lung tissue and BAL fluid but not in serum (202, 203). Dowlati et al. (1997) investigated 
soluble CD71 in the serum of NSCLC patients. They verified no difference in the level of 
secreted CD71 in NSCLC patients compared to the control group (202). Similar to this 
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outcome we demonstrated that there was no significant difference in surface expression of 
CD71 on classical monocytes in NSCLC patients compared to non-cancer controls.   
CD44 expression was also investigated in this study as it has been suggested to be a 
potential marker of tumour onset in lung cancer. Elevated CD44 expression has been 
observed in the serum of patients with gastric and renal cancer (204, 205). However, another 
study showed that NSCLC does not influence CD44 level in the serum of NSCLC patients 
compared to benign lung diseases (190). Similarly, this study revealed no significant 
difference in surface expression of CD44 on classical monocytes in NSCLC patients 
compared to non-cancer controls.  
The presence of cytokines is essential for initiation of immune responses (22, 206). 
Th1 cells have been found to play a major role in anti-tumour immunity and stimulation of 
cell-mediated responses. Pro-inflammatory cytokines such as TNF-α and IFN-γ are known to 
stimulate Th1 cells. In contrast, Th2 cells are known to act as the helper cells that influence 
B-cell development and produce anti-inflammatory cytokines such as IL-4 and IL-10 (207, 
208). Analysis of Th1 and Th2 cytokines in the serum revealed no differences in NSCLC 
patients overall compared to non-cancer controls. Similarly, Gursel et al. (1995) also 
observed no differences in TNF-α concentration between pleural effusion and serum in 
patients with cancer (209). Although many studies have not looked at specific cytokine 
profiles in lung cancer, it has been shown that freshly prepared monocytes do not show any 
differences in pro-inflammatory and anti-inflammatory cytokine responses except IL-12 
(p70) in endometrial cancer patients when compared to controls (77). In our study, IL-1β, IL-
4, IL-6 and IL-8 cytokine levels were found to be up-regulated in the serum of large cell lung 
carcinoma patients. IL-6 levels in serum was found to be significantly increased in patients 
with large cell lung carcinoma compared to non-cancer controls and to patients with 
adenocarcinoma. Different studies have demonstrated the ability of IL-6 to promote lung 
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tumour growth and it has an association with a poor prognosis. Also, the IL-6 level in serum 
was investigated in patients with lung cancer before and during radiotherapy (RT). They 
found that IL-6 levels were higher compared to controls and were further elevated during RT 
(119-122). In addition, IL-1β and IL-8 both are known to promote tumour progression 
through regulating tumour growth and invasion (210, 211). IL-1β promotes matrix 
metalloproteinase secretion and angiogenic factors in the tumour microenvironment (212). 
The elevation of IL-1β gene expression in normal lung tissue was also shown to be related to 
increased risk of developing lung cancer (212). In this study, IL-1β level in serum was 
significantly increased in patients with large cell lung carcinoma compared to non-cancer 
controls and to patients with squamous cell lung carcinoma. Moreover, increased IL-8 
expression was shown to be associated with poor lung cancer patient survival (135). Elevated 
circulating IL-8 level has been shown to be associated with lung cancer models (213). 
Similarly, our results indicated that the IL-4 and IL-8 level in serum was highly increased in 
patients with large cell lung carcinoma compared to non-cancer controls and to patients with 
adenocarcinoma as well as squamous cell lung carcinoma. Taken together, IL-1β, IL-4, IL-6 
and IL-8 levels have been found to be elevated in most patients suffering from different 
common cancers (214, 215). Our results indicate that large cell lung carcinoma is associated 
with a systemic alteration in cytokines (IL-1β, IL-4, IL-6 and IL-8) and these cytokines have 
been shown to promote tumour growth and metastasis. However, all non-cancer controls 
were female and 76.6% of NSCLC patients were male so this may influence the accuracy of 
this outcome. Gender difference was described to have the ability to influence the Th1/Th2 
production pathways in health and some disease states (216). For example, sex steroids have 
been shown to influence the regulation of TH cell network balance and to alter the response 
type of Th1 and/or Th2 (217). Although the majority of NSCLC serum samples were 
collected from male patients in this study, only large cell lung carcinoma was shown to 
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influence Th1/Th2 cytokine expression and not the other NSCLC subtypes compared to non-
cancer controls, which might exclude the effect of gender difference in this case.   
 Although the final results of CBA and Bio-Plex, MAGPIX-Luminex were similar 
regarding adenocarcinoma and squamous cell lung carcinoma, the sensitivity, reproducibility 
and quality of CBA results was not ideal compared to Bio-Plex, MAGPIX-Luminex. As the 
majority of tested cytokines such as IL-2, IL-4, IL-5 and IL-8 were hardly identified using the 
CBA assay unlike their expression using the Bio-Plex, MAGPIX-Luminex technique. These 
results are similar to the recent studies that have questioned the sensitivity and reproducibility 
of the CBA assay and suggest the Luminex-based kit with magnetic beads to be a better 
technique (187-189). 
In this study, there are some limitations including an inability to compare results of 
monocyte and Th1/Th2 cytokine profile (using CBA assay) from subtypes within the NSCLC 
grouping as all patients’ samples were undifferentiated NSCLC, lung adenocarcinoma and 
squamous cell lung carcinoma and not large cell lung carcinoma. However, the large cell lung 
carcinoma samples were included to study Th1/Th2 cytokine level using the Bio-Plex assay. 
In future studies, examining monocyte phenotype and function in non-cancer controls versus 
lung cancer should be done on all monocytes subsets by using freshly isolated un-stimulated 
monocytes as well as cytokine treated monocytes at the same time to observe any variation 
that may occur. Other lung cancer subtypes should be considered to inspect if they have any 
potential role in altering monocyte functions and phenotypes. Also the samples of control and 
cancer should be properly balanced to exclude the influence of gender differences.  
In conclusion, the studies described in this chapter showed that monocyte phenotype 
and function were not impaired in the presence of NSCLC subtypes (undifferentiated 
NSCLC, adenocarcinoma and squamous cell lung carcinoma) compared to non-cancer 
controls. It also indicated that there was no alteration in Th1/Th2 cytokine level in the serum 
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of patients with adenocarcinoma and squamous cell lung carcinoma compared to non-cancer 
controls. However, patients with large cell lung carcinoma showed significant difference in 
the level of IL-1β, IL-4, IL-6 and IL-8 compared to non-cancer controls. Serum biomarkers 
are a practical and non-invasive method of diagnosing disease, and predicting prognosis and 
possibly treatment response. Thus, the elevated cytokines IL-1, IL-4, IL-6 and IL-8 might be 
utilised in the future as a potential diagnostic and/or prognostic biomarker in the serum of 
patients with large cell lung carcinoma. 
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Chapter 4 Alveolar Macrophage Phenotype and Function is 
Altered in NSCLC 
4.1. Introduction  
The human lungs are highly vascularised and expose to numerous toxic substances from the 
external environment possibly resulting in lung injury. However, the respiratory tract has 
various defence mechanisms, including mucus, cilia and phagocytosis that are mainly 
operated by alveolar macrophages (AMs) (2, 3). The lungs are altered due to environmental 
challenges, infection, smoking and tumour, so AMs as well are known to be adjusted in 
response to these challenges (218, 219). AMs are mononuclear phagocytic cells, which 
migrate as circulating monocytes from the circulation to the lungs, where they differentiate 
into AMs (16). AMs play an important role in immunity and inflammation of the lungs 
through various mechanisms such as phagocytosis and pro-inflammatory action (19). Two 
phenotypes of macrophage have been described: M1 and M2 macrophage subsets.  
The M1 macrophage is activated by interferon-γ with or without LPS and TNF-α (19). 
The M1 macrophage is able to control local inflammatory reactions via the release of 
cytokines (e.g. TNF-α, IL-1 and IL-12) and provides a primary defence mechanism by 
phagocytosis. The existence of M1 macrophage has also been related to the increased 
expression of pro-inflammatory cytokines (e.g. IL-12 and IL-1) in NSCLC (89). These pro-
inflammatory cytokines (IL-12 and IL-1) have been identified to play an essential role in 
tumour regression (220). In addition, the M1 macrophage has been associated with a positive 
prognosis and extended survival time in patients with NSCLC (18). In contrast, the M2 
macrophage is known to secrete anti-inflammatory cytokines such as IL-10, MMPs, TGF-β 
and IL-13 (14, 19). These cytokines are known to be associated with tumour cell 
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proliferation, progression and metastasis (19, 96). The M2 macrophages have the ability to 
stimulate the expression of the mannose receptor while reducing the iNOS expression (19). 
M2 can also inhibit antigen presentation and T-cell proliferation (13, 19). In addition, 
increased expression of cytokines such as IL-10 and IL-13 that regulate M2 activation have 
been shown to be associated with NSCLC (20). 
A dual role of macrophages in cancer has been suggested with the idea that they may 
both inhibit and promote tumour progression (12, 24). The macrophage subsets have been 
well characterised in many cancers, however AMs phenotype and function in lung cancer still 
needs further investigation. Therefore this study will investigate their role by examining the 
influence of NSCLC on AMs phenotype by characterising the M1 and M2 subsets using well 
defined markers (HLA-DR and CD163). Also, a number of main functions of AMs are 
assessed in patients with NSCLC compared to non-cancer controls using CD11b, CD71 and 
CD44 markers. The expressions of IL-6, IL-12, IL-10 and MMP-9 cytokines are also 
measured to examine the impact of NSCLC on the level of these cytokines as they are related 
to macrophages phenotype and function.  
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4.2. Results 
The demographic details of all NSCLC and non-cancer control subjects are shown in Table 8. 
BAL fluid samples were collected at Austin Health (Heidelberg, VIC, Australia), AMs 
isolated and further processed for flow cytometry and RT-PCR investigations. AMs were 
analysed using flow cytometry, where FSC and SSC linear scale were selected in order to 
identify the AM (CD68
+
) populations (Fig. 25). CD68 marker was used as the principal 
surface marker to identify the AMs populations within BAL fluid (Fig. 26). Over 65% of the 
gated cells within BAL fluids were CD68 positive. Dot plots showed fairly consistent 
FSC/SSC and CD68
+
 profiles within BAL fluid cells whereby AMs could be clearly 
identified.  
% surface expression (%SE) of CD68, CD163 (M2 marker), CD71 and CD44 on 
AMs were highly expressed in patients with NSCLC compared to non-cancer control 
subjects. In addition, there were no significant differences in the %SE of M1 marker (HLA-
DR) (p=0.9131) and myeloid markers CD11b (P=0.8884) in patients with NSCLC compared 
to non-cancer controls (Figs. 27, 28 and 29). In addition, different cytokines (IL-6, IL-12, IL-
10 and MMP-9) were measured as they are correlated to macrophages phenotype and 
function. The expression of IL-6 on AMs (P=0.4835) was not statistically significant in 
NSCLC patients compared to non-cancer controls. IL-12 expression on AMs as well was not 
statistically significant (P=0.3080) in NSCLC patients compared to non-cancer controls. The 
mRNA expression of IL-10 (P=0.0327) was found to be significantly increased in 
adenocarcinoma but not in squamous cell lung carcinoma and large cell lung carcinoma. 
Finally, mRNA expression of MMP-9 level was highly increased in all NSCLC subtypes 
patients compared to non-cancer controls (Fig. 30).  
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Table 8: Demographic details of NSCLC patients and non-cancer control subjects 
 n 
Age (years) 
Mean ± SD 
Gender 
Smoking 
status 
Stages Subtypes 
   M/F N/Ex/S I/II/III/IV A/S/L 
Control 16 49.5±18.6 9/7 7/4/5   
Cancer 13 62.8±10.1 7/6 1/6/6 2/2/2/7 8/3/2 
n: number; SD: standard deviation; M: male; F: female; N: non-smoker; Ex: ex-smoker; S: 
smoker; A: adenocarcinoma; S: squamous cell lung cancer; L: large cell lung carcinoma.  
Demographic details of the participants and staging details of lung cancer patients. This table 
shows the total number of patient samples, age, gender, smoking status and lung tumour 
stages and subtypes. Full samples detail (e.g. GOLD stages) are displayed in Appendix A - 
Tables 16 and 17. 
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Figure 25: FSC and SSC profiles from freshly isolated AMs from BAL fluid using flow 
cytometry. The figure shows representative examples of AMs that have been collected from 
BAL fluid and analysed using flow cytometry: (A and B) FSC/SSC profiles of freshly 
isolated AMs prior to gating, (C and D) gating profiles of FSC/SSC plots of freshly isolated 
AMs from non-cancer controls (green colour) and cancer samples (red colour) based on 
CD68
+ 
expression.  All data was collected on a BD FACS Canto (BD Biosciences, San Jose, 
CA, USA) within the RMIT Flow Cytometry Facility (Bundoora, Melbourne) and analysed 
using FACSDiva analysis software (BD Biosciences, USA).  
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Figure 26: CD68
+
 expression on freshly isolated AMs obtained from BAL fluid using flow 
cytometry. Expression of CD68
+
 against FSC profiles from freshly isolated AMs from (A) 
non-cancer controls and (B) cancer subjects. (C and D) Histograms display the unstained 
AMs (black line) and CD68
+
 expression of non-cancer controls (green line) and NSCLC 
AMs (red line). All data was collected on a BD FACS Canto (BD Biosciences, San Jose, CA, 
USA) within the RMIT Flow Cytometry Facility (Bundoora, Melbourne) and analysed using 
FACSDiva analysis software (BD Biosciences, USA).  
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4.2.1. Analysis of functional receptors CD11b, CD71 and CD44 on AMs from patients with 
NSCLC and non-cancer controls by flow cytometry 
The potential impact of NSCLC on the AMs expression of CD11b, CD71 and CD44 was 
investigated in patients with NSCLC compared to non-cancer controls using flow cytometry. 
Freshly isolated AMs were gated based on CD68
+ 
marker expression. There was no 
significant difference (P=0.8884) in the CD11b expression between NSCLC and non-cancer 
controls. Transferrin receptor CD71 was also measured and used as an indicator of monocyte-
macrophage differentiation in BAL fluid. CD71 expression was found to be significantly 
increased in NSCLC patients compared to non-cancer control participants (Fig. 27). In 
addition, CD44 was also analysed on AMs of NSCLC patients and non-cancer controls. 
CD44 expression increased in NSCLC patients versus non-cancer controls (Fig. 27). 
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Figure 27: CD11b, CD71 and CD44 marker expression in AMs by flow cytometry. 
Representative graphs show %SE ± SEM of (A) CD11b, (B) CD71 and (C) CD44 in AMs 
from control and NSCLC patients. Results expressed as mean values of %SE ± SEM, (n= 16 
control, 8 adenocarcinoma, 3 squamous cell lung carcinoma and 2 large cell lung carcinoma). 
One-way ANOVA multiple comparison test (as a post-test analysis) was performed with the 
Tukey test (multiple comparison test comparing every group with every other group). 
*P≤0.05, **P≤0.01 and ***P≤0.001 indicates statistical significance.  
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4.2.2. Analysis of M1 marker (HLA-DR) and M2 marker (CD163) surface expression on 
AMs from patients with NSCLC and non-cancer controls by flow cytometry 
The potential impact of NSCLC on the AMs expression of HLA-DR (M1) and CD163 (M2) 
was examined in patients with NSCLC compared to non-cancer controls using flow 
cytometry. HLA-DR and CD163 markers were used to differentiate between M1 and M2 
macrophage subsets by flow cytometry. Around 45% of AMs that were CD68
+
 positive 
expressed HLA-DR marker, while CD163 was expressed by 25% of AMs. There was no 
significant difference in the expression of HLA-DR on AMs (P=0.9131) from NSCLC 
patients compared to non-cancer controls (Fig. 28). However, patients with NSCLC showed 
higher expression of CD163 on AMs in comparison to non-cancer controls (Figs. 28 and 29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 116 Chapter 5 Alveolar Macrophage Phenotype and Function is Altered in NSCLC 
 
Figure 28: M1 and M2 marker expression on AMs (CD68) by flow cytometry. Representative 
dot plots (A and C) CD68
+
 AMs stained against HLA-DR and CD163 of non-cancer controls 
and (B and D) of NSCLC. All data was collected on a BD FACS Canto (BD Biosciences, San 
Jose, CA, USA) and analysed using FACSDiva software within the RMIT Flow Cytometry 
Facility (Bundoora, Melbourne). 
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Figure 29: HLA-DR (M1) and CD163 (M2) surface expression on AMs from patients with 
NSCLC and non-cancer controls by flow cytometry. The graphs show %SE ± SEM of (A) 
HLA-DR and (B) CD163 on AMs from non-cancer control and (adenocarcinoma (n=8), 
squamous cell (n=3) and large cell (n=2) primary lung cancer patients. Results expressed as 
mean values of %SE ± SEM. One-way ANOVA multiple comparison test (as a post-test 
analysis) was performed with the Tukey test (multiple comparison test comparing every 
group with every other group). ****P≤0.0001 indicates statistical significance difference  
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4.2.3. IL-6, IL-12, IL-10 and MMP-9 mRNA expression level in NSCLC compared to non-
cancer controls  
The mRNA expression of IL-6, IL-12, IL-10 and MMP-9 was measured on AMs to 
investigate the impact of NSCLC their levels as they are related to macrophage phenotype 
and function. The expression of IL-6 (P=0.4835) and IL-12 (P=0.3080) was similar in 
NSCLC patients compared to non-cancer controls. However, the expression of IL-10 was 
found to be highly increased in adenocarcinoma patients compared to non-cancer controls. 
However, the IL-10 expression was not altered in other NSCLC subtypes (squamous cell lung 
carcinoma and large cell lung carcinoma) compared to non-cancer controls. Lastly, the 
mRNA expression level of MMP-9 was found to be increased in all NSCLC subtypes 
compared to non-cancer controls (Fig. 30). 
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Figure 30: mRNA expression of IL-6, IL-12, IL-10 and MMP-9 on AMs in patients with 
NSCLC compared to non-cancer controls. Results show mRNA expression ± SEM, (n= 16 
control, 8 adenocarcinoma, 3 squamous cell lung carcinoma and 2 large cell lung carcinoma). 
One-way ANOVA multiple comparison test (as a post-test analysis) was performed with the 
Tukey test (multiple comparison test comparing every group with every other group). 
*P≤0.05, **P≤0.01 and ***P≤0.001 indicates statistical significance.  
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4.3. Discussion  
Macrophages have been shown to exhibit several phenotypes, mainly depending on their 
environment (18, 104-106). Characterisation of macrophage phenotypes (M1 and M2) is 
likely to be an overgeneralisation, as macrophages have been described as a highly plastic 
cell that can display several phenotypes (104). The macrophage’s ability to display different 
phenotypes and functions has led to their broad classification as either M1 macrophages or 
M2 macrophages.  
 HLA-DR and CD163 markers were used to distinguish between M1 and M2 
phenotypes using flow cytometry. There was no significant difference in the surface 
expression of HLA-DR in all NSCLC subtypes patients compared to non-cancer controls. 
This result confirms our previous study that looked at HLA-DR expression on AMs from 
NSCLC patients compared to controls (27). However, AMs from all NSCLC subtypes 
patients showed high expression of CD163 compared to non-cancer controls. Similarly, a 
recent study demonstrated higher CD163 expression associated with lung cancer compared to 
non-malignant controls (221). Expression of CD163 on macrophages is associated with 
tumours and inflammation (18, 221). Our results verify the previous observations of the co-
existence of macrophages in different activation states and unique or mixed phenotypes (106, 
222). 
Not all CD68
+ 
cells were CD11b positive and this because both neutrophils and 
dendritic cells are detectable in BAL fluid and they can, similarly to macrophages, express 
high levels of CD11b (223, 224). Also, CD11b is known to be expressed on newly migrant 
macrophages more than resident macrophages (223). Thus, using this marker to examine cells 
within BAL fluid is fairly complicated, as it is hard to differentiate between macrophages and 
dendritic cells (224). Here, AMs from patients with all NSCLC subtypes expressed similar 
CD11b level compared to non-cancer control subjects.  
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The transferrin receptor (CD71) was measured as an indicator of macrophage 
differentiation in BAL fluid. In this study, 70% of AMs expressed CD71 and was found to be 
highly expressed on AMs from all NSCLC subtypes patients compared to non-cancer control 
participants. Increased CD71 expression has been shown in many malignant tumours 
including lung cancer, gastric cancer and breast cancer using different methods (201, 202, 
225). In particular, a study has shown elevated expression of CD71 in COPD patients on 
AMs using flow cytometry (147). Similar to our results, it has been shown that the expression 
of CD71 correlates with tumour differentiation. Dowlati et al. (1997) showed that cell-
associated CD71 levels are significantly higher in the BAL fluid of NSCLC patients 
compared to patients with small cell carcinoma and COPD (202). No correlation existed, 
however, between BAL fluid cells associated CD71 and tumour size, nodal status, the 
presence of metastases and serum transferrin receptor (202). Another study also displayed 
high expression of cellular CD71 in adenocarcinoma of the lung (226).  
CD44 is a membrane glycoprotein with multiple functions including cell proliferation, 
differentiation, migration, and angiogenesis (227). It has been shown to be expressed on the 
surface of several human cells including AMs (228). CD44 has also been demonstrated to 
interact with osteopontin (OPN) and regulate its cellular functions leading to tumour 
progression (229). Here, CD44 surface expression was increased in all NSCLC subtypes 
patients compared to non-cancer controls. Similarly, other studies that examined the 
expression of CD44 on NSCLC patients demonstrated results (230, 231). Taken together, all 
these results are consistent with the prior suggestion regarding the association of CD44 with 
the proliferation, migration, angiogenesis (229).  
AMs derived from patients with lung cancer have been shown in vitro to function 
efficiently against tumour cell growth (22-25, 114). They are able to control local 
inflammatory reactions via the release of cytokines such as IL-12 and IL-6 (87). These 
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cytokines are involved in numerous immune reactions, including tumouricidal activity (22). 
However, AMs secrete both pro-inflammatory cytokines and anti-inflammatory cytokines 
(13, 24, 89, 90). The M1 macrophages have been related to the increased expression of pro-
inflammatory cytokines (e.g. IL-6 and IL-12) within NSCLC tumours and play a role in 
tumour regression (18). The ability of IL-6 to inhibit tumour cell growth has been suggested 
(22). Although IL-6 release can contribute to the anti-tumour function of AMs, a pro-tumour 
function has also been proposed (121). Even with IFN-γ and LPS stimulation, IL-6 inhibited 
the development of tumouricidal function in AMs of patients with lung cancer (26). Reduced 
IL-6 secretion was demonstrated in AMs that were derived from patients with large cell 
undifferentiated and small cell subtype tumours (13, 27). However, significantly elevated IL-
6 levels have been detected in BAL fluid cell cultures from patients with lung cancer 
compared to those with benign disease (22). A study demonstrated that IL-6 levels in BAL 
fluid of lung cancer were higher compared to controls and were further elevated during 
radiotherapy, potentially confirming the role of IL-6 in mediating an inflammatory response 
(119). However, our results indicated the mRNA expression of IL-6 in all NSCLC subtypes 
patients compared to non-cancer controls was not statistically significant. This might be 
because of the lower number of NSCLC samples and the fact that tumour samples were from 
different stages, subtypes and early-diagnosed patients who have had no therapy as yet. IL-12 
expression was also examined in this study and we found that there was no significant 
difference between non-cancer controls and NSCLC patients. Similar results have been 
shown in TAMs (tumour associated macrophages) from patients with NSCLC using RT-PCR 
(232).     
AMs have been shown to promote tumour growth in patients with lung cancer (26, 27, 
116, 125). Inhibition of pro-inflammatory cytokine secretion has been reported in the 
presence of elevated levels of serum IL-10 (116, 125). IL-10 is a potent angiogenesis 
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inhibitor and in AMs culture is released with or without LPS stimulation. Interestingly, 
following LPS stimulation, Yanagawa et al. (1999) found no significant differences in IL-10 
production by AMs from patients with lung cancer compared to non-cancer controls (13, 25). 
However, increased IL-10 expression from TAMs has been confirmed in patients with 
NSCLC using RT-PCR technique (232). Here, mRNA expression of IL-10 was examined and 
found to be increased in patients with adenocarcinoma compared to non-cancer controls. 
However, the mRNA level was found not to be affected in the patients with squamous cell 
lung carcinoma and large cell lung carcinoma compared to non-cancer controls. This might 
be because of the fact that the majority of the analysed cancer samples (61%) were from 
patients with adenocarcinoma. In addition, as 70% of the samples that were processed were 
from NSCLC patients with late stage disease, these findings suggest that AMs in patients 
with advanced lung cancer express high levels of IL-10, which can inhibit pro-inflammatory 
functions and other cytotoxic molecules that mediate the killing of tumour cells. Taken 
together, IL-10 may be able to inhibit the anti-tumour activities of AMs and may contribute 
to tumour progression (125).     
MMPs are matrix degrading enzymes that facilitate tumour growth through metastasis 
and the breakdown of basement membranes (87). In patients with lung cancer, macrophage 
MMP-12 and MMP-9 have been shown to promote lung tumour growth (140, 141). MMPs 
are an attractive target for therapeutic purposes because of their involvement in tumour 
progression. However, a recent trial has suggested that some MMPs might play a crucial role 
in host resistance against tumour progression (142). Collectively, these studies suggested an 
important role for MMP-9 in lung metastasis and indicated that MMP inhibitors could be 
designed to target tumour-promoting MMPs in order to inhibit tumour growth (142). 
Elevated MMP-9 levels have been demonstrated in BAL fluid and plasma samples of 
NSCLC patients (143). It has also been suggested that serum MMP-9 level (but not BAL 
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fluid MMP-9 level) might be useful to distinguish between malignant and benign lung 
diseases. The same study also demonstrated that serum MMP-9 levels relate to both disease 
stage and general clinical status of patients with NSCLC (144). Rui Wang et al. (2011) 
demonstrated using RT-PCR that macrophage expression of MMP-9 was higher in NSCLC 
patients compared to controls and associated with tumour progression (232). Similarly, our 
results indicated that the expression of MMP-9 was increased in all NSCLC subtypes patients 
compared to non-cancer controls (143).  
The quality of BAL fluid samples was always a concern throughout the study, in 
particular the quality of sample, the amount of blood present within the samples and overall 
quantity of AM recovered from the processing method. Also, most of the collected samples 
were from patients with advanced stage disease, so we could not confidently address the 
question of whether NSCLC influences AM function and polarisation changes with tumour 
progression. The number of collected samples was from a relatively small pool of subjects 
(61% of the NSCLC samples were adenocarcinoma) and needs to be confirmed with a larger 
and more diverse cohort of patients with NSCLC. Despite our relatively comprehensive 
methodology, further techniques would be worth adding to future studies such as enzyme-
linked immunosorbent assay (ELISA) and Western blot in order to strengthen some of the 
study outcomes. For example, ELISA could be used to investigate the up-regulated markers 
and cytokines in other body fluids e.g. serum. Based on the experience that we gained from 
this work, we believe that further improvements in BAL fluid sample preparation protocols 
would be highly desirable and necessary. 
In conclusion, AM phenotype was found to be altered in patients with NSCLC 
compared to non-cancer controls. The M2 macrophage marker (CD163) significantly 
increased in NSCLC patients compared to non-cancer controls. The elevation of M2 
macrophage is expected to be associated with angiogenesis and poor prognosis. In addition, 
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the CD71 and CD44 expression was found to be increased in NSCLC patients compared to 
non-cancer controls. The IL-10 and MMP-9 levels were also recognised to be increased in 
NSCLC patients compared to non-cancer controls. These results show that AM phenotype 
and function is altered in the presence of NSCLC compared to non-cancer controls. These 
results indicate the potential importance of targeting M2 macrophage and their pro-tumour 
activity to eventually skew them back to the M1 phenotype to promote a more potent anti-
tumour activity. The elevated expression of CD163, CD71, CD44, IL-10 and MMP-9 may be 
utilised in the future as a potential diagnostic and/or prognostic biomarker in the BAL fluid of 
patients with NSCLC. 
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Chapter 5 Quantitative Proteomics of Bronchoalveolar Lavage 
Fluid in Primary Lung Adenocarcinoma 
5.1. Introduction 
Adenocarcinoma is the most frequently reported subtype of lung cancer in many countries 
(233, 234). Advances in the knowledge of the molecular pathways that are related to 
malignancy have opened up new methods for lung cancer treatment, particularly for 
adenocarcinoma, where molecular characterisation has led to the use of agents with high 
levels of antitumor activity. For example, epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors are being used to treat patients with metastatic lung adenocarcinoma and an 
active mutation in EGFR (41, 42). As lung adenocarcinoma has been described histologically 
to be the most variable and heterogeneous subtype of lung cancer (233), urgent further 
research is needed in this area to understand its onset and progression.  
Recently, quantitative proteomics has been utilised as a new technique to investigate 
the complex mix of proteins present in the tissue of patients with cancer compared to non-
cancer controls (235). Extensive efforts have been directed towards examining protein 
dynamics, which eventually determine cell behaviour (236). Cellular proteins mostly function 
as components of protein complexes rather than as single polypeptides. Therefore, 
characterising the structure and dynamics of multi-protein complexes is crucial to understand 
and possibly manipulate the tumour microenvironment via various therapies (237). These 
investigations are aimed at understanding the proteins and protein interactions that may lead 
to treatments that can favour improved patient outcomes as well as developing valuable 
cancer biomarkers (236).  
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Proteomic studies of human body fluids, such as BAL fluid, are important in 
understanding both tumour pathways and identifying potential tumour biomarkers, which 
may ultimately lead to new treatments for lung cancer. The investigation of the BAL fluid 
proteome has already delivered vital information concerning alterations in protein expression 
and secretion in a range of pulmonary disorders including lung cancer (235, 238, 239). 
Alterations in protein expression have been shown in sarcoidosis, cystic fibrosis, 
hypersensitivity pneumonitis, COPD, as well as lung cancer (238-242). BAL fluid has been 
sampled during bronchoscopy of patients with a range of pulmonary disorders and has 
provided a sample of physiological fluid from the pulmonary compartment (243, 244). BAL 
fluid has been commonly used to obtain inflammatory cells (alveolar macrophages, 
neutrophils and monocytes) and other soluble components that are present in alveoli (244). 
Proteins that are found in BAL fluid are secreted from epithelial and inflammatory cells as 
well as being derived from the bloodstream (244). An advantage of using BAL fluid samples 
in proteomic analysis is the low protein concentration in the fluid. This advantage increases 
the chances of detecting more lung cancer biomarkers due to the absence of highly abundant 
and non-specific proteins in BAL fluid samples that potentially mask lung-derived molecules 
in other physiological fluids such as serum (238, 244). Thus, the proteomic analysis of BAL 
fluid can be utilised to investigate important pathophysiological functions that relate to a 
particular pulmonary disease, such as lung cancer (238). However, not all proteins that are 
present in BAL fluid can be identified using mass spectrometry, given that the dynamic range 
of BAL fluid protein abundance is estimated to be around 10
10
, while the resolving power of 
mass spectrometry is limited to 10
2
-10
4 
(245). 
In this part of the study, adenocarcinoma was chosen for investigation, as it is the 
most frequent primary lung cancer in many countries. The study aim was to identify 
biological processes, cellular components and molecular functions in BAL fluid samples 
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from patients with adenocarcinoma of the lung compared to non-cancer control subjects using 
quantitative proteomics. We also categorised the up-regulated proteins and their biological 
processes, cellular components and molecular functions in patients with adenocarcinoma of 
the lung. Identification of up- or down-regulated proteins in patients with primary lung 
adenocarcinoma may provide increased knowledge regarding the tumour microenvironment, 
cancer pathways and potential biomarkers.  
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5.2. Results 
5.2.1. Lung adenocarcinoma alters BAL fluid protein expression 
In this study, quantitative proteomics was used to identify biological processes, cellular 
components and molecular functions in BAL fluid samples from patients with 
adenocarcinoma of the lung compared to non-cancer control subjects. Also to categorise the 
up-regulated proteins and their biological processes, cellular components and molecular 
functions in patients with adenocarcinoma of the lung.  
The demographic details of all adenocarcinoma and non-cancer controls subjects are 
shown in Table 9. BAL fluid samples were collected at Austin Health (Heidelberg, VIC, 
Australia) to isolate protein samples (analysed using proteomics). The number of proteins 
that were consistently identified in all samples was approximately 1,100. The main biological 
processes that were associated with BAL fluid proteins were metabolic processes (~19%), 
response to stimulus (~12%) and transport (~9%). Additionally, the main cellular components 
or compartments found to be linked to BAL fluid proteins were the cytoplasm (~23%), cell 
membrane (~14%), cytosol (~9%), nucleus (~8%), extracellular (~8%) and organelle lumen 
(~8%), respectively. For molecular functions, protein binding (~28%), catalytic activity 
(~22%), nucleotide binding (~11%), metal ion binding (~9%) and RNA binding (~5%) were 
found to be the leading molecular functions that BAL fluid proteins displayed (Fig. 31).   
In this study, 1,100 proteins were identified (Appendix A, Table 18), of which 33 
were found to be up-regulated consistently in all lung adenocarcinoma samples compared to 
non-cancer controls (Table 10). Eighteen percent of the up-regulated proteins were expressed 
at levels 3- to 5-fold higher in BAL fluid from patients with lung adenocarcinoma compared 
to non-cancer controls. The remaining up-regulated proteins (81%) were found to have a 
higher fold change, with a 5- to 11-fold increase in BAL fluid from patients with 
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adenocarcinoma compared to non-cancer controls. The top five up-regulated proteins were 
galectin-1, ADP/ATP translocase 2, 78 kDa glucose-regulated protein, cystatin-B and 
carbonic anhydrase II, respectively (Table 10). Other well recognised proteins were also 
identified to be up-regulated in the BAL fluid of lung adenocarcinoma compared to non-
cancer controls such as S100-A8, annexin A1, annexin A2, thymidine phosphorylase (TP), 
transglutaminase 2 (TG2), Alpha-actinin-4. The biological processes, cellular components 
and molecular functions of all 33 up-regulated proteins were also shown in this study (Table 
11). 
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Table 9: Demographic details of lung adenocarcinoma and non-cancer control subjects 
 n 
Age (years) 
Mean ± SD 
Gender 
Smoking 
status 
Stages 
   M/F N/Ex/S I/II/III/IV 
Control 8 60 ± 8.71 3/5 3/2/3  
Cancer 8 
 
68.1 ± 7.56 
 
5/3 1/2/5 2/2/1/3 
n: number; SD: standard deviation; M: male; F: Female; N: non-smoker; Ex: Ex-smoker; S: 
smoker. Demographic details of the participants and staging details of lung adenocarcinoma 
patients. This table shows the total number of patient samples, age, gender, smoking status 
and stages. Full sample details are displayed in appendix A - Tables 16 and 17. 
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Figure 31: Distribution and classification of all proteins that were identified in BAL fluid 
samples. The Pie charts display the profiles of (A) biological process, (B) cellular component 
and (C) molecular function of all proteins that were identified in all BAL fluid samples 
(n=16) of lung adenocarcinoma and non-cancer controls. The data of these graphs are shown 
in the Appendix A (Tables 13, 14 and 15). The Orbitrap MS data were analysed using 
Proteome Discoverer (Thermo Scientific version 1.4, Rockford, IL, USA) with the Mascot 
search engine (Matrix Science version 2.4, Boston, MA, USA) against the Uniprot database 
maintained at the Bio21 Institute, University of Melbourne, Australia (currently containing 
26,617,536 sequences).  
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Table 10: List of up-regulated proteins in BAL fluid from patients with lung adenocarcinoma compared to non-cancer controls using 
quantitative proteomic analysis 
No. Protein name
a
 Protein description
a
 
MW 
[KDa]
a
 
# Peptide 
count 
# Unique 
peptide 
Fold change (A 
vs. N)
b
 
1 ACTN4_HUMAN Alpha-actinin-4 104.8 19 8 3.095 
2 ADT2_HUMAN ADP/ATP translocase 2 32.8 9 2 10.611 
3 ANXA1_HUMAN Annexin A1 38.7 12 12 6.283 
4 ANXA2_HUMAN Annexin A2 38.6 17 17 5.799 
5 B4DIT7_HUMAN Transglutaminase 2 (TG2) 68.6 11 11 7.073 
6 B4DJV2_HUMAN Citrate synthase 50.4 5 4 5.681 
7 B4DQJ8_HUMAN 6-phosphogluconate dehydrogenase, decarboxylating 51.8 6 6 4.774 
8 B4DW52_HUMAN 
cDNA FLJ55253, highly similar to Actin, 
cytoplasmic 1 
38.6 13 7 4.949 
9 B4E1F5_HUMAN 
cDNA FLJ57475, highly similar to Pulmonary 
surfactant-associated protein B 
38.5 5 5 8.734 
10 B7Z7A9_HUMAN Phosphoglycerate kinase B 41.4 9 9 7.414 
11 C9JGI3_HUMAN Thymidine phosphorylase (TP) 46.1 9 9 4.928 
12 CAH2_HUMAN Carbonic anhydrase-II (CA II) 29.2 9 9 9.888 
13 CATA_HUMAN Catalase 59.7 16 16 8.358 
14 CLIC1_HUMAN Chloride intracellular channel protein 1 26.9 5 5 6.092 
15 CX7A2_HUMAN Cytochrome c oxidase subunit 7A2, mitochondrial 9.4 2 2 7.147 
16 CYTB_HUMAN Cystatin-B 11.1 3 3 10.051 
17 EFHD2_HUMAN Swiprosin-1 26.7 5 5 6.037 
18 ENOA_HUMAN Alpha-enolase 47.1 14 11 6.060 
19 F8W0P2_HUMAN 
HLA class II histocompatibility antigen, DR alpha 
chain 
26.9 6 5 6.313 
20 GRP78_HUMAN 78 kDa glucose-regulated protein 72.3 15 13 10.385 
21 H4_HUMAN Histone H4 11.4 3 3 8.292 
22 LEG1_HUMAN Galectin-1 14.7 4 4 11.386 
23 LKHA4_HUMAN Leukotriene A-4 hydrolase 69.2 22 22 6.851 
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24 MYH9_HUMAN Myosin-9 226.4 20 20 4.034 
25 O60744_HUMAN Thioredoxin delta 3 9.3 2 2 8.664 
26 PLSL_HUMAN Plastin-2 70.2 21 21 5.640 
27 PROF1_HUMAN Profilin-1 15.0 6 6 8.870 
28 Q53FJ5_HUMAN Prosaposin 58.1 9 9 9.982 
29 Q5TCU6_HUMAN Talin 1 257.9 23 23 7.410 
30 Q6DC98_HUMAN LMNB1 protein 38.1 6 5 7.298 
31 S10A8_HUMAN Protein S100-A8 10.8 4 4 8.512 
32 SAMH1_HUMAN SAM domain and HD domain-containing protein 1 72.2 10 10 4.769 
33 TAGL2_HUMAN Transgelin-2 22.4 9 9 9.572 
MW: Molecular weight; #peptide count: sum of peptide count; #unique peptides: sum of unique peptides; A: lung adenocarcinoma; N: non-
cancer controls; HLA: human leukocyte antigen; DR: D related; SAM: sterile alpha motif; HD: homodimer. 
a 
Refers to the
 
accession number of 
proteins, protein name and molecular weight from the Uniprot database.
b 
Refers to the fold difference in expression in patients with cancer 
versus controls. The Orbitrap MS data were analysed using Proteome Discoverer (Thermo Scientific version 1.4, Rockford, IL, USA) with the 
Mascot search engine (Matrix Science version 2.4, Boston, MA, USA) against the Uniprot database maintained at the Bio21 institute, University 
of Melbourne, Australia (currently containing 26,617,536 sequences). Search parameters were precursor mass tolerance of 10 ppm and fragment 
mass tolerance of 0.2 Da. Carbamidomethyl of cysteine was set as fixed modification and dimethyl labelling (light and medium at +28.0313 and 
+32.0564, respectively) at the peptide N-terminus and lysine set as variable modifications. Trypsin with a maximum of 0 missed cleavage was 
used as the cleavage enzyme. A false discovery rate threshold of 1% was applied and identification of two or more unique peptides and two or 
more peptides were required for positive identification and quantification, respectively. A two-fold differential expression was chosen as being 
significant. The number of the samples that were processed is 8 controls and 8 adenocarcinomas.   
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Table 11: The molecular functions, cellular components and biological processes of up-regulated proteins identified in the BAL fluid 
from patients with adenocarcinoma compared to non-cancer controls by proteomic analysis  
 
 
Protein name Protein description 
Molecular 
function 
Cellular component Biological process 
1 ACTN4_HUMAN Alpha-actinin-4   
 
     
 
       
 
2 ADT2_HUMAN ADP/ATP translocase 2   
 
     
 
        
 
3 ANXA1_HUMAN Annexin A1       
 
      
 
             
 
4 ANXA2_HUMAN Annexin A2     
 
     
 
         
 
5 B4DIT7_HUMAN Transglutaminase 2 (TG2)     
 
   
 
          
 
6 B4DJV2_HUMAN Citrate synthase  
 
   
 
 
 
7 B4DQJ8_HUMAN 
6-phosphogluconate dehydrogenase, 
decarboxylating 
  
 
  
 
 
 
8 B4DW52_HUMAN 
cDNA FLJ55253, highly similar to 
Actin, cytoplasmic 1 
   
 
      
 
           
 
9 B4E1F5_HUMAN 
cDNA FLJ57475, highly similar to 
Pulmonary surfactant-associated 
protein B 
       
 
   
 
10 B7Z7A9_HUMAN Phosphoglycerate kinase B    
 
  
 
 
 
11 C9JGI3_HUMAN Thymidine phosphorylase (TP)    
 
   
 
12 CAH2_HUMAN Carbonic anhydrase II (CA II)    
 
    
 
        
 
13 CATA_HUMAN Catalase      
 
         
 
         
 
14 CLIC1_HUMAN Chloride intracellular channel protein 1   
 
     
 
     
 
15 CX7A2_HUMAN 
Cytochrome c oxidase subunit 7A2, 
mitochondrial 
  
 
   
 
 
 
16 CYTB_HUMAN Cystatin-B    
 
    
 
    
 
17 EFHD2_HUMAN Swiprosin-1  
 
 
 
  
18 ENOA_HUMAN Alpha-enolase      
 
     
 
     
 
19 F8W0P2_HUMAN 
HLA class II histocompatibility 
antigen, DR alpha chain 
   
 
 
 
20 GRP78_HUMAN 78 kDa glucose-regulated protein      
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21 H4_HUMAN Histone H4     
 
     
 
       
 
22 LEG1_HUMAN Galectin-1    
 
    
 
        
 
23 LKHA4_HUMAN Leukotriene A-4 hydrolase    
 
     
 
     
 
24 MYH9_HUMAN Myosin-9      
 
       
 
           
 
25 O60744_HUMAN Thioredoxin delta 3   
 
      
 
         
 
26 PLSL_HUMAN Plastin-2   
 
     
 
       
 
27 PROF1_HUMAN Profilin-1     
 
     
 
         
 
28 Q53FJ5_HUMAN Prosaposin  
 
       
 
         
 
29 Q5TCU6_HUMAN Talin 1   
 
      
 
          
 
30 Q6DC98_HUMAN LMNB1 protein   
 
    
 
    
 
31 S10A8_HUMAN Protein S100-A8   
 
     
 
          
 
32 SAMH1_HUMAN 
SAM domain and HD domain-
containing protein 1 
     
 
   
 
     
 
33 TAGL2_HUMAN Transgelin-2  
 
   
 
  
 
HLA: human leukocyte antigen; DR: D related; SAM: sterile alpha motif; HD: homodimer. Colours definition: (I) Molecular function: protein 
binding, metal  ion binding, catalytic activity, nucleotide binding, structural molecule activity, enzyme regulator activity, RNA binding, DNA 
binding, transporter activity,  motor activity, signal transducer activity, antioxidant activity; (II) Cellular component: cytoskeleton, extracellular, 
nucleus, cytoplasm, mitochondrion, organelle lumen, membrane, endosome, cell surface, cytosol, vacuole, endoplasmic reticulum, Golgi, 
chromosome; (III) Biological process: response to stimulus, transport, coagulation, regulation of biological process, cell death, cell organisation 
and biogenesis, cellular component movement, metabolic process, cell communication, defence response, cell differentiation, development, cell 
proliferation, reproduction development, cellular homeostasis, reproduction, cell division, cell growth. The Orbitrap MS data were analysed 
using Proteome Discoverer (Thermo Scientific version 1.4, Rockford, IL, USA) with the Mascot search engine (Matrix Science version 2.4, 
Boston, MA, USA) against the Uniprot database maintained at the Bio21 Institute, University of Melbourne, Australia (currently containing 
26,617,536 sequences).  
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5.3. Discussion   
Lung cancer is one of the most common cancers with a poor prognosis and high mortality 
rate (6, 53). Adenocarcinoma, squamous cell lung carcinoma and large cell carcinoma are 
classified as one group (NSCLC) of lung cancers because they show a very similar behaviour 
in response to treatment. However, a new pathologic typing of lung cancer was established in 
2011 by the IASLC, ATS and ERS (246). The alteration of lung cancer classification 
regarding treatment was significant because it has been recognised that different lung cancer 
subtypes respond differently to treatment. For example, metastatic lung adenocarcinoma that 
express EGFR or KRAS (Kirsten rat sarcoma viral oncogene homolog) can be treated with 
biological agents that are not as yet helpful for other subtypes, e.g. squamous cell lung 
carcinoma (41, 42). Lung adenocarcinoma is the most common diagnosed subtype of lung 
cancer and shows high variability and heterogeneity in its histological features (233, 234, 
247). Therefore, it is essential and necessary to use new techniques to improve our 
knowledge about the complexity of the lung adenocarcinoma molecular environment. 
Quantitative proteomics is a new technique that has recently been utilised to investigate the 
protein dynamics in lung cancer and other pulmonary disorders (235). To date, most of the 
published literature has focused on plasma samples, cell lines associated with squamous cell 
lung carcinoma but not lung adenocarcinoma (235). In this study, BAL fluid was used as the 
source of proteins to be studied. We focused on displaying biological processes, cellular 
components and molecular functions of all identified proteins as well as examining the 
impact of lung adenocarcinoma on protein expression comparing cancer samples to non-
cancer controls using quantitative proteomics.   
Traditional biochemical methods investigate only one or a few proteins, while 
proteomics has the ability to identify thousands of proteins and provide comprehensive BAL 
fluid proteome information (248, 249). Being able to access all of this information can be 
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significant in understanding the molecular mechanisms underlying lung adenocarcinoma. In 
this study, 1,100 distinct proteins were identified and their biological processes, cellular 
components and molecular functions were discussed. Previous studies identified a similar 
number of up-regulated proteins in BAL fluid samples of normal and asthmatic subjects (245, 
248). Biological processes, cellular components and molecular functions have been examined 
previously in normal, allergic asthma, lung cancer cell lines and pulmonary squamous cell 
lung carcinoma (245, 248, 250, 251). In this study, different biological processes associated 
with BAL fluid proteins such as metabolism, response to stimuli, transport, cell proliferation, 
cell growth and cell differentiation. Also, numerous cellular components were found to be 
associated to BAL fluid proteins such as cytoplasm, membrane, cytosol, nucleus, 
extracellular, organelle lumen and cell surface. The molecular functions that were recognised 
in BAL fluid proteins include protein binding, catalytic activity, nucleotide binding, metal ion 
binding, DNA binding and RNA binding.  
Up-regulated proteins that were associated with lung adenocarcinoma samples are 
shown in Table 10. All 33 proteins were found to be consistently up-regulated in all lung 
adenocarcinoma patient samples compared to non-cancer controls. These proteins were 
considered significant as they had a minimum of two-fold change and ≥2 of unique peptides 
and peptide counts. A number of over-expressed proteins have been shown previously to be 
related to lung cancer progression including S100-A8, annexin A1, annexin A2, thymidine 
phosphorylase (TP) and transglutaminase 2 (TG2) (252-255). In our laboratory, a number of 
those over-expressed proteins were previously identified to be up-regulated in peripheral 
cholangiocarcinoma, including Alpha-actinin-4 and 78 kDa glucose-regulated protein (256).  
S100-A8 is an important protein and recent studies have focused on its critical role in 
tumour growth, progression and invasion. It was also proposed to be both a potential 
therapeutic target and as an indicator for tumour progression in different tumours including 
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lung adenocarcinoma (252, 257). In this study, the expression of S100-A8 was significantly 
increased in lung adenocarcinoma samples compared to non-cancer controls. S100-A8 is a 
low molecular weight member of the S100 protein family which is characterised by the 
presence of two calcium ion Ca
2+
 binding EF-hand motifs (258). It naturally presents at high 
concentrations in the cytoplasm of monocytes and neutrophils and has been shown to play an 
essential role in lung tumour growth, progression and invasion (252, 258). In previous 
studies, the up-regulation of S100-A8 has been shown in the tissue of lung adenocarcinoma 
subjects and in BAL fluid of patients with acute respiratory distress syndrome (252, 259). 
S100-A8 has been established as a pro-inflammatory mediator in chronic and acute 
inflammation (260). It has also been correlated to tumour progression in other cancer types 
including kidney and breast cancer (261, 262). Another study has also confirmed the role of 
S100-A8 protein in promoting cell migration and invasion by the activation of p38 MAPK 
(p38 mitogen-activated protein kinases) and nuclear factor-κB (NF-κB) in gastric cancer cells 
(257).  
Other proteins shown to be up-regulated in the BAL fluid of lung adenocarcinoma 
subjects have been shown to be associated with tumour growth and treatment resistance such 
as annexin A1 and A2 (253). These proteins belong to the annexin superfamily of 
calphobindin and play vital physiological roles in cytoskeletal movement, regulating cell 
growth and forming ion channels (263). Annexin A1 and A2 have been shown to participate 
in tumour drug resistance in lung adenocarcinoma in vivo and in vitro (253). Our results 
revealed that annexin A1 and A2 proteins to be over-expressed in lung adenocarcinoma 
patients compared to non-cancer controls. Similarly, a number of studies have indicated that 
high annexin expression is important for lung cancer (e.g. NSCLC) progression and 
suggested annexin to be a potential prognostic and diagnostic factor and therapeutic target for 
new lung cancer drug development (253, 264-266). In fact, circulating antibodies to annexin 
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A1 and another protein named DEAD box protein 53 (DDX53) have been used as biomarkers 
for early lung cancer diagnosis (265).  
Another protein up-regulated in adenocarcinoma is thymidine phosphorylase (TP), 
also known as platelet-derived endothelial cell growth factor (PD-ECGF). Overexpression of 
TP has been shown in lung cancer, including lung adenocarcinoma (254, 267). It has been 
reported that high TP expression is associated with tumour growth, invasiveness, increased 
microvessel density, metastasis and poor prognosis in lung cancer (254, 267, 268). TP has 
also been suggested by many studies as a potential biomarker for poor prognosis and a novel 
target for treatment of lung adenocarcinoma and other cancers (267, 269, 270). Interestingly, 
TP is one of the major catabolic enzymes of 5-fluorouracil (5-FU) cancer chemotherapy and 
its level in NSCLC tissue correlates to the effectiveness of 5-FU treatment (271).  
The other protein that was found to be elevated in patients with adenocarcinoma is 
Transglutaminase 2 (TG2). It has been linked to invasion and metastasis in different cancer 
types including breast, ovarian cancer and lung cancer (255, 272, 273). It is a multi-functional 
protein that plays an essential role in drug resistance in NSCLC (274, 275). A previous study 
has verified that increased TG2 expression is associated with increased invasion and 
migration in NSCLC cells in vitro and suggested TG2 to be a promising prognostic marker 
(255). Our study confirmed the association of elevated expression of TG2 protein in the BAL 
fluid of patients with lung adenocarcinoma compared to non-cancer controls.  
Other overexpressed proteins such as chloride intracellular channel protein 1, 
transgelin-2, catalase, carbonic anhydrase II, galectin-1, and Lamin-B1 have been shown to 
be promising new lung cancer biomarkers (239, 275-278). CA II protein has been suggested 
to be a potential biomarker for early diagnosis for colorectal cancer and as a significant 
prognostic factor in gastrointestinal stromal tumour (279, 280). CA II has potential roles in 
both proliferation via changes in pH and the association with Na/H transporter and also 
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adaptation to acidified pH as is seen in tumour microenvironments. Another CA family 
member (CA IX) has been associated with adenocarcinoma progression and poor prognosis 
(281).  
 This study not only identified proteins that are associated with lung cancer 
progression, but also proteins that have been suggested to play anti-cancer roles and can thus 
be used as an indication of good tumour prognosis or as potential biomarkers for tumour 
aggressiveness such as profilin-1, prosaposin (282-284). Identifying proteins with pro-tumour 
functions as well as anti-tumour functions may validate the previous proposal that some of 
the inflammatory cells, such as macrophages which are found in BAL fluid samples may play 
a dual role in the tumour microenvironment (13).  
Our study does have a number of limitations, which include small sample size number 
because of the low quality and quantity of BAL fluid samples. Therefore the number of 
samples needs to be expanded to confirm these results. Individual proteins that have been 
shown to be up-regulated in proteomics studies need to be validated using other techniques 
such as ELISA and/or Western blot to ascertain tissue distribution and specificity. Despite the 
broad coverage of proteomics technique, proteomics still has a tendency to detect proteins 
with higher abundance and larger molecular weight. Unfortunately, even the depletion of 
high abundance proteins in the BAL fluid has been shown previously to be associated with 
protein sample loss (285). Thus, further improvements in BAL fluid sample preparation 
protocols and proteomic technology are highly desirable.  
In conclusion, biological processes, cellular components and molecular functions in 
BAL fluid samples from patients with and without adenocarcinoma were identified using 
quantitative proteomics. 33 different proteins were identified to be up-regulated in patients 
with adenocarcinoma compared to non-cancer controls. Identification of these up-regulated 
proteins may provide further knowledge regarding the tumour microenvironment, cancer 
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pathways and potential biomarkers. Finally, using proteomics to study BAL fluid samples in 
lung cancer is a promising technique that can be utilised to discover new biomarkers, 
treatment targets and prognostic and diagnostic indicators. 
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Chapter 6 Characterisation of M1 and M2 Tumour-Associated 
Macrophages (TAMs) in Patients with NSCLC 
6.1. Introduction 
The progression of lung cancer is a complex and multistep process where several 
mechanisms such as transformation, hypoxia, invasion, migration and metastasis are known 
to be the main hallmarks (286, 287). Improving our understanding of these mechanisms is a 
fundamental approach to control the aggressiveness of lung cancer and eventually overcome 
the obstacles to successful lung cancer treatment. Macrophages within the tumour 
microenvironment termed tumour associated macrophages (TAMs) are known to be crucial 
cells in lung cancer as they are in close proximity to tumour cells compared to other stromal 
cells (286). They are known to be responsible for releasing several growth factors, cytokines, 
chemokines, inflammatory mediators and other molecules (20). Many of these factors are 
well known and have been associated with tumour growth, poor prognosis and metastasis 
including VEGF, PDGF and IL-10 (20). In addition, the presence of high numbers of TAMs 
has been connected with the invasion, angiogenesis, hypoxia and early occurrence of 
metastasis in different tumour types including lung cancer (287-290).  
TAMs are a type of cell that belong to the monocyte-macrophage lineage and like 
other macrophages have been described as a heterogeneous population (290). The activation 
of TAMs in response to cytokines, pro- (e.g. IFN-γ, TNF and IL-12) or anti-inflammatory 
(e.g. IL-4 and IL-10) molecules and microbial agents such as LPS (lipopolysaccharide) are 
well known (19, 20, 287). There are two main phenotypes of macrophages: M1 and M2. The 
M1 phenotype is activated by IFN-LPS and TNF-α (18-20, 103). The M1 macrophage 
phenotype has been connected to the expression of IL-1, IL-12, TNF-α, and inducible nitric 
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oxide synthase (iNOS) and also has been correlated with extended survival time in patients 
with NSCLC (18, 20). On the other hand, the M2 macrophages have been correlated with 
tumour initiation and progression and have also been described as inhibitor of inflammation 
(18, 103). The M2 macrophages produce anti-inflammatory cytokines such as IL-10 and 
reduce the expression of iNOS, inhibit antigen presentation and T cell proliferation (19, 107, 
109). The M2 macrophages have been found to encourage the growth of various tumour cells 
in vitro (111) and to increase tumour cell survival (112). They also play a vital role in 
promoting angiogenesis via VEGF, which is a prominent mediator of angiogenesis (18, 113).  
In this study, lung tissues from patients with NSCLC were used to determine the 
possible phenotypic changes in TAM phenotype and this was compared to non-tumour tissue 
from the same patient. TAM phenotype was determined using immunohistochemistry (IHC). 
The TAM phenotype was determined using CD68 (macrophage marker), iNOS (M1) and 
CD163 (M2) antibodies, respectively. This study aims to provide a better understanding of 
the effect of NSCLC on TAM phenotype and is an important aspect of macrophage 
investigation since TAMs are the macrophages most likely to come in direct contact with 
lung tumour cells.  
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6.2. Results 
6.2.1. Expression of CD68, iNOS (M1 marker) and CD163 (M2 marker) in NSCLC tumour 
tissue compared to non-tumour tissue  
In this study, immunohistochemistry (IHC) were used to determine the possible phenotypic 
changes in TAM phenotype of NSCLC compared to non-tumour tissue from the same patient. 
The TAM phenotype was determined using CD68 (macrophage marker), iNOS (M1) and 
CD163 (M2) antibodies, respectively.  
The demographic details of tissue samples are presented in Table 12. CD68 staining 
was used to evaluate TAMs in the NSCLC lung tissue compared to non-cancer tissue. The 
presence of TAMs (CD68 positive staining) was significantly higher in all NSCLC subtypes 
(adenocarcinoma P≤0.0001, squamous cell lung carcinoma P≤0.0001 and large cell lung 
carcinoma P≤0.0001) compared to non-tumour tissue. This result was expected as previous 
studies suggested that more TAMs are recruited to the tumour area and are associated with 
pulmonary disorders such as lung cancer (232, 291). All NSCLC subtypes (adenocarcinoma 
P≤0.0001, squamous cell lung carcinoma P≤0.0001 and large cell lung carcinoma P≤0.0001) 
were found to have significantly higher CD68 and CD163-positive cells when compared to 
non-tumour tissues (Figs. 32, 33 and 34). The % area of positive staining for CD163 was 
greatly increased in all NSCLC tissues (adenocarcinoma P≤0.0001, squamous cell lung 
carcinoma P≤0.0001 and large cell lung carcinoma P≤0.0001) compared to non-tumour 
tissues (Fig. 35).  
For iNOS-stained M1 TAMs, staining was found to be decreased in the tissues of 
patients with adenocarcinoma P≤0.01 and squamous cell lung carcinoma P≤0.05 but not in 
large cell lung carcinoma compared to non-tumour tissue (Figs. 32, 33 and 34). Surprisingly, 
the result of the multiple comparison tests demonstrated that the % area of positive staining 
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for iNOS was significantly decreased in adenocarcinoma P≤0.01 and squamous cell lung 
carcinoma P≤0.01 compared to large cell lung carcinoma (Fig. 35).  
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Table 12: Demographic details of lung cancer subjects for TAM tissue samples using 
immunohistochemistry staining (IHC) 
 n 
Age (years) 
Mean ± SD 
Gender Stages 
Smoking 
status 
Subtypes 
   M/F I/II/III/IV N/Ex/S A/S/L 
       
Tissue 
samples 
32 66.78 ± 11.51 20/12 2/18/11/1 9/11/12 11/10/11 
n: number; SD: standard deviation; M: male; F: female; N: non-smoker; Ex: ex-smoker; S: 
smoker; A: adenocarcinoma; S: squamous cell lung carcinoma; L: large cell lung carcinoma. 
TAMs of tumour and non-cancer tissue samples were obtained from the same patients with 
NSCLC. Samples were purchased from the Victorian Cancer Bio-Bank, Melbourne, 
Australia.  
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 7 Characterisation of M1 and M2 Tumour-Associated Macrophages (TAMs) in Patients with NSCLC 149 
 
Figure 32: Expression of CD68, iNOS and CD163 in tumour (adenocarcinoma) and non-
tumour tissue by immunohistochemistry. (A and B) CD68 (macrophage marker), (C and D) 
iNOS (M1 macrophage marker) and (E and F) CD163 (M2 macrophage marker) were used to 
stain tumour (adenocarcinoma) and non-tumour tissue. Black arrows indicate the expression 
of CD68/iNOS/CD163, x20. The slides were viewed and analysed using ImageScope 
analysis software. The colocalisation algorithm was applied to quantify IHC staining. The 
algorithm calculated the percentage area of positive staining based on the deconvolution 
method to separate the stains and classify each pixel according to the number of stains 
present. The slides were observed and all photos were taken using Leica DMD108 (Leica 
Microsystems, Germany). Please refer to pages 78-79.   
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Figure 33: Expression of CD68, iNOS and CD163 in tumour (squamous cell lung carcinoma) 
and non-tumour tissue by immunohistochemistry. (A and B) CD68 (macrophage marker), (C 
and D) iNOS (M1 macrophage marker) and (E and F) CD163 (M2 macrophage marker) were 
used to stain tumour (squamous cell lung carcinoma) and non-tumour tissue. Black arrows 
indicate the expression of CD68/iNOS/CD163, x20. The slides were viewed and analysed 
using ImageScope analysis software. The colocalisation algorithm was applied to quantify 
IHC staining. The algorithm calculated the percentage area of positive staining based on the 
deconvolution method to separate the stains and classify each pixel according to the number 
of stains present. The slides were observed and all photos were taken using Leica DMD108 
(Leica Microsystems, Germany). Please refer to pages 78-79.   
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Figure 34: Expression of CD68, iNOS and CD163 in tumour (large cell lung carcinoma) and 
non-tumour tissue by immunohistochemistry. (A and B) CD68 (macrophage marker), (C and 
D) iNOS (M1 macrophage marker) and (E and F) CD163 (M2 macrophage marker) were 
used to stain tumour (large cell lung carcinoma) and non-tumour tissue. Black arrows indicate 
the expression of CD68/iNOS/CD163, x20. The slides were viewed and analysed using 
ImageScope analysis software. The colocalisation algorithm was applied to quantify IHC 
staining. The algorithm calculated the percentage area of positive staining based on the 
deconvolution method to separate the stains and classify each pixel according to the number 
of stains present. The slides were observed and all photos were taken using Leica DMD108 
(Leica Microsystems, Germany). Please refer to pages 78-79.   
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Figure 35: Percentage area of positive staining of CD68, iNOS and CD163 in lung tissue of 
different NSCLC subtypes (adenocarcinoma, squamous cell lung carcinoma and large cell 
lung carcinoma) compared to non-tumour tissue. The graphs show % area of positive staining 
± SEM of (A) CD68, (B) iNOS and (C) CD163 on TAMs from non-tumour and tumour 
tissues from the same patient. Results expressed as % area of positive staining ± SEM, (n= 30 
non-tumour tissues, 10 adenocarcinoma, 10 squamous cell lung carcinoma and 10 large cell 
lung carcinoma). Slides were viewed and analysed using the ImageScope analysis software 
and co-localisation algorithm were applied to quantify IHC staining. One-way ANOVA 
multiple comparison test (as a post-test analysis) was performed with the Tukey test (multiple 
comparison test comparing every group with every other group). *P≤0.05, **P≤0.01, 
***P≤0.001 and ****P≤0.0001 indicates statistical significance.  
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6.3. Discussion 
TAMs have been suggested to represent M2 macrophage-like phenotype in lung cancer and 
other tumour types, however it has become clear that TAMs consist of multiple distinct 
populations with different features (20, 290). Factors that contribute to altering TAMs 
towards a M2 phenotype include the location of TAMs within the tumour microenvironment, 
tumour stage and type of cancer. Nevertheless, it is still not fully defined whether the 
diversity within the TAM population is due to the maturation of unique monocytic precursors 
or rom the various factors within the local tumour microenvironment (290). In addition, 
further clarification regarding TAM phenotype within NSCLC subtypes is needed. Here, lung 
tissues from patients with NSCLC (adenocarcinoma, squamous cell lung carcinoma and large 
cell lung carcinoma) were used to investigate M1 and M2 marker expression in TAM 
populations within tumour and non-tumour tissue using immunohistochemistry.  
  Various studies have demonstrated increased TAM infiltration in NSCLC using 
CD68 macrophage marker (62, 159, 232, 291, 292). Some of these studies indicated the 
clinical importance of detecting increased macrophage number and was suggested as a 
powerful predictor of survival in NSCLC (18, 291, 293). In our study, all NSCLC subtypes 
were found to have significantly more CD68-positive cells when compared to non-tumour 
tissues. Similarly, other studies have shown the extensive TAM infiltration with lung tumour 
tissue and linked it with poor prognosis (87, 287). Taken together, these results suggest that 
TAMs contribute to tumour growth and lung cancer progression rather than supporting an 
effective host anti-tumour response. Interestingly, other studies have not supported this 
correlation between TAMs and good and/or poor prognosis in human lung cancer, as they 
reported no correlation with prognosis (294, 295). Differences between study results may 
relate to the examination of different lung cancer histological subtypes, different tumour 
stages or examination of macrophages from different lung segments. Other factors may also 
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contribute to differences such as patient demographics (e.g. smoking status and gender) and 
the presence or absence of comorbidities such as COPD.  
TAMs that express iNOS have been found to be associated with extended survival in 
patients with NSCLC (18, 296). Ohri et al. (2009) used phenotypic markers including iNOS 
and CD163 to study the association of TAM subsets with prognosis (18). They looked at 
NSCLC patients with extended survival versus NSCLC patients with poor survival and 
established that M1 macrophages (CD68
+ 
and iNOS
+
) within tumour islets was greatly 
increased in patients with extended survival compared to poor survival group (18). Also, the 
ratio of M1 macrophages in tumour islets and stroma was significantly increased compared to 
M2 (CD68
+
 and CD163
+
) macrophages in patients with extended survival but not the reduced 
survival cohort (18). All these results tend to validate the association of M1 TAMs with better 
lung cancer prognosis. In our study, M1 TAMs were identified using CD68 and iNOS marker 
in tumour compared to non-tumour tissue in NSCLC patients. Our results indicate that the 
presence of NSCLC correlated with significantly decreased expression of iNOS in patients 
with adenocarcinoma and squamous cell lung carcinoma compared to non-tumour tissues but 
this was not the case in large cell lung carcinoma. Similarly, decreased expression of iNOS in 
TAMs has been demonstrated in previous studies (108, 297). A previous study showed 
reduced iNOS expression in TAMs that were directly isolated from the tumour in tumour-
bearing mice (108). Reduced iNOS expression has also been associated with defective NF-kB 
signalling, which eventually may lead to incorrect regulation of immune response (297). 
Overall these results suggest iNOS as an important mediator that might be targeted in future 
studies to alter the TAM phenotype and to be able eventually to manipulate these cells to 
improve tumour suppressing function. Also, the differences between the NSCLC subtypes 
expression of iNOS might be a possible explanation to recent queries that different lung 
cancer subtypes present different behaviour and respond differently to treatment (298). 
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TAMs that express M2 marker CD163 can stimulate tumour growth by producing 
cytokines to induce proliferation of tumour cells directly or indirectly through increasing 
endothelial cell proliferation and angiogenesis (20). In addition, the percentage of TAMs 
within a tumour microenvironment has been linked with tumour metastasis (299). Our results 
showed that the expression of CD163 was significantly increased in all NSCLC subtypes 
(adenocarcinoma, squamous cell lung carcinoma and large cell lung carcinoma) compared to 
non-tumour tissues. A study that investigated TAMs in advanced NSCLC found that more 
than 95% of CD68
+
 TAMs were located in the tumour stroma and were positively co-stained 
with CD163 (300). Also, the CD68
+
 and CD163
+ 
TAMs count was found to be significantly 
increased in patients with progressive disease (300). Furthermore, other studies have shown 
that the expression of the M2 marker in TAMs was significantly correlated to poor prognosis, 
p-TNM staging and lymph node metastasis in patients with adenocarcinoma (292, 299).  
Despite the relatively comprehensive and high sensitivity and specificity 
methodology, further techniques would be worth adding to future studies such as Western 
blot, immunofluorescence (IF) in order to strengthen the study outcomes. For example, 
immunofluorescence (IF) method would be used to generate high-resolution image, 
quantitate the fluorescence signal and perform multiple staining. Other lung cancer subtypes 
should be considered to inspect if they have any potential role in altering TAM functions and 
phenotypes. Also, the number of tissue samples needs to be expanded to confirm these results 
in a larger cohort.  
In conclusion, the results of this study indicate that all NSCLC subtypes 
(adenocarcinoma, squamous cell lung carcinoma and large cell lung carcinoma) express 
significantly more CD68 and CD163 compared to non-tumour tissues. Also, the expression of 
iNOS in patients with adenocarcinoma and squamous cell lung carcinoma was significantly 
decreased compared to non-tumour tissues but not to that in the large cell lung carcinoma. 
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Also, all these results of TAMs indicate the importance of aiming to target M2 TAMs and 
their pro-tumour activity to eventually skew them back to the M1 TAMs phenotype and thus 
stimulate their anti-tumour activity. This could be potentially done by targeting M2 TAMs 
recruitment, polarisation and pro-tumour functions.  
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This thesis hypothesised that macrophages in local and systemic environment (AMs, 
monocytes and TAMs) alter from M1 to M2-activated phenotype. It has been suggested in 
the literature that NSCLC might have the ability to alter macrophage phenotypes and 
functions and thus eventually lead to tumour onset, progression and metastasis. The aim of 
this study was to assess this theory by identifying if patients diagnosed with NSCLC have 
altered macrophage phenotypes and functions in the local (AMs and TAMs) and/or systemic 
environment (monocytes and serum). This study also looked at identifying potential 
biomarkers that could be associated with NSCLC. Different biological samples (BAL fluid, 
serum, PBMC, RNA, lung tissue and protein) were collected from NSCLC and non-cancer 
controls to assess evidence supporting our hypothesis. Serum samples for Bio-Plex, 
MAGPIX-Luminex were obtained from the Victorian Cancer Bio-Bank to include all 
NSCLC subtypes, especially large cell lung carcinoma as it is not a common subtype 
(accounts for 10-15% of lung cancers). A number of methods were also utilised including 
flow cytometry, RT-PCR, CBA, Bio-Plex, MAGPIX-Luminex assay, IHC and proteomics.   
The study results suggest that NSCLC have the ability to alter some macrophage (AMs 
and TAMs) functions and play a role in changing the AM and TAM phenotype. The 
expression of CD163, a M2 macrophage marker was increased on AMs and TAMs from 
patients with NSCLC compared to non-cancer controls. The expression of CD71 and CD44 
was also increased on AMs from NSCLC patients compared to non-cancer controls. The 
mRNA level of MMP-9 and IL-10 was shown to be higher in NSCLC compared to non-
cancer controls. Also, a number of specific proteins such as S100-A8, annexin A1 and 
annexin A2 in BAL fluid of NSCLC patients were found to be up-regulated in 
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adenocarcinoma compared to non-cancer controls. Although this study showed alteration in 
macrophage populations such as AMs and TAMs, it did not show any alteration in peripheral 
classical monocyte phenotype in patients with NSCLC compared to non-cancer controls. This 
has been associated with unchanged Th1 and Th2 cytokine levels in the serum of NSCLC 
(except large cell lung carcinoma) patients compared to non-cancer controls. Therefore, these 
results suggest that there is no systemic impairment in Th1/Th2 cytokine expression and 
monocyte phenotype and function in patients with NSCLC versus non-cancer controls. 
However, only patients with large cell lung carcinoma showed increased serum levels of IL-
1β, IL-4, IL-6 and IL-8. This result suggests that the impact of NSCLC on macrophage 
phenotypes and functions might change based on tumour subtypes. Another example of the 
influence of tumour subtypes is the recognised difference in the expression of iNOS on 
TAMs between NSCLC subtypes (adenocarcinoma, squamous cell lung carcinoma and large 
cell lung carcinoma). These results suggest that different lung cancer subtypes present a 
unique behaviour and pathway within the tumour microenvironment.  
Taken together, the results of this study suggest for the first time that NSCLC might 
have the ability to alter macrophage phenotype and function within the local tumour 
microenvironment (AMs and TAMs) but not in the systemic environment (classical 
monocytes and serum) except for the patients with large cell lung carcinoma. This might be 
because of the direct interaction between macrophages (AMs and TAMs) and tumour cells 
within the tumour microenvironment. This contact potentially makes the AMs and TAMs 
more vulnerable to the influence of tumour cells through various growth factors, cytokines, 
chemokines, cell-surface receptors and other molecules in the local environment unlike in the 
systemic environment (monocytes).  
In addition, the up-regulation of specific proteins in BAL fluid of lung adenocarcinoma 
patients may be useful as potential biomarkers for lung adenocarcinoma. Using proteomic 
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techniques to study BAL fluid samples in lung cancer patients and other pulmonary disorders 
is a promising technique that may be utilised to identify new biomarkers, treatment targets 
and prognostic and diagnostic indicators. Further investigations are required to ascertain if 
the skewing of M1 to M2 phenotype in primary lung cancer can lead to the upregulation of 
new biomarkers that can be used for diagnostic and/or therapeutic benefits.  
Despite the findings described in this study, it does present with some limitations 
including an inability to compare results from subtypes within NSCLC groups, as the 
majority of the NSCLC samples were adenocarcinoma. Therefore, we could not confidently 
address the question of whether alteration in AM phenotype and function was NSCLC 
subtype dependent (e.g. squamous cell lung carcinoma and large cell lung carcinoma). The 
small sample size of AM tested may explain the different results seen in IL-6 expression 
between serum and mRNA samples. Although, IL-6 level was increased in the serum of large 
cell lung carcinoma patients compared to non-cancer controls, the IL-6 mRNA expression 
was not affected in the presence of large cell lung carcinoma. Therefore, the number of AM 
samples needs to be expanded to confirm if large cell lung carcinoma would have the same 
impact on IL-6 mRNA expression. For the proteomics study, we suggest that the sample size 
number needs to be expanded to confirm these results. Also, individual proteins that have 
been shown to be up-regulated in the proteomics studies should be validated using other 
techniques such as ELISA and/or Western blot. In future studies, examining macrophage 
phenotype and function in non-cancer controls versus lung cancer should be done by using 
fresh un-stimulated AMs and monocytes as well as cytokine treated AMs and monocytes at 
the same time to observe any variation that may occur. Future studies should also be 
performed to clarify if the alteration in macrophage phenotypes (skewing to M2-activated 
phenotype) and functions is a cause and/or an effect. The illumination of the complex 
relationship between NSCLC and macrophage would be highly beneficial in improving our 
 Chapter 8 General Discussion & Conclusion 161 
understanding regarding this association. Also, the quality of BAL fluid samples need to be 
kept in mind as some samples were processed below the optimum quality and quantity of 
BAL cells. Therefore, further improvements in BAL fluid collection protocols are needed. In 
addition, proteomics has a tendency to detect proteins with higher abundance and larger 
molecular weight. Unfortunately, even the depletion of high abundance proteins in BAL fluid 
has been shown previously to be associated with protein sample loss. Thus, further 
improvements in BAL fluid sample preparation protocols and proteomic technology are 
highly desirable. Despite the comprehensive nature of our methodology, further techniques 
would be worth adding to future studies such as ELISA and Western blot in order to 
strengthen some of the study outcomes. For example, the up-regulated proteins (e.g. CD163, 
S100-A8, annexin A1, annexin A2, thymidine phosphorylase and transglutaminase 2) that 
were identified in our study are desired to be confirmed using Western blot technique.  
Finally, the outcome of this work suggests that the presence of NSCLC is associated 
with a certain alteration in macrophages phenotype and function. Therefore, these results 
suggest that targeting M2 macrophages to reduce their numbers or function, as well as to 
skew the M2 macrophages back to a M1 phenotype, may be beneficial to the outcomes of 
primary lung cancer patients. Lastly, this study revealed a number of specific proteins (e.g. 
CD163, S100-A8, annexin A1, annexin A2, thymidine phosphorylase and transglutaminase 
2) and cytokines (IL-1β, IL-4, IL-6, IL-8, IL-10 and MMP-9) that were identified to be 
associated with NSCLC patients may be used as novel prognostic and/or diagnostic 
biomarkers in patients with NSCLC. 
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Chapter 9  Appendices 
Appendix A: Additional tables 
Table 13: A list of the molecular functions that were found using proteomics technique  
No. Molecular functions Percentage 
1 Protein binding 28.42% 
2 Catalytic activity 22.06% 
3 Nucleotide binding 10.72% 
4 Metal ion binding 9.07% 
5 RNA binding 5.36% 
6  Transporter activity 4.66% 
7 No annotation available  4.53% 
8 Structural molecule activity  4.10% 
9 Enzyme regulator activity 2.75% 
10 DNA binding 2.44% 
11  Signal tranducer activity 1.79% 
12 Receptor activity 1.70% 
13 Anti-oxidant activity 1.39% 
14 Motor activity 0.78% 
15 Translation regulator activity  0.17% 
16 Transcription regulator activity  0.04% 
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Table 14: A list of the cellular components that were found using proteomics technique  
No. Cellular components Percentage 
1 Cytoplasm 22.55% 
2 Membrane 14.44% 
3 Cytosol 8.65% 
4 Nucleus 8.35% 
5 Extracellular 8.16% 
6 Organelle lumen 7.87% 
7 Mitochondrion 6.52% 
8 Cytoskeleton 3.96% 
9 Endoplasmic reticulum 3.85% 
10 No annotation available  3.07% 
11 Vacuole 2.96% 
12 Golgi 2.69% 
13 Endosome 2.13% 
14 Cell surface 1.46% 
15 Ribosome 1.40% 
16 Chromosome 0.75% 
17 Proteasome 0.65% 
18 Spliceosomal complex 0.51% 
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Table 15: A list of the biological processes that were found using proteomics technique 
No. Biological process Percentage 
1 Metabolic process 18.59% 
2 Regulation of biological process  12.56% 
3 Responose to stimulus 12.42% 
4 Transport 9.44% 
5 Cell organization and biogenesis 9.17% 
6 Cell communication 7.47% 
7 Development 5.32% 
8 Cell death 4.07% 
9 Defence response 3.78% 
10 Cell differentiation 3.34% 
11 Cellular component movement  2.85% 
12 No annotation available  2.63% 
13 Cell proliferation 2.34% 
14 Cellular homeostasis  1.83% 
15 Coagulation 1.68% 
16 Reproduction 1.15% 
17 Cell division 0.68% 
18 Cell growth 0.66% 
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Table 16: A list of all BAL fluid and blood processed samples with the diagnosis and stages 
Subject ID 
Small cell 
carcinoma 
Non-small 
cell 
carcinoma 
Squamous 
cell 
Adenocarc
inoma 
Large cell Infection Negative  Control Stage GOLD 
1 0 0 0 0 0 0 1 1  0 
2 0 0 0 0 0 0 1 0 3B 4 
3 0 1 0 0 0 0 1 0 1A 2 
4 0 0 1 0 0 0 0 0 2B 0 
5 0 0 0 0 0 0 1 1  0 
6 0 1 0 0 0 0 1 0 3A 0 
7 0 0 0 0 0 0 1 1  2 
8 0 0 0 0 0 0 1 1  Not tested 
9 0 0 0 0 0 0 1 1  2 
10 0 0 0 0 0 0 1 1  0 
11 0 0 0 1 0 0 0 0  0 
12 0 0 0 0 0 0 1 1  0 
13 0 0 1 0 0 0 0 0 3B Not tested 
14 0 0 0 0 0 0 1 0 1B 0 
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15 0 0 0 0 0 0 1 1  0 
16 0 0 0 0 0 0 1 1  1 
17 0 0 0 0 0 0 1 1  1 
18 0 0 0 0 0 0 1 1  2 
19 0 0 0 1 0 0 0 
Metastasis 
from Renal 
Carcinoma 
 Not tested 
20 0 0 0 0 0 0 1 1  1 
21 0 0 0 0 0 0 1 1  Not tested 
22 0 0 0 0 0 0 1 0 1A 0 
23 0 0 0 0 0 0 1 1  Not tested  
24 0 0 0 0 0 0 1 1  0 
25 0 0 0 0 1 0 0 0 4 Not tested 
26 0 0 1 0 0 0 0 0 4 0 
27 0 0 0 0 0 1 0 0  1 
28 0 0 1 0 0 0 0 0  Not tested  
29 0 1 0 0 0 1 1 0 1A 2 
30 0 0 0 0 0 0 1 1  0 
31 0 0 0 1 0 0 0 0 4 2 
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32 0 0 0 0 0 0 1 1  Not tested 
33 0 0 0 0 0 0 1 1  Not tested 
34 0 0 0 0 0 0 1 1  0 
35 0 0 0 0 0 0 1 1  3 
36 0 0 0 0 0 0 1 1  Not tested 
37 0 0 0 0 0 0 1 1  Not tested 
38 0 0 0 0 0 0 1 1  0 
39 0 1 0 0 0 0 0 0 4 3 
40 0 0 0 0 0 0 1 1  0 
41 0 0 0 1 0 0 1 0 2A 0 
42 0 1 0 1 0 0 0 
Breast  Ca 
Metastisis 
 1 
43 0 0 0 0 0 0 1 0 3B 0 
44 0 1 1 0 0 0 0 0 4 0 
45 0 1 0 1 0 0 0 0 4 Not tested 
46 0 1 0 1 0 0 0 0 2A 0 
47 0 0 0 0 0 0 1 1  2 
48 0 0 0 0 0 0 1 1  3 
49 0 0 1 0 0 0 0 0 3A 2 
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50 0 0 0 0 0 0 0   2 
51 0 0 0 0 0 0 1 
 
 2 
52 0 0 0 0 0 0 0 
 
 3 
53 0 0 0 1 0 0 0 0 1A 4 
54 0 0 0 0 0 0 1 1  Not tested 
55 0 0 0 1 0 0 0 0 4 3 
56 0 0 1 0 0 0 0 0 3A 2 
57 0 1 1 0 0 0 0 0 1A 2 
58 0 0 0 0 0 0 1 0  0 
59 0 0 0 1 0 0 0 0 4 3 
60 0 0 1 0 0 0 0 0 4 Not tested 
61 0 1 0 1 0 0 0 0 4 0 
62 0 1 0 1 0 0 0 0 4 2 
63 0 0 0 0 0 0 1 
 
 0 
64 0 0 0 1 0 0 0 0 4 4 
65 0 0 1 0 0 0 0 0 3A 2 
66 0 0 0 0 0 1 0 1  2 
67 0 0 1 0 0 0 0 0 4 1 
68 0 0 1 0 0 0 0 0 3A 0 
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69 0 0 0 0 0 0 1 1  Not tested 
70 0 1 0 1 0 0 0 0 1B 1 
71 0 1 1 0 0 0 0 0 2A 0 
72 0 0 1 0 0 0 0 0 4 2 
73 0 1 0 1 0 0 0 0 4 0 
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Table 17: A list of all BAL fluid and blood processed samples with age, smoking, cough, haemoptysis and malignancy data 
Subject 
ID 
Age Smoker 
Ex-
smoker 
Never 
smoked 
Cigarettes 
per day 
Smoking 
years 
Pack-years Cough Haemoptysis Malignancy 
1 18 1 0 0 7 2 0.7 1 0 0 
2 67 0 1 0 
  
50 0 0 1 
3 81 0 1 0 
  
75 0 0 1 
4 70 0 1 0 
  
40 0 0 1 
5 44 0 0 1 
  
0 0 1 0 
6 65 1 0 0 15 30 22.5 0 0 1 
7 75 0 1 0 40 50 100 0 1 0 
8 77 0 0 1 0 0 0 0 0 1 
9 71 0 1 0 50 55 137.5 0 0 1 
10 80 0 0 1 0 0 0 1 0 0 
11 73 1 0 0 2 
 
10 0 0 1 
12 48 0 1 0 
  
25 0 1 0 
13 73 0 0 1 0 0 0 0 0 1 
14 75 1 0 0 30 63 94.5 0 0 1 
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15 38 0 0 1 0 0 0 0 0 1 
16 64 0 0 1 0 0 0 0 1 1 
17 66 0 1 0 0 
 
56 0 1 1 
18 60 1 0 0 10 
 
63 0 0 1 
19 67 0 0 1 0 0 0 1 0 1 
20 69 0 1 0 
  
20 0 0 1 
21 60 0 1 0 
  
38 0 1 0 
22 73 0 1 0 10 50 25 0 0 1 
23 40 0 0 1 0 0 0 1 0 0 
24 63 1 0 0 6 24 7.2 0 0 1 
25 55 0 1 0 
  
15 0 0 1 
26 63 0 1 0 
  
50 0 1 1 
27 81 0 1 0 
  
60 0 0 1 
28 54 0 1 0 
  
35 0 0 1 
29 72 0 1 0 0 0 44 0 0 1 
30 39 0 1 0 
  
5 1 0 0 
31 74 1 0 0 12 60 36 0 0 1 
32 26 0 0 1 0 0 0 1 1 0 
33 55 0 0 1 0 0 0 0 0 1 
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34 41 1 0 0 5 
 
10 0 1 0 
35 64 0 1 0 
  
66 1 0 1 
36 47 1 0 0 5 20 4 1 0 0 
37 42 0 0 1 0 0 0 0 1 0 
38 20 1 0 0 2 
 
2 1 0 0 
39 66 0 1 0 40 35 70 0 0 1 
40 51 0 0 1 0 0 0 1 0 0 
41 66 0 1 0 
  
66 0 0 1 
42 62 0 1 0 5 22 5 0 0 1 
43 58 0 0 1 0 0 0 0 0 1 
44 50 1 0 0 
  
15 0 0 1 
45 63 0 1 0 
   
0 0 1 
46 66 0 1 0 
  
100 0 0 1 
47 78 0 1 0 
  
40 0 0 1 
48 84 0 1 0 
   
0 0 1 
49 74 1 0 0 
  
108 0 0 1 
50 57 1 0 0 
  
13 0 0 1 
51 66 1 0 0 10 
 
40 0 0 1 
52 67 0 1 0 
  
55 0 0 1 
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53 61 1 0 0 15 41 30.75 0 0 1 
54 72 0 1 0 5 20 4 0 0 1 
55 75 0 1 0 
  
15 0 0 1 
56 81 0 1 0 
  
82.5 0 0 1 
57 79 0 1 0 
  
55 0 0 1 
58 70 0 1 0 
  
50 0 0 1 
59 57 1 0 0 
  
41.25 0 0 1 
60 42 0 1 0 
  
20 0 0 1 
61 67 0 0 1 0 0 0 0 0 1 
62 80 1 0 0 
  
55 0 0 1 
63 82 0 1 0 
  
26 0 0 1 
64 63 1 0 0 
  
45 0 0 1 
65 54 0 1 0 
  
80 0 0 1 
66 74 0 1 0 
  
110 0 0 1 
67 82 0 1 0 
  
18 0 0 1 
68 69 0 1 0 12 30 18 0 0 1 
69 68 0 1 0 
  
53 0 0 1 
70 77 1 0 0 
  
140 0 0 1 
71 72 0 1 0 
  
5 0 0 1 
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72 76 1 0 0 
  
60 0 0 1 
73 75 0 0 1 0 0 0 0 0 1 
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Table 18: A list of all identified proteins in BAL fluid samples 
No. Protein name Description 
MW 
[kDa] 
Σ# 
Peptides 
Σ# 
Unique 
Peptide
s 
1 1433B_HUMAN 
RecName: Full=14-3-3 protein beta/alpha; AltName: Full=Protein 1054; AltName: Full=Protein kinase 
C inhibitor protein 1; Short=KCIP-1; Contains: RecName: Full=14-3-3 protein beta/alpha, N-
terminally processed; - OS=Homo sapiens (Human). 
28.1 8 6 
2 1433E_HUMAN RecName: Full=14-3-3 protein epsilon; Short=14-3-3E; - OS=Homo sapiens (Human). 29.2 6 4 
3 1433F_HUMAN RecName: Full=14-3-3 protein eta; AltName: Full=Protein AS1; - OS=Homo sapiens (Human). 28.2 4 2 
4 1433T_HUMAN 
RecName: Full=14-3-3 protein theta; AltName: Full=14-3-3 protein T-cell; AltName: Full=14-3-3 
protein tau; AltName: Full=Protein HS1; - OS=Homo sapiens (Human). 
27.7 4 2 
5 1433Z_HUMAN 
RecName: Full=14-3-3 protein zeta/delta; AltName: Full=Protein kinase C inhibitor protein 1; 
Short=KCIP-1; - OS=Homo sapiens (Human). 
27.7 7 5 
6 3HIDH_HUMAN 
RecName: Full=3-hydroxyisobutyrate dehydrogenase, mitochondrial; Short=HIBADH; EC=1.1.1.31; 
Flags: Precursor; - OS=Homo sapiens (Human). 
35.3 3 3 
7 6PGL_HUMAN 
RecName: Full=6-phosphogluconolactonase; Short=6PGL; EC=3.1.1.31; - OS=Homo sapiens 
(Human). 
27.5 2 2 
8 A0PJ62_HUMAN SubName: Full=RPL14 protein; Flags: Fragment; - OS=Homo sapiens (Human). 14.6 1 1 
9 A1A5C5_HUMAN SubName: Full=RRBP1 protein; - OS=Homo sapiens (Human). 84.3 4 4 
10 A1AT_HUMAN 
RecName: Full=Alpha-1-antitrypsin; AltName: Full=Alpha-1 protease inhibitor; AltName: 
Full=Alpha-1-antiproteinase; AltName: Full=Serpin A1; Contains: RecName: Full=Short peptide from 
AAT; Short=SPAAT; Flags: Precursor; - OS=Homo sapiens (Human). 
46.7 4 4 
11 A1JUI8_HUMAN SubName: Full=Chaperonin subunit 6A; Flags: Fragment; - OS=Homo sapiens (Human). 53.6 5 4 
12 A1L0W4_HUMAN SubName: Full=CDC37 protein; SubName: Full=MBD5 protein; Flags: Fragment; - OS=Homo 12.2 1 1 
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sapiens (Human). 
13 A1L172_HUMAN SubName: Full=Acyl-CoA thioesterase 1; - OS=Homo sapiens (Human). 46.3 7 7 
14 A2A2D0_HUMAN RecName: Full=Stathmin; Flags: Fragment; - OS=Homo sapiens (Human). 9.9 2 2 
15 A2A2F9_HUMAN 
SubName: Full=Chromosome 20 open reading frame 3; Flags: Fragment; - OS=Homo sapiens 
(Human). 
45.3 5 5 
16 A2ACR1_HUMAN RecName: Full=Proteasome subunit beta type; EC=3.4.25.1; - OS=Homo sapiens (Human). 20.9 2 2 
17 A2BEY0_HUMAN SubName: Full=Valyl-tRNA synthetase; Flags: Fragment; - OS=Homo sapiens (Human). 131.7 1 1 
18 A2VCQ4_HUMAN SubName: Full=PRKCSH protein; Flags: Fragment; - OS=Homo sapiens (Human). 20.3 3 2 
19 A4D1R6_HUMAN 
SubName: Full=Similar to 60S ribosomal protein L17 (L23) (Amino acid starvation-induced protein) 
(ASI); - OS=Homo sapiens (Human). 
11.9 1 1 
20 A4FRB6_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 21.7 2 2 
21 A4FU71_HUMAN 
SubName: Full=C3orf60 protein; SubName: Full=Chromosome 3 open reading frame 60, isoform 
CRA_c; - OS=Homo sapiens (Human). 
13.8 1 1 
22 A4QPB0_HUMAN SubName: Full=IQ motif containing GTPase activating protein 1; - OS=Homo sapiens (Human). 189.2 16 16 
23 A4UCS8_HUMAN RecName: Full=Enolase; EC=4.2.1.11; Flags: Fragment; - OS=Homo sapiens (Human). 17.8 4 1 
24 A5YM50_HUMAN SubName: Full=RAB11B protein; - OS=Homo sapiens (Human). 24.5 5 5 
25 A6H8Y6_HUMAN SubName: Full=EML4 protein; - OS=Homo sapiens (Human). 102.4 4 4 
26 A6NKB8_HUMAN SubName: Full=Aminopeptidase B; - OS=Homo sapiens (Human). 68.1 2 2 
27 A6NMU3_HUMAN 
SubName: Full=Signal transducing adapter molecule 1; Flags: Fragment; - OS=Homo sapiens 
(Human). 
19.2 1 1 
28 A7UMH1_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 10.8 4 0 
29 A7UP02_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 11.0 3 0 
30 A7Y9J9_HUMAN SubName: Full=Mucin 5AC, oligomeric mucus/gel-forming; - OS=Homo sapiens (Human). 648.4 7 3 
31 A8K0T9_HUMAN 
SubName: Full=cDNA FLJ75422, highly similar to Homo sapiens capping protein (actin filament) 
muscle Z-line, alpha 1, mRNA; - OS=Homo sapiens (Human). 
32.9 5 4 
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32 A8K2Q6_HUMAN RecName: Full=Peptidyl-prolyl cis-trans isomerase; EC=5.2.1.8; - OS=Homo sapiens (Human). 22.7 1 1 
33 A8K335_HUMAN 
SubName: Full=cDNA FLJ76254, highly similar to Homo sapiens gamma-glutamyl hydrolase (GGH), 
mRNA; - OS=Homo sapiens (Human). 
36.0 2 2 
34 A8K3W4_HUMAN 
SubName: Full=cDNA FLJ75163, highly similar to Homo sapiens heterogeneous nuclear 
ribonucleoprotein U-like 1 (HNRPUL1), transcript variant 4, mRNA; - OS=Homo sapiens (Human). 
84.8 2 2 
35 A8K486_HUMAN RecName: Full=Peptidyl-prolyl cis-trans isomerase; EC=5.2.1.8; - OS=Homo sapiens (Human). 18.0 5 5 
36 A8K4G3_HUMAN 
SubName: Full=Tyrosine-protein kinase HCK; SubName: Full=cDNA FLJ78472, highly similar to 
Human hemopoietic cell protein-tyrosine kinase (HCK) gene; - OS=Homo sapiens (Human). 
57.4 2 2 
37 A8K4W2_HUMAN 
SubName: Full=cDNA FLJ78635, highly similar to Homo sapiens ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit b, isoform 1 (ATP5F1), transcript variant 1, mRNA; - OS=Homo 
sapiens (Human). 
28.9 3 3 
38 A8K4W5_HUMAN 
SubName: Full=cDNA FLJ76813, highly similar to Homo sapiens acetyl-Coenzyme A 
acetyltransferase 2 (acetoacetyl Coenzyme A thiolase), mRNA; - OS=Homo sapiens (Human). 
41.4 3 3 
39 A8K590_HUMAN 
SubName: Full=cDNA FLJ77456, highly similar to Homo sapiens interleukin enhancer binding factor 
3, 90kDa (ILF3), transcript variant 2, mRNA; - OS=Homo sapiens (Human). 
76.0 2 2 
40 A8K5W7_HUMAN 
RecName: Full=Isoleucine--tRNA ligase A; EC=6.1.1.5; AltName: Full=Isoleucyl-tRNA synthetase A; 
- OS=Homo sapiens (Human). 
105.9 5 5 
41 A8K646_HUMAN 
SubName: Full=cDNA FLJ75699, highly similar to Homo sapiens osteoclast stimulating factor 1 
(OSTF1), mRNA; - OS=Homo sapiens (Human). 
23.7 2 2 
42 A8K766_HUMAN 
SubName: Full=cDNA FLJ77343, highly similar to Homo sapiens electron-transfer-flavoprotein, beta 
polypeptide(ETFB), mRNA; - OS=Homo sapiens (Human). 
27.9 2 2 
43 A8K7J3_HUMAN 
SubName: Full=cDNA FLJ75535, highly similar to Homo sapiens early endosome antigen 1, 162kD 
(EEA1), mRNA; Flags: Fragment; - OS=Homo sapiens (Human). 
92.6 1 1 
44 A8K7W1_HUMAN 
SubName: Full=cDNA FLJ75779, highly similar to Homo sapiens docking protein 2, 56kDa (DOK2), 
transcript variant 1, mRNA; - OS=Homo sapiens (Human). 
45.4 2 2 
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45 A8K8F6_HUMAN 
SubName: Full=cDNA FLJ78417, highly similar to Homo sapiens low density lipoprotein receptor-
related protein associated protein 1 (LRPAP1), mRNA; - OS=Homo sapiens (Human). 
41.4 1 1 
46 A8K8J9_HUMAN 
SubName: Full=Dynactin 2 (P50), isoform CRA_b; SubName: Full=cDNA FLJ31120 fis, clone 
IMR322000730, highly similar to Dynactin subunit 2; SubName: Full=cDNA FLJ77785; - OS=Homo 
sapiens (Human). 
34.5 3 3 
47 A8K9B9_HUMAN 
SubName: Full=cDNA FLJ77391, highly similar to Homo sapiens EH-domain containing 4 (EHD4), 
mRNA; - OS=Homo sapiens (Human). 
61.1 1 1 
48 A8K9J7_HUMAN RecName: Full=Histone H2B; - OS=Homo sapiens (Human). 14.0 3 1 
49 A8K9K4_HUMAN 
SubName: Full=cDNA FLJ75504, highly similar to Homo sapiens glucosidase I, mRNA; - OS=Homo 
sapiens (Human). 
62.2 2 2 
50 A8KA41_HUMAN 
SubName: Full=cDNA FLJ75060, highly similar to Homo sapiens 2'-5'-oligoadenylate synthetase 2, 
69/71kDa, mRNA; - OS=Homo sapiens (Human). 
78.8 2 2 
51 A8KA83_HUMAN 
SubName: Full=cDNA FLJ78586, highly similar to Homo sapiens VAMP (vesicle-associated 
membrane protein)-associated protein A, 33kDa (VAPA), mRNA; SubName: Full=cDNA, FLJ96653, 
Homo sapiens VAMP (vesicle-associated membrane protein)-associated protein A, 33kDa (VAPA), 
mRNA; - OS=Homo sapiens (Human). 
27.3 2 2 
52 A8KAK1_HUMAN 
SubName: Full=cDNA FLJ77398, highly similar to Homo sapiens UDP-glucose ceramide 
glucosyltransferase-like 1, transcript variant 2, mRNA; - OS=Homo sapiens (Human). 
174.9 2 2 
53 A8MTY9_HUMAN SubName: Full=Down syndrome critical region protein 3; - OS=Homo sapiens (Human). 27.9 1 1 
54 A8MXL6_HUMAN SubName: Full=Protein SEC13 homolog; - OS=Homo sapiens (Human). 31.6 1 1 
55 ABRAL_HUMAN 
RecName: Full=Costars family protein ABRACL; AltName: Full=ABRA C-terminal-like protein; - 
OS=Homo sapiens (Human). 
9.1 1 1 
56 ACBP_HUMAN 
RecName: Full=Acyl-CoA-binding protein; Short=ACBP; AltName: Full=Diazepam-binding 
inhibitor; Short=DBI; AltName: Full=Endozepine; Short=EP; - OS=Homo sapiens (Human). 
10.0 2 2 
57 ACOT9_HUMAN RecName: Full=Acyl-coenzyme A thioesterase 9, mitochondrial; Short=Acyl-CoA thioesterase 9; 49.9 2 2 
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EC=3.1.2.-; AltName: Full=Acyl-CoA thioester hydrolase 9; Flags: Precursor; - OS=Homo sapiens 
(Human). 
58 ACOX1_HUMAN 
RecName: Full=Peroxisomal acyl-coenzyme A oxidase 1; Short=AOX; EC=1.3.3.6; AltName: 
Full=Palmitoyl-CoA oxidase; AltName: Full=Straight-chain acyl-CoA oxidase; Short=SCOX; - 
OS=Homo sapiens (Human). 
74.4 7 7 
59 ACTN4_HUMAN 
RecName: Full=Alpha-actinin-4; AltName: Full=F-actin cross-linking protein; AltName: Full=Non-
muscle alpha-actinin 4; - OS=Homo sapiens (Human). 
104.8 19 8 
60 ADT2_HUMAN 
RecName: Full=ADP/ATP translocase 2; AltName: Full=ADP,ATP carrier protein 2; AltName: 
Full=ADP,ATP carrier protein, fibroblast isoform; AltName: Full=Adenine nucleotide translocator 2; 
Short=ANT 2; AltName: Full=Solute carrier family 25 member 5; - OS=Homo sapiens (Human). 
32.8 9 2 
61 ADT3_HUMAN 
RecName: Full=ADP/ATP translocase 3; AltName: Full=ADP,ATP carrier protein 3; AltName: 
Full=ADP,ATP carrier protein, isoform T2; Short=ANT 2; AltName: Full=Adenine nucleotide 
translocator 3; Short=ANT 3; AltName: Full=Solute carrier family 25 member 6; - OS=Homo sapiens 
(Human). 
32.8 9 2 
62 ADX_HUMAN 
RecName: Full=Adrenodoxin, mitochondrial; AltName: Full=Adrenal ferredoxin; AltName: 
Full=Ferredoxin-1; AltName: Full=Hepatoredoxin; Flags: Precursor; - OS=Homo sapiens (Human). 
19.4 1 1 
63 AHNK_HUMAN 
RecName: Full=Neuroblast differentiation-associated protein AHNAK; AltName: Full=Desmoyokin; - 
OS=Homo sapiens (Human). 
628.7 49 46 
64 AHSP_HUMAN 
RecName: Full=Alpha-hemoglobin-stabilizing protein; AltName: Full=Erythroid differentiation-
related factor; AltName: Full=Erythroid-associated factor; - OS=Homo sapiens (Human). 
11.8 2 2 
65 AIFM1_HUMAN 
RecName: Full=Apoptosis-inducing factor 1, mitochondrial; EC=1.-.-.-; AltName: Full=Programmed 
cell death protein 8; Flags: Precursor; - OS=Homo sapiens (Human). 
66.9 4 4 
66 AK1A1_HUMAN 
RecName: Full=Alcohol dehydrogenase [NADP(+)]; EC=1.1.1.2; AltName: Full=Aldehyde reductase; 
AltName: Full=Aldo-keto reductase family 1 member A1; - OS=Homo sapiens (Human). 
36.5 5 4 
67 AL5AP_HUMAN RecName: Full=Arachidonate 5-lipoxygenase-activating protein; AltName: Full=FLAP; AltName: 18.1 3 3 
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Full=MK-886-binding protein; - OS=Homo sapiens (Human). 
68 ALDH2_HUMAN 
RecName: Full=Aldehyde dehydrogenase, mitochondrial; EC=1.2.1.3; AltName: Full=ALDH class 2; 
AltName: Full=ALDH-E2; AltName: Full=ALDHI; Flags: Precursor; - OS=Homo sapiens (Human). 
56.3 20 18 
69 ALDR_HUMAN 
RecName: Full=Aldose reductase; Short=AR; EC=1.1.1.21; AltName: Full=Aldehyde reductase; 
AltName: Full=Aldo-keto reductase family 1 member B1; - OS=Homo sapiens (Human). 
35.8 2 1 
70 AMPL_HUMAN 
RecName: Full=Cytosol aminopeptidase; EC=3.4.11.1; AltName: Full=Leucine aminopeptidase 3; 
Short=LAP-3; AltName: Full=Leucyl aminopeptidase; AltName: Full=Peptidase S; AltName: 
Full=Proline aminopeptidase; EC=3.4.11.5; AltName: Full=Prolyl aminopeptidase; - OS=Homo 
sapiens (Human). 
56.1 9 9 
71 ANK1_HUMAN 
RecName: Full=Ankyrin-1; Short=ANK-1; AltName: Full=Ankyrin-R; AltName: Full=Erythrocyte 
ankyrin; - OS=Homo sapiens (Human). 
206.1 9 9 
72 ANXA1_HUMAN 
RecName: Full=Annexin A1; AltName: Full=Annexin I; AltName: Full=Annexin-1; AltName: 
Full=Calpactin II; AltName: Full=Calpactin-2; AltName: Full=Chromobindin-9; AltName: 
Full=Lipocortin I; AltName: Full=Phospholipase A2 inhibitory protein; AltName: Full=p35; - 
OS=Homo sapiens (Human). 
38.7 12 12 
73 ANXA2_HUMAN 
RecName: Full=Annexin A2; AltName: Full=Annexin II; AltName: Full=Annexin-2; AltName: 
Full=Calpactin I heavy chain; AltName: Full=Calpactin-1 heavy chain; AltName: Full=Chromobindin-
8; AltName: Full=Lipocortin II; AltName: Full=Placental anticoagulant protein IV; Short=PAP-IV; 
AltName: Full=Protein I; AltName: Full=p36; - OS=Homo sapiens (Human). 
38.6 17 17 
74 ANXA5_HUMAN 
RecName: Full=Annexin A5; AltName: Full=Anchorin CII; AltName: Full=Annexin V; AltName: 
Full=Annexin-5; AltName: Full=Calphobindin I; Short=CBP-I; AltName: Full=Endonexin II; 
AltName: Full=Lipocortin V; AltName: Full=Placental anticoagulant protein 4; Short=PP4; AltName: 
Full=Placental anticoagulant protein I; Short=PAP-I; AltName: Full=Thromboplastin inhibitor; 
AltName: Full=Vascular anticoagulant-alpha; Short=VAC-alpha; - OS=Homo sapiens (Human). 
35.9 11 10 
75 AP2A1_HUMAN RecName: Full=AP-2 complex subunit alpha-1; AltName: Full=100 kDa coated vesicle protein A; 107.5 3 3 
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AltName: Full=Adapter-related protein complex 2 alpha-1 subunit; AltName: Full=Adaptor protein 
complex AP-2 subunit alpha-1; AltName: Full=Alpha-adaptin A; AltName: Full=Alpha1-adaptin; 
AltName: Full=Clathrin assembly protein complex 2 alpha-A large chain; AltName: Full=Plasma 
membrane adaptor HA2/AP2 adaptin alpha A subunit; - OS=Homo sapiens (Human). 
76 APOA1_HUMAN 
RecName: Full=Apolipoprotein A-I; Short=Apo-AI; Short=ApoA-I; AltName: Full=Apolipoprotein 
A1; Contains: RecName: Full=Truncated apolipoprotein A-I; AltName: Full=Apolipoprotein A-I(1-
242); Flags: Precursor; - OS=Homo sapiens (Human). 
30.8 6 6 
77 APOA2_HUMAN 
RecName: Full=Apolipoprotein A-II; Short=Apo-AII; Short=ApoA-II; AltName: Full=Apolipoprotein 
A2; Contains: RecName: Full=Truncated apolipoprotein A-II; AltName: Full=Apolipoprotein A-II(1-
76); Flags: Precursor; - OS=Homo sapiens (Human). 
11.2 1 1 
78 APOD_HUMAN 
RecName: Full=Apolipoprotein D; Short=Apo-D; Short=ApoD; Flags: Precursor; - OS=Homo sapiens 
(Human). 
21.3 1 1 
79 ARC1B_HUMAN 
RecName: Full=Actin-related protein 2/3 complex subunit 1B; AltName: Full=Arp2/3 complex 41 kDa 
subunit; AltName: Full=p41-ARC; - OS=Homo sapiens (Human). 
40.9 4 4 
80 ARF6_HUMAN RecName: Full=ADP-ribosylation factor 6; - OS=Homo sapiens (Human). 20.1 2 2 
81 ARP2_HUMAN 
RecName: Full=Actin-related protein 2; AltName: Full=Actin-like protein 2; - OS=Homo sapiens 
(Human). 
44.7 3 3 
82 ARP3_HUMAN 
RecName: Full=Actin-related protein 3; AltName: Full=Actin-like protein 3; - OS=Homo sapiens 
(Human). 
47.3 9 9 
83 ARP5L_HUMAN 
RecName: Full=Actin-related protein 2/3 complex subunit 5-like protein; AltName: Full=Arp2/3 
complex 16 kDa subunit 2; Short=ARC16-2; - OS=Homo sapiens (Human). 
16.9 1 1 
84 ARPC2_HUMAN 
RecName: Full=Actin-related protein 2/3 complex subunit 2; AltName: Full=Arp2/3 complex 34 kDa 
subunit; Short=p34-ARC; - OS=Homo sapiens (Human). 
34.3 4 4 
85 ARPC4_HUMAN 
RecName: Full=Actin-related protein 2/3 complex subunit 4; AltName: Full=Arp2/3 complex 20 kDa 
subunit; Short=p20-ARC; - OS=Homo sapiens (Human). 
19.7 3 3 
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86 ARPC5_HUMAN 
RecName: Full=Actin-related protein 2/3 complex subunit 5; AltName: Full=Arp2/3 complex 16 kDa 
subunit; Short=p16-ARC; - OS=Homo sapiens (Human). 
16.3 1 1 
87 ASC_HUMAN 
RecName: Full=Apoptosis-associated speck-like protein containing a CARD; Short=hASC; AltName: 
Full=Caspase recruitment domain-containing protein 5; AltName: Full=PYD and CARD domain-
containing protein; AltName: Full=Target of methylation-induced silencing 1; - OS=Homo sapiens 
(Human). 
21.6 3 3 
88 AT2A2_HUMAN 
RecName: Full=Sarcoplasmic/endoplasmic reticulum calcium ATPase 2; Short=SERCA2; Short=SR 
Ca(2+)-ATPase 2; EC=3.6.3.8; AltName: Full=Calcium pump 2; AltName: Full=Calcium-transporting 
ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform; AltName: 
Full=Endoplasmic reticulum class 1/2 Ca(2+) ATPase; - OS=Homo sapiens (Human). 
114.7 5 5 
89 ATG3_HUMAN 
RecName: Full=Ubiquitin-like-conjugating enzyme ATG3; EC=6.3.2.-; AltName: Full=Autophagy-
related protein 3; Short=APG3-like; Short=hApg3; AltName: Full=Protein PC3-96; - OS=Homo 
sapiens (Human). 
35.8 2 2 
90 ATP5H_HUMAN 
RecName: Full=ATP synthase subunit d, mitochondrial; Short=ATPase subunit d; - OS=Homo sapiens 
(Human). 
18.5 5 5 
91 ATP5I_HUMAN 
RecName: Full=ATP synthase subunit e, mitochondrial; Short=ATPase subunit e; - OS=Homo sapiens 
(Human). 
7.9 1 1 
92 ATPA_HUMAN 
RecName: Full=ATP synthase subunit alpha, mitochondrial; Flags: Precursor; - OS=Homo sapiens 
(Human). 
59.7 12 12 
93 ATPD_HUMAN 
RecName: Full=ATP synthase subunit delta, mitochondrial; AltName: Full=F-ATPase delta subunit; 
Flags: Precursor; - OS=Homo sapiens (Human). 
17.5 1 1 
94 ATPO_HUMAN 
RecName: Full=ATP synthase subunit O, mitochondrial; AltName: Full=Oligomycin sensitivity 
conferral protein; Short=OSCP; Flags: Precursor; - OS=Homo sapiens (Human). 
23.3 6 6 
95 ATRAP_HUMAN 
RecName: Full=Type-1 angiotensin II receptor-associated protein; AltName: Full=AT1 receptor-
associated protein; - OS=Homo sapiens (Human). 
17.4 1 1 
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96 B0I1T1_HUMAN SubName: Full=MYO1F variant protein; - OS=Homo sapiens (Human). 124.7 4 4 
97 B0QY04_HUMAN 
SubName: Full=Neutrophil cytosol factor 4; SubName: Full=Neutrophil cytosolic factor 4, 40kDa; 
Flags: Fragment; - OS=Homo sapiens (Human). 
18.9 3 3 
98 B0QY68_HUMAN 
SubName: Full=SUN domain-containing protein 2; SubName: Full=Unc-84 homolog B (C. elegans); 
Flags: Fragment; - OS=Homo sapiens (Human). 
11.1 1 1 
99 B0QYR9_HUMAN 
SubName: Full=ADP-ribosylation factor-binding protein GGA1; SubName: Full=Golgi associated, 
gamma adaptin ear containing, ARF binding protein 1; Flags: Fragment; - OS=Homo sapiens 
(Human). 
3.3 1 1 
100 B0QZK4_HUMAN 
SubName: Full=Heterochromatin protein 1, binding protein 3; SubName: Full=Heterochromatin 
protein 1-binding protein 3; Flags: Fragment; - OS=Homo sapiens (Human). 
28.5 1 1 
101 B0UZC1_HUMAN 
SubName: Full=Proteasome (Prosome, macropain) subunit, beta type, 8 (Large multifunctional 
peptidase 7); SubName: Full=Proteasome subunit beta type-8; - OS=Homo sapiens (Human). 
27.8 1 1 
102 B0V109_HUMAN 
SubName: Full=Flotillin 1; SubName: Full=Flotillin-1; Flags: Fragment; - OS=Homo sapiens 
(Human). 
39.8 2 2 
103 B1AHA8_HUMAN 
SubName: Full=Heme oxygenase (Decycling) 1; SubName: Full=Heme oxygenase 1; Flags: Fragment; 
- OS=Homo sapiens (Human). 
21.6 4 4 
104 B1AHC7_HUMAN 
SubName: Full=X-ray repair complementing defective repair in Chinese hamster cells 6 (Ku 
autoantigen, 70kDa); SubName: Full=X-ray repair cross-complementing protein 6; - OS=Homo 
sapiens (Human). 
64.0 2 2 
105 B1AHM1_HUMAN SubName: Full=DEAD (Asp-Glu-Ala-Asp) box polypeptide 17; - OS=Homo sapiens (Human). 72.5 4 2 
106 B1AJY5_HUMAN 
SubName: Full=26S proteasome non-ATPase regulatory subunit 10; SubName: Full=Proteasome 
(Prosome, macropain) 26S subunit, non-ATPase, 10; - OS=Homo sapiens (Human). 
20.2 1 1 
107 B1AK13_HUMAN 
SubName: Full=3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase; SubName: Full=3-
hydroxymethyl-3-methylglutaryl-Coenzyme A lyase (Hydroxymethylglutaricaciduria), isoform 
CRA_b; SubName: Full=Hydroxymethylglutaryl-CoA lyase, mitochondrial; SubName: Full=cDNA 
31.7 2 2 
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FLJ16378 fis, clone TKIDN2016399, highly similar to Hydroxymethylglutaryl-CoA lyase, 
mitochondrial (EC 4.1.3.4); - OS=Homo sapiens (Human). 
108 B1AK87_HUMAN 
SubName: Full=Capping protein (Actin filament) muscle Z-line, beta; SubName: Full=Capping protein 
(Actin filament) muscle Z-line, beta, isoform CRA_a; SubName: Full=F-actin-capping protein subunit 
beta; - OS=Homo sapiens (Human). 
29.3 3 3 
109 B1ALA7_HUMAN 
SubName: Full=Phosphoribosyl pyrophosphate synthetase 1; SubName: Full=Ribose-phosphate 
pyrophosphokinase 1; - OS=Homo sapiens (Human). 
18.4 2 2 
110 B1AMI8_HUMAN SubName: Full=Torsin A interacting protein 1; Flags: Fragment; - OS=Homo sapiens (Human). 33.6 2 2 
111 B1APM4_HUMAN 
SubName: Full=Sterol O-acyltransferase (Acyl-Coenzyme A: cholesterol acyltransferase) 1; SubName: 
Full=Sterol O-acyltransferase 1; Flags: Fragment; - OS=Homo sapiens (Human). 
29.9 1 1 
112 B1AVS1_HUMAN SubName: Full=Metaxin 1; Flags: Fragment; - OS=Homo sapiens (Human). 35.1 1 1 
113 B1B5Q3_HUMAN SubName: Full=N-acylsphingosine amidohydrolase 1; Flags: Fragment; - OS=Homo sapiens (Human). 24.7 5 1 
114 B2M1S7_HUMAN SubName: Full=Beta-globin Showa Yakushiji variant; Flags: Fragment; - OS=Homo sapiens (Human). 4.5 3 1 
115 B2MG_HUMAN 
RecName: Full=Beta-2-microglobulin; Contains: RecName: Full=Beta-2-microglobulin form pI 5.3; 
Flags: Precursor; - OS=Homo sapiens (Human). 
13.7 2 2 
116 B2R4A2_HUMAN 
SubName: Full=cDNA, FLJ92016, highly similar to Homo sapiens ubiquinol-cytochrome c reductase 
binding protein (UQCRB), mRNA; - OS=Homo sapiens (Human). 
13.5 1 1 
117 B2R4J7_HUMAN 
SubName: Full=cDNA, FLJ92117, highly similar to Homo sapiens chemokine (C-X-C motif) ligand 9 
(CXCL9), mRNA; - OS=Homo sapiens (Human). 
13.9 1 1 
118 B2R4M6_HUMAN 
SubName: Full=cDNA, FLJ92148, highly similar to Homo sapiens S100 calcium binding protein A9 
(calgranulin B) (S100A9), mRNA; - OS=Homo sapiens (Human). 
13.2 4 4 
119 B2R4V4_HUMAN 
SubName: Full=cDNA, FLJ92232, highly similar to Homo sapiens barrier to autointegration factor 1 
(BANF1), mRNA; - OS=Homo sapiens (Human). 
10.0 1 1 
120 B2R5B6_HUMAN RecName: Full=Histone H2A; - OS=Homo sapiens (Human). 14.1 3 1 
121 B2R5M8_HUMAN RecName: Full=Isocitrate dehydrogenase [NADP]; EC=1.1.1.42; - OS=Homo sapiens (Human). 46.6 10 9 
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122 B2R6C0_HUMAN 
SubName: Full=cDNA, FLJ92881, highly similar to Homo sapiens glycerol-3-phosphate 
dehydrogenase 1 (soluble) (GPD1), mRNA; - OS=Homo sapiens (Human). 
37.6 5 5 
123 B2R6K1_HUMAN 
SubName: Full=cDNA, FLJ92992, highly similar to Homo sapiens methylmalonyl Coenzyme A 
mutase (MUT), nuclear gene encoding mitochondrial protein, mRNA; - OS=Homo sapiens (Human). 
83.0 1 1 
124 B2R6X6_HUMAN RecName: Full=Peptidyl-prolyl cis-trans isomerase; EC=5.2.1.8; - OS=Homo sapiens (Human). 22.0 1 1 
125 B2R774_HUMAN 
SubName: Full=cDNA, FLJ93313, highly similar to Homo sapiens lectin, mannose-binding, 1 
(LMAN1), mRNA; - OS=Homo sapiens (Human). 
57.5 1 1 
126 B2R7M1_HUMAN 
SubName: Full=cDNA, FLJ93507, highly similar to Homo sapiens ATPase, H+ transporting, 
lysosomal 38kDa, V0 subunit d isoform 1 (ATP6V0D1), mRNA; - OS=Homo sapiens (Human). 
40.3 7 7 
127 B2R7Z6_HUMAN SubName: Full=cDNA, FLJ93674; - OS=Homo sapiens (Human). 52.5 11 11 
128 B2R8A2_HUMAN 
SubName: Full=cDNA, FLJ93804, highly similar to Homo sapiens gp25L2 protein (HSGP25L2G), 
mRNA; - OS=Homo sapiens (Human). 
25.1 1 1 
129 B2R8N0_HUMAN 
SubName: Full=cDNA, FLJ93975, highly similar to Homo sapiens epoxide hydrolase 1, microsomal 
(xenobiotic) (EPHX1), mRNA; - OS=Homo sapiens (Human). 
52.9 4 4 
130 B2R923_HUMAN SubName: Full=cDNA, FLJ94174; - OS=Homo sapiens (Human). 37.3 2 2 
131 B2R959_HUMAN 
SubName: Full=cDNA, FLJ94229, highly similar to Homo sapiens heterogeneous nuclear 
ribonucleoprotein L (HNRPL),mRNA; - OS=Homo sapiens (Human). 
60.2 1 1 
132 B2R983_HUMAN 
SubName: Full=cDNA, FLJ94267, highly similar to Homo sapiens glutathione S-transferase omega 1 
(GSTO1), mRNA; - OS=Homo sapiens (Human). 
27.5 7 7 
133 B2R9S4_HUMAN 
SubName: Full=cDNA, FLJ94534, highly similar to Homo sapiens capping protein (actin filament), 
gelsolin-like(CAPG), mRNA; - OS=Homo sapiens (Human). 
38.5 9 9 
134 B2RAL6_HUMAN 
SubName: Full=cDNA, FLJ94991, highly similar to Homo sapiens integrin, alpha L (antigen CD11A 
(p180), lymphocyte function-associated antigen 1; alpha polypeptide) (ITGAL), mRNA; - OS=Homo 
sapiens (Human). 
128.8 1 1 
135 B2RAQ8_HUMAN SubName: Full=cDNA, FLJ95058, highly similar to Homo sapiens carnitine palmitoyltransferase 1A 88.3 1 1 
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(liver) (CPT1A),nuclear gene encoding mitochondrial protein, mRNA; - OS=Homo sapiens (Human). 
136 B2RAW0_HUMAN 
SubName: Full=cDNA, FLJ95154, highly similar to Homo sapiens disabled homolog 2, mitogen-
responsive phosphoprotein (Drosophila) (DAB2), mRNA; - OS=Homo sapiens (Human). 
82.4 3 3 
137 B2RB06_HUMAN 
SubName: Full=cDNA, FLJ95242, highly similar to Homo sapiens L-3-hydroxyacyl-Coenzyme A 
dehydrogenase, short chain (HADHSC), mRNA; - OS=Homo sapiens (Human). 
34.2 4 4 
138 B2RB23_HUMAN 
SubName: Full=cDNA, FLJ95265, highly similar to Homo sapiens acetyl-Coenzyme A acyltransferase 
2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) (ACAA2), nuclear gene encoding mitochondrial 
protein, mRNA; - OS=Homo sapiens (Human). 
42.0 9 9 
139 B2RBG3_HUMAN 
SubName: Full=cDNA, FLJ95493, highly similar to Homo sapiens fucosidase, alpha-L- 1, tissue 
(FUCA1), mRNA; - OS=Homo sapiens (Human). 
53.2 1 1 
140 B2RDI5_HUMAN 
SubName: Full=cDNA, FLJ96627, highly similar to Homo sapiens calpain 1, (mu/I) large subunit 
(CAPN1), mRNA; - OS=Homo sapiens (Human). 
81.8 3 3 
141 B2RDM2_HUMAN 
SubName: Full=HCG1811539, isoform CRA_b; SubName: Full=Thioredoxin domain-containing 
protein 5; SubName: Full=cDNA, FLJ96678, Homo sapiens thioredoxin domain containing 5 
(TXNDC5), mRNA; - OS=Homo sapiens (Human). 
36.2 2 2 
142 B2RE38_HUMAN 
SubName: Full=cDNA, FLJ96906, highly similar to Homo sapiens solute carrier family 17 
(anion/sugar transporter), member 5 (SLC17A5), mRNA; - OS=Homo sapiens (Human). 
54.6 1 1 
143 B2RE46_HUMAN 
SubName: Full=cDNA, FLJ96923, highly similar to Homo sapiens ribophorin II (RPN2), mRNA; - 
OS=Homo sapiens (Human). 
69.3 7 7 
144 B2REB8_HUMAN SubName: Full=Protein SET; SubName: Full=SET nuclear oncogene; - OS=Homo sapiens (Human). 31.0 2 2 
145 B2ZP79_HUMAN 
SubName: Full=BH3 interacting domain death agonist, isoform CRA_b; SubName: Full=BID isoform 
ES(1b); - OS=Homo sapiens (Human). 
11.3 1 1 
146 B3AT_HUMAN 
RecName: Full=Band 3 anion transport protein; AltName: Full=Anion exchange protein 1; Short=AE 
1; Short=Anion exchanger 1; AltName: Full=Solute carrier family 4 member 1; AltName: 
CD_antigen=CD233; - OS=Homo sapiens (Human). 
101.7 14 14 
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147 B3KM80_HUMAN 
SubName: Full=Nucleolin, isoform CRA_c; SubName: Full=cDNA FLJ10452 fis, clone 
NT2RP1000966, highly similar to NUCLEOLIN; - OS=Homo sapiens (Human). 
58.5 10 10 
148 B3KM97_HUMAN 
SubName: Full=cDNA FLJ10554 fis, clone NT2RP2002385, highly similar to Synaptic glycoprotein 
SC2; - OS=Homo sapiens (Human). 
36.0 1 1 
149 B3KMR6_HUMAN 
SubName: Full=cDNA FLJ12440 fis, clone NT2RM1000131, highly similar to Homo sapiens 
transmembrane protein 63A (TMEM63A), mRNA; - OS=Homo sapiens (Human). 
92.0 1 1 
150 B3KMV5_HUMAN 
SubName: Full=cDNA FLJ12728 fis, clone NT2RP2000040, highly similar to Protein FAM62A; - 
OS=Homo sapiens (Human). 
122.8 15 15 
151 B3KN06_HUMAN 
SubName: Full=cDNA FLJ13143 fis, clone NT2RP3003230, highly similar to Coronin-1C; - 
OS=Homo sapiens (Human). 
53.2 8 8 
152 B3KNM6_HUMAN 
SubName: Full=cDNA FLJ14968 fis, clone THYRO1000288, highly similar to CAAX prenyl protease 
1 homolog (EC 3.4.24.84); - OS=Homo sapiens (Human). 
27.1 1 1 
153 B3KPA6_HUMAN 
SubName: Full=Acyl-Coenzyme A dehydrogenase, very long chain, isoform CRA_e; SubName: 
Full=cDNA FLJ31521 fis, clone NT2RI2000255, highly similar to Very-long-chain specific acyl-
CoAdehydrogenase, mitochondrial (EC 1.3.99.-); - OS=Homo sapiens (Human). 
62.5 15 15 
154 B3KPH8_HUMAN RecName: Full=Lon protease homolog; EC=3.4.21.-; - OS=Homo sapiens (Human). 85.5 2 2 
155 B3KPP1_HUMAN 
SubName: Full=cDNA FLJ32014 fis, clone NTONG1000047, highly similar to Lymphocyte-specific 
protein 1; - OS=Homo sapiens (Human). 
30.2 1 1 
156 B3KPS3_HUMAN 
SubName: Full=cDNA FLJ32131 fis, clone PEBLM2000267, highly similar to Tubulin alpha-
ubiquitous chain; - OS=Homo sapiens (Human). 
46.2 11 2 
157 B3KPZ7_HUMAN 
SubName: Full=cDNA FLJ32517 fis, clone SMINT1000117, highly similar to Pyruvate 
dehydrogenase (lipoamide)-phosphatase 1 (EC 3.1.3.43); - OS=Homo sapiens (Human). 
60.8 1 1 
158 B3KQK0_HUMAN 
SubName: Full=cDNA FLJ90599 fis, clone PLACE1001340, highly similar to Mitochondrial proteins 
importreceptor; - OS=Homo sapiens (Human). 
26.5 1 1 
159 B3KQQ3_HUMAN SubName: Full=cDNA PSEC0016 fis, clone NT2RM1001076, highly similar to Procollagen-lysine,2- 84.6 2 2 
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oxoglutarate 5-dioxygenase 3 (EC 1.14.11.4); - OS=Homo sapiens (Human). 
160 B3KQT9_HUMAN 
SubName: Full=cDNA PSEC0175 fis, clone OVARC1000169, highly similar to Protein disulfide-
isomerase A3 (EC 5.3.4.1); - OS=Homo sapiens (Human). 
54.1 13 11 
161 B3KQV6_HUMAN 
SubName: Full=cDNA FLJ33169 fis, clone ADRGL2000384, highly similar to Serine/threonine-
protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform; - OS=Homo sapiens (Human). 
45.6 3 3 
162 B3KR50_HUMAN 
SubName: Full=cDNA FLJ33691 fis, clone BRAWH2002976, highly similar to GROWTH FACTOR 
RECEPTOR-BOUND PROTEIN 2; - OS=Homo sapiens (Human). 
25.2 4 4 
163 B3KRW2_HUMAN 
SubName: Full=cDNA FLJ34977 fis, clone NTONG2005822, highly similar to Homo sapiens RAB11 
family interacting protein 1 (class I) (RAB11FIP1), transcript variant 1, mRNA; - OS=Homo sapiens 
(Human). 
45.4 1 1 
164 B3KRY3_HUMAN 
SubName: Full=cDNA FLJ35079 fis, clone PLACE6005283, highly similar to Lysosome-associated 
membrane glycoprotein 1; - OS=Homo sapiens (Human). 
42.6 3 3 
165 B3KS31_HUMAN 
SubName: Full=Tubulin beta-6 chain; SubName: Full=Tubulin, beta 6, isoform CRA_a; SubName: 
Full=cDNA FLJ35358 fis, clone PUAEN2000497, highly similar to Tubulin beta-6 chain; - OS=Homo 
sapiens (Human). 
41.9 4 1 
166 B3KS50_HUMAN 
SubName: Full=cDNA FLJ35494 fis, clone SMINT2008720, highly similar to Interferon-induced 
protein with tetratricopeptide repeats 1; - OS=Homo sapiens (Human). 
51.7 1 1 
167 B3KT32_HUMAN 
SubName: Full=cDNA FLJ37546 fis, clone BRCAN2027364, highly similar to Homo sapiens formin-
like 2 (FMNL2), transcript variant 2, mRNA; - OS=Homo sapiens (Human). 
41.7 1 1 
168 B3KT45_HUMAN 
SubName: Full=cDNA FLJ37607 fis, clone BRCOC2010980, highly similar to Thioredoxin-like 
protein 1; - OS=Homo sapiens (Human). 
18.9 1 1 
169 B3KT93_HUMAN 
SubName: Full=cDNA FLJ37875 fis, clone BRSSN2018771, highly similar to Poly(A)-binding 
protein 1; - OS=Homo sapiens (Human). 
70.6 3 3 
170 B3KUH7_HUMAN 
SubName: Full=cDNA FLJ39919 fis, clone SPLEN2020154, highly similar to Coronin-7; - OS=Homo 
sapiens (Human). 
66.4 3 3 
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171 B3KUK2_HUMAN RecName: Full=Superoxide dismutase; EC=1.15.1.1; - OS=Homo sapiens (Human). 19.7 5 5 
172 B3KUR3_HUMAN 
RecName: Full=2,3-bisphosphoglycerate-dependent phosphoglycerate mutase B; Short=BPG-
dependent PGAM B; Short=PGAM B; Short=Phosphoglyceromutase B; Short=dPGM B; EC=5.4.2.1; 
- OS=Homo sapiens (Human). 
28.0 2 2 
173 B3KUZ8_HUMAN RecName: Full=Aspartate aminotransferase; EC=2.6.1.1; - OS=Homo sapiens (Human). 41.3 3 3 
174 B3KVN0_HUMAN 
SubName: Full=cDNA FLJ16785 fis, clone NT2RI2015342, highly similar to Solute carrier family 2, 
facilitated glucose transporter member 1; - OS=Homo sapiens (Human). 
45.8 2 2 
175 B3KVX6_HUMAN 
SubName: Full=cDNA FLJ41699 fis, clone HCHON2004776, highly similar to Homo sapiens 
cytoskeleton-associated protein 4 (CKAP4), mRNA; - OS=Homo sapiens (Human). 
58.1 1 1 
176 B3KW21_HUMAN 
SubName: Full=cDNA FLJ41945 fis, clone PLACE6019676, highly similar to Coatomer subunit 
gamma; - OS=Homo sapiens (Human). 
67.8 3 3 
177 B3KW79_HUMAN 
SubName: Full=cDNA FLJ42481 fis, clone BRACE2032090, highly similar to Probable serine 
carboxypeptidase CPVL (EC 3.4.16.-); - OS=Homo sapiens (Human). 
54.1 3 3 
178 B3KWA1_HUMAN 
SubName: Full=Iduronate 2-sulfatase; SubName: Full=Iduronate 2-sulfatase (Hunter syndrome), 
isoform CRA_e; SubName: Full=cDNA FLJ42669 fis, clone BRAMY2022168, highly similar to 
IDURONATE 2-SULFATASE (EC 3.1.6.13); - OS=Homo sapiens (Human). 
38.6 1 1 
179 B3KWD9_HUMAN 
SubName: Full=cDNA FLJ42834 fis, clone BRCAN2019002, highly similar to GTP:AMP 
phosphotransferase mitochondrial (EC 2.7.4.10); - OS=Homo sapiens (Human). 
18.2 3 3 
180 B3KX15_HUMAN 
SubName: Full=cDNA FLJ44468 fis, clone UTERU2026025, moderately similar to SPLICING 
FACTOR, ARGININE/SERINE-RICH 2; - OS=Homo sapiens (Human). 
13.8 1 1 
181 B3KXF2_HUMAN 
SubName: Full=cDNA FLJ45314 fis, clone BRHIP3005142, highly similar to Proteasome-associated 
protein ECM29 homolog; - OS=Homo sapiens (Human). 
145.3 1 1 
182 B3KY04_HUMAN 
SubName: Full=cDNA FLJ46506 fis, clone THYMU3030752, highly similar to BTB/POZ domain-
containing protein KCTD12; - OS=Homo sapiens (Human). 
35.7 3 3 
183 B3VL17_HUMAN SubName: Full=Beta globin; Flags: Fragment; - OS=Homo sapiens (Human). 11.5 10 2 
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184 B3VTQ2_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 10.9 4 0 
185 B4DDF8_HUMAN 
SubName: Full=cDNA FLJ51786, highly similar to Retinal dehydrogenase 1 (EC 1.2.1.36); - 
OS=Homo sapiens (Human). 
46.0 9 7 
186 B4DDG1_HUMAN 
SubName: Full=Ubiquitin-conjugating enzyme E2 L3; SubName: Full=cDNA FLJ59174, highly 
similar to Ubiquitin-conjugating enzyme E2 L3 (EC 6.3.2.19); - OS=Homo sapiens (Human). 
14.1 2 2 
187 B4DDM5_HUMAN 
SubName: Full=cDNA FLJ53298, highly similar to Peroxisomal multifunctional enzyme type 2; - 
OS=Homo sapiens (Human). 
77.4 9 9 
188 B4DDV4_HUMAN 
SubName: Full=cDNA FLJ52530, highly similar to Tumor protein D54; - OS=Homo sapiens 
(Human). 
17.2 2 2 
189 B4DE02_HUMAN RecName: Full=Annexin; - OS=Homo sapiens (Human). 34.4 6 5 
190 B4DE36_HUMAN RecName: Full=Glucose-6-phosphate isomerase; EC=5.3.1.9; - OS=Homo sapiens (Human). 60.1 6 6 
191 B4DE67_HUMAN 
SubName: Full=cDNA FLJ57259, highly similar to Lysosomal acid lipase/cholesteryl esterhydrolase 
(EC 3.1.1.13); - OS=Homo sapiens (Human). 
23.5 1 1 
192 B4DEA3_HUMAN 
SubName: Full=cDNA FLJ56531, highly similar to UV excision repair protein RAD23 homolog B; - 
OS=Homo sapiens (Human). 
42.3 3 3 
193 B4DEB9_HUMAN 
SubName: Full=cDNA FLJ61099, highly similar to ADP-ribosylation factor 1; - OS=Homo sapiens 
(Human). 
19.6 4 2 
194 B4DEK4_HUMAN 
SubName: Full=Sorting nexin-2; SubName: Full=cDNA FLJ51799, highly similar to Sorting nexin-2; 
- OS=Homo sapiens (Human). 
46.1 4 4 
195 B4DEQ0_HUMAN 
SubName: Full=cDNA FLJ59482, highly similar to Electron transfer flavoprotein-ubiquinone 
oxidoreductase, mitochondrial (EC 1.5.5.1); - OS=Homo sapiens (Human). 
61.3 1 1 
196 B4DF22_HUMAN 
SubName: Full=cDNA FLJ55615, highly similar to SWI/SNF-related matrix-associatedactin-
dependent regulator of chromatin subfamily C member 2; - OS=Homo sapiens (Human). 
112.1 1 1 
197 B4DF70_HUMAN 
SubName: Full=cDNA FLJ60461, highly similar to Peroxiredoxin-2 (EC 1.11.1.15); - OS=Homo 
sapiens (Human). 
20.1 6 5 
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198 B4DF97_HUMAN 
SubName: Full=cDNA FLJ59673, highly similar to Homo sapiens growth and transformation-
dependent protein (E2IG5), mRNA; - OS=Homo sapiens (Human). 
15.9 1 1 
199 B4DFH3_HUMAN 
SubName: Full=Inorganic pyrophosphatase 2, mitochondrial; SubName: Full=cDNA FLJ59863, 
highly similar to Inorganic pyrophosphatase 2, mitochondrial (EC 3.6.1.1); - OS=Homo sapiens 
(Human). 
23.0 2 1 
200 B4DFL1_HUMAN RecName: Full=Dihydrolipoyl dehydrogenase; EC=1.8.1.4; - OS=Homo sapiens (Human). 48.9 6 6 
201 B4DFL2_HUMAN RecName: Full=Isocitrate dehydrogenase [NADP]; EC=1.1.1.42; - OS=Homo sapiens (Human). 45.2 7 6 
202 B4DFM0_HUMAN 
SubName: Full=Phenylalanine-tRNA synthetase-like, beta subunit, isoform CRA_c; SubName: 
Full=cDNA FLJ57266, highly similar to Phenylalanyl-tRNA synthetase beta chain (EC 6.1.1.20); - 
OS=Homo sapiens (Human). 
54.8 1 1 
203 B4DFP1_HUMAN 
SubName: Full=cDNA FLJ51818, highly similar to Phosphoglucomutase-1 (EC 5.4.2.2); - OS=Homo 
sapiens (Human). 
58.7 2 2 
204 B4DG62_HUMAN 
SubName: Full=cDNA FLJ56506, highly similar to Hexokinase-1 (EC 2.7.1.1); - OS=Homo sapiens 
(Human). 
102.2 9 9 
205 B4DGK8_HUMAN 
SubName: Full=cDNA FLJ57723, moderately similar to Protein-tyrosine phosphatase mitochondrial 1, 
mitochondrial (EC 3.1.3.48); - OS=Homo sapiens (Human). 
15.8 1 1 
206 B4DGN5_HUMAN RecName: Full=Glutamate dehydrogenase; - OS=Homo sapiens (Human). 46.5 5 5 
207 B4DGN8_HUMAN 
SubName: Full=cDNA FLJ53377, highly similar to Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 
1 (EC 1.14.11.4); - OS=Homo sapiens (Human). 
79.3 1 1 
208 B4DHC4_HUMAN 
SubName: Full=cDNA FLJ51843, highly similar to 14-3-3 protein gamma; - OS=Homo sapiens 
(Human). 
25.6 5 3 
209 B4DHP6_HUMAN 
SubName: Full=Non-specific lipid-transfer protein; SubName: Full=cDNA FLJ53991, highly similar 
to Nonspecific lipid-transfer protein (EC 2.3.1.176); - OS=Homo sapiens (Human). 
50.3 7 7 
210 B4DI38_HUMAN RecName: Full=Adenylyl cyclase-associated protein; - OS=Homo sapiens (Human). 49.0 11 8 
211 B4DIC4_HUMAN SubName: Full=cDNA FLJ52195, highly similar to LIM and SH3 domain protein 1; - OS=Homo 14.6 1 1 
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sapiens (Human). 
212 B4DIH0_HUMAN 
SubName: Full=cDNA FLJ58381, highly similar to COMM domain-containing protein 9; - OS=Homo 
sapiens (Human). 
13.5 1 1 
213 B4DIT7_HUMAN 
SubName: Full=Protein-glutamine gamma-glutamyltransferase 2; SubName: Full=cDNA FLJ58187, 
highly similar to Protein-glutamine gamma-glutamyltransferase 2(EC 2.3.2.13); - OS=Homo sapiens 
(Human). 
68.6 11 11 
214 B4DJ24_HUMAN 
SubName: Full=cDNA FLJ58575, highly similar to Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A (EC 2.4.1.119); - OS=Homo sapiens (Human). 
69.6 1 1 
215 B4DJ81_HUMAN 
SubName: Full=NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial; SubName: 
Full=cDNA FLJ60586, highly similar to NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial (EC 1.6.5.3); - OS=Homo sapiens (Human). 
66.9 1 1 
216 B4DJD7_HUMAN 
SubName: Full=cDNA FLJ52505, highly similar to Homo sapiens lectin, galactoside-binding, soluble 
9, transcript variant short, mRNA; - OS=Homo sapiens (Human). 
29.9 2 2 
217 B4DJI2_HUMAN SubName: Full=cDNA FLJ53342, highly similar to Granulins; - OS=Homo sapiens (Human). 56.8 4 4 
218 B4DJV2_HUMAN RecName: Full=Citrate synthase; - OS=Homo sapiens (Human). 50.4 5 4 
219 B4DKS8_HUMAN 
SubName: Full=cDNA FLJ57121, highly similar to Heterogeneous nuclear ribonucleoprotein F; - 
OS=Homo sapiens (Human). 
37.2 2 1 
220 B4DL14_HUMAN RecName: Full=ATP synthase gamma chain; - OS=Homo sapiens (Human). 27.5 3 3 
221 B4DL49_HUMAN 
SubName: Full=cDNA FLJ58073, moderately similar to Cathepsin B (EC 3.4.22.1); - OS=Homo 
sapiens (Human). 
30.7 6 6 
222 B4DLI2_HUMAN 
SubName: Full=cDNA FLJ55714, highly similar to Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit (EC 2.4.1.119); - OS=Homo sapiens (Human). 
48.9 4 4 
223 B4DLL8_HUMAN 
SubName: Full=cDNA FLJ59335, highly similar to Transmembrane glycoprotein NMB; - OS=Homo 
sapiens (Human). 
50.5 2 2 
224 B4DLW8_HUMAN SubName: Full=Probable ATP-dependent RNA helicase DDX5; SubName: Full=cDNA FLJ59339, 60.5 3 1 
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highly similar to Probable ATP-dependent RNA helicase DDX5 (EC 3.6.1.-); - OS=Homo sapiens 
(Human). 
225 B4DLX4_HUMAN 
SubName: Full=cDNA FLJ54021, highly similar to Dipeptidyl-peptidase 3 (EC 3.4.14.4); - OS=Homo 
sapiens (Human). 
79.2 1 1 
226 B4DM33_HUMAN 
SubName: Full=cDNA FLJ52068, highly similar to Microtubule-associated protein RP/EB family 
member 1; - OS=Homo sapiens (Human). 
26.6 1 1 
227 B4DMA2_HUMAN 
RecName: Full=Chaperone protein HtpG B; AltName: Full=Heat shock protein HtpG B; AltName: 
Full=High temperature protein G B; - OS=Homo sapiens (Human). 
79.1 13 6 
228 B4DMQ7_HUMAN 
SubName: Full=Tumor protein p53 inducible protein 3, isoform CRA_c; SubName: Full=cDNA 
FLJ61719, highly similar to quinone oxidoreductase (EC 1.-.-.-); - OS=Homo sapiens (Human). 
26.8 1 1 
229 B4DMT4_HUMAN SubName: Full=cDNA FLJ52695, highly similar to Alpha-centractin; - OS=Homo sapiens (Human). 34.5 1 1 
230 B4DN40_HUMAN 
SubName: Full=cDNA FLJ54368, highly similar to Phosphoglucomutase-2 (EC 5.4.2.2); - OS=Homo 
sapiens (Human). 
50.7 1 1 
231 B4DN45_HUMAN RecName: Full=S-adenosylmethionine synthase; EC=2.5.1.6; - OS=Homo sapiens (Human). 32.9 1 1 
232 B4DNR3_HUMAN 
SubName: Full=cDNA FLJ52710, highly similar to Abhydrolase domain-containing protein 14B; - 
OS=Homo sapiens (Human). 
19.8 1 1 
233 B4DNS2_HUMAN 
SubName: Full=cDNA FLJ51602, highly similar to Interferon-induced guanylate-binding protein 1; - 
OS=Homo sapiens (Human). 
41.2 2 1 
234 B4DNS3_HUMAN 
SubName: Full=cDNA FLJ50593, moderately similar to Pulmonary surfactant-associated protein A1; - 
OS=Homo sapiens (Human). 
20.1 3 3 
235 B4DP50_HUMAN 
RecName: Full=Proline--tRNA ligase A; EC=6.1.1.15; AltName: Full=Prolyl-tRNA synthetase A; - 
OS=Homo sapiens (Human). 
54.1 1 1 
236 B4DPJ2_HUMAN RecName: Full=Annexin; - OS=Homo sapiens (Human). 45.6 4 4 
237 B4DPN0_HUMAN 
SubName: Full=cDNA FLJ51265, moderately similar to Beta-2-glycoprotein 1 (Beta-2-glycoprotein 
I); - OS=Homo sapiens (Human). 
30.3 4 4 
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238 B4DQ03_HUMAN 
SubName: Full=cDNA FLJ57859, highly similar to Ras-related GTP-binding protein C; - OS=Homo 
sapiens (Human). 
31.7 1 1 
239 B4DQH4_HUMAN 
SubName: Full=T-complex protein 1 subunit theta; SubName: Full=cDNA FLJ59382, highly similar 
to T-complex protein 1 subunit theta; - OS=Homo sapiens (Human). 
51.6 2 2 
240 B4DQJ8_HUMAN 
RecName: Full=6-phosphogluconate dehydrogenase, decarboxylating; EC=1.1.1.44; - OS=Homo 
sapiens (Human). 
51.8 6 6 
241 B4DQT8_HUMAN 
SubName: Full=cDNA FLJ61158, highly similar to ADP-ribosylation factor-like protein 8B; - 
OS=Homo sapiens (Human). 
20.6 2 2 
242 B4DR31_HUMAN 
SubName: Full=Dihydropyrimidinase-related protein 2; SubName: Full=cDNA FLJ53166, highly 
similar to Dihydropyrimidinase-related protein 2; - OS=Homo sapiens (Human). 
58.1 10 10 
243 B4DR68_HUMAN 
RecName: Full=Chaperone protein HtpG C; AltName: Full=Heat shock protein HtpG C; AltName: 
Full=High temperature protein G C; - OS=Homo sapiens (Human). 
74.2 3 2 
244 B4DRD7_HUMAN 
SubName: Full=cDNA FLJ54752, highly similar to Poly(rC)-binding protein 2; - OS=Homo sapiens 
(Human). 
29.7 5 4 
245 B4DRF4_HUMAN 
SubName: Full=3-hydroxyacyl-CoA dehydratase 3; SubName: Full=cDNA FLJ54138, highly similar 
to Homo sapiens butyrate-induced transcript 1 (HSPC121), mRNA; - OS=Homo sapiens (Human). 
36.4 1 1 
246 B4DRK5_HUMAN 
SubName: Full=cDNA FLJ59584, highly similar to Mitochondrial-processing peptidase alpha subunit, 
mitochondrial (EC 3.4.24.64); - OS=Homo sapiens (Human). 
28.2 1 1 
247 B4DS27_HUMAN 
SubName: Full=cDNA FLJ51288, highly similar to Kinesin heavy chain; - OS=Homo sapiens 
(Human). 
49.9 1 1 
248 B4DS43_HUMAN 
SubName: Full=cDNA FLJ51063, highly similar to Dihydrolipoyllysine-residue 
acetyltransferasecomponent of pyruvate dehydrogenase complex, mitochondrial (EC 2.3.1.12); - 
OS=Homo sapiens (Human). 
44.6 2 2 
249 B4DSA8_HUMAN 
SubName: Full=cDNA FLJ51067, highly similar to DNA damage-binding protein 1; - OS=Homo 
sapiens (Human). 
111.9 1 1 
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250 B4DSD8_HUMAN RecName: Full=Phosphorylase; EC=2.4.1.1; - OS=Homo sapiens (Human). 85.7 2 1 
251 B4DSE2_HUMAN 
SubName: Full=cDNA FLJ57277, highly similar to Tripeptidyl-peptidase 1 (EC 3.4.14.9); - OS=Homo 
sapiens (Human). 
41.6 6 6 
252 B4DSF0_HUMAN 
SubName: Full=cDNA FLJ56734, moderately similar to Sepiapterin reductase (EC 1.1.1.153); - 
OS=Homo sapiens (Human). 
13.0 1 1 
253 B4DSR6_HUMAN 
SubName: Full=cDNA FLJ52684, highly similar to Dynein heavy chain, cytosolic; - OS=Homo 
sapiens (Human). 
28.4 1 1 
254 B4DSU9_HUMAN 
SubName: Full=cDNA FLJ58421, highly similar to Cleavage and polyadenylation specificity factor 6; 
- OS=Homo sapiens (Human). 
33.6 2 2 
255 B4DSZ1_HUMAN SubName: Full=cDNA FLJ54877, highly similar to Syntaxin-12; - OS=Homo sapiens (Human). 26.6 2 2 
256 B4DT77_HUMAN RecName: Full=Annexin; - OS=Homo sapiens (Human). 37.8 1 1 
257 B4DTB1_HUMAN 
SubName: Full=cDNA FLJ52936, weakly similar to Tropomyosin alpha-4 chain; - OS=Homo sapiens 
(Human). 
17.6 3 1 
258 B4DTT0_HUMAN 
SubName: Full=cDNA FLJ51090, highly similar to N-acetylglucosamine-6-sulfatase (EC 3.1.6.14); - 
OS=Homo sapiens (Human). 
53.4 6 6 
259 B4DUB7_HUMAN RecName: Full=Phosphorylase; EC=2.4.1.1; - OS=Homo sapiens (Human). 92.9 3 2 
260 B4DUH1_HUMAN 
SubName: Full=cDNA FLJ51323, highly similar to Short-chain specific acyl-CoA dehydrogenase, 
mitochondrial (EC 1.3.99.2); - OS=Homo sapiens (Human). 
43.6 1 1 
261 B4DUJ3_HUMAN 
SubName: Full=cDNA FLJ52895, highly similar to Carbonic anhydrase 3 (EC 4.2.1.1); - OS=Homo 
sapiens (Human). 
26.8 2 2 
262 B4DUL5_HUMAN 
SubName: Full=cDNA FLJ51625, highly similar to Ubiquinol-cytochrome-c reductase complex 
coreprotein I, mitochondrial (EC 1.10.2.2); - OS=Homo sapiens (Human). 
40.3 5 5 
263 B4DUP0_HUMAN 
SubName: Full=cDNA FLJ59433, highly similar to Elongation factor 1-gamma; - OS=Homo sapiens 
(Human). 
24.1 1 1 
264 B4DV28_HUMAN SubName: Full=cDNA FLJ54170, highly similar to Cytosolic nonspecific dipeptidase; - OS=Homo 51.5 5 5 
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sapiens (Human). 
265 B4DVD8_HUMAN 
SubName: Full=Caspase-1 subunit p10; SubName: Full=cDNA FLJ59442, highly similar to Caspase-1 
(EC 3.4.22.36); - OS=Homo sapiens (Human). 
33.0 3 3 
266 B4DVE1_HUMAN 
SubName: Full=cDNA FLJ53478, highly similar to Galectin-3-binding protein; - OS=Homo sapiens 
(Human). 
64.1 4 4 
267 B4DVS2_HUMAN SubName: Full=cDNA FLJ57617; - OS=Homo sapiens (Human). 88.8 1 1 
268 B4DVT4_HUMAN SubName: Full=cDNA FLJ53761, highly similar to Macrosialin; - OS=Homo sapiens (Human). 34.6 1 1 
269 B4DVZ4_HUMAN RecName: Full=Sulfurtransferase; - OS=Homo sapiens (Human). 27.7 1 1 
270 B4DW52_HUMAN 
SubName: Full=cDNA FLJ55253, highly similar to Actin, cytoplasmic 1; - OS=Homo sapiens 
(Human). 
38.6 13 7 
271 B4DW94_HUMAN 
SubName: Full=Ras-related protein Rap-1b; SubName: Full=cDNA FLJ50714, moderately similar to 
Ras-related protein Rap-1b; - OS=Homo sapiens (Human). 
15.3 5 5 
272 B4DWD1_HUMAN 
SubName: Full=cDNA FLJ60919, highly similar to Cytochrome b-245 heavy chain; - OS=Homo 
sapiens (Human). 
35.1 3 3 
273 B4DWM8_HUMAN 
SubName: Full=cDNA FLJ56259, highly similar to Vacuolar ATP synthase subunit S1 (EC 3.6.3.14); 
- OS=Homo sapiens (Human). 
32.9 1 1 
274 B4DWN0_HUMAN 
SubName: Full=cDNA FLJ51351, highly similar to GTPase, IMAP family member 4; - OS=Homo 
sapiens (Human). 
29.9 1 1 
275 B4DWN1_HUMAN 
SubName: Full=cDNA FLJ52285, highly similar to Vesicular integral-membrane protein VIP36; - 
OS=Homo sapiens (Human). 
32.6 3 3 
276 B4DWS6_HUMAN 
SubName: Full=cDNA FLJ61181, highly similar to Homo sapiens hydroxysteroid (17-beta) 
dehydrogenase 12 (HSD17B12), mRNA; - OS=Homo sapiens (Human). 
33.5 2 2 
277 B4DWU0_HUMAN 
SubName: Full=cDNA FLJ56791, highly similar to Keratin, type I cytoskeletal 16; - OS=Homo 
sapiens (Human). 
15.7 3 1 
278 B4DWV5_HUMAN RecName: Full=Protein GrpE A; AltName: Full=HSP-70 cofactor A; - OS=Homo sapiens (Human). 21.9 1 1 
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279 B4DWX6_HUMAN 
SubName: Full=cDNA FLJ53936, highly similar to Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial (EC 1.3.99.3); - OS=Homo sapiens (Human). 
42.5 4 4 
280 B4DXC4_HUMAN SubName: Full=cDNA FLJ58636, moderately similar to Atlastin; - OS=Homo sapiens (Human). 58.7 3 3 
281 B4DXN0_HUMAN 
SubName: Full=cDNA FLJ53371, highly similar to Major vault protein; - OS=Homo sapiens 
(Human). 
92.7 5 5 
282 B4DY09_HUMAN 
SubName: Full=cDNA FLJ51660, highly similar to Interleukin enhancer-binding factor 2; - OS=Homo 
sapiens (Human). 
38.9 1 1 
283 B4DY46_HUMAN 
SubName: Full=cDNA FLJ53447, highly similar to Syntaxin-binding protein 2; - OS=Homo sapiens 
(Human). 
62.7 3 3 
284 B4DZ08_HUMAN 
SubName: Full=cDNA FLJ51705, highly similar to Aconitate hydratase, mitochondrial (EC 4.2.1.3); - 
OS=Homo sapiens (Human). 
83.4 8 8 
285 B4DZW6_HUMAN 
SubName: Full=Regulator of microtubule dynamics protein 1; SubName: Full=cDNA FLJ53118, 
highly similar to Protein FAM82B; - OS=Homo sapiens (Human). 
32.3 2 2 
286 B4E022_HUMAN 
SubName: Full=Transketolase; SubName: Full=cDNA FLJ56274, highly similar to Transketolase (EC 
2.2.1.1); - OS=Homo sapiens (Human). 
62.8 11 11 
287 B4E054_HUMAN 
SubName: Full=cDNA FLJ58444, highly similar to Vacuolar ATP synthase subunit H (EC 3.6.3.14); - 
OS=Homo sapiens (Human). 
52.7 4 4 
288 B4E0K9_HUMAN 
SubName: Full=cDNA FLJ54572, highly similar to Lysosomal alpha-mannosidase (EC 3.2.1.24); - 
OS=Homo sapiens (Human). 
107.4 4 4 
289 B4E0N6_HUMAN 
SubName: Full=cDNA FLJ56280, highly similar to Endoplasmic reticulum-Golgi intermediate 
compartment protein 1; - OS=Homo sapiens (Human). 
26.2 1 1 
290 B4E0R1_HUMAN RecName: Full=Integrin beta; - OS=Homo sapiens (Human). 77.3 7 7 
291 B4E108_HUMAN 
SubName: Full=cDNA FLJ61026, highly similar to Homo sapiens phosphofructokinase, liver (PFKL), 
transcript variant 1, mRNA; - OS=Homo sapiens (Human). 
26.9 1 1 
292 B4E1D8_HUMAN SubName: Full=cDNA FLJ51597, highly similar to C4b-binding protein alpha chain; - OS=Homo 60.4 1 1 
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sapiens (Human). 
293 B4E1F5_HUMAN 
SubName: Full=cDNA FLJ57475, highly similar to Pulmonary surfactant-associated protein B; - 
OS=Homo sapiens (Human). 
38.5 5 5 
294 B4E1K7_HUMAN 
SubName: Full=Stomatin-like protein 2; SubName: Full=cDNA FLJ61039, highly similar to Stomatin-
like protein 2; - OS=Homo sapiens (Human). 
33.3 1 1 
295 B4E1X2_HUMAN 
SubName: Full=cDNA FLJ51620, highly similar to Coatomer subunit delta; - OS=Homo sapiens 
(Human). 
47.2 2 2 
296 B4E216_HUMAN SubName: Full=cDNA FLJ57339, highly similar to Complement C3; - OS=Homo sapiens (Human). 122.5 2 2 
297 B4E261_HUMAN 
SubName: Full=cDNA FLJ55646, highly similar to Adapter-relatedprotein complex 2 beta-1 subunit; - 
OS=Homo sapiens (Human). 
76.2 4 2 
298 B4E2S7_HUMAN 
SubName: Full=Lysosome-associated membrane glycoprotein 2; SubName: Full=cDNA FLJ58780, 
highly similar to Homo sapiens lysosomal-associated membrane protein 2 (LAMP2), transcript variant 
LAMP2B, mRNA; - OS=Homo sapiens (Human). 
39.8 2 2 
299 B4E2T4_HUMAN 
SubName: Full=cDNA FLJ54121, highly similar to Cysteine and glycine-rich protein 1; - OS=Homo 
sapiens (Human). 
15.0 2 2 
300 B4E2V5_HUMAN 
SubName: Full=Erythrocyte band 7 integral membrane protein; SubName: Full=Uncharacterized 
protein; SubName: Full=cDNA FLJ52062, highly similar to Erythrocyte band 7 integral membrane 
protein; - OS=Homo sapiens (Human). 
25.9 3 3 
301 B4E2W0_HUMAN 
SubName: Full=3-ketoacyl-CoA thiolase; SubName: Full=cDNA FLJ56214, highly similar to 
Trifunctional enzyme subunit beta, mitochondrial; - OS=Homo sapiens (Human). 
48.8 7 7 
302 B4E2Y1_HUMAN 
SubName: Full=cDNA FLJ52879, highly similar to Peroxisome proliferator-activated receptordelta; - 
OS=Homo sapiens (Human). 
38.8 1 1 
303 B4E2Z3_HUMAN 
SubName: Full=cDNA FLJ54090, highly similar to 4F2 cell-surface antigen heavy chain; - OS=Homo 
sapiens (Human). 
55.9 2 2 
304 B4E324_HUMAN SubName: Full=cDNA FLJ60397, highly similar to Lysosomal protective protein (EC 3.4.16.5); - 54.2 3 3 
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OS=Homo sapiens (Human). 
305 B4E363_HUMAN 
SubName: Full=Phenylalanine--tRNA ligase alpha subunit; SubName: Full=cDNA FLJ50378, highly 
similar to Phenylalanyl-tRNA synthetase alpha chain (EC 6.1.1.20); - OS=Homo sapiens (Human). 
54.1 1 1 
306 B4E380_HUMAN RecName: Full=Histone H3; - OS=Homo sapiens (Human). 12.9 2 2 
307 B4E3A8_HUMAN 
SubName: Full=cDNA FLJ53963, highly similar to Leukocyte elastase inhibitor; - OS=Homo sapiens 
(Human). 
38.7 2 2 
308 B4E3B6_HUMAN 
SubName: Full=cDNA FLJ54408, highly similar to Heat shock 70 kDa protein 1; - OS=Homo sapiens 
(Human). 
63.9 11 8 
309 B4E3F7_HUMAN 
SubName: Full=Muscleblind-like protein 2; SubName: Full=cDNA FLJ57455, moderately similar to 
Homo sapiens muscleblind-like 2 (Drosophila) (MBNL2), transcript variant 3, mRNA; - OS=Homo 
sapiens (Human). 
23.0 1 1 
310 B4E3M5_HUMAN 
SubName: Full=cDNA FLJ57816, highly similar to Triple functional domain protein; - OS=Homo 
sapiens (Human). 
174.8 2 1 
311 B4E3Q4_HUMAN 
SubName: Full=Adenosine deaminase CECR1; SubName: Full=cDNA FLJ58672, highly similar to 
Cat eye syndrome critical region protein 1; - OS=Homo sapiens (Human). 
54.3 2 2 
312 B5BU25_HUMAN SubName: Full=U2 small nuclear RNA auxiliary factor 2 isoform b; - OS=Homo sapiens (Human). 53.1 2 2 
313 B5MCP9_HUMAN SubName: Full=40S ribosomal protein S7; - OS=Homo sapiens (Human). 21.3 1 1 
314 B5MCX3_HUMAN SubName: Full=Septin-2; - OS=Homo sapiens (Human). 36.9 5 5 
315 B7Z1R5_HUMAN 
SubName: Full=V-type proton ATPase catalytic subunit A; SubName: Full=cDNA FLJ51804, highly 
similar to Vacuolar ATP synthase catalytic subunit A, ubiquitous isoform (EC 3.6.3.14); - OS=Homo 
sapiens (Human). 
64.7 7 7 
316 B7Z238_HUMAN 
SubName: Full=Bcl-2-like protein 13; SubName: Full=cDNA FLJ55839, highly similar to Bcl-2-like 
13 protein; - OS=Homo sapiens (Human). 
39.0 1 1 
317 B7Z254_HUMAN 
SubName: Full=Protein disulfide-isomerase A6; SubName: Full=cDNA FLJ58502, highly similar to 
Protein disulfide-isomerase A6 (EC 5.3.4.1); - OS=Homo sapiens (Human). 
47.8 8 8 
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318 B7Z2E2_HUMAN 
SubName: Full=cDNA FLJ54671, highly similar to Calcium-binding mitochondrial carrier protein 
Aralar2; - OS=Homo sapiens (Human). 
62.2 1 1 
319 B7Z2F4_HUMAN RecName: Full=T-complex protein 1 subunit delta; - OS=Homo sapiens (Human). 42.3 1 1 
320 B7Z361_HUMAN SubName: Full=cDNA FLJ50772, highly similar to Reticulon-3; - OS=Homo sapiens (Human). 22.9 1 1 
321 B7Z3Q4_HUMAN 
SubName: Full=cDNA FLJ51873, highly similar to Alkyldihydroxyacetonephosphate synthase, 
peroxisomal (EC 2.5.1.26); - OS=Homo sapiens (Human). 
63.8 4 4 
322 B7Z438_HUMAN 
SubName: Full=cDNA FLJ56352, highly similar to Succinyl-CoA ligase (GDP-forming) subunit 
alpha, mitochondrial (EC 6.2.1.4); - OS=Homo sapiens (Human). 
26.5 1 1 
323 B7Z478_HUMAN 
SubName: Full=Proteasome (Prosome, macropain) subunit, beta type, 2, isoform CRA_b; SubName: 
Full=cDNA FLJ51890, highly similar to Proteasome subunit beta type 2 (EC 3.4.25.1); - OS=Homo 
sapiens (Human). 
20.2 1 1 
324 B7Z4K6_HUMAN 
SubName: Full=Deoxyribonuclease-2-alpha; SubName: Full=cDNA FLJ51996, highly similar to 
Deoxyribonuclease-2-alpha (EC 3.1.22.1); - OS=Homo sapiens (Human). 
33.6 2 2 
325 B7Z4V2_HUMAN 
RecName: Full=Chaperone protein DnaK A; AltName: Full=HSP70 A; AltName: Full=Heat shock 70 
kDa protein A; AltName: Full=Heat shock protein 70 A; - OS=Homo sapiens (Human). 
72.4 11 11 
326 B7Z4Y1_HUMAN SubName: Full=cDNA FLJ58031, highly similar to Tuftelin; - OS=Homo sapiens (Human). 46.4 1 1 
327 B7Z4Y5_HUMAN 
SubName: Full=cDNA FLJ51553, highly similar to HLA class II histocompatibility antigen, DMalpha 
chain; - OS=Homo sapiens (Human). 
14.1 1 1 
328 B7Z553_HUMAN SubName: Full=cDNA FLJ51266, highly similar to Vitronectin; - OS=Homo sapiens (Human). 23.6 1 1 
329 B7Z565_HUMAN SubName: Full=cDNA FLJ54739, highly similar to Alpha-actinin-1; - OS=Homo sapiens (Human). 94.7 18 6 
330 B7Z570_HUMAN 
SubName: Full=cDNA FLJ53078, highly similar to Splicing factor, arginine/serine-rich 1; - OS=Homo 
sapiens (Human). 
16.2 1 1 
331 B7Z5C0_HUMAN 
SubName: Full=DnaJ homolog subfamily A member 1; SubName: Full=cDNA FLJ52352, highly 
similar to DnaJ homolog subfamily A member 1; - OS=Homo sapiens (Human). 
27.5 2 2 
332 B7Z5E7_HUMAN SubName: Full=cDNA FLJ51046, highly similar to 60 kDa heat shock protein, mitochondrial; - 55.0 13 13 
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OS=Homo sapiens (Human). 
333 B7Z5N4_HUMAN 
SubName: Full=cDNA FLJ51950, highly similar to Homo sapiens src family associated 
phosphoprotein 2 (SCAP2), mRNA; - OS=Homo sapiens (Human). 
39.6 1 1 
334 B7Z5P7_HUMAN 
SubName: Full=Leupaxin; SubName: Full=cDNA FLJ51550, highly similar to Leupaxin; - OS=Homo 
sapiens (Human). 
41.6 1 1 
335 B7Z5V6_HUMAN 
SubName: Full=cDNA FLJ57046, highly similar to Lysosomal alpha-glucosidase (EC 3.2.1.20); - 
OS=Homo sapiens (Human). 
71.7 4 2 
336 B7Z601_HUMAN 
SubName: Full=cDNA FLJ57187, highly similar to Glycerol-3-phosphate dehydrogenase, 
mitochondrial (EC 1.1.99.5); - OS=Homo sapiens (Human). 
55.7 8 8 
337 B7Z6A4_HUMAN 
SubName: Full=Surfeit 4, isoform CRA_c; SubName: Full=Surfeit locus protein 4; SubName: 
Full=Uncharacterized protein; SubName: Full=cDNA FLJ50656, highly similar to Surfeit locus protein 
4; - OS=Homo sapiens (Human). 
14.8 1 1 
338 B7Z6A8_HUMAN 
SubName: Full=Abhydrolase domain-containing protein 10, mitochondrial; SubName: Full=cDNA 
FLJ50858, highly similar to Homo sapiens abhydrolase domain containing 10 (ABHD10), mRNA; - 
OS=Homo sapiens (Human). 
16.9 1 1 
339 B7Z6B8_HUMAN 
SubName: Full=2,4-dienoyl-CoA reductase, mitochondrial; SubName: Full=cDNA FLJ50204, highly 
similar to 2,4-dienoyl-CoA reductase, mitochondrial (EC 1.3.1.34); - OS=Homo sapiens (Human). 
35.0 7 7 
340 B7Z766_HUMAN 
SubName: Full=cDNA FLJ54564, highly similar to 150 kDa oxygen-regulated protein (Orp150); - 
OS=Homo sapiens (Human). 
94.1 2 2 
341 B7Z7A9_HUMAN RecName: Full=Phosphoglycerate kinase B; EC=2.7.2.3; - OS=Homo sapiens (Human). 41.4 9 9 
342 B7Z7T2_HUMAN 
SubName: Full=cDNA FLJ58709, highly similar to Homo sapiens neuropathy target esterase (NTE), 
mRNA; - OS=Homo sapiens (Human). 
143.3 2 2 
343 B7Z7X2_HUMAN 
SubName: Full=cDNA FLJ52367, highly similar to Ras GTPase-activating-like protein IQGAP2; - 
OS=Homo sapiens (Human). 
43.6 1 1 
344 B7Z7Z9_HUMAN SubName: Full=Shootin-1; SubName: Full=cDNA FLJ58712, highly similar to Mus musculus myosin, 56.3 1 1 
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heavy polypeptide 9, non-muscle (Myh9), transcript variant 1, mRNA; - OS=Homo sapiens (Human). 
345 B7Z8D3_HUMAN 
SubName: Full=Proteasome activator complex subunit 3; SubName: Full=cDNA FLJ57249, highly 
similar to Proteasome activator complex subunit 3; - OS=Homo sapiens (Human). 
14.8 1 1 
346 B7Z8T9_HUMAN 
SubName: Full=cDNA FLJ52526, highly similar to Lysosomal acid phosphatase (EC 3.1.3.2); - 
OS=Homo sapiens (Human). 
26.6 1 1 
347 B7Z8Y6_HUMAN 
SubName: Full=cDNA FLJ58394, highly similar to Platelet endothelial cell adhesion molecule; - 
OS=Homo sapiens (Human). 
81.7 2 2 
348 B7Z972_HUMAN 
RecName: Full=Protein-L-isoaspartate O-methyltransferase; EC=2.1.1.77; - OS=Homo sapiens 
(Human). 
20.7 1 1 
349 B7Z992_HUMAN SubName: Full=cDNA FLJ53698, highly similar to Gelsolin; - OS=Homo sapiens (Human). 78.8 12 12 
350 B7ZAL5_HUMAN 
SubName: Full=cDNA, FLJ79229, highly similar to Lactotransferrin (EC 3.4.21.-); - OS=Homo 
sapiens (Human). 
73.1 6 6 
351 B7ZB41_HUMAN 
SubName: Full=cDNA, FLJ79405, highly similar to Homo sapiens solute carrier family 25, member 
24, transcript variant 1, mRNA; - OS=Homo sapiens (Human). 
53.3 9 9 
352 B7ZBK6_HUMAN 
SubName: Full=Aminolevulinate, delta-, dehydratase; SubName: Full=Delta-aminolevulinic acid 
dehydratase; Flags: Fragment; - OS=Homo sapiens (Human). 
13.3 1 1 
353 B7ZLF0_HUMAN 
SubName: Full=Fibronectin 1; SubName: Full=Fibronectin 1, isoform CRA_g; - OS=Homo sapiens 
(Human). 
239.5 10 10 
354 B8XPJ7_HUMAN SubName: Full=Soluble catechol-O-methyltransferase; - OS=Homo sapiens (Human). 24.5 4 4 
355 B8XPR9_HUMAN SubName: Full=MHC class I antigen; Flags: Fragment; - OS=Homo sapiens (Human). 31.6 3 1 
356 B8ZZ35_HUMAN SubName: Full=N-acetylgalactosaminidase, alpha-; Flags: Fragment; - OS=Homo sapiens (Human). 23.6 1 1 
357 B8ZZ51_HUMAN SubName: Full=Malate dehydrogenase, cytoplasmic; - OS=Homo sapiens (Human). 18.7 3 3 
358 B8ZZU8_HUMAN 
SubName: Full=Transcription elongation factor B (SIII), polypeptide 2 (18kDa, elongin B), isoform 
CRA_b; SubName: Full=Transcription elongation factor B polypeptide 2; - OS=Homo sapiens 
(Human). 
12.5 1 1 
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359 B9EJA8_HUMAN SubName: Full=Mannose receptor, C type 1-like 1; - OS=Homo sapiens (Human). 165.9 16 16 
360 B9EJE3_HUMAN SubName: Full=Putative uncharacterized protein; - OS=Homo sapiens (Human). 17.5 1 1 
361 BGAL_HUMAN 
RecName: Full=Beta-galactosidase; EC=3.2.1.23; AltName: Full=Acid beta-galactosidase; 
Short=Lactase; AltName: Full=Elastin receptor 1; Flags: Precursor; - OS=Homo sapiens (Human). 
76.0 5 5 
362 BIEA_HUMAN 
RecName: Full=Biliverdin reductase A; Short=BVR A; EC=1.3.1.24; AltName: Full=Biliverdin-IX 
alpha-reductase; Flags: Precursor; - OS=Homo sapiens (Human). 
33.4 3 3 
363 BLVRB_HUMAN 
RecName: Full=Flavin reductase (NADPH); Short=FR; EC=1.5.1.30; AltName: Full=Biliverdin 
reductase B; Short=BVR-B; EC=1.3.1.24; AltName: Full=Biliverdin-IX beta-reductase; AltName: 
Full=Green heme-binding protein; Short=GHBP; AltName: Full=NADPH-dependent diaphorase; 
AltName: Full=NADPH-flavin reductase; Short=FLR; - OS=Homo sapiens (Human). 
22.1 4 4 
364 BOLA2_HUMAN RecName: Full=BolA-like protein 2; - OS=Homo sapiens (Human). 10.1 1 1 
365 C0H5Y3_HUMAN 
SubName: Full=Natural resistance-associated macrophage protein 1; SubName: Full=SLC11A1 
protein; SubName: Full=Solute carrier family 11 (Proton-coupled divalent metal ion transporters), 
member 1, isoform CRA_a; - OS=Homo sapiens (Human). 
47.3 1 1 
366 C1KJL2_HUMAN SubName: Full=MHC class I antigen; Flags: Fragment; - OS=Homo sapiens (Human). 21.0 2 0 
367 C1TC_HUMAN 
RecName: Full=C-1-tetrahydrofolate synthase, cytoplasmic; Short=C1-THF synthase; Includes: 
RecName: Full=Methylenetetrahydrofolate dehydrogenase; EC=1.5.1.5; Includes: RecName: 
Full=Methenyltetrahydrofolate cyclohydrolase; EC=3.5.4.9; Includes: RecName: 
Full=Formyltetrahydrofolate synthetase; EC=6.3.4.3; - OS=Homo sapiens (Human). 
101.5 5 5 
368 C6KXN3_HUMAN 
SubName: Full=Lambda light chain of human immunoglobulin surface antigen-related protein; Flags: 
Fragment; - OS=Homo sapiens (Human). 
24.7 4 4 
369 C9J0D1_HUMAN RecName: Full=Histone H2A; - OS=Homo sapiens (Human). 13.2 3 1 
370 C9J0K6_HUMAN SubName: Full=Sorcin; - OS=Homo sapiens (Human). 17.6 2 2 
371 C9J3L8_HUMAN SubName: Full=Translocon-associated protein subunit alpha; - OS=Homo sapiens (Human). 29.6 3 3 
372 C9J815_HUMAN SubName: Full=Apolipoprotein B receptor; - OS=Homo sapiens (Human). 113.0 5 5 
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373 C9J8F3_HUMAN SubName: Full=Fructose-bisphosphate aldolase C; Flags: Fragment; - OS=Homo sapiens (Human). 16.3 1 1 
374 C9J8H9_HUMAN SubName: Full=ATP synthase subunit f, mitochondrial; - OS=Homo sapiens (Human). 5.7 1 1 
375 C9J9K3_HUMAN SubName: Full=40S ribosomal protein SA; Flags: Fragment; - OS=Homo sapiens (Human). 29.5 5 5 
376 C9JAQ9_HUMAN SubName: Full=U5 small nuclear ribonucleoprotein 200 kDa helicase; - OS=Homo sapiens (Human). 71.4 1 1 
377 C9JBL0_HUMAN SubName: Full=Nuclear autoantigen Sp-100; Flags: Fragment; - OS=Homo sapiens (Human). 22.0 1 1 
378 C9JCN0_HUMAN SubName: Full=Myoferlin; - OS=Homo sapiens (Human). 233.3 14 14 
379 C9JDR0_HUMAN 
SubName: Full=Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating; Flags: Fragment; - 
OS=Homo sapiens (Human). 
28.1 1 1 
380 C9JFR7_HUMAN SubName: Full=Cytochrome c; Flags: Fragment; - OS=Homo sapiens (Human). 11.3 5 5 
381 C9JGI3_HUMAN SubName: Full=Thymidine phosphorylase; Flags: Fragment; - OS=Homo sapiens (Human). 46.1 9 9 
382 C9JH92_HUMAN SubName: Full=Quinone oxidoreductase; Flags: Fragment; - OS=Homo sapiens (Human). 21.9 1 1 
383 C9JIS1_HUMAN 
SubName: Full=Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2; Flags: Fragment; - 
OS=Homo sapiens (Human). 
25.5 2 1 
384 C9JJ34_HUMAN 
SubName: Full=Ran-specific GTPase-activating protein; Flags: Fragment; - OS=Homo sapiens 
(Human). 
18.8 1 1 
385 C9JJ47_HUMAN SubName: Full=AP-2 complex subunit mu; Flags: Fragment; - OS=Homo sapiens (Human). 28.8 1 1 
386 C9JJK5_HUMAN SubName: Full=Zyxin; Flags: Fragment; - OS=Homo sapiens (Human). 19.1 1 1 
387 C9JL12_HUMAN SubName: Full=Prolyl 4-hydroxylase subunit alpha-1; - OS=Homo sapiens (Human). 58.9 1 1 
388 C9JMD7_HUMAN SubName: Full=B-cell receptor-associated protein 31; Flags: Fragment; - OS=Homo sapiens (Human). 20.2 1 1 
389 C9JPM4_HUMAN SubName: Full=ADP-ribosylation factor 4; Flags: Fragment; - OS=Homo sapiens (Human). 14.5 5 3 
390 C9JTK6_HUMAN SubName: Full=Obg-like ATPase 1; Flags: Fragment; - OS=Homo sapiens (Human). 12.3 1 1 
391 C9JTV7_HUMAN SubName: Full=Ephexin-1; Flags: Fragment; - OS=Homo sapiens (Human). 22.0 1 1 
392 C9JW96_HUMAN SubName: Full=Prohibitin; Flags: Fragment; - OS=Homo sapiens (Human). 26.9 7 7 
393 CA031_HUMAN RecName: Full=Uncharacterized protein C1orf31; - OS=Homo sapiens (Human). 14.1 2 2 
394 CAH1_HUMAN RecName: Full=Carbonic anhydrase 1; EC=4.2.1.1; AltName: Full=Carbonate dehydratase I; 28.9 9 9 
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AltName: Full=Carbonic anhydrase B; Short=CAB; AltName: Full=Carbonic anhydrase I; Short=CA-
I; - OS=Homo sapiens (Human). 
395 CAH2_HUMAN 
RecName: Full=Carbonic anhydrase 2; EC=4.2.1.1; AltName: Full=Carbonate dehydratase II; 
AltName: Full=Carbonic anhydrase C; Short=CAC; AltName: Full=Carbonic anhydrase II; Short=CA-
II; - OS=Homo sapiens (Human). 
29.2 9 9 
396 CALX_HUMAN 
RecName: Full=Calnexin; AltName: Full=IP90; AltName: Full=Major histocompatibility complex 
class I antigen-binding protein p88; AltName: Full=p90; Flags: Precursor; - OS=Homo sapiens 
(Human). 
67.5 7 7 
397 CATA_HUMAN RecName: Full=Catalase; EC=1.11.1.6; - OS=Homo sapiens (Human). 59.7 16 16 
398 CATD_HUMAN 
RecName: Full=Cathepsin D; EC=3.4.23.5; Contains: RecName: Full=Cathepsin D light chain; 
Contains: RecName: Full=Cathepsin D heavy chain; Flags: Precursor; - OS=Homo sapiens (Human). 
44.5 11 11 
399 CATH_HUMAN 
RecName: Full=Pro-cathepsin H; Contains: RecName: Full=Cathepsin H mini chain; Contains: 
RecName: Full=Cathepsin H; EC=3.4.22.16; Contains: RecName: Full=Cathepsin H heavy chain; 
Contains: RecName: Full=Cathepsin H light chain; Flags: Precursor; - OS=Homo sapiens (Human). 
37.4 5 5 
400 CATS_HUMAN RecName: Full=Cathepsin S; EC=3.4.22.27; Flags: Precursor; - OS=Homo sapiens (Human). 37.5 5 5 
401 CATZ_HUMAN 
RecName: Full=Cathepsin Z; EC=3.4.18.1; AltName: Full=Cathepsin P; AltName: Full=Cathepsin X; 
Flags: Precursor; - OS=Homo sapiens (Human). 
33.8 2 2 
402 CAZA2_HUMAN 
RecName: Full=F-actin-capping protein subunit alpha-2; AltName: Full=CapZ alpha-2; - OS=Homo 
sapiens (Human). 
32.9 3 2 
403 CBR1_HUMAN 
RecName: Full=Carbonyl reductase [NADPH] 1; EC=1.1.1.184; AltName: Full=15-
hydroxyprostaglandin dehydrogenase [NADP(+)]; EC=1.1.1.197; AltName: Full=NADPH-dependent 
carbonyl reductase 1; AltName: Full=Prostaglandin 9-ketoreductase; AltName: Full=Prostaglandin-
E(2) 9-reductase; EC=1.1.1.189; - OS=Homo sapiens (Human). 
30.4 3 3 
404 CD47_HUMAN 
RecName: Full=Leukocyte surface antigen CD47; AltName: Full=Antigenic surface determinant 
protein OA3; AltName: Full=Integrin-associated protein; Short=IAP; AltName: Full=Protein MER6; 
35.2 1 1 
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AltName: CD_antigen=CD47; Flags: Precursor; - OS=Homo sapiens (Human). 
405 CDC42_HUMAN 
RecName: Full=Cell division control protein 42 homolog; AltName: Full=G25K GTP-binding protein; 
Flags: Precursor; - OS=Homo sapiens (Human). 
21.2 3 2 
406 CHCH3_HUMAN 
RecName: Full=Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial; - 
OS=Homo sapiens (Human). 
26.1 2 2 
407 CHID1_HUMAN 
RecName: Full=Chitinase domain-containing protein 1; AltName: Full=Stabilin-1-interacting 
chitinase-like protein; Short=SI-CLP; Flags: Precursor; - OS=Homo sapiens (Human). 
44.9 1 1 
408 CK5P3_HUMAN 
RecName: Full=CDK5 regulatory subunit-associated protein 3; AltName: Full=CDK5 activator-
binding protein C53; AltName: Full=Protein HSF-27; - OS=Homo sapiens (Human). 
56.9 2 2 
409 CLH1_HUMAN 
RecName: Full=Clathrin heavy chain 1; AltName: Full=Clathrin heavy chain on chromosome 17; 
Short=CLH-17; - OS=Homo sapiens (Human). 
191.5 30 30 
410 CLIC1_HUMAN 
RecName: Full=Chloride intracellular channel protein 1; AltName: Full=Chloride channel ABP; 
AltName: Full=Nuclear chloride ion channel 27; Short=NCC27; AltName: Full=Regulatory nuclear 
chloride ion channel protein; Short=hRNCC; - OS=Homo sapiens (Human). 
26.9 5 5 
411 CNOT1_HUMAN 
RecName: Full=CCR4-NOT transcription complex subunit 1; AltName: Full=CCR4-associated factor 
1; AltName: Full=Negative regulator of transcription subunit 1 homolog; Short=NOT1H; 
Short=hNOT1; - OS=Homo sapiens (Human). 
266.8 1 1 
412 COPB_HUMAN 
RecName: Full=Coatomer subunit beta; AltName: Full=Beta-coat protein; Short=Beta-COP; - 
OS=Homo sapiens (Human). 
107.1 1 1 
413 COR1A_HUMAN 
RecName: Full=Coronin-1A; AltName: Full=Coronin-like protein A; Short=Clipin-A; AltName: 
Full=Coronin-like protein p57; AltName: Full=Tryptophan aspartate-containing coat protein; 
Short=TACO; - OS=Homo sapiens (Human). 
51.0 2 2 
414 COTL1_HUMAN RecName: Full=Coactosin-like protein; - OS=Homo sapiens (Human). 15.9 5 5 
415 COX41_HUMAN 
RecName: Full=Cytochrome c oxidase subunit 4 isoform 1, mitochondrial; AltName: 
Full=Cytochrome c oxidase polypeptide IV; AltName: Full=Cytochrome c oxidase subunit IV isoform 
19.6 2 2 
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1; Short=COX IV-1; Flags: Precursor; - OS=Homo sapiens (Human). 
416 COX5B_HUMAN 
RecName: Full=Cytochrome c oxidase subunit 5B, mitochondrial; AltName: Full=Cytochrome c 
oxidase polypeptide Vb; Flags: Precursor; - OS=Homo sapiens (Human). 
13.7 3 3 
417 CP27A_HUMAN 
RecName: Full=Sterol 26-hydroxylase, mitochondrial; EC=1.14.13.15; AltName: Full=5-beta-
cholestane-3-alpha,7-alpha,12-alpha-triol 27-hydroxylase; AltName: Full=Cytochrome P-450C27/25; 
AltName: Full=Cytochrome P450 27; AltName: Full=Sterol 27-hydroxylase; AltName: Full=Vitamin 
D(3) 25-hydroxylase; Flags: Precursor; - OS=Homo sapiens (Human). 
60.2 7 7 
418 CP2S1_HUMAN 
RecName: Full=Cytochrome P450 2S1; EC=1.14.14.1; AltName: Full=CYPIIS1; - OS=Homo sapiens 
(Human). 
55.8 1 1 
419 CPNS1_HUMAN 
RecName: Full=Calpain small subunit 1; Short=CSS1; AltName: Full=Calcium-activated neutral 
proteinase small subunit; Short=CANP small subunit; AltName: Full=Calcium-dependent protease 
small subunit; Short=CDPS; AltName: Full=Calcium-dependent protease small subunit 1; AltName: 
Full=Calpain regulatory subunit; - OS=Homo sapiens (Human). 
28.3 2 2 
420 CREG1_HUMAN 
RecName: Full=Protein CREG1; AltName: Full=Cellular repressor of E1A-stimulated genes 1; Flags: 
Precursor; - OS=Homo sapiens (Human). 
24.1 2 2 
421 CS010_HUMAN 
RecName: Full=UPF0556 protein C19orf10; AltName: Full=Interleukin-25; Short=IL-25; AltName: 
Full=Stromal cell-derived growth factor SF20; Flags: Precursor; - OS=Homo sapiens (Human). 
18.8 2 2 
422 CT027_HUMAN RecName: Full=UPF0687 protein C20orf27; - OS=Homo sapiens (Human). 19.3 1 1 
423 CUTA_HUMAN 
RecName: Full=Protein CutA; AltName: Full=Acetylcholinesterase-associated protein; AltName: 
Full=Brain acetylcholinesterase putative membrane anchor; Flags: Precursor; - OS=Homo sapiens 
(Human). 
19.1 2 2 
424 CX6B1_HUMAN 
RecName: Full=Cytochrome c oxidase subunit 6B1; AltName: Full=Cytochrome c oxidase subunit 
VIb isoform 1; Short=COX VIb-1; - OS=Homo sapiens (Human). 
10.2 3 3 
425 CX7A2_HUMAN 
RecName: Full=Cytochrome c oxidase subunit 7A2, mitochondrial; AltName: Full=Cytochrome c 
oxidase subunit VIIa-liver/heart; Short=Cytochrome c oxidase subunit VIIa-L; Short=Cytochrome c 
9.4 2 2 
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oxidase subunit VIIaL; Flags: Precursor; - OS=Homo sapiens (Human). 
426 CYTB_HUMAN 
RecName: Full=Cystatin-B; AltName: Full=CPI-B; AltName: Full=Liver thiol proteinase inhibitor; 
AltName: Full=Stefin-B; - OS=Homo sapiens (Human). 
11.1 3 3 
427 CYTC_HUMAN 
RecName: Full=Cystatin-C; AltName: Full=Cystatin-3; AltName: Full=Gamma-trace; AltName: 
Full=Neuroendocrine basic polypeptide; AltName: Full=Post-gamma-globulin; Flags: Precursor; - 
OS=Homo sapiens (Human). 
15.8 1 1 
428 D2Y6Y7_HUMAN SubName: Full=ATP synthase subunit 6; Flags: Fragment; - OS=Homo sapiens (Human). 5.1 1 1 
429 D3DP13_HUMAN SubName: Full=Fibrinogen beta chain, isoform CRA_e; - OS=Homo sapiens (Human). 39.7 2 2 
430 D3DP16_HUMAN SubName: Full=Fibrinogen gamma chain, isoform CRA_a; - OS=Homo sapiens (Human). 37.7 3 3 
431 D3DUJ0_HUMAN 
SubName: Full=AFG3 ATPase family gene 3-like 2 (Yeast), isoform CRA_a; Flags: Fragment; - 
OS=Homo sapiens (Human). 
84.4 3 3 
432 D3DV53_HUMAN 
SubName: Full=S100 calcium binding protein A13, isoform CRA_a; Flags: Fragment; - OS=Homo 
sapiens (Human). 
5.8 1 1 
433 D3DVH1_HUMAN 
SubName: Full=Succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa, 
isoform CRA_a; - OS=Homo sapiens (Human). 
11.3 1 1 
434 D3DW07_HUMAN SubName: Full=Putative uncharacterized protein RP5-1022P6.2; - OS=Homo sapiens (Human). 45.2 1 1 
435 D3YTB1_HUMAN SubName: Full=60S ribosomal protein L32; Flags: Fragment; - OS=Homo sapiens (Human). 15.6 1 1 
436 D5KJA2_HUMAN 
SubName: Full=Dehydrogenase/reductase (SDR family) member 4 like 2A; - OS=Homo sapiens 
(Human). 
15.2 2 2 
437 D6CHE9_HUMAN 
SubName: Full=Proteinase 3; SubName: Full=Proteinase 3 (Serine proteinase, neutrophil, Wegener 
granulomatosis autoantigen), isoform CRA_a; - OS=Homo sapiens (Human). 
23.6 1 1 
438 D6R937_HUMAN 
SubName: Full=Endothelial monocyte-activating polypeptide 2; Flags: Fragment; - OS=Homo sapiens 
(Human). 
16.6 1 1 
439 D6R9B6_HUMAN 
SubName: Full=40S ribosomal protein S3a; SubName: Full=Ribosomal protein S3A, isoform CRA_e; 
- OS=Homo sapiens (Human). 
16.5 2 2 
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440 D6R9P3_HUMAN SubName: Full=Heterogeneous nuclear ribonucleoprotein A/B; - OS=Homo sapiens (Human). 30.3 2 1 
441 D6RA08_HUMAN 
SubName: Full=Complement C1q subcomponent subunit B; Flags: Fragment; - OS=Homo sapiens 
(Human). 
24.1 1 1 
442 D6RAA2_HUMAN SubName: Full=GTP-binding protein SAR1b; Flags: Fragment; - OS=Homo sapiens (Human). 11.5 1 1 
443 D6RAA6_HUMAN SubName: Full=Transmembrane protein 33; Flags: Fragment; - OS=Homo sapiens (Human). 25.2 2 2 
444 D6RAW0_HUMAN 
SubName: Full=Ubiquitin-conjugating enzyme E2 D3; Flags: Fragment; - OS=Homo sapiens 
(Human). 
8.2 1 1 
445 D6RBB5_HUMAN SubName: Full=Microsomal glutathione S-transferase 2; - OS=Homo sapiens (Human). 8.4 1 1 
446 D6RDU5_HUMAN SubName: Full=Septin-11; Flags: Fragment; - OS=Homo sapiens (Human). 43.1 2 1 
447 D6RE99_HUMAN SubName: Full=Histidine triad nucleotide-binding protein 1; - OS=Homo sapiens (Human). 8.6 2 2 
448 D6RF23_HUMAN 
SubName: Full=Guanine nucleotide-binding protein subunit beta-2-like 1; - OS=Homo sapiens 
(Human). 
11.2 2 2 
449 D6RF44_HUMAN 
SubName: Full=Heterogeneous nuclear ribonucleoprotein D0; Flags: Fragment; - OS=Homo sapiens 
(Human). 
12.6 3 2 
450 D6RFM5_HUMAN 
SubName: Full=Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial; - 
OS=Homo sapiens (Human). 
63.5 4 4 
451 D6RG00_HUMAN SubName: Full=Ubiquitin-conjugating enzyme E2 variant 1; - OS=Homo sapiens (Human). 10.1 1 1 
452 D6RHZ5_HUMAN SubName: Full=Protein transport protein Sec31A; - OS=Homo sapiens (Human). 96.4 1 1 
453 D6RIZ4_HUMAN 
SubName: Full=Major facilitator superfamily domain-containing protein 10; - OS=Homo sapiens 
(Human). 
38.2 1 1 
454 D6RJD1_HUMAN SubName: Full=Clathrin light chain B; Flags: Fragment; - OS=Homo sapiens (Human). 13.1 1 1 
455 D6W507_HUMAN SubName: Full=HCG1990625, isoform CRA_a; - OS=Homo sapiens (Human). 16.6 2 2 
456 D7GNM6_HUMAN SubName: Full=MHC class I antigen; Flags: Fragment; - OS=Homo sapiens (Human). 31.7 6 1 
457 DDRGK_HUMAN 
RecName: Full=DDRGK domain-containing protein 1; Flags: Precursor; - OS=Homo sapiens 
(Human). 
35.6 2 2 
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458 DEF1_HUMAN 
RecName: Full=Neutrophil defensin 1; AltName: Full=Defensin, alpha 1; AltName: Full=HNP-1; 
Short=HP-1; Short=HP1; Contains: RecName: Full=HP 1-56; Contains: RecName: Full=Neutrophil 
defensin 2; AltName: Full=HNP-2; Short=HP-2; Short=HP2; Flags: Precursor; - OS=Homo sapiens 
(Human). 
10.2 1 1 
459 DHB11_HUMAN 
RecName: Full=Estradiol 17-beta-dehydrogenase 11; EC=1.1.1.62; AltName: Full=17-beta-
hydroxysteroid dehydrogenase 11; Short=17-beta-HSD 11; Short=17bHSD11; Short=17betaHSD11; 
AltName: Full=17-beta-hydroxysteroid dehydrogenase XI; Short=17-beta-HSD XI; 
Short=17betaHSDXI; AltName: Full=Cutaneous T-cell lymphoma-associated antigen HD-CL-03; 
Short=CTCL-associated antigen HD-CL-03; AltName: Full=Dehydrogenase/reductase SDR family 
member 8; AltName: Full=Retinal short-chain dehydrogenase/reductase 2; Short=retSDR2; Flags: 
Precursor; - OS=Homo sapiens (Human). 
32.9 5 5 
460 DHX9_HUMAN 
RecName: Full=ATP-dependent RNA helicase A; Short=RHA; EC=3.6.4.13; AltName: Full=DEAH 
box protein 9; AltName: Full=Leukophysin; Short=LKP; AltName: Full=Nuclear DNA helicase II; 
Short=NDH II; - OS=Homo sapiens (Human). 
140.9 6 6 
461 DLRB1_HUMAN 
RecName: Full=Dynein light chain roadblock-type 1; AltName: Full=Bithoraxoid-like protein; 
Short=BLP; AltName: Full=Dynein light chain 2A, cytoplasmic; AltName: Full=Dynein-associated 
protein Km23; AltName: Full=Roadblock domain-containing protein 1; - OS=Homo sapiens (Human). 
10.9 1 1 
462 DMBT1_HUMAN 
RecName: Full=Deleted in malignant brain tumors 1 protein; AltName: Full=Glycoprotein 340; 
Short=Gp-340; AltName: Full=Hensin; AltName: Full=Salivary agglutinin; Short=SAG; AltName: 
Full=Surfactant pulmonary-associated D-binding protein; Flags: Precursor; - OS=Homo sapiens 
(Human). 
260.6 1 1 
463 DNJC3_HUMAN 
RecName: Full=DnaJ homolog subfamily C member 3; AltName: Full=Endoplasmic reticulum DnaJ 
protein 6; Short=ERdj6; AltName: Full=Interferon-induced, double-stranded RNA-activated protein 
kinase inhibitor; AltName: Full=Protein kinase inhibitor of 58 kDa; Short=Protein kinase inhibitor 
p58; Flags: Precursor; - OS=Homo sapiens (Human). 
57.5 1 1 
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464 DPP2_HUMAN 
RecName: Full=Dipeptidyl peptidase 2; EC=3.4.14.2; AltName: Full=Dipeptidyl aminopeptidase II; 
AltName: Full=Dipeptidyl peptidase 7; AltName: Full=Dipeptidyl peptidase II; Short=DPP II; 
AltName: Full=Quiescent cell proline dipeptidase; Flags: Precursor; - OS=Homo sapiens (Human). 
54.3 6 6 
465 DPY30_HUMAN 
RecName: Full=Protein dpy-30 homolog; AltName: Full=Dpy-30-like protein; Short=Dpy-30L; - 
OS=Homo sapiens (Human). 
11.2 2 2 
466 E4W6B6_HUMAN SubName: Full=RPL27/NME2 fusion protein; Flags: Fragment; - OS=Homo sapiens (Human). 14.2 1 1 
467 E5RFX7_HUMAN 
SubName: Full=Proline synthase co-transcribed bacterial homolog protein; Flags: Fragment; - 
OS=Homo sapiens (Human). 
15.3 1 1 
468 E5RGJ2_HUMAN SubName: Full=Protein EMC2; Flags: Fragment; - OS=Homo sapiens (Human). 13.5 1 1 
469 E5RHJ4_HUMAN SubName: Full=DBIRD complex subunit KIAA1967; Flags: Fragment; - OS=Homo sapiens (Human). 31.1 1 1 
470 E5RHW4_HUMAN SubName: Full=Erlin-2; Flags: Fragment; - OS=Homo sapiens (Human). 37.7 3 3 
471 E5RI99_HUMAN SubName: Full=60S ribosomal protein L30; Flags: Fragment; - OS=Homo sapiens (Human). 12.6 2 2 
472 E5RJA0_HUMAN SubName: Full=Acyl-protein thioesterase 1; - OS=Homo sapiens (Human). 15.1 1 1 
473 E5RK61_HUMAN SubName: Full=Protein FAM49B; Flags: Fragment; - OS=Homo sapiens (Human). 7.1 1 1 
474 E5RK69_HUMAN RecName: Full=Annexin; - OS=Homo sapiens (Human). 51.7 2 2 
475 E7EMM4_HUMAN SubName: Full=Acid ceramidase subunit beta; - OS=Homo sapiens (Human). 41.8 12 8 
476 E7EQV9_HUMAN RecName: Full=Ribosomal protein L15; Flags: Fragment; - OS=Homo sapiens (Human). 20.5 2 2 
477 E7ERH2_HUMAN SubName: Full=S-phase kinase-associated protein 1; Flags: Fragment; - OS=Homo sapiens (Human). 16.0 2 2 
478 E7ERW8_HUMAN SubName: Full=Protein diaphanous homolog 1; - OS=Homo sapiens (Human). 135.3 2 2 
479 E7EUT4_HUMAN 
RecName: Full=Glyceraldehyde-3-phosphate dehydrogenase; EC=1.2.1.12; - OS=Homo sapiens 
(Human). 
31.5 8 8 
480 E7EWI9_HUMAN SubName: Full=Heterogeneous nuclear ribonucleoprotein A3; - OS=Homo sapiens (Human). 34.1 1 1 
481 E9LUX2_HUMAN SubName: Full=Hemoglobin alpha-2 chain variant; Flags: Fragment; - OS=Homo sapiens (Human). 7.7 3 1 
482 E9PAU8_HUMAN SubName: Full=Liver carboxylesterase 1; - OS=Homo sapiens (Human). 62.4 18 18 
483 E9PCY7_HUMAN SubName: Full=Heterogeneous nuclear ribonucleoprotein H, N-terminally processed; - OS=Homo 47.1 5 4 
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sapiens (Human). 
484 E9PDQ8_HUMAN 
SubName: Full=Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial; - OS=Homo sapiens 
(Human). 
41.4 4 4 
485 E9PH29_HUMAN 
SubName: Full=Thioredoxin-dependent peroxide reductase, mitochondrial; - OS=Homo sapiens 
(Human). 
25.8 5 5 
486 E9PHX3_HUMAN SubName: Full=Neutrophil cytosol factor 2; - OS=Homo sapiens (Human). 54.4 5 5 
487 E9PI87_HUMAN SubName: Full=Oxidoreductase HTATIP2; - OS=Homo sapiens (Human). 22.0 1 1 
488 E9PID9_HUMAN 
SubName: Full=SID1 transmembrane family member 2; Flags: Fragment; - OS=Homo sapiens 
(Human). 
12.4 1 1 
489 E9PIQ8_HUMAN SubName: Full=Stromal interaction molecule 1; Flags: Fragment; - OS=Homo sapiens (Human). 16.2 1 1 
490 E9PJD9_HUMAN SubName: Full=60S ribosomal protein L27a; - OS=Homo sapiens (Human). 10.1 2 2 
491 E9PJK1_HUMAN SubName: Full=CD81 antigen; - OS=Homo sapiens (Human). 18.0 1 1 
492 E9PKD5_HUMAN SubName: Full=26S protease regulatory subunit 6A; Flags: Fragment; - OS=Homo sapiens (Human). 32.7 2 2 
493 E9PKH0_HUMAN 
SubName: Full=Receptor-type tyrosine-protein phosphatase C; Flags: Fragment; - OS=Homo sapiens 
(Human). 
67.6 2 2 
494 E9PKW8_HUMAN 
SubName: Full=Ubiquitin/ISG15-conjugating enzyme E2 L6; Flags: Fragment; - OS=Homo sapiens 
(Human). 
7.5 1 1 
495 E9PLX3_HUMAN SubName: Full=Hepatitis B virus X-interacting protein; - OS=Homo sapiens (Human). 9.5 1 1 
496 E9PN17_HUMAN SubName: Full=ATP synthase subunit g, mitochondrial; - OS=Homo sapiens (Human). 8.4 2 2 
497 E9PN51_HUMAN 
SubName: Full=NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial; Flags: 
Fragment; - OS=Homo sapiens (Human). 
12.4 1 1 
498 E9PN91_HUMAN SubName: Full=Elongation factor 1-delta; - OS=Homo sapiens (Human). 11.6 2 2 
499 E9PNT8_HUMAN SubName: Full=Mitochondrial carrier homolog 2; Flags: Fragment; - OS=Homo sapiens (Human). 17.6 3 3 
500 E9PP60_HUMAN SubName: Full=GDP-L-fucose synthase; - OS=Homo sapiens (Human). 12.1 1 1 
501 E9PP76_HUMAN RecName: Full=Superoxide dismutase [Cu-Zn]; EC=1.15.1.1; Flags: Fragment; - OS=Homo sapiens 7.3 1 1 
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(Human). 
502 E9PPM9_HUMAN 
SubName: Full=Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha; Flags: 
Fragment; - OS=Homo sapiens (Human). 
7.5 1 1 
503 E9PPQ4_HUMAN SubName: Full=Ferritin heavy chain; Flags: Fragment; - OS=Homo sapiens (Human). 6.7 2 2 
504 E9PPS5_HUMAN 
SubName: Full=NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial; Flags: Fragment; - 
OS=Homo sapiens (Human). 
8.3 1 1 
505 E9PR95_HUMAN SubName: Full=Ester hydrolase C11orf54; Flags: Fragment; - OS=Homo sapiens (Human). 8.3 1 1 
506 E9PSB0_HUMAN SubName: Full=EH domain-binding protein 1-like protein 1; - OS=Homo sapiens (Human). 14.9 1 1 
507 ECH1_HUMAN 
RecName: Full=Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial; EC=5.3.3.-; Flags: 
Precursor; - OS=Homo sapiens (Human). 
35.8 4 4 
508 ECHA_HUMAN 
RecName: Full=Trifunctional enzyme subunit alpha, mitochondrial; AltName: Full=78 kDa gastrin-
binding protein; AltName: Full=TP-alpha; Includes: RecName: Full=Long-chain enoyl-CoA 
hydratase; EC=4.2.1.17; Includes: RecName: Full=Long chain 3-hydroxyacyl-CoA dehydrogenase; 
EC=1.1.1.211; Flags: Precursor; - OS=Homo sapiens (Human). 
82.9 13 13 
509 ECHD1_HUMAN 
RecName: Full=Ethylmalonyl-CoA decarboxylase; EC=4.1.1.94; AltName: Full=Enoyl-CoA 
hydratase domain-containing protein 1; AltName: Full=Methylmalonyl-CoA decarboxylase; 
Short=MMCD; EC=4.1.1.41; - OS=Homo sapiens (Human). 
33.7 2 2 
510 ECHM_HUMAN 
RecName: Full=Enoyl-CoA hydratase, mitochondrial; EC=4.2.1.17; AltName: Full=Enoyl-CoA 
hydratase 1; AltName: Full=Short-chain enoyl-CoA hydratase; Short=SCEH; Flags: Precursor; - 
OS=Homo sapiens (Human). 
31.4 4 4 
511 EF1A1_HUMAN 
RecName: Full=Elongation factor 1-alpha 1; Short=EF-1-alpha-1; AltName: Full=Elongation factor 
Tu; Short=EF-Tu; AltName: Full=Eukaryotic elongation factor 1 A-1; Short=eEF1A-1; AltName: 
Full=Leukocyte receptor cluster member 7; - OS=Homo sapiens (Human). 
50.1 10 10 
512 EF1B_HUMAN RecName: Full=Elongation factor 1-beta; Short=EF-1-beta; - OS=Homo sapiens (Human). 24.7 2 2 
513 EF2_HUMAN RecName: Full=Elongation factor 2; Short=EF-2; - OS=Homo sapiens (Human). 95.3 6 6 
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514 EFHD2_HUMAN 
RecName: Full=EF-hand domain-containing protein D2; AltName: Full=Swiprosin-1; - OS=Homo 
sapiens (Human). 
26.7 5 5 
515 EFTU_HUMAN 
RecName: Full=Elongation factor Tu, mitochondrial; Short=EF-Tu; AltName: Full=P43; Flags: 
Precursor; - OS=Homo sapiens (Human). 
49.5 10 10 
516 EGLN2_HUMAN 
RecName: Full=Egl nine homolog 2; EC=1.14.11.29; AltName: Full=Estrogen-induced tag 6; 
AltName: Full=HPH-3; AltName: Full=Hypoxia-inducible factor prolyl hydroxylase 1; Short=HIF-
PH1; Short=HIF-prolyl hydroxylase 1; Short=HPH-1; AltName: Full=Prolyl hydroxylase domain-
containing protein 1; Short=PHD1; - OS=Homo sapiens (Human). 
43.6 1 1 
517 ELAV1_HUMAN 
RecName: Full=ELAV-like protein 1; AltName: Full=Hu-antigen R; Short=HuR; - OS=Homo sapiens 
(Human). 
36.1 1 1 
518 ENOA_HUMAN 
RecName: Full=Alpha-enolase; EC=4.2.1.11; AltName: Full=2-phospho-D-glycerate hydro-lyase; 
AltName: Full=C-myc promoter-binding protein; AltName: Full=Enolase 1; AltName: Full=MBP-1; 
AltName: Full=MPB-1; AltName: Full=Non-neural enolase; Short=NNE; AltName: 
Full=Phosphopyruvate hydratase; AltName: Full=Plasminogen-binding protein; - OS=Homo sapiens 
(Human). 
47.1 14 11 
519 ENPP4_HUMAN 
RecName: Full=Ectonucleotide pyrophosphatase/phosphodiesterase family member 4; Short=E-NPP 4; 
Short=NPP-4; EC=3.1.-.-; Flags: Precursor; - OS=Homo sapiens (Human). 
51.6 2 2 
520 EPDR1_HUMAN 
RecName: Full=Mammalian ependymin-related protein 1; Short=MERP-1; AltName: 
Full=Upregulated in colorectal cancer 512gene 1 protein; Flags: Precursor; - OS=Homo sapiens 
(Human). 
25.4 1 1 
521 ERAP1_HUMAN 
RecName: Full=Endoplasmic reticulum aminopeptidase 1; EC=3.4.11.-; AltName: Full=ARTS-1; 
AltName: Full=Adipocyte-derived leucine aminopeptidase; Short=A-LAP; AltName: 
Full=Aminopeptidase PILS; AltName: Full=Puromycin-insensitive leucyl-specific aminopeptidase; 
Short=PILS-AP; AltName: Full=Type 1 tumor necrosis factor receptor shedding aminopeptidase 
regulator; - OS=Homo sapiens (Human). 
107.2 13 13 
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522 ERO1A_HUMAN 
RecName: Full=ERO1-like protein alpha; Short=ERO1-L; Short=ERO1-L-alpha; EC=1.8.4.-; 
AltName: Full=Endoplasmic oxidoreductin-1-like protein; AltName: Full=Oxidoreductin-1-L-alpha; 
Flags: Precursor; - OS=Homo sapiens (Human). 
54.4 4 4 
523 ERP29_HUMAN 
RecName: Full=Endoplasmic reticulum resident protein 29; Short=ERp29; AltName: 
Full=Endoplasmic reticulum resident protein 28; Short=ERp28; AltName: Full=Endoplasmic 
reticulum resident protein 31; Short=ERp31; Flags: Precursor; - OS=Homo sapiens (Human). 
29.0 5 5 
524 ERP44_HUMAN 
RecName: Full=Endoplasmic reticulum resident protein 44; Short=ER protein 44; Short=ERp44; 
AltName: Full=Thioredoxin domain-containing protein 4; Flags: Precursor; - OS=Homo sapiens 
(Human). 
46.9 9 9 
525 ETFA_HUMAN 
RecName: Full=Electron transfer flavoprotein subunit alpha, mitochondrial; Short=Alpha-ETF; Flags: 
Precursor; - OS=Homo sapiens (Human). 
35.1 8 8 
526 ETHE1_HUMAN 
RecName: Full=Protein ETHE1, mitochondrial; EC=3.-.-.-; AltName: Full=Ethylmalonic 
encephalopathy protein 1; AltName: Full=Hepatoma subtracted clone one protein; Flags: Precursor; - 
OS=Homo sapiens (Human). 
27.9 5 5 
527 EVI5_HUMAN 
RecName: Full=Ecotropic viral integration site 5 protein homolog; Short=EVI-5; AltName: 
Full=Neuroblastoma stage 4S gene protein; - OS=Homo sapiens (Human). 
92.9 1 1 
528 EZRI_HUMAN 
RecName: Full=Ezrin; AltName: Full=Cytovillin; AltName: Full=Villin-2; AltName: Full=p81; - 
OS=Homo sapiens (Human). 
69.4 7 4 
529 F138A_HUMAN 
RecName: Full=Protein FAM138A/B/C/F; AltName: Full=Retina-specific protein F379; - OS=Homo 
sapiens (Human). 
9.2 1 1 
530 F2Z2Y4_HUMAN SubName: Full=Pyridoxal kinase; - OS=Homo sapiens (Human). 30.6 2 2 
531 F2Z2Y8_HUMAN SubName: Full=Toll-interacting protein; - OS=Homo sapiens (Human). 23.3 2 2 
532 F5GWX2_HUMAN SubName: Full=Heme-binding protein 1; - OS=Homo sapiens (Human). 14.7 1 1 
533 F5GWY2_HUMAN 
SubName: Full=Phosphoribosylaminoimidazolecarboxamide formyltransferase; - OS=Homo sapiens 
(Human). 
58.6 3 3 
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534 F5GX11_HUMAN SubName: Full=Proteasome subunit alpha type-1; - OS=Homo sapiens (Human). 26.5 3 3 
535 F5GXN4_HUMAN SubName: Full=Ras-related protein Rab-6A; Flags: Fragment; - OS=Homo sapiens (Human). 8.5 2 1 
536 F5GXT8_HUMAN SubName: Full=Diablo homolog, mitochondrial; Flags: Fragment; - OS=Homo sapiens (Human). 15.2 1 1 
537 F5GZE5_HUMAN SubName: Full=Septin-7; - OS=Homo sapiens (Human). 26.6 2 1 
538 F5GZZ9_HUMAN SubName: Full=Soluble CD163; - OS=Homo sapiens (Human). 120.2 5 5 
539 F5H0T1_HUMAN SubName: Full=Stress-induced-phosphoprotein 1; - OS=Homo sapiens (Human). 59.7 4 4 
540 F5H1L4_HUMAN SubName: Full=Thioredoxin reductase 2, mitochondrial; - OS=Homo sapiens (Human). 53.4 1 1 
541 F5H1S8_HUMAN SubName: Full=Malectin; Flags: Fragment; - OS=Homo sapiens (Human). 16.7 1 1 
542 F5H265_HUMAN SubName: Full=Ubiquitin; Flags: Fragment; - OS=Homo sapiens (Human). 16.8 2 2 
543 F5H282_HUMAN RecName: Full=T-complex protein 1 subunit alpha; - OS=Homo sapiens (Human). 36.4 1 1 
544 F5H2R5_HUMAN SubName: Full=Rho GDP-dissociation inhibitor 2; Flags: Fragment; - OS=Homo sapiens (Human). 9.8 1 1 
545 F5H390_HUMAN SubName: Full=Coronin-1B; - OS=Homo sapiens (Human). 31.0 2 2 
546 F5H5E2_HUMAN SubName: Full=Putative phospholipase B-like 2; - OS=Homo sapiens (Human). 61.8 2 2 
547 F5H6N3_HUMAN SubName: Full=Clathrin light chain A; - OS=Homo sapiens (Human). 17.7 2 2 
548 F5H7F6_HUMAN 
SubName: Full=Microsomal glutathione S-transferase 1; Flags: Fragment; - OS=Homo sapiens 
(Human). 
8.9 1 1 
549 F5H801_HUMAN SubName: Full=2-oxoglutarate dehydrogenase, mitochondrial; - OS=Homo sapiens (Human). 110.5 6 6 
550 F5H895_HUMAN 
SubName: Full=Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1; - 
OS=Homo sapiens (Human). 
7.3 1 1 
551 F6IQD3_HUMAN SubName: Full=MHC class I antigen; Flags: Fragment; - OS=Homo sapiens (Human). 39.2 3 0 
552 F6KPG5_HUMAN SubName: Full=Albumin; Flags: Fragment; - OS=Homo sapiens (Human). 66.5 14 14 
553 F6RFD5_HUMAN SubName: Full=Destrin; - OS=Homo sapiens (Human). 15.4 1 1 
554 F6UXX1_HUMAN 
SubName: Full=Heterogeneous nuclear ribonucleoprotein Q; Flags: Fragment; - OS=Homo sapiens 
(Human). 
20.2 2 1 
555 F8VPF7_HUMAN SubName: Full=Voltage-gated hydrogen channel 1; - OS=Homo sapiens (Human). 11.7 1 1 
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556 F8VQ14_HUMAN SubName: Full=T-complex protein 1 subunit beta; - OS=Homo sapiens (Human). 44.8 2 2 
557 F8VR50_HUMAN 
SubName: Full=Actin-related protein 2/3 complex subunit 3; Flags: Fragment; - OS=Homo sapiens 
(Human). 
9.7 1 1 
558 F8VSD4_HUMAN SubName: Full=Ubiquitin-conjugating enzyme E2 N; - OS=Homo sapiens (Human). 12.0 2 2 
559 F8VTQ5_HUMAN 
SubName: Full=Heterogeneous nuclear ribonucleoprotein A1; Flags: Fragment; - OS=Homo sapiens 
(Human). 
16.5 2 2 
560 F8VU65_HUMAN SubName: Full=60S acidic ribosomal protein P0; Flags: Fragment; - OS=Homo sapiens (Human). 27.2 2 2 
561 F8VVM2_HUMAN SubName: Full=Phosphate carrier protein, mitochondrial; - OS=Homo sapiens (Human). 36.1 4 4 
562 F8VVW6_HUMAN 
SubName: Full=HLA class II histocompatibility antigen, DP beta 1 chain; - OS=Homo sapiens 
(Human). 
14.9 2 1 
563 F8VW92_HUMAN SubName: Full=Tubulin beta chain; - OS=Homo sapiens (Human). 48.5 13 5 
564 F8VWC5_HUMAN RecName: Full=60S ribosomal protein L18; - OS=Homo sapiens (Human). 18.1 3 3 
565 F8VZY5_HUMAN SubName: Full=Keratin, type II cytoskeletal 7; Flags: Fragment; - OS=Homo sapiens (Human). 38.1 3 3 
566 F8W031_HUMAN SubName: Full=Uncharacterized protein; Flags: Fragment; - OS=Homo sapiens (Human). 29.2 5 4 
567 F8W0P2_HUMAN 
SubName: Full=HLA class II histocompatibility antigen, DR alpha chain; - OS=Homo sapiens 
(Human). 
26.9 6 5 
568 F8W181_HUMAN RecName: Full=60S ribosomal protein L6; Flags: Fragment; - OS=Homo sapiens (Human). 25.9 2 2 
569 F8W1A4_HUMAN 
RecName: Full=Adenylate kinase C; Short=AK C; EC=2.7.4.3; AltName: Full=ATP-AMP 
transphosphorylase C; - OS=Homo sapiens (Human). 
25.6 6 6 
570 F8W1N5_HUMAN 
SubName: Full=Nascent polypeptide-associated complex subunit alpha; Flags: Fragment; - OS=Homo 
sapiens (Human). 
7.8 2 2 
571 F8WAM2_HUMAN SubName: Full=T-complex protein 1 subunit eta; Flags: Fragment; - OS=Homo sapiens (Human). 10.5 1 1 
572 F8WAS3_HUMAN 
SubName: Full=NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5; - OS=Homo 
sapiens (Human). 
7.8 1 1 
573 F8WBG8_HUMAN SubName: Full=Drebrin-like protein; - OS=Homo sapiens (Human). 13.7 1 1 
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574 F8WCC8_HUMAN SubName: Full=Arylsulfatase A component C; - OS=Homo sapiens (Human). 44.9 1 1 
575 F8WD51_HUMAN SubName: Full=Uridine phosphorylase 1; - OS=Homo sapiens (Human). 9.3 1 1 
576 F8WDL0_HUMAN SubName: Full=AP-1 complex subunit beta-1; - OS=Homo sapiens (Human). 101.3 4 2 
577 F8WEU4_HUMAN SubName: Full=Cytochrome b5; - OS=Homo sapiens (Human). 14.2 1 1 
578 FABP4_HUMAN 
RecName: Full=Fatty acid-binding protein, adipocyte; AltName: Full=Adipocyte lipid-binding protein; 
Short=ALBP; AltName: Full=Adipocyte-type fatty acid-binding protein; Short=A-FABP; 
Short=AFABP; AltName: Full=Fatty acid-binding protein 4; - OS=Homo sapiens (Human). 
14.7 4 4 
579 FABP5_HUMAN 
RecName: Full=Fatty acid-binding protein, epidermal; AltName: Full=Epidermal-type fatty acid-
binding protein; Short=E-FABP; AltName: Full=Fatty acid-binding protein 5; AltName: 
Full=Psoriasis-associated fatty acid-binding protein homolog; Short=PA-FABP; - OS=Homo sapiens 
(Human). 
15.2 5 5 
580 FABPH_HUMAN 
RecName: Full=Fatty acid-binding protein, heart; AltName: Full=Fatty acid-binding protein 3; 
AltName: Full=Heart-type fatty acid-binding protein; Short=H-FABP; AltName: Full=Mammary-
derived growth inhibitor; Short=MDGI; AltName: Full=Muscle fatty acid-binding protein; Short=M-
FABP; - OS=Homo sapiens (Human). 
14.8 2 2 
581 FAHD1_HUMAN 
RecName: Full=Acylpyruvase FAHD1, mitochondrial; EC=3.7.1.5; AltName: 
Full=Fumarylacetoacetate hydrolase domain-containing protein 1; AltName: Full=YisK-like protein; 
Flags: Precursor; - OS=Homo sapiens (Human). 
24.8 1 1 
582 FIS1_HUMAN 
RecName: Full=Mitochondrial fission 1 protein; AltName: Full=FIS1 homolog; Short=hFis1; 
AltName: Full=Tetratricopeptide repeat protein 11; Short=TPR repeat protein 11; - OS=Homo sapiens 
(Human). 
16.9 1 1 
583 FKBP2_HUMAN 
RecName: Full=Peptidyl-prolyl cis-trans isomerase FKBP2; Short=PPIase FKBP2; EC=5.2.1.8; 
AltName: Full=13 kDa FK506-binding protein; Short=13 kDa FKBP; Short=FKBP-13; AltName: 
Full=FK506-binding protein 2; Short=FKBP-2; AltName: Full=Immunophilin FKBP13; AltName: 
Full=Rotamase; Flags: Precursor; - OS=Homo sapiens (Human). 
15.6 1 1 
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584 FMNL_HUMAN 
RecName: Full=Formin-like protein 1; AltName: Full=CLL-associated antigen KW-13; AltName: 
Full=Leukocyte formin; - OS=Homo sapiens (Human). 
121.8 2 2 
585 FRIL_HUMAN RecName: Full=Ferritin light chain; Short=Ferritin L subunit; - OS=Homo sapiens (Human). 20.0 4 4 
586 FUMH_HUMAN 
RecName: Full=Fumarate hydratase, mitochondrial; Short=Fumarase; EC=4.2.1.2; Flags: Precursor; - 
OS=Homo sapiens (Human). 
54.6 3 3 
587 G1EMZ1_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 10.9 3 1 
588 G3V184_HUMAN 
SubName: Full=ADP-ribosylation factor-like protein 2; SubName: Full=HCG23373, isoform CRA_b; 
- OS=Homo sapiens (Human). 
18.0 1 1 
589 G3V1A4_HUMAN 
SubName: Full=Cofilin 1 (Non-muscle), isoform CRA_a; SubName: Full=Cofilin-1; - OS=Homo 
sapiens (Human). 
16.8 5 5 
590 G3V1N2_HUMAN 
SubName: Full=HCG1745306, isoform CRA_a; SubName: Full=Hemoglobin subunit alpha; - 
OS=Homo sapiens (Human). 
11.9 7 2 
591 G3V1U9_HUMAN 
SubName: Full=Tubulin alpha-1A chain; SubName: Full=Tubulin, alpha 3, isoform CRA_c; - 
OS=Homo sapiens (Human). 
46.3 11 2 
592 G3V2V6_HUMAN SubName: Full=V-type proton ATPase subunit D; - OS=Homo sapiens (Human). 17.4 1 1 
593 G3V3A0_HUMAN 
SubName: Full=Alpha-1-antichymotrypsin; SubName: Full=Serpin peptidase inhibitor, clade A 
(Alpha-1 antiproteinase, antitrypsin), member 3, isoform CRA_a; - OS=Homo sapiens (Human). 
23.4 3 3 
594 G3V3U4_HUMAN RecName: Full=Proteasome subunit alpha type; EC=3.4.25.1; - OS=Homo sapiens (Human). 11.6 4 4 
595 G3V4X5_HUMAN SubName: Full=Proteasome subunit alpha type-3; - OS=Homo sapiens (Human). 20.3 1 1 
596 G3V4Y7_HUMAN SubName: Full=Kinectin; - OS=Homo sapiens (Human). 68.9 2 2 
597 G3V576_HUMAN SubName: Full=Heterogeneous nuclear ribonucleoproteins C1/C2; - OS=Homo sapiens (Human). 25.2 5 5 
598 G3V5W3_HUMAN SubName: Full=Son of sevenless homolog 2; - OS=Homo sapiens (Human). 8.1 1 1 
599 G3XAI1_HUMAN 
SubName: Full=55 kDa erythrocyte membrane protein; SubName: Full=Membrane protein, 
palmitoylated 1, 55kDa, isoform CRA_a; - OS=Homo sapiens (Human). 
49.8 1 1 
600 G3XAN0_HUMAN SubName: Full=40S ribosomal protein S20; SubName: Full=Ribosomal protein S20, isoform CRA_a; 7.2 1 1 
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- OS=Homo sapiens (Human). 
601 G8FT56_HUMAN SubName: Full=MHC class I antigen; Flags: Fragment; - OS=Homo sapiens (Human). 31.9 3 0 
602 G9HTG4_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 25.4 6 0 
603 GALK1_HUMAN 
RecName: Full=Galactokinase; EC=2.7.1.6; AltName: Full=Galactose kinase; - OS=Homo sapiens 
(Human). 
42.2 1 1 
604 GANAB_HUMAN 
RecName: Full=Neutral alpha-glucosidase AB; EC=3.2.1.84; AltName: Full=Alpha-glucosidase 2; 
AltName: Full=Glucosidase II subunit alpha; Flags: Precursor; - OS=Homo sapiens (Human). 
106.8 8 8 
605 GAPR1_HUMAN 
RecName: Full=Golgi-associated plant pathogenesis-related protein 1; Short=GAPR-1; Short=Golgi-
associated PR-1 protein; AltName: Full=Glioma pathogenesis-related protein 2; Short=GliPR 2; - 
OS=Homo sapiens (Human). 
17.2 3 3 
606 GDIB_HUMAN 
RecName: Full=Rab GDP dissociation inhibitor beta; Short=Rab GDI beta; AltName: Full=Guanosine 
diphosphate dissociation inhibitor 2; Short=GDI-2; - OS=Homo sapiens (Human). 
50.6 8 8 
607 GLRX1_HUMAN 
RecName: Full=Glutaredoxin-1; AltName: Full=Thioltransferase-1; Short=TTase-1; - OS=Homo 
sapiens (Human). 
11.8 2 2 
608 GLRX3_HUMAN 
RecName: Full=Glutaredoxin-3; AltName: Full=PKC-interacting cousin of thioredoxin; Short=PICOT; 
AltName: Full=PKC-theta-interacting protein; Short=PKCq-interacting protein; AltName: 
Full=Thioredoxin-like protein 2; - OS=Homo sapiens (Human). 
37.4 1 1 
609 GMFG_HUMAN RecName: Full=Glia maturation factor gamma; Short=GMF-gamma; - OS=Homo sapiens (Human). 16.8 3 2 
610 GPC5_HUMAN 
RecName: Full=Glypican-5; Contains: RecName: Full=Secreted glypican-5; Flags: Precursor; - 
OS=Homo sapiens (Human). 
63.7 1 1 
611 GPX4_HUMAN 
RecName: Full=Phospholipid hydroperoxide glutathione peroxidase, mitochondrial; Short=PHGPx; 
EC=1.11.1.12; AltName: Full=Glutathione peroxidase 4; Short=GPx-4; Short=GSHPx-4; Flags: 
Precursor; - OS=Homo sapiens (Human). 
22.2 3 3 
612 GRHPR_HUMAN 
RecName: Full=Glyoxylate reductase/hydroxypyruvate reductase; EC=1.1.1.79; EC=1.1.1.81; - 
OS=Homo sapiens (Human). 
35.6 1 1 
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613 GRP78_HUMAN 
RecName: Full=78 kDa glucose-regulated protein; Short=GRP-78; AltName: Full=Endoplasmic 
reticulum lumenal Ca(2+)-binding protein grp78; AltName: Full=Heat shock 70 kDa protein 5; 
AltName: Full=Immunoglobulin heavy chain-binding protein; Short=BiP; Flags: Precursor; - 
OS=Homo sapiens (Human). 
72.3 15 13 
614 GSTP1_HUMAN 
RecName: Full=Glutathione S-transferase P; EC=2.5.1.18; AltName: Full=GST class-pi; AltName: 
Full=GSTP1-1; - OS=Homo sapiens (Human). 
23.3 4 4 
615 GT251_HUMAN 
RecName: Full=Procollagen galactosyltransferase 1; EC=2.4.1.50; AltName: Full=Glycosyltransferase 
25 family member 1; AltName: Full=Hydroxylysine galactosyltransferase 1; Flags: Precursor; - 
OS=Homo sapiens (Human). 
71.6 4 4 
616 H0Y3Y6_HUMAN 
SubName: Full=Serine/threonine-protein phosphatase PP1-beta catalytic subunit; Flags: Fragment; - 
OS=Homo sapiens (Human). 
9.7 2 2 
617 H0Y897_HUMAN SubName: Full=Target of Nesh-SH3; Flags: Fragment; - OS=Homo sapiens (Human). 124.2 1 1 
618 H0Y923_HUMAN 
SubName: Full=Protein kinase C and casein kinase substrate in neurons protein 2; Flags: Fragment; - 
OS=Homo sapiens (Human). 
6.4 1 1 
619 H0Y9R4_HUMAN SubName: Full=60S ribosomal protein L9; Flags: Fragment; - OS=Homo sapiens (Human). 10.1 1 1 
620 H0YAE9_HUMAN SubName: Full=Uncharacterized protein; Flags: Fragment; - OS=Homo sapiens (Human). 21.9 1 1 
621 H0YB56_HUMAN SubName: Full=Protein LYRIC; Flags: Fragment; - OS=Homo sapiens (Human). 24.5 1 1 
622 H0YCX0_HUMAN 
SubName: Full=Translationally-controlled tumor protein; Flags: Fragment; - OS=Homo sapiens 
(Human). 
9.1 1 1 
623 H0YCY8_HUMAN SubName: Full=Dipeptidyl peptidase 1 light chain; Flags: Fragment; - OS=Homo sapiens (Human). 27.9 3 3 
624 H0YD97_HUMAN 
SubName: Full=Pyruvate dehydrogenase protein X component, mitochondrial; Flags: Fragment; - 
OS=Homo sapiens (Human). 
20.7 1 1 
625 H0YDG0_HUMAN SubName: Full=Puromycin-sensitive aminopeptidase; Flags: Fragment; - OS=Homo sapiens (Human). 19.0 1 1 
626 H0YDP7_HUMAN 
SubName: Full=39S ribosomal protein L49, mitochondrial; Flags: Fragment; - OS=Homo sapiens 
(Human). 
14.7 1 1 
 Chapter 10 Appendices 249 
627 H0YDX6_HUMAN SubName: Full=CD44 antigen; Flags: Fragment; - OS=Homo sapiens (Human). 19.6 2 2 
628 H0YE04_HUMAN SubName: Full=Signal peptidase complex subunit 2; Flags: Fragment; - OS=Homo sapiens (Human). 18.7 1 1 
629 H0YEN5_HUMAN SubName: Full=40S ribosomal protein S2; Flags: Fragment; - OS=Homo sapiens (Human). 21.1 4 4 
630 H0YEU5_HUMAN SubName: Full=Histone-binding protein RBBP4; Flags: Fragment; - OS=Homo sapiens (Human). 19.0 1 1 
631 H0YGF3_HUMAN SubName: Full=Pre-mRNA-processing factor 19; Flags: Fragment; - OS=Homo sapiens (Human). 5.2 1 1 
632 H0YJ63_HUMAN 
SubName: Full=Activator of 90 kDa heat shock protein ATPase homolog 1; Flags: Fragment; - 
OS=Homo sapiens (Human). 
10.1 1 1 
633 H0YJE4_HUMAN 
SubName: Full=Dehydrogenase/reductase SDR family member 7; Flags: Fragment; - OS=Homo 
sapiens (Human). 
17.9 1 1 
634 H0YJE9_HUMAN SubName: Full=26S protease regulatory subunit 10B; Flags: Fragment; - OS=Homo sapiens (Human). 8.7 1 1 
635 H0YJN9_HUMAN SubName: Full=Legumain; Flags: Fragment; - OS=Homo sapiens (Human). 9.8 1 1 
636 H0YKU1_HUMAN SubName: Full=Tropomodulin-3; Flags: Fragment; - OS=Homo sapiens (Human). 20.9 1 1 
637 H0YKV0_HUMAN 
SubName: Full=Isovaleryl-CoA dehydrogenase, mitochondrial; Flags: Fragment; - OS=Homo sapiens 
(Human). 
15.8 1 1 
638 H0YLA2_HUMAN SubName: Full=Signal recognition particle 14 kDa protein; - OS=Homo sapiens (Human). 13.0 1 1 
639 H0YLS6_HUMAN RecName: Full=Proteasome subunit alpha type; EC=3.4.25.1; - OS=Homo sapiens (Human). 13.9 1 1 
640 H0YM46_HUMAN 
SubName: Full=Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial; Flags: Fragment; - 
OS=Homo sapiens (Human). 
5.3 1 1 
641 H0YNE9_HUMAN SubName: Full=Ras-related protein Rab-8B; Flags: Fragment; - OS=Homo sapiens (Human). 21.9 4 1 
642 H0YNX5_HUMAN 
SubName: Full=Signal peptidase complex catalytic subunit SEC11A; Flags: Fragment; - OS=Homo 
sapiens (Human). 
12.0 1 1 
643 H0YNX7_HUMAN 
SubName: Full=GTP cyclohydrolase 1 feedback regulatory protein; SubName: Full=GTP 
cyclohydrolase I feedback regulator, isoform CRA_a; - OS=Homo sapiens (Human). 
7.8 1 1 
644 H12_HUMAN 
RecName: Full=Histone H1.2; AltName: Full=Histone H1c; AltName: Full=Histone H1d; AltName: 
Full=Histone H1s-1; - OS=Homo sapiens (Human). 
21.4 3 3 
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645 H15_HUMAN 
RecName: Full=Histone H1.5; AltName: Full=Histone H1a; AltName: Full=Histone H1b; AltName: 
Full=Histone H1s-3; - OS=Homo sapiens (Human). 
22.6 3 3 
646 H2A1A_HUMAN RecName: Full=Histone H2A type 1-A; AltName: Full=Histone H2A/r; - OS=Homo sapiens (Human). 14.2 3 1 
647 H2A1H_HUMAN RecName: Full=Histone H2A type 1-H; AltName: Full=Histone H2A/s; - OS=Homo sapiens (Human). 13.9 3 1 
648 H2AY_HUMAN 
RecName: Full=Core histone macro-H2A.1; Short=Histone macroH2A1; Short=mH2A1; AltName: 
Full=Histone H2A.y; Short=H2A/y; AltName: Full=Medulloblastoma antigen MU-MB-50.205; - 
OS=Homo sapiens (Human). 
39.6 6 6 
649 H2B1B_HUMAN 
RecName: Full=Histone H2B type 1-B; AltName: Full=Histone H2B.1; AltName: Full=Histone 
H2B.f; Short=H2B/f; - OS=Homo sapiens (Human). 
13.9 3 1 
650 H3BLU7_HUMAN 
SubName: Full=Aflatoxin B1 aldehyde reductase member 2; Flags: Fragment; - OS=Homo sapiens 
(Human). 
34.7 1 1 
651 H3BM47_HUMAN SubName: Full=Group XV phospholipase A2; Flags: Fragment; - OS=Homo sapiens (Human). 18.3 1 1 
652 H3BMU1_HUMAN SubName: Full=IST1 homolog; Flags: Fragment; - OS=Homo sapiens (Human). 23.4 1 1 
653 H3BP04_HUMAN 
SubName: Full=Cytochrome b-c1 complex subunit 2, mitochondrial; Flags: Fragment; - OS=Homo 
sapiens (Human). 
19.5 3 3 
654 H3BPF6_HUMAN SubName: Full=Prefoldin subunit 5; Flags: Fragment; - OS=Homo sapiens (Human). 17.1 1 1 
655 H3BPK3_HUMAN 
SubName: Full=Hydroxyacylglutathione hydrolase, mitochondrial; Flags: Fragment; - OS=Homo 
sapiens (Human). 
26.4 1 1 
656 H3BQH0_HUMAN SubName: Full=Calponin-2; Flags: Fragment; - OS=Homo sapiens (Human). 23.1 1 1 
657 H3BQN4_HUMAN RecName: Full=Fructose-bisphosphate aldolase; EC=4.1.2.13; - OS=Homo sapiens (Human). 39.3 6 6 
658 H3BQZ7_HUMAN 
SubName: Full=HCG2044799; SubName: Full=Uncharacterized protein; - OS=Homo sapiens 
(Human). 
84.6 1 1 
659 H3BR27_HUMAN 
SubName: Full=RNA-binding motif protein, X chromosome, N-terminally processed; - OS=Homo 
sapiens (Human). 
8.6 2 2 
660 H3BTE6_HUMAN SubName: Full=Erythrocyte membrane protein band 4.2; Flags: Fragment; - OS=Homo sapiens 59.8 2 2 
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(Human). 
661 H3BTY8_HUMAN 
SubName: Full=Eukaryotic translation initiation factor 3 subunit C; Flags: Fragment; - OS=Homo 
sapiens (Human). 
9.5 1 1 
662 H4_HUMAN RecName: Full=Histone H4; - OS=Homo sapiens (Human). 11.4 3 3 
663 H6SSQ1_HUMAN SubName: Full=MHC class I antigen; Flags: Fragment; - OS=Homo sapiens (Human). 31.5 3 1 
664 H6UYS7_HUMAN 
SubName: Full=Alpha-synuclein transcript variant 12; SubName: Full=Alpha-synuclein transcript 
variant 15; SubName: Full=Alpha-synuclein transcript variant 6; SubName: Full=Alpha-synuclein 
transcript variant 9; - OS=Homo sapiens (Human). 
10.0 1 1 
665 H6VRF8_HUMAN SubName: Full=Keratin 1; - OS=Homo sapiens (Human). 66.0 6 6 
666 H6X377_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 19.8 4 1 
667 H7BXF3_HUMAN SubName: Full=Transformer-2 protein homolog beta; Flags: Fragment; - OS=Homo sapiens (Human). 15.2 1 1 
668 H7BXK9_HUMAN 
SubName: Full=ATP-binding cassette sub-family B member 6, mitochondrial; Flags: Fragment; - 
OS=Homo sapiens (Human). 
77.5 1 1 
669 H7BZD1_HUMAN 
SubName: Full=Glutaminase kidney isoform, mitochondrial; Flags: Fragment; - OS=Homo sapiens 
(Human). 
12.6 1 1 
670 H7BZI1_HUMAN SubName: Full=Nucleobindin-1; Flags: Fragment; - OS=Homo sapiens (Human). 34.9 3 3 
671 H7BZJ3_HUMAN RecName: Full=Thioredoxin; Flags: Fragment; - OS=Homo sapiens (Human). 13.5 3 1 
672 H7BZT4_HUMAN SubName: Full=Uncharacterized protein; - OS=Homo sapiens (Human). 10.8 1 1 
673 H7BZX2_HUMAN 
SubName: Full=Metalloendopeptidase OMA1, mitochondrial; Flags: Fragment; - OS=Homo sapiens 
(Human). 
37.8 1 1 
674 H7C124_HUMAN SubName: Full=Protein THEMIS2; Flags: Fragment; - OS=Homo sapiens (Human). 44.3 2 2 
675 H7C131_HUMAN 
SubName: Full=3-ketoacyl-CoA thiolase, peroxisomal; Flags: Fragment; - OS=Homo sapiens 
(Human). 
30.3 5 5 
676 H7C1C6_HUMAN 
SubName: Full=Translocon-associated protein subunit delta; Flags: Fragment; - OS=Homo sapiens 
(Human). 
13.1 1 1 
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677 H7C1K4_HUMAN SubName: Full=Syndecan-1; Flags: Fragment; - OS=Homo sapiens (Human). 22.0 1 1 
678 H7C2A0_HUMAN SubName: Full=Glycerol kinase; Flags: Fragment; - OS=Homo sapiens (Human). 13.1 1 1 
679 H7C2G3_HUMAN SubName: Full=ES1 protein homolog, mitochondrial; Flags: Fragment; - OS=Homo sapiens (Human). 20.3 1 1 
680 H7C2Y5_HUMAN 
SubName: Full=DnaJ homolog subfamily B member 11; Flags: Fragment; - OS=Homo sapiens 
(Human). 
19.3 1 1 
681 H7C2Z6_HUMAN SubName: Full=Grancalcin; Flags: Fragment; - OS=Homo sapiens (Human). 16.8 4 4 
682 H7C342_HUMAN SubName: Full=D-dopachrome decarboxylase; Flags: Fragment; - OS=Homo sapiens (Human). 5.7 1 1 
683 H7C3M7_HUMAN 
SubName: Full=FERM, RhoGEF and pleckstrin domain-containing protein 2; Flags: Fragment; - 
OS=Homo sapiens (Human). 
23.7 1 1 
684 H7C456_HUMAN SubName: Full=Microtubule-associated protein 4; Flags: Fragment; - OS=Homo sapiens (Human). 31.6 1 1 
685 H7C463_HUMAN 
SubName: Full=Mitochondrial inner membrane protein; Flags: Fragment; - OS=Homo sapiens 
(Human). 
68.1 7 7 
686 H7C4F6_HUMAN SubName: Full=Importin subunit alpha-4; Flags: Fragment; - OS=Homo sapiens (Human). 18.9 1 1 
687 H7C531_HUMAN 
SubName: Full=26S proteasome non-ATPase regulatory subunit 6; Flags: Fragment; - OS=Homo 
sapiens (Human). 
16.0 1 1 
688 H7C597_HUMAN 
SubName: Full=Staphylococcal nuclease domain-containing protein 1; Flags: Fragment; - OS=Homo 
sapiens (Human). 
26.2 1 1 
689 H90B4_HUMAN RecName: Full=Putative heat shock protein HSP 90-beta 4; - OS=Homo sapiens (Human). 58.2 3 1 
690 H9E7B8_HUMAN RecName: Full=Cytochrome c oxidase subunit 2; Flags: Fragment; - OS=Homo sapiens (Human). 24.8 1 1 
691 H9KVC7_HUMAN 
SubName: Full=Interferon-induced GTP-binding protein Mx1; Flags: Fragment; - OS=Homo sapiens 
(Human). 
20.9 3 3 
692 HBAZ_HUMAN 
RecName: Full=Hemoglobin subunit zeta; AltName: Full=HBAZ; AltName: Full=Hemoglobin zeta 
chain; AltName: Full=Zeta-globin; - OS=Homo sapiens (Human). 
15.6 4 3 
693 HBD_HUMAN 
RecName: Full=Hemoglobin subunit delta; AltName: Full=Delta-globin; AltName: Full=Hemoglobin 
delta chain; - OS=Homo sapiens (Human). 
16.0 11 2 
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694 HCD2_HUMAN 
RecName: Full=3-hydroxyacyl-CoA dehydrogenase type-2; EC=1.1.1.35; AltName: Full=17-beta-
hydroxysteroid dehydrogenase 10; Short=17-beta-HSD 10; AltName: Full=3-hydroxy-2-
methylbutyryl-CoA dehydrogenase; EC=1.1.1.178; AltName: Full=3-hydroxyacyl-CoA 
dehydrogenase type II; AltName: Full=Endoplasmic reticulum-associated amyloid beta-peptide-
binding protein; AltName: Full=Mitochondrial ribonuclease P protein 2; Short=Mitochondrial RNase P 
protein 2; AltName: Full=Short-chain type dehydrogenase/reductase XH98G2; AltName: Full=Type II 
HADH; - OS=Homo sapiens (Human). 
26.9 7 7 
695 HEBP2_HUMAN 
RecName: Full=Heme-binding protein 2; AltName: Full=Placental protein 23; Short=PP23; AltName: 
Full=Protein SOUL; - OS=Homo sapiens (Human). 
22.9 1 1 
696 HEXB_HUMAN 
RecName: Full=Beta-hexosaminidase subunit beta; EC=3.2.1.52; AltName: Full=Beta-N-
acetylhexosaminidase subunit beta; Short=Hexosaminidase subunit B; AltName: Full=Cervical cancer 
proto-oncogene 7 protein; Short=HCC-7; AltName: Full=N-acetyl-beta-glucosaminidase subunit beta; 
Contains: RecName: Full=Beta-hexosaminidase subunit beta chain B; Contains: RecName: Full=Beta-
hexosaminidase subunit beta chain A; Flags: Precursor; - OS=Homo sapiens (Human). 
63.1 7 6 
697 HG2A_HUMAN 
RecName: Full=HLA class II histocompatibility antigen gamma chain; AltName: Full=HLA-DR 
antigens-associated invariant chain; AltName: Full=Ia antigen-associated invariant chain; Short=Ii; 
AltName: Full=p33; AltName: CD_antigen=CD74; - OS=Homo sapiens (Human). 
33.5 3 3 
698 HM13_HUMAN 
RecName: Full=Minor histocompatibility antigen H13; EC=3.4.23.-; AltName: Full=Intramembrane 
protease 1; Short=IMP-1; Short=IMPAS-1; Short=hIMP1; AltName: Full=Presenilin-like protein 3; 
AltName: Full=Signal peptide peptidase; - OS=Homo sapiens (Human). 
41.5 1 1 
699 HNRH3_HUMAN 
RecName: Full=Heterogeneous nuclear ribonucleoprotein H3; Short=hnRNP H3; AltName: 
Full=Heterogeneous nuclear ribonucleoprotein 2H9; Short=hnRNP 2H9; - OS=Homo sapiens 
(Human). 
36.9 2 2 
700 HNRPM_HUMAN 
RecName: Full=Heterogeneous nuclear ribonucleoprotein M; Short=hnRNP M; - OS=Homo sapiens 
(Human). 
77.5 4 4 
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701 HPRT_HUMAN 
RecName: Full=Hypoxanthine-guanine phosphoribosyltransferase; Short=HGPRT; Short=HGPRTase; 
EC=2.4.2.8; - OS=Homo sapiens (Human). 
24.6 2 2 
702 HS90A_HUMAN 
RecName: Full=Heat shock protein HSP 90-alpha; AltName: Full=Heat shock 86 kDa; Short=HSP 86; 
Short=HSP86; AltName: Full=Renal carcinoma antigen NY-REN-38; - OS=Homo sapiens (Human). 
84.6 13 7 
703 HSPB1_HUMAN 
RecName: Full=Heat shock protein beta-1; Short=HspB1; AltName: Full=28 kDa heat shock protein; 
AltName: Full=Estrogen-regulated 24 kDa protein; AltName: Full=Heat shock 27 kDa protein; 
Short=HSP 27; AltName: Full=Stress-responsive protein 27; Short=SRP27; - OS=Homo sapiens 
(Human). 
22.8 3 3 
704 HXK3_HUMAN 
RecName: Full=Hexokinase-3; EC=2.7.1.1; AltName: Full=Hexokinase type III; Short=HK III; - 
OS=Homo sapiens (Human). 
99.0 7 7 
705 I1VE16_HUMAN SubName: Full=SEC22 vesicle trafficking protein B; Flags: Fragment; - OS=Homo sapiens (Human). 4.1 1 1 
706 I1VZV6_HUMAN SubName: Full=Hemoglobin alpha 1; - OS=Homo sapiens (Human). 15.3 7 1 
707 I2G9G1_HUMAN SubName: Full=MHC class II antigen; - OS=Homo sapiens (Human). 29.4 3 3 
708 I3L1P8_HUMAN 
SubName: Full=Mitochondrial 2-oxoglutarate/malate carrier protein; Flags: Fragment; - OS=Homo 
sapiens (Human). 
32.2 7 7 
709 I3L397_HUMAN 
SubName: Full=Eukaryotic translation initiation factor 5A-1; Flags: Fragment; - OS=Homo sapiens 
(Human). 
16.1 2 2 
710 I3L3D0_HUMAN SubName: Full=Syntaxin-8; - OS=Homo sapiens (Human). 5.2 1 1 
711 I3L3Q4_HUMAN 
SubName: Full=Glyoxalase domain-containing protein 4; Flags: Fragment; - OS=Homo sapiens 
(Human). 
25.5 1 1 
712 I3L3Q7_HUMAN 
SubName: Full=Complement component 1 Q subcomponent-binding protein, mitochondrial; Flags: 
Fragment; - OS=Homo sapiens (Human). 
20.0 2 2 
713 I3L471_HUMAN SubName: Full=Phosphatidylinositol transfer protein alpha isoform; - OS=Homo sapiens (Human). 11.0 1 1 
714 I3L4U1_HUMAN SubName: Full=Basigin; Flags: Fragment; - OS=Homo sapiens (Human). 5.7 1 1 
715 I3WTX1_HUMAN SubName: Full=Allograft inflammatory factor 1 isoform 1; - OS=Homo sapiens (Human). 10.4 1 1 
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716 I6L965_HUMAN SubName: Full=KRT18 protein; Flags: Fragment; - OS=Homo sapiens (Human). 42.1 1 1 
717 I7HJT1_HUMAN 
SubName: Full=HLA class II region expressed gene KE2; SubName: Full=Prefoldin subunit 6, 
isoform CRA_a; - OS=Homo sapiens (Human). 
9.8 1 1 
718 IGHA1_HUMAN RecName: Full=Ig alpha-1 chain C region; - OS=Homo sapiens (Human). 37.6 4 4 
719 IGHG1_HUMAN RecName: Full=Ig gamma-1 chain C region; - OS=Homo sapiens (Human). 36.1 10 5 
720 IGHG3_HUMAN 
RecName: Full=Ig gamma-3 chain C region; AltName: Full=HDC; AltName: Full=Heavy chain 
disease protein; - OS=Homo sapiens (Human). 
41.3 6 1 
721 IGHG4_HUMAN RecName: Full=Ig gamma-4 chain C region; - OS=Homo sapiens (Human). 35.9 6 1 
722 IL21_HUMAN 
RecName: Full=Interleukin-21; Short=IL-21; AltName: Full=Za11; Flags: Precursor; - OS=Homo 
sapiens (Human). 
17.9 1 1 
723 INF2_HUMAN 
RecName: Full=Inverted formin-2; AltName: Full=HBEBP2-binding protein C; - OS=Homo sapiens 
(Human). 
135.5 2 2 
724 ITB1_HUMAN 
RecName: Full=Integrin beta-1; AltName: Full=Fibronectin receptor subunit beta; AltName: 
Full=VLA-4 subunit beta; AltName: CD_antigen=CD29; Flags: Precursor; - OS=Homo sapiens 
(Human). 
88.4 1 1 
725 J3K000_HUMAN SubName: Full=PEPD protein; - OS=Homo sapiens (Human). 54.5 1 1 
726 J3KMX5_HUMAN SubName: Full=40S ribosomal protein S13; - OS=Homo sapiens (Human). 16.7 2 2 
727 J3KMY5_HUMAN SubName: Full=Epididymal secretory protein E1; - OS=Homo sapiens (Human). 16.2 6 6 
728 J3KPX7_HUMAN SubName: Full=Prohibitin-2; - OS=Homo sapiens (Human). 33.4 7 7 
729 J3KRC6_HUMAN SubName: Full=Inositol-3-phosphate synthase 1; Flags: Fragment; - OS=Homo sapiens (Human). 23.6 1 1 
730 J3KRE2_HUMAN SubName: Full=Rho GDP-dissociation inhibitor 1; - OS=Homo sapiens (Human). 14.8 1 1 
731 J3KSI4_HUMAN SubName: Full=Mannose-P-dolichol utilization defect 1 protein; - OS=Homo sapiens (Human). 5.8 1 1 
732 J3KSM3_HUMAN SubName: Full=Proteasome subunit beta type-3; - OS=Homo sapiens (Human). 12.1 1 1 
733 J3QL15_HUMAN SubName: Full=60S ribosomal protein L19; Flags: Fragment; - OS=Homo sapiens (Human). 15.0 1 1 
734 J3QL48_HUMAN SubName: Full=Uncharacterized protein; Flags: Fragment; - OS=Homo sapiens (Human). 8.3 1 1 
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735 J3QLE5_HUMAN 
SubName: Full=Small nuclear ribonucleoprotein-associated protein N; Flags: Fragment; - OS=Homo 
sapiens (Human). 
17.5 1 1 
736 J3QLI9_HUMAN SubName: Full=Small nuclear ribonucleoprotein Sm D1; - OS=Homo sapiens (Human). 8.4 1 1 
737 J3QLR8_HUMAN SubName: Full=28S ribosomal protein S23, mitochondrial; - OS=Homo sapiens (Human). 17.5 1 1 
738 J3QR48_HUMAN SubName: Full=Importin subunit beta-1; Flags: Fragment; - OS=Homo sapiens (Human). 16.5 1 1 
739 J3QRY4_HUMAN 
SubName: Full=26S proteasome non-ATPase regulatory subunit 11; Flags: Fragment; - OS=Homo 
sapiens (Human). 
21.2 1 1 
740 J3QS45_HUMAN SubName: Full=L-xylulose reductase; Flags: Fragment; - OS=Homo sapiens (Human). 10.8 1 1 
741 K1C19_HUMAN 
RecName: Full=Keratin, type I cytoskeletal 19; AltName: Full=Cytokeratin-19; Short=CK-19; 
AltName: Full=Keratin-19; Short=K19; - OS=Homo sapiens (Human). 
44.1 8 6 
742 K1C9_HUMAN 
RecName: Full=Keratin, type I cytoskeletal 9; AltName: Full=Cytokeratin-9; Short=CK-9; AltName: 
Full=Keratin-9; Short=K9; - OS=Homo sapiens (Human). 
62.0 2 1 
743 K2C75_HUMAN 
RecName: Full=Keratin, type II cytoskeletal 75; AltName: Full=Cytokeratin-75; Short=CK-75; 
AltName: Full=Keratin-6 hair follicle; Short=hK6hf; AltName: Full=Keratin-75; Short=K75; 
AltName: Full=Type II keratin-K6hf; AltName: Full=Type-II keratin Kb18; - OS=Homo sapiens 
(Human). 
59.5 3 1 
744 KAD1_HUMAN 
RecName: Full=Adenylate kinase isoenzyme 1; Short=AK 1; EC=2.7.4.3; AltName: Full=ATP-AMP 
transphosphorylase 1; AltName: Full=Myokinase; - OS=Homo sapiens (Human). 
21.6 1 1 
745 KPYM_HUMAN 
RecName: Full=Pyruvate kinase isozymes M1/M2; EC=2.7.1.40; AltName: Full=Cytosolic thyroid 
hormone-binding protein; Short=CTHBP; AltName: Full=Opa-interacting protein 3; Short=OIP-3; 
AltName: Full=Pyruvate kinase 2/3; AltName: Full=Pyruvate kinase muscle isozyme; AltName: 
Full=Thyroid hormone-binding protein 1; Short=THBP1; AltName: Full=Tumor M2-PK; AltName: 
Full=p58; - OS=Homo sapiens (Human). 
57.9 14 14 
746 KV101_HUMAN RecName: Full=Ig kappa chain V-I region AG; - OS=Homo sapiens (Human). 12.0 1 1 
747 KV301_HUMAN RecName: Full=Ig kappa chain V-III region B6; - OS=Homo sapiens (Human). 11.6 2 1 
 Chapter 10 Appendices 257 
748 LACTB_HUMAN 
RecName: Full=Serine beta-lactamase-like protein LACTB, mitochondrial; EC=3.4.-.-; Flags: 
Precursor; - OS=Homo sapiens (Human). 
60.7 3 3 
749 LDHA_HUMAN 
RecName: Full=L-lactate dehydrogenase A chain; Short=LDH-A; EC=1.1.1.27; AltName: Full=Cell 
proliferation-inducing gene 19 protein; AltName: Full=LDH muscle subunit; Short=LDH-M; 
AltName: Full=Renal carcinoma antigen NY-REN-59; - OS=Homo sapiens (Human). 
36.7 8 7 
750 LDHB_HUMAN 
RecName: Full=L-lactate dehydrogenase B chain; Short=LDH-B; EC=1.1.1.27; AltName: Full=LDH 
heart subunit; Short=LDH-H; AltName: Full=Renal carcinoma antigen NY-REN-46; - OS=Homo 
sapiens (Human). 
36.6 8 7 
751 LEG1_HUMAN 
RecName: Full=Galectin-1; Short=Gal-1; AltName: Full=14 kDa laminin-binding protein; 
Short=HLBP14; AltName: Full=14 kDa lectin; AltName: Full=Beta-galactoside-binding lectin L-14-I; 
AltName: Full=Galaptin; AltName: Full=HBL; AltName: Full=HPL; AltName: Full=Lactose-binding 
lectin 1; AltName: Full=Lectin galactoside-binding soluble 1; AltName: Full=Putative MAPK-
activating protein PM12; AltName: Full=S-Lac lectin 1; - OS=Homo sapiens (Human). 
14.7 4 4 
752 LGUL_HUMAN 
RecName: Full=Lactoylglutathione lyase; EC=4.4.1.5; AltName: Full=Aldoketomutase; AltName: 
Full=Glyoxalase I; Short=Glx I; AltName: Full=Ketone-aldehyde mutase; AltName: 
Full=Methylglyoxalase; AltName: Full=S-D-lactoylglutathione methylglyoxal lyase; - OS=Homo 
sapiens (Human). 
20.8 2 2 
753 LHPP_HUMAN 
RecName: Full=Phospholysine phosphohistidine inorganic pyrophosphate phosphatase; Short=hLHPP; 
EC=3.1.3.-; EC=3.6.1.1; - OS=Homo sapiens (Human). 
29.1 1 1 
754 LKHA4_HUMAN 
RecName: Full=Leukotriene A-4 hydrolase; Short=LTA-4 hydrolase; EC=3.3.2.6; AltName: 
Full=Leukotriene A(4) hydrolase; - OS=Homo sapiens (Human). 
69.2 22 22 
755 LMBD1_HUMAN 
RecName: Full=Probable lysosomal cobalamin transporter; AltName: Full=HDAg-L-interacting 
protein NESI; AltName: Full=LMBR1 domain-containing protein 1; AltName: Full=Nuclear export 
signal-interacting protein; - OS=Homo sapiens (Human). 
61.3 1 1 
756 LMNB2_HUMAN RecName: Full=Lamin-B2; Flags: Precursor; - OS=Homo sapiens (Human). 67.6 6 5 
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757 LOX5_HUMAN 
RecName: Full=Arachidonate 5-lipoxygenase; Short=5-LO; Short=5-lipoxygenase; EC=1.13.11.34; - 
OS=Homo sapiens (Human). 
77.9 11 11 
758 LPPRC_HUMAN 
RecName: Full=Leucine-rich PPR motif-containing protein, mitochondrial; AltName: Full=130 kDa 
leucine-rich protein; Short=LRP 130; AltName: Full=GP130; Flags: Precursor; - OS=Homo sapiens 
(Human). 
157.8 5 5 
759 LR16B_HUMAN RecName: Full=Leucine-rich repeat-containing protein 16B; - OS=Homo sapiens (Human). 150.1 1 1 
760 LRC59_HUMAN RecName: Full=Leucine-rich repeat-containing protein 59; - OS=Homo sapiens (Human). 34.9 3 3 
761 LRP1_HUMAN 
RecName: Full=Prolow-density lipoprotein receptor-related protein 1; Short=LRP-1; AltName: 
Full=Alpha-2-macroglobulin receptor; Short=A2MR; AltName: Full=Apolipoprotein E receptor; 
Short=APOER; AltName: CD_antigen=CD91; Contains: RecName: Full=Low-density lipoprotein 
receptor-related protein 1 85 kDa subunit; Short=LRP-85; Contains: RecName: Full=Low-density 
lipoprotein receptor-related protein 1 515 kDa subunit; Short=LRP-515; Contains: RecName: 
Full=Low-density lipoprotein receptor-related protein 1 intracellular domain; Short=LRPICD; Flags: 
Precursor; - OS=Homo sapiens (Human). 
504.3 9 9 
762 LRRF1_HUMAN 
RecName: Full=Leucine-rich repeat flightless-interacting protein 1; Short=LRR FLII-interacting 
protein 1; AltName: Full=GC-binding factor 2; AltName: Full=TAR RNA-interacting protein; - 
OS=Homo sapiens (Human). 
89.2 2 2 
763 LTOR1_HUMAN 
RecName: Full=Ragulator complex protein LAMTOR1; AltName: Full=Late endosomal/lysosomal 
adaptor and MAPK and MTOR activator 1; AltName: Full=Lipid raft adaptor protein p18; AltName: 
Full=Protein associated with DRMs and endosomes; AltName: Full=p27Kip1-releasing factor from 
RhoA; Short=p27RF-Rho; - OS=Homo sapiens (Human). 
17.7 3 3 
764 LTOR3_HUMAN 
RecName: Full=Ragulator complex protein LAMTOR3; AltName: Full=Late endosomal/lysosomal 
adaptor and MAPK and MTOR activator 3; AltName: Full=MEK-binding partner 1; Short=Mp1; 
AltName: Full=Mitogen-activated protein kinase kinase 1-interacting protein 1; AltName: 
Full=Mitogen-activated protein kinase scaffold protein 1; - OS=Homo sapiens (Human). 
13.6 2 2 
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765 LYAG_HUMAN 
RecName: Full=Lysosomal alpha-glucosidase; EC=3.2.1.20; AltName: Full=Acid maltase; AltName: 
Full=Aglucosidase alfa; Contains: RecName: Full=76 kDa lysosomal alpha-glucosidase; Contains: 
RecName: Full=70 kDa lysosomal alpha-glucosidase; Flags: Precursor; - OS=Homo sapiens (Human). 
105.3 8 6 
766 LYSC_HUMAN 
RecName: Full=Lysozyme C; EC=3.2.1.17; AltName: Full=1,4-beta-N-acetylmuramidase C; Flags: 
Precursor; - OS=Homo sapiens (Human). 
16.5 3 3 
767 MANF_HUMAN 
RecName: Full=Mesencephalic astrocyte-derived neurotrophic factor; AltName: Full=Arginine-rich 
protein; AltName: Full=Protein ARMET; Flags: Precursor; - OS=Homo sapiens (Human). 
20.7 2 2 
768 MAOM_HUMAN 
RecName: Full=NAD-dependent malic enzyme, mitochondrial; Short=NAD-ME; EC=1.1.1.38; 
AltName: Full=Malic enzyme 2; Flags: Precursor; - OS=Homo sapiens (Human). 
65.4 4 4 
769 MGST3_HUMAN 
RecName: Full=Microsomal glutathione S-transferase 3; Short=Microsomal GST-3; EC=2.5.1.18; 
AltName: Full=Microsomal GST-III; - OS=Homo sapiens (Human). 
16.5 2 2 
770 ML12A_HUMAN 
RecName: Full=Myosin regulatory light chain 12A; AltName: Full=MLC-2B; AltName: Full=Myosin 
RLC; AltName: Full=Myosin regulatory light chain 2, nonsarcomeric; AltName: Full=Myosin 
regulatory light chain MRLC3; - OS=Homo sapiens (Human). 
19.8 2 2 
771 MOB1A_HUMAN 
RecName: Full=MOB kinase activator 1A; AltName: Full=Mob1 alpha; Short=Mob1A; AltName: 
Full=Mob1 homolog 1B; AltName: Full=Mps one binder kinase activator-like 1B; - OS=Homo sapiens 
(Human). 
25.1 1 1 
772 MOES_HUMAN 
RecName: Full=Moesin; AltName: Full=Membrane-organizing extension spike protein; - OS=Homo 
sapiens (Human). 
67.8 12 9 
773 MSRA_HUMAN 
RecName: Full=Mitochondrial peptide methionine sulfoxide reductase; EC=1.8.4.11; AltName: 
Full=Peptide-methionine (S)-S-oxide reductase; Short=Peptide Met(O) reductase; AltName: 
Full=Protein-methionine-S-oxide reductase; Short=PMSR; Flags: Precursor; - OS=Homo sapiens 
(Human). 
26.1 1 1 
774 MTPN_HUMAN RecName: Full=Myotrophin; AltName: Full=Protein V-1; - OS=Homo sapiens (Human). 12.9 2 2 
775 MUC5A_HUMAN RecName: Full=Mucin-5AC; Short=MUC-5AC; AltName: Full=Gastric mucin; AltName: Full=Lewis 526.3 10 5 
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B blood group antigen; Short=LeB; AltName: Full=Major airway glycoprotein; AltName: Full=Mucin-
5 subtype AC, tracheobronchial; AltName: Full=Tracheobronchial mucin; Short=TBM; Flags: 
Precursor; Fragments; - OS=Homo sapiens (Human). 
776 MYCBP_HUMAN 
RecName: Full=C-Myc-binding protein; AltName: Full=Associate of Myc 1; Short=AMY-1; - 
OS=Homo sapiens (Human). 
12.0 2 2 
777 MYH9_HUMAN 
RecName: Full=Myosin-9; AltName: Full=Cellular myosin heavy chain, type A; AltName: 
Full=Myosin heavy chain 9; AltName: Full=Myosin heavy chain, non-muscle IIa; AltName: 
Full=Non-muscle myosin heavy chain A; Short=NMMHC-A; AltName: Full=Non-muscle myosin 
heavy chain IIa; Short=NMMHC II-a; Short=NMMHC-IIA; - OS=Homo sapiens (Human). 
226.4 20 20 
778 NAAA_HUMAN 
RecName: Full=N-acylethanolamine-hydrolyzing acid amidase; EC=3.5.1.-; AltName: Full=Acid 
ceramidase-like protein; AltName: Full=N-acylsphingosine amidohydrolase-like; Short=ASAH-like 
protein; Contains: RecName: Full=N-acylethanolamine-hydrolyzing acid amidase subunit alpha; 
Contains: RecName: Full=N-acylethanolamine-hydrolyzing acid amidase subunit beta; Flags: 
Precursor; - OS=Homo sapiens (Human). 
40.0 2 2 
779 NAGK_HUMAN 
RecName: Full=N-acetyl-D-glucosamine kinase; Short=N-acetylglucosamine kinase; EC=2.7.1.59; 
AltName: Full=GlcNAc kinase; - OS=Homo sapiens (Human). 
37.4 8 8 
780 NAPSA_HUMAN 
RecName: Full=Napsin-A; EC=3.4.23.-; AltName: Full=Aspartyl protease 4; Short=ASP4; Short=Asp 
4; AltName: Full=Napsin-1; AltName: Full=TA01/TA02; Flags: Precursor; - OS=Homo sapiens 
(Human). 
45.4 5 5 
781 NB5R3_HUMAN 
RecName: Full=NADH-cytochrome b5 reductase 3; Short=B5R; Short=Cytochrome b5 reductase; 
EC=1.6.2.2; AltName: Full=Diaphorase-1; Contains: RecName: Full=NADH-cytochrome b5 reductase 
3 membrane-bound form; Contains: RecName: Full=NADH-cytochrome b5 reductase 3 soluble form; - 
OS=Homo sapiens (Human). 
34.2 3 3 
782 NCEH1_HUMAN 
RecName: Full=Neutral cholesterol ester hydrolase 1; Short=NCEH; EC=3.1.1.-; AltName: 
Full=Arylacetamide deacetylase-like 1; - OS=Homo sapiens (Human). 
45.8 7 7 
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783 NCF1_HUMAN 
RecName: Full=Neutrophil cytosol factor 1; Short=NCF-1; AltName: Full=47 kDa autosomal chronic 
granulomatous disease protein; AltName: Full=47 kDa neutrophil oxidase factor; AltName: Full=NCF-
47K; AltName: Full=Neutrophil NADPH oxidase factor 1; AltName: Full=Nox organizer 2; AltName: 
Full=Nox-organizing protein 2; AltName: Full=SH3 and PX domain-containing protein 1A; AltName: 
Full=p47-phox; - OS=Homo sapiens (Human). 
44.6 3 3 
784 NCPR_HUMAN 
RecName: Full=NADPH--cytochrome P450 reductase; Short=CPR; Short=P450R; EC=1.6.2.4; - 
OS=Homo sapiens (Human). 
76.6 8 8 
785 NDKA_HUMAN 
RecName: Full=Nucleoside diphosphate kinase A; Short=NDK A; Short=NDP kinase A; EC=2.7.4.6; 
AltName: Full=Granzyme A-activated DNase; Short=GAAD; AltName: Full=Metastasis inhibition 
factor nm23; AltName: Full=Tumor metastatic process-associated protein; AltName: Full=nm23-H1; - 
OS=Homo sapiens (Human). 
17.1 4 4 
786 NDUA4_HUMAN 
RecName: Full=NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4; AltName: 
Full=Complex I-MLRQ; Short=CI-MLRQ; AltName: Full=NADH-ubiquinone oxidoreductase MLRQ 
subunit; - OS=Homo sapiens (Human). 
9.4 2 2 
787 NNTM_HUMAN 
RecName: Full=NAD(P) transhydrogenase, mitochondrial; EC=1.6.1.2; AltName: Full=Nicotinamide 
nucleotide transhydrogenase; AltName: Full=Pyridine nucleotide transhydrogenase; Flags: Precursor; - 
OS=Homo sapiens (Human). 
113.8 6 6 
788 NPM_HUMAN 
RecName: Full=Nucleophosmin; Short=NPM; AltName: Full=Nucleolar phosphoprotein B23; 
AltName: Full=Nucleolar protein NO38; AltName: Full=Numatrin; - OS=Homo sapiens (Human). 
32.6 3 3 
789 NUP62_HUMAN 
RecName: Full=Nuclear pore glycoprotein p62; AltName: Full=62 kDa nucleoporin; AltName: 
Full=Nucleoporin Nup62; - OS=Homo sapiens (Human). 
53.2 1 1 
790 O19678_HUMAN SubName: Full=HLA-DRB4 protein; Flags: Fragment; - OS=Homo sapiens (Human). 25.4 6 0 
791 O19763_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 25.5 6 0 
792 O60744_HUMAN SubName: Full=Thioredoxin delta 3; Flags: Fragment; - OS=Homo sapiens (Human). 9.3 2 2 
793 ODO2_HUMAN RecName: Full=Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 48.7 4 4 
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dehydrogenase complex, mitochondrial; EC=2.3.1.61; AltName: Full=2-oxoglutarate dehydrogenase 
complex component E2; Short=OGDC-E2; AltName: Full=Dihydrolipoamide succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex; AltName: Full=E2K; Flags: Precursor; - 
OS=Homo sapiens (Human). 
794 ODPB_HUMAN 
RecName: Full=Pyruvate dehydrogenase E1 component subunit beta, mitochondrial; Short=PDHE1-B; 
EC=1.2.4.1; Flags: Precursor; - OS=Homo sapiens (Human). 
39.2 4 4 
795 P79547_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 10.9 4 0 
796 PA1B2_HUMAN 
RecName: Full=Platelet-activating factor acetylhydrolase IB subunit beta; EC=3.1.1.47; AltName: 
Full=PAF acetylhydrolase 30 kDa subunit; Short=PAF-AH 30 kDa subunit; AltName: Full=PAF-AH 
subunit beta; Short=PAFAH subunit beta; - OS=Homo sapiens (Human). 
25.6 2 2 
797 PARK7_HUMAN 
RecName: Full=Protein DJ-1; EC=3.4.-.-; AltName: Full=Oncogene DJ1; AltName: Full=Parkinson 
disease protein 7; Flags: Precursor; - OS=Homo sapiens (Human). 
19.9 1 1 
798 PCBP1_HUMAN 
RecName: Full=Poly(rC)-binding protein 1; AltName: Full=Alpha-CP1; AltName: 
Full=Heterogeneous nuclear ribonucleoprotein E1; Short=hnRNP E1; AltName: Full=Nucleic acid-
binding protein SUB2.3; - OS=Homo sapiens (Human). 
37.5 5 4 
799 PCKGM_HUMAN 
RecName: Full=Phosphoenolpyruvate carboxykinase [GTP], mitochondrial; Short=PEPCK-M; 
EC=4.1.1.32; AltName: Full=Phosphoenolpyruvate carboxylase; Flags: Precursor; - OS=Homo sapiens 
(Human). 
70.7 9 9 
800 PDC6I_HUMAN 
RecName: Full=Programmed cell death 6-interacting protein; Short=PDCD6-interacting protein; 
AltName: Full=ALG-2-interacting protein 1; AltName: Full=Hp95; - OS=Homo sapiens (Human). 
96.0 6 6 
801 PDIA1_HUMAN 
RecName: Full=Protein disulfide-isomerase; Short=PDI; EC=5.3.4.1; AltName: Full=Cellular thyroid 
hormone-binding protein; AltName: Full=Prolyl 4-hydroxylase subunit beta; AltName: Full=p55; 
Flags: Precursor; - OS=Homo sapiens (Human). 
57.1 15 15 
802 PDIA4_HUMAN 
RecName: Full=Protein disulfide-isomerase A4; EC=5.3.4.1; AltName: Full=Endoplasmic reticulum 
resident protein 70; Short=ER protein 70; Short=ERp70; AltName: Full=Endoplasmic reticulum 
72.9 9 9 
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resident protein 72; Short=ER protein 72; Short=ERp-72; Short=ERp72; Flags: Precursor; - OS=Homo 
sapiens (Human). 
803 PDLI1_HUMAN 
RecName: Full=PDZ and LIM domain protein 1; AltName: Full=C-terminal LIM domain protein 1; 
AltName: Full=Elfin; AltName: Full=LIM domain protein CLP-36; - OS=Homo sapiens (Human). 
36.0 2 2 
804 PEBP1_HUMAN 
RecName: Full=Phosphatidylethanolamine-binding protein 1; Short=PEBP-1; AltName: 
Full=HCNPpp; AltName: Full=Neuropolypeptide h3; AltName: Full=Prostatic-binding protein; 
AltName: Full=Raf kinase inhibitor protein; Short=RKIP; Contains: RecName: Full=Hippocampal 
cholinergic neurostimulating peptide; Short=HCNP; - OS=Homo sapiens (Human). 
21.0 6 6 
805 PERE_HUMAN 
RecName: Full=Eosinophil peroxidase; Short=EPO; EC=1.11.1.7; Contains: RecName: 
Full=Eosinophil peroxidase light chain; Contains: RecName: Full=Eosinophil peroxidase heavy chain; 
Flags: Precursor; - OS=Homo sapiens (Human). 
81.0 2 2 
806 PERM_HUMAN 
RecName: Full=Myeloperoxidase; Short=MPO; EC=1.11.2.2; Contains: RecName: 
Full=Myeloperoxidase; Contains: RecName: Full=89 kDa myeloperoxidase; Contains: RecName: 
Full=84 kDa myeloperoxidase; Contains: RecName: Full=Myeloperoxidase light chain; Contains: 
RecName: Full=Myeloperoxidase heavy chain; Flags: Precursor; - OS=Homo sapiens (Human). 
83.8 2 2 
807 PEX14_HUMAN 
RecName: Full=Peroxisomal membrane protein PEX14; AltName: Full=PTS1 receptor-docking 
protein; AltName: Full=Peroxin-14; AltName: Full=Peroxisomal membrane anchor protein PEX14; - 
OS=Homo sapiens (Human). 
41.2 2 2 
808 PFD2_HUMAN RecName: Full=Prefoldin subunit 2; - OS=Homo sapiens (Human). 16.6 1 1 
809 PGAM1_HUMAN 
RecName: Full=Phosphoglycerate mutase 1; EC=3.1.3.13; EC=5.4.2.1; EC=5.4.2.4; AltName: 
Full=BPG-dependent PGAM 1; AltName: Full=Phosphoglycerate mutase isozyme B; Short=PGAM-
B; - OS=Homo sapiens (Human). 
28.8 3 3 
810 PIGR_HUMAN 
RecName: Full=Polymeric immunoglobulin receptor; Short=PIgR; Short=Poly-Ig receptor; AltName: 
Full=Hepatocellular carcinoma-associated protein TB6; Contains: RecName: Full=Secretory 
component; Flags: Precursor; - OS=Homo sapiens (Human). 
83.2 3 3 
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811 PLBL1_HUMAN 
RecName: Full=Phospholipase B-like 1; EC=3.1.1.-; AltName: Full=LAMA-like protein 1; AltName: 
Full=Lamina ancestor homolog 1; AltName: Full=Phospholipase B domain-containing protein 1; 
Flags: Precursor; - OS=Homo sapiens (Human). 
63.2 4 4 
812 PLCH1_HUMAN 
RecName: Full=1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-1; EC=3.1.4.11; 
AltName: Full=Phosphoinositide phospholipase C-eta-1; AltName: Full=Phospholipase C-eta-1; 
Short=PLC-eta-1; AltName: Full=Phospholipase C-like protein 3; Short=PLC-L3; - OS=Homo sapiens 
(Human). 
189.1 1 1 
813 PLD3_HUMAN 
RecName: Full=Phospholipase D3; Short=PLD 3; EC=3.1.4.4; AltName: Full=Choline phosphatase 3; 
AltName: Full=HindIII K4L homolog; AltName: Full=Hu-K4; AltName: Full=Phosphatidylcholine-
hydrolyzing phospholipase D3; - OS=Homo sapiens (Human). 
54.7 6 6 
814 PLEC_HUMAN 
RecName: Full=Plectin; Short=PCN; Short=PLTN; AltName: Full=Hemidesmosomal protein 1; 
Short=HD1; AltName: Full=Plectin-1; - OS=Homo sapiens (Human). 
531.5 55 55 
815 PLEK_HUMAN 
RecName: Full=Pleckstrin; AltName: Full=Platelet 47 kDa protein; Short=p47; - OS=Homo sapiens 
(Human). 
40.1 2 2 
816 PLIN3_HUMAN 
RecName: Full=Perilipin-3; AltName: Full=47 kDa mannose 6-phosphate receptor-binding protein; 
Short=47 kDa MPR-binding protein; AltName: Full=Cargo selection protein TIP47; AltName: 
Full=Mannose-6-phosphate receptor-binding protein 1; AltName: Full=Placental protein 17; 
Short=PP17; - OS=Homo sapiens (Human). 
47.0 4 4 
817 PLSL_HUMAN 
RecName: Full=Plastin-2; AltName: Full=L-plastin; AltName: Full=LC64P; AltName: 
Full=Lymphocyte cytosolic protein 1; Short=LCP-1; - OS=Homo sapiens (Human). 
70.2 21 21 
818 PNPH_HUMAN 
RecName: Full=Purine nucleoside phosphorylase; Short=PNP; EC=2.4.2.1; AltName: Full=Inosine 
phosphorylase; - OS=Homo sapiens (Human). 
32.1 2 2 
819 POTEI_HUMAN RecName: Full=POTE ankyrin domain family member I; - OS=Homo sapiens (Human). 121.2 6 2 
820 PPA5_HUMAN 
RecName: Full=Tartrate-resistant acid phosphatase type 5; Short=TR-AP; EC=3.1.3.2; AltName: 
Full=Tartrate-resistant acid ATPase; Short=TrATPase; AltName: Full=Type 5 acid phosphatase; Flags: 
36.6 5 5 
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Precursor; - OS=Homo sapiens (Human). 
821 PPAC_HUMAN 
RecName: Full=Low molecular weight phosphotyrosine protein phosphatase; Short=LMW-PTP; 
Short=LMW-PTPase; EC=3.1.3.48; AltName: Full=Adipocyte acid phosphatase; AltName: Full=Low 
molecular weight cytosolic acid phosphatase; EC=3.1.3.2; AltName: Full=Red cell acid phosphatase 1; 
- OS=Homo sapiens (Human). 
18.0 1 1 
822 PPIB_HUMAN 
RecName: Full=Peptidyl-prolyl cis-trans isomerase B; Short=PPIase B; EC=5.2.1.8; AltName: 
Full=CYP-S1; AltName: Full=Cyclophilin B; AltName: Full=Rotamase B; AltName: Full=S-
cyclophilin; Short=SCYLP; Flags: Precursor; - OS=Homo sapiens (Human). 
23.7 3 3 
823 PPT1_HUMAN 
RecName: Full=Palmitoyl-protein thioesterase 1; Short=PPT-1; EC=3.1.2.22; AltName: 
Full=Palmitoyl-protein hydrolase 1; Flags: Precursor; - OS=Homo sapiens (Human). 
34.2 3 3 
824 PRDX1_HUMAN 
RecName: Full=Peroxiredoxin-1; EC=1.11.1.15; AltName: Full=Natural killer cell-enhancing factor 
A; Short=NKEF-A; AltName: Full=Proliferation-associated gene protein; Short=PAG; AltName: 
Full=Thioredoxin peroxidase 2; AltName: Full=Thioredoxin-dependent peroxide reductase 2; - 
OS=Homo sapiens (Human). 
22.1 7 5 
825 PRDX4_HUMAN 
RecName: Full=Peroxiredoxin-4; EC=1.11.1.15; AltName: Full=Antioxidant enzyme AOE372; 
Short=AOE37-2; AltName: Full=Peroxiredoxin IV; Short=Prx-IV; AltName: Full=Thioredoxin 
peroxidase AO372; AltName: Full=Thioredoxin-dependent peroxide reductase A0372; Flags: 
Precursor; - OS=Homo sapiens (Human). 
30.5 6 5 
826 PRDX5_HUMAN 
RecName: Full=Peroxiredoxin-5, mitochondrial; EC=1.11.1.15; AltName: Full=Alu corepressor 1; 
AltName: Full=Antioxidant enzyme B166; Short=AOEB166; AltName: Full=Liver tissue 2D-page 
spot 71B; AltName: Full=PLP; AltName: Full=Peroxiredoxin V; Short=Prx-V; AltName: 
Full=Peroxisomal antioxidant enzyme; AltName: Full=TPx type VI; AltName: Full=Thioredoxin 
peroxidase PMP20; AltName: Full=Thioredoxin reductase; Flags: Precursor; - OS=Homo sapiens 
(Human). 
22.1 6 6 
827 PRDX6_HUMAN RecName: Full=Peroxiredoxin-6; EC=1.11.1.15; AltName: Full=1-Cys peroxiredoxin; Short=1-Cys 25.0 5 5 
 266 Chapter 10 Appendices 
PRX; AltName: Full=24 kDa protein; AltName: Full=Acidic calcium-independent phospholipase A2; 
Short=aiPLA2; EC=3.1.1.-; AltName: Full=Antioxidant protein 2; AltName: Full=Liver 2D page spot 
40; AltName: Full=Non-selenium glutathione peroxidase; Short=NSGPx; EC=1.11.1.9; AltName: 
Full=Red blood cells page spot 12; - OS=Homo sapiens (Human). 
828 PRG3_HUMAN 
RecName: Full=Proteoglycan 3; AltName: Full=Eosinophil major basic protein homolog; AltName: 
Full=Prepro-major basic protein homolog; Short=Prepro-MBPH; Flags: Precursor; - OS=Homo 
sapiens (Human). 
25.4 1 1 
829 PROF1_HUMAN 
RecName: Full=Profilin-1; AltName: Full=Epididymis tissue protein Li 184a; AltName: Full=Profilin 
I; - OS=Homo sapiens (Human). 
15.0 6 6 
830 PRS6B_HUMAN 
RecName: Full=26S protease regulatory subunit 6B; AltName: Full=26S proteasome AAA-ATPase 
subunit RPT3; AltName: Full=MB67-interacting protein; AltName: Full=MIP224; AltName: 
Full=Proteasome 26S subunit ATPase 4; AltName: Full=Tat-binding protein 7; Short=TBP-7; - 
OS=Homo sapiens (Human). 
47.3 1 1 
831 PSA2_HUMAN 
RecName: Full=Proteasome subunit alpha type-2; EC=3.4.25.1; AltName: Full=Macropain subunit 
C3; AltName: Full=Multicatalytic endopeptidase complex subunit C3; AltName: Full=Proteasome 
component C3; - OS=Homo sapiens (Human). 
25.9 2 2 
832 PSA5_HUMAN 
RecName: Full=Proteasome subunit alpha type-5; EC=3.4.25.1; AltName: Full=Macropain zeta chain; 
AltName: Full=Multicatalytic endopeptidase complex zeta chain; AltName: Full=Proteasome zeta 
chain; - OS=Homo sapiens (Human). 
26.4 2 2 
833 PSME1_HUMAN 
RecName: Full=Proteasome activator complex subunit 1; AltName: Full=11S regulator complex 
subunit alpha; Short=REG-alpha; AltName: Full=Activator of multicatalytic protease subunit 1; 
AltName: Full=Interferon gamma up-regulated I-5111 protein; Short=IGUP I-5111; AltName: 
Full=Proteasome activator 28 subunit alpha; Short=PA28a; Short=PA28alpha; - OS=Homo sapiens 
(Human). 
28.7 5 5 
834 PSME2_HUMAN RecName: Full=Proteasome activator complex subunit 2; AltName: Full=11S regulator complex 27.4 4 4 
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subunit beta; Short=REG-beta; AltName: Full=Activator of multicatalytic protease subunit 2; 
AltName: Full=Proteasome activator 28 subunit beta; Short=PA28b; Short=PA28beta; - OS=Homo 
sapiens (Human). 
835 PTBP1_HUMAN 
RecName: Full=Polypyrimidine tract-binding protein 1; Short=PTB; AltName: Full=57 kDa RNA-
binding protein PPTB-1; AltName: Full=Heterogeneous nuclear ribonucleoprotein I; Short=hnRNP I; - 
OS=Homo sapiens (Human). 
57.2 1 1 
836 PTN6_HUMAN 
RecName: Full=Tyrosine-protein phosphatase non-receptor type 6; EC=3.1.3.48; AltName: 
Full=Hematopoietic cell protein-tyrosine phosphatase; AltName: Full=Protein-tyrosine phosphatase 
1C; Short=PTP-1C; AltName: Full=Protein-tyrosine phosphatase SHP-1; AltName: Full=SH-PTP1; - 
OS=Homo sapiens (Human). 
67.5 12 12 
837 Q05CP4_HUMAN SubName: Full=EIF2AK2 protein; Flags: Fragment; - OS=Homo sapiens (Human). 40.7 1 1 
838 Q05CU9_HUMAN SubName: Full=MNDA protein; Flags: Fragment; - OS=Homo sapiens (Human). 35.0 3 3 
839 Q05DH1_HUMAN 
RecName: Full=Proteasome subunit alpha type; EC=3.4.25.1; Flags: Fragment; - OS=Homo sapiens 
(Human). 
26.7 3 3 
840 Q06AH7_HUMAN SubName: Full=Transferrin; - OS=Homo sapiens (Human). 76.9 10 10 
841 Q08AS4_HUMAN SubName: Full=HLA-DQA1 protein; - OS=Homo sapiens (Human). 27.9 4 1 
842 Q08ES8_HUMAN SubName: Full=Cell growth-inhibiting protein 34; - OS=Homo sapiens (Human). 20.1 2 2 
843 Q0KKI6_HUMAN SubName: Full=Immunoblobulin light chain; Flags: Fragment; - OS=Homo sapiens (Human). 24.0 5 5 
844 Q0QEN7_HUMAN 
RecName: Full=ATP synthase subunit beta; EC=3.6.3.14; Flags: Fragment; - OS=Homo sapiens 
(Human). 
48.1 16 16 
845 Q0QEY7_HUMAN 
SubName: Full=Succinate dehydrogenase complex subunit B; Flags: Fragment; - OS=Homo sapiens 
(Human). 
28.9 1 1 
846 Q0QF37_HUMAN RecName: Full=Malate dehydrogenase; EC=1.1.1.37; Flags: Fragment; - OS=Homo sapiens (Human). 31.9 15 15 
847 Q0VGA5_HUMAN SubName: Full=SARS protein; - OS=Homo sapiens (Human). 58.4 1 1 
848 Q0VGD6_HUMAN SubName: Full=HNRPR protein; Flags: Fragment; - OS=Homo sapiens (Human). 67.8 3 2 
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849 Q108N1_HUMAN 
SubName: Full=Acyl-CoA synthetase long-chain family member 1 isoform a; Flags: Fragment; - 
OS=Homo sapiens (Human). 
41.5 3 3 
850 Q12898_HUMAN SubName: Full=Adenine phosphoribosyltransferase; Flags: Fragment; - OS=Homo sapiens (Human). 3.5 1 1 
851 Q14476_HUMAN 
SubName: Full=G-gamma-hemoglobin gene from Greek HPFH mutant, .; Flags: Fragment; - 
OS=Homo sapiens (Human). 
11.0 3 2 
852 Q14485_HUMAN SubName: Full=Delta-hemoglobin; Flags: Fragment; - OS=Homo sapiens (Human). 6.7 5 1 
853 Q14730_HUMAN SubName: Full=La 4.1 protein; Flags: Fragment; - OS=Homo sapiens (Human). 33.7 1 1 
854 Q14887_HUMAN SubName: Full=Mucin; Flags: Fragment; - OS=Homo sapiens (Human). 50.6 2 1 
855 Q15136_HUMAN SubName: Full=Protein kinase A-alpha; Flags: Fragment; - OS=Homo sapiens (Human). 23.9 1 1 
856 Q1JQ76_HUMAN RecName: Full=Ribosomal protein; Flags: Fragment; - OS=Homo sapiens (Human). 23.5 2 2 
857 Q1JUQ3_HUMAN SubName: Full=FK506 binding protein12; - OS=Homo sapiens (Human). 4.0 1 1 
858 Q1RMG2_HUMAN RecName: Full=Adenosylhomocysteinase; EC=3.3.1.1; - OS=Homo sapiens (Human). 33.8 1 1 
859 Q1RMY8_HUMAN SubName: Full=GNB1 protein; Flags: Fragment; - OS=Homo sapiens (Human). 36.3 2 1 
860 Q2NLC8_HUMAN SubName: Full=GSTK1 protein; Flags: Fragment; - OS=Homo sapiens (Human). 19.4 4 4 
861 Q2Q9H2_HUMAN 
RecName: Full=Glucose-6-phosphate 1-dehydrogenase; EC=1.1.1.49; Flags: Fragment; - OS=Homo 
sapiens (Human). 
54.8 6 6 
862 Q2TU34_HUMAN 
RecName: Full=Fructose-1,6-bisphosphatase class 1 D; Short=FBPase class 1 D; EC=3.1.3.11; 
AltName: Full=D-fructose-1,6-bisphosphate 1-phosphohydrolase class 1 D; - OS=Homo sapiens 
(Human). 
36.8 7 7 
863 Q30131_HUMAN SubName: Full=HLA DR-beta-III; Flags: Precursor; Fragment; - OS=Homo sapiens (Human). 27.2 6 1 
864 Q32XH3_HUMAN SubName: Full=Ribosomal protein L18a-like protein; - OS=Homo sapiens (Human). 15.8 1 1 
865 Q330K1_HUMAN 
SubName: Full=Mitochondrial import inner membrane translocase subunit TIM50; SubName: 
Full=TIM50L; SubName: Full=TIMM50 protein; - OS=Homo sapiens (Human). 
27.6 1 1 
866 Q38G99_HUMAN SubName: Full=C-myc intron-binding protein 1; - OS=Homo sapiens (Human). 268.6 1 1 
867 Q3LAB6_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 20.8 6 2 
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868 Q3LAB7_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 21.1 4 0 
869 Q3LAC1_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 21.3 4 0 
870 Q3LR79_HUMAN SubName: Full=Hemoglobin beta; Flags: Fragment; - OS=Homo sapiens (Human). 11.5 8 1 
871 Q45KI0_HUMAN SubName: Full=Trypsin I; Flags: Fragment; - OS=Homo sapiens (Human). 9.2 1 1 
872 Q49AG2_HUMAN SubName: Full=TMED5 protein; - OS=Homo sapiens (Human). 19.9 1 1 
873 Q4G1A8_HUMAN SubName: Full=CAMK2D protein; Flags: Fragment; - OS=Homo sapiens (Human). 38.9 1 1 
874 Q4TZM4_HUMAN SubName: Full=Hemoglobin beta chain; Flags: Fragment; - OS=Homo sapiens (Human). 11.0 7 1 
875 Q4VXM1_HUMAN 
SubName: Full=Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like; SubName: 
Full=Monofunctional C1-tetrahydrofolate synthase, mitochondrial; Flags: Fragment; - OS=Homo 
sapiens (Human). 
6.2 1 1 
876 Q4VXN1_HUMAN 
SubName: Full=Band 4.1-like protein 1; SubName: Full=Erythrocyte membrane protein band 4.1-like 
1; Flags: Fragment; - OS=Homo sapiens (Human). 
22.9 1 1 
877 Q4W5I3_HUMAN 
SubName: Full=Putative uncharacterized protein ABCG2; Flags: Fragment; - OS=Homo sapiens 
(Human). 
66.8 1 1 
878 Q53ET5_HUMAN 
SubName: Full=ATPase, H+ transporting, lysosomal V0 subunit a isoform 1 variant; Flags: Fragment; 
- OS=Homo sapiens (Human). 
95.7 1 1 
879 Q53FJ5_HUMAN 
SubName: Full=Prosaposin (Variant Gaucher disease and variant metachromatic leukodystrophy) 
variant; Flags: Fragment; - OS=Homo sapiens (Human). 
58.1 9 9 
880 Q53G25_HUMAN SubName: Full=Ribosomal protein S5 variant; Flags: Fragment; - OS=Homo sapiens (Human). 23.0 2 2 
881 Q53G71_HUMAN SubName: Full=Calreticulin variant; Flags: Fragment; - OS=Homo sapiens (Human). 46.9 5 5 
882 Q53G74_HUMAN SubName: Full=Ribosomal protein L4 variant; Flags: Fragment; - OS=Homo sapiens (Human). 47.7 4 4 
883 Q53G79_HUMAN 
SubName: Full=Carnitine O-palmitoyltransferase II, mitochondrial variant; Flags: Fragment; - 
OS=Homo sapiens (Human). 
64.7 5 5 
884 Q53G83_HUMAN SubName: Full=Ribosomal protein S3 variant; Flags: Fragment; - OS=Homo sapiens (Human). 26.7 4 4 
885 Q53GN4_HUMAN SubName: Full=WD repeat domain 1, isoform CRA_a; SubName: Full=WD repeat-containing protein 66.1 9 9 
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1 isoform 1 variant; Flags: Fragment; - OS=Homo sapiens (Human). 
886 Q53HF2_HUMAN 
SubName: Full=Heat shock 70kDa protein 8 isoform 2 variant; Flags: Fragment; - OS=Homo sapiens 
(Human). 
53.5 13 10 
887 Q53HP9_HUMAN 
SubName: Full=Chromosome 14 open reading frame 159 variant; Flags: Fragment; - OS=Homo 
sapiens (Human). 
44.2 2 2 
888 Q53QE9_HUMAN 
SubName: Full=Putative uncharacterized protein UGP2; Flags: Fragment; - OS=Homo sapiens 
(Human). 
49.2 4 4 
889 Q53T09_HUMAN 
SubName: Full=Putative uncharacterized protein XRCC5; Flags: Fragment; - OS=Homo sapiens 
(Human). 
64.2 1 1 
890 Q562M5_HUMAN SubName: Full=Actin-like protein; Flags: Fragment; - OS=Homo sapiens (Human). 11.6 3 1 
891 Q562V5_HUMAN SubName: Full=Actin-like protein; Flags: Fragment; - OS=Homo sapiens (Human). 11.4 2 1 
892 Q567R0_HUMAN 
SubName: Full=UQCRH protein; SubName: Full=Ubiquinol-cytochrome c reductase hinge protein, 
isoform CRA_c; - OS=Homo sapiens (Human). 
9.9 1 1 
893 Q567R6_HUMAN RecName: Full=Single-stranded DNA-binding protein; - OS=Homo sapiens (Human). 17.3 2 2 
894 Q56FN6_HUMAN SubName: Full=MHC class II antigen; - OS=Homo sapiens (Human). 30.0 6 0 
895 Q56FP5_HUMAN SubName: Full=MHC class II antigen; - OS=Homo sapiens (Human). 30.1 6 0 
896 Q59EW3_HUMAN 
SubName: Full=RAB18, member RAS oncogene family variant; Flags: Fragment; - OS=Homo sapiens 
(Human). 
14.4 1 1 
897 Q59F83_HUMAN 
SubName: Full=Major histocompatibility complex, class II, DM beta variant; Flags: Fragment; - 
OS=Homo sapiens (Human). 
16.8 2 2 
898 Q59FQ8_HUMAN SubName: Full=Spinster variant; Flags: Fragment; - OS=Homo sapiens (Human). 36.4 1 1 
899 Q59G96_HUMAN SubName: Full=Dynamin 2 isoform 4 variant; Flags: Fragment; - OS=Homo sapiens (Human). 55.1 2 2 
900 Q59GN1_HUMAN 
RecName: Full=Proteasome subunit beta type; EC=3.4.25.1; Flags: Fragment; - OS=Homo sapiens 
(Human). 
21.3 2 2 
901 Q59GS3_HUMAN SubName: Full=Proteasome 26S ATPase subunit 5 variant; Flags: Fragment; - OS=Homo sapiens 38.7 2 2 
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(Human). 
902 Q59H47_HUMAN 
SubName: Full=Guanylate binding protein 1, interferon-inducible, 67kD variant; Flags: Fragment; - 
OS=Homo sapiens (Human). 
32.7 2 1 
903 Q59H95_HUMAN SubName: Full=Flightless I homolog variant; Flags: Fragment; - OS=Homo sapiens (Human). 125.2 1 1 
904 Q5CAQ5_HUMAN 
RecName: Full=Chaperone protein HtpG I; AltName: Full=Heat shock protein HtpG I; AltName: 
Full=High temperature protein G I; - OS=Homo sapiens (Human). 
92.3 13 12 
905 Q5HYB6_HUMAN SubName: Full=Putative uncharacterized protein DKFZp686J1372; - OS=Homo sapiens (Human). 27.2 5 3 
906 Q5HYD9_HUMAN 
SubName: Full=Putative uncharacterized protein DKFZp686M0619; Flags: Fragment; - OS=Homo 
sapiens (Human). 
11.9 1 1 
907 Q5HYM2_HUMAN 
SubName: Full=Putative uncharacterized protein DKFZp686O2462; Flags: Fragment; - OS=Homo 
sapiens (Human). 
72.0 3 3 
908 Q5J7W2_HUMAN SubName: Full=Migration-inducing gene 9 protein; - OS=Homo sapiens (Human). 9.6 1 1 
909 Q5JPE4_HUMAN SubName: Full=Putative uncharacterized protein DKFZp667O202; - OS=Homo sapiens (Human). 20.4 1 1 
910 Q5JPU2_HUMAN 
SubName: Full=Pyruvate dehydrogenase (Lipoamide) alpha 1; SubName: Full=Pyruvate 
dehydrogenase E1 component subunit alpha, somatic form, mitochondrial; Flags: Fragment; - 
OS=Homo sapiens (Human). 
13.8 1 1 
911 Q5JQ44_HUMAN 
SubName: Full=Putative uncharacterized protein DKFZp547A0616; Flags: Fragment; - OS=Homo 
sapiens (Human). 
20.3 1 1 
912 Q5JR06_HUMAN 
SubName: Full=Ras homolog gene family, member C; SubName: Full=Rho-related GTP-binding 
protein RhoC; Flags: Fragment; - OS=Homo sapiens (Human). 
10.3 3 3 
913 Q5JR95_HUMAN 
SubName: Full=40S ribosomal protein S8; SubName: Full=Ribosomal protein S8; - OS=Homo sapiens 
(Human). 
21.9 3 3 
914 Q5JTW5_HUMAN 
SubName: Full=Propionyl Coenzyme A carboxylase, alpha polypeptide; Flags: Fragment; - OS=Homo 
sapiens (Human). 
15.6 1 1 
915 Q5JVH5_HUMAN SubName: Full=Ribosomal protein 26 (RPS26) pseudogene; - OS=Homo sapiens (Human). 13.0 1 1 
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916 Q5JW01_HUMAN 
SubName: Full=Engulfment and cell motility 2; SubName: Full=Engulfment and cell motility protein 
2; Flags: Fragment; - OS=Homo sapiens (Human). 
33.2 1 1 
917 Q5JXH9_HUMAN 
SubName: Full=Four and a half LIM domains 1; SubName: Full=Four and a half LIM domains protein 
1; Flags: Fragment; - OS=Homo sapiens (Human). 
17.8 1 1 
918 Q5QPE4_HUMAN 
SubName: Full=Sorting nexin 5; SubName: Full=Sorting nexin-5; Flags: Fragment; - OS=Homo 
sapiens (Human). 
26.3 2 2 
919 Q5QPM0_HUMAN 
SubName: Full=RNA binding protein, autoantigenic (HnRNP-associated with lethal yellow homolog 
(Mouse)); SubName: Full=RNA-binding protein Raly; Flags: Fragment; - OS=Homo sapiens (Human). 
18.7 2 2 
920 Q5QTQ6_HUMAN 
SubName: Full=MSTP010; SubName: Full=cDNA FLJ11394 fis, clone HEMBA1000592, highly 
similar to Sorting nexin-6; - OS=Homo sapiens (Human). 
24.6 1 1 
921 Q5R370_HUMAN 
SubName: Full=Calcyclin binding protein; SubName: Full=Calcyclin-binding protein; - OS=Homo 
sapiens (Human). 
21.2 1 1 
922 Q5S4N1_HUMAN SubName: Full=Putative uncharacterized protein; Flags: Fragment; - OS=Homo sapiens (Human). 40.2 2 2 
923 Q5SQT6_HUMAN 
SubName: Full=Inorganic pyrophosphatase; SubName: Full=Pyrophosphatase (Inorganic) 1; - 
OS=Homo sapiens (Human). 
20.0 2 1 
924 Q5SYT8_HUMAN 
SubName: Full=Novel protein similar to Pre-B cell enhancing factor (PBEF); SubName: Full=Protein 
NAMPTL; Flags: Fragment; - OS=Homo sapiens (Human). 
53.4 5 5 
925 Q5T0R9_HUMAN RecName: Full=Adenylyl cyclase-associated protein; Flags: Fragment; - OS=Homo sapiens (Human). 28.7 4 1 
926 Q5T123_HUMAN 
SubName: Full=SH3 domain binding glutamic acid-rich protein like 3; SubName: Full=SH3 domain-
binding glutamic acid-rich-like protein 3; - OS=Homo sapiens (Human). 
9.4 1 1 
927 Q5T204_HUMAN SubName: Full=Nicastrin; Flags: Fragment; - OS=Homo sapiens (Human). 30.0 3 3 
928 Q5T6W5_HUMAN SubName: Full=Heterogeneous nuclear ribonucleoprotein K; - OS=Homo sapiens (Human). 47.5 6 6 
929 Q5T6W8_HUMAN 
SubName: Full=Acidic (Leucine-rich) nuclear phosphoprotein 32 family, member B; SubName: 
Full=Acidic leucine-rich nuclear phosphoprotein 32 family member B; Flags: Fragment; - OS=Homo 
sapiens (Human). 
17.9 1 1 
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930 Q5TB53_HUMAN 
SubName: Full=SM-11044 binding protein (SMBP)(EP70-P-iso); SubName: Full=Transmembrane 9 
superfamily member 3; Flags: Fragment; - OS=Homo sapiens (Human). 
29.9 1 1 
931 Q5TCU6_HUMAN SubName: Full=Talin 1; SubName: Full=Talin-1; - OS=Homo sapiens (Human). 257.9 23 23 
932 Q5VU21_HUMAN 
SubName: Full=PAI-1 mRNA-binding protein variant; SubName: Full=SERPINE1 mRNA binding 
protein 1; SubName: Full=cDNA, FLJ92551, Homo sapiens PAI-1 mRNA-binding protein (PAI-
RBP1), mRNA; - OS=Homo sapiens (Human). 
42.4 1 1 
933 Q5VXS2_HUMAN SubName: Full=Ubiquitin-fold modifier 1; Flags: Fragment; - OS=Homo sapiens (Human). 8.5 1 1 
934 Q5XTR9_HUMAN 
SubName: Full=Hemoglobin delta-beta fusion protein; Flags: Fragment; - OS=Homo sapiens 
(Human). 
3.9 3 1 
935 Q60FE6_HUMAN SubName: Full=Filamin A; - OS=Homo sapiens (Human). 277.3 65 65 
936 Q67AU1_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 10.8 1 1 
937 Q68CW8_HUMAN 
SubName: Full=Putative uncharacterized protein DKFZp434I2216; Flags: Fragment; - OS=Homo 
sapiens (Human). 
6.0 1 1 
938 Q68D64_HUMAN 
SubName: Full=Putative uncharacterized protein DKFZp686E23276; Flags: Fragment; - OS=Homo 
sapiens (Human). 
37.0 4 4 
939 Q68DR3_HUMAN 
SubName: Full=Putative uncharacterized protein DKFZp779H1622; Flags: Fragment; - OS=Homo 
sapiens (Human). 
35.1 1 1 
940 Q69YR1_HUMAN 
SubName: Full=Putative uncharacterized protein DKFZp667C1917; Flags: Fragment; - OS=Homo 
sapiens (Human). 
23.5 1 1 
941 Q69YT6_HUMAN 
SubName: Full=Putative uncharacterized protein DKFZp547B159; Flags: Fragment; - OS=Homo 
sapiens (Human). 
21.2 1 1 
942 Q6AW83_HUMAN 
SubName: Full=Putative uncharacterized protein DKFZp686G08243; Flags: Fragment; - OS=Homo 
sapiens (Human). 
15.5 1 1 
943 Q6DC98_HUMAN SubName: Full=LMNB1 protein; Flags: Fragment; - OS=Homo sapiens (Human). 38.1 6 5 
944 Q6FG43_HUMAN SubName: Full=FLOT2 protein; SubName: Full=Flotillin 2; SubName: Full=HCG1998851, isoform 41.7 4 4 
 274 Chapter 10 Appendices 
CRA_e; - OS=Homo sapiens (Human). 
945 Q6FGE5_HUMAN SubName: Full=S100A10 protein; Flags: Fragment; - OS=Homo sapiens (Human). 11.2 1 1 
946 Q6IBG5_HUMAN SubName: Full=MYL6 protein; - OS=Homo sapiens (Human). 13.0 4 4 
947 Q6IPN0_HUMAN SubName: Full=RTN4 protein; - OS=Homo sapiens (Human). 36.9 5 5 
948 Q6LBZ1_HUMAN SubName: Full=MRNA for apolipoprotein E (apo E); Flags: Fragment; - OS=Homo sapiens (Human). 19.9 1 1 
949 Q6LER7_HUMAN SubName: Full=Alpha-galactosidase A; EC=3.2.1.22; Flags: Fragment; - OS=Homo sapiens (Human). 45.8 2 2 
950 Q6NSD4_HUMAN RecName: Full=Glutathione peroxidase; - OS=Homo sapiens (Human). 16.2 4 4 
951 Q6P1N7_HUMAN SubName: Full=TAPBP protein; SubName: Full=Tapasin; - OS=Homo sapiens (Human). 16.4 1 1 
952 Q6PIX2_HUMAN SubName: Full=SFPQ protein; Flags: Fragment; - OS=Homo sapiens (Human). 55.4 3 3 
953 Q6UYC3_HUMAN 
SubName: Full=Lamin A/C; SubName: Full=Prelamin-A/C; SubName: Full=Progerin; - OS=Homo 
sapiens (Human). 
69.2 21 21 
954 Q6VFQ6_HUMAN SubName: Full=Hemoglobin beta chain; Flags: Fragment; - OS=Homo sapiens (Human). 4.5 3 2 
955 Q6ZNK5_HUMAN SubName: Full=FLJ00293 protein; Flags: Fragment; - OS=Homo sapiens (Human). 92.8 2 2 
956 Q6ZR81_HUMAN 
SubName: Full=cDNA FLJ46566 fis, clone THYMU3040829, moderately similar to Cold-inducible 
RNA-binding protein; - OS=Homo sapiens (Human). 
15.3 1 1 
957 Q70T18_HUMAN SubName: Full=BBF2H7/FUS protein; Flags: Fragment; - OS=Homo sapiens (Human). 16.1 1 1 
958 Q7KYN0_HUMAN SubName: Full=HS24/P52 protein; Flags: Fragment; - OS=Homo sapiens (Human). 29.4 2 2 
959 Q7Z4Q5_HUMAN 
SubName: Full=Heterogeneous nuclear ribonucleoprotein U (Scaffold attachment factor A), isoform 
CRA_a; - OS=Homo sapiens (Human). 
57.6 1 1 
960 Q7Z4W8_HUMAN SubName: Full=Heparin-binding protein HBp15; - OS=Homo sapiens (Human). 14.8 1 1 
961 Q7Z612_HUMAN SubName: Full=Acidic ribosomal phosphoprotein P1; - OS=Homo sapiens (Human). 11.4 1 1 
962 Q861F4_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 21.5 3 1 
963 Q86TY5_HUMAN 
SubName: Full=Full-length cDNA clone CS0DI041YE05 of Placenta of Homo sapiens (human); - 
OS=Homo sapiens (Human). 
13.9 4 4 
964 Q86UL7_HUMAN SubName: Full=Putative uncharacterized protein TBXAS1; Flags: Fragment; - OS=Homo sapiens 35.6 3 3 
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(Human). 
965 Q86YQ1_HUMAN SubName: Full=Hemoglobin alpha-2; Flags: Fragment; - OS=Homo sapiens (Human). 9.7 4 1 
966 Q86YQ4_HUMAN SubName: Full=Alpha-1 globin; Flags: Fragment; - OS=Homo sapiens (Human). 9.5 4 1 
967 Q86Z09_HUMAN SubName: Full=FGA protein; Flags: Fragment; - OS=Homo sapiens (Human). 7.0 1 1 
968 Q8HWG4_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 10.8 4 0 
969 Q8IUL9_HUMAN 
SubName: Full=Hemoglobin beta chain variant Hb.Sinai-Bel Air; Flags: Fragment; - OS=Homo 
sapiens (Human). 
11.5 8 1 
970 Q8IWL5_HUMAN SubName: Full=CLU; Flags: Fragment; - OS=Homo sapiens (Human). 16.3 1 1 
971 Q8IZ29_HUMAN SubName: Full=Tubulin, beta 2C; - OS=Homo sapiens (Human). 49.8 12 4 
972 Q8IZI0_HUMAN 
SubName: Full=Hemoglobin beta chain variant Hb-I_Toulouse; Flags: Fragment; - OS=Homo sapiens 
(Human). 
11.5 8 1 
973 Q8N730_HUMAN 
SubName: Full=Peripheral-type Benzodiazepine Receptor; Flags: Fragment; - OS=Homo sapiens 
(Human). 
6.7 1 1 
974 Q8N9C4_HUMAN 
SubName: Full=cDNA FLJ37765 fis, clone BRHIP2024742, highly similar to ATP-CITRATE; - 
OS=Homo sapiens (Human). 
76.4 1 1 
975 Q8NB80_HUMAN 
SubName: Full=cDNA FLJ34106 fis, clone FCBBF3008073, highly similar to SPLICING FACTOR, 
ARGININE/SERINE-RICH 7; - OS=Homo sapiens (Human). 
15.9 1 1 
976 Q8TC97_HUMAN SubName: Full=CTBS protein; - OS=Homo sapiens (Human). 11.7 2 2 
977 Q8TES5_HUMAN SubName: Full=FLJ00114 protein; Flags: Fragment; - OS=Homo sapiens (Human). 38.9 1 1 
978 Q8WVH4_HUMAN SubName: Full=Putative uncharacterized protein; Flags: Fragment; - OS=Homo sapiens (Human). 20.1 1 1 
979 Q8WYJ5_HUMAN SubName: Full=Protein kinase C inhibitor-2; - OS=Homo sapiens (Human). 13.9 2 2 
980 Q93020_HUMAN 
SubName: Full=GTP-binding regulatory protein Gi alpha-2 chain; Flags: Fragment; - OS=Homo 
sapiens (Human). 
22.1 4 4 
981 Q95379_HUMAN SubName: Full=MHC class II HLA-DR2; Flags: Fragment; - OS=Homo sapiens (Human). 24.7 6 0 
982 Q95HL2_HUMAN SubName: Full=MHC class I antigen; Flags: Fragment; - OS=Homo sapiens (Human). 37.9 4 1 
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983 Q969I0_HUMAN SubName: Full=KRT8 protein; Flags: Fragment; - OS=Homo sapiens (Human). 41.1 7 6 
984 Q96B07_HUMAN SubName: Full=EIF4A2 protein; - OS=Homo sapiens (Human). 21.0 1 1 
985 Q96ET4_HUMAN SubName: Full=Similar to calcyphosine; Flags: Fragment; - OS=Homo sapiens (Human). 18.4 1 1 
986 Q96HX3_HUMAN SubName: Full=Similar to ribophorin I; Flags: Fragment; - OS=Homo sapiens (Human). 64.5 10 10 
987 Q96IR1_HUMAN SubName: Full=RPS4X protein; Flags: Fragment; - OS=Homo sapiens (Human). 27.2 2 2 
988 Q9BCN9_HUMAN SubName: Full=MHC class II antigen; Flags: Fragment; - OS=Homo sapiens (Human). 20.2 6 1 
989 Q9BS19_HUMAN SubName: Full=HPX protein; - OS=Homo sapiens (Human). 28.6 1 1 
990 Q9BVJ8_HUMAN SubName: Full=HEXA protein; Flags: Fragment; - OS=Homo sapiens (Human). 47.1 9 8 
991 Q9BZU1_HUMAN SubName: Full=PNAS-20; - OS=Homo sapiens (Human). 9.0 1 1 
992 Q9H9J7_HUMAN 
SubName: Full=cDNA FLJ12692 fis, clone NT2RM4002623, weakly similar to ASPARTYL-TRNA 
SYNTHETASE (EC 6.1.1.12); - OS=Homo sapiens (Human). 
52.6 1 1 
993 Q9HBB2_HUMAN 
SubName: Full=Cytoplasmic aconitate hydratase; SubName: Full=Iron regulatory protein 1; - 
OS=Homo sapiens (Human). 
87.0 5 5 
994 Q9HBQ7_HUMAN SubName: Full=Cathepsin L, isoform CRA_b; - OS=Homo sapiens (Human). 16.8 2 2 
995 Q9NP01_HUMAN SubName: Full=Fibrillin 15; Flags: Fragment; - OS=Homo sapiens (Human). 56.5 1 1 
996 Q9P1N8_HUMAN 
SubName: Full=PRO0868; SubName: Full=cDNA FLJ51293, highly similar to Lamina-associated 
polypeptide 2, isoforms beta/gamma; - OS=Homo sapiens (Human). 
12.1 1 1 
997 Q9TQD9_HUMAN 
SubName: Full=MHC class II antigen HLA-DR-beta 1; Flags: Fragment; - OS=Homo sapiens 
(Human). 
27.2 6 0 
998 Q9UEH5_HUMAN 
SubName: Full=24-kDa subunit of complex I; EC=1.6.5.3; Flags: Fragment; - OS=Homo sapiens 
(Human). 
25.4 2 2 
999 Q9UF24_HUMAN 
SubName: Full=Putative uncharacterized protein DKFZp586K0821; Flags: Fragment; - OS=Homo 
sapiens (Human). 
22.2 3 3 
1000 Q9UHS8_HUMAN SubName: Full=PRO1975; - OS=Homo sapiens (Human). 44.1 9 9 
1001 Q9UK54_HUMAN SubName: Full=Hemoglobin beta subunit variant; Flags: Fragment; - OS=Homo sapiens (Human). 14.0 8 1 
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1002 Q9UNM1_HUMAN SubName: Full=Chaperonin 10-related protein; Flags: Fragment; - OS=Homo sapiens (Human). 10.3 5 5 
1003 Q9UPE4_HUMAN 
SubName: Full=Putative mitochondrial inner membrane protein import receptor; - OS=Homo sapiens 
(Human). 
47.3 1 1 
1004 Q9UQT9_HUMAN 
SubName: Full=Leucocyte antigen DR52 beta 1 chain; Flags: Fragment; - OS=Homo sapiens 
(Human). 
10.8 4 0 
1005 QCR9_HUMAN 
RecName: Full=Cytochrome b-c1 complex subunit 9; AltName: Full=Complex III subunit 9; 
AltName: Full=Complex III subunit X; AltName: Full=Cytochrome c1 non-heme 7 kDa protein; 
AltName: Full=Ubiquinol-cytochrome c reductase complex 7.2 kDa protein; - OS=Homo sapiens 
(Human). 
7.3 1 1 
1006 R13AX_HUMAN RecName: Full=Putative 60S ribosomal protein L13a-like MGC87657; - OS=Homo sapiens (Human). 12.1 1 1 
1007 RAB10_HUMAN RecName: Full=Ras-related protein Rab-10; - OS=Homo sapiens (Human). 22.5 4 2 
1008 RAB14_HUMAN RecName: Full=Ras-related protein Rab-14; - OS=Homo sapiens (Human). 23.9 4 3 
1009 RAB1A_HUMAN 
RecName: Full=Ras-related protein Rab-1A; AltName: Full=YPT1-related protein; - OS=Homo 
sapiens (Human). 
22.7 6 3 
1010 RAB21_HUMAN RecName: Full=Ras-related protein Rab-21; Flags: Precursor; - OS=Homo sapiens (Human). 24.3 3 3 
1011 RAB2A_HUMAN RecName: Full=Ras-related protein Rab-2A; - OS=Homo sapiens (Human). 23.5 3 3 
1012 RAB31_HUMAN 
RecName: Full=Ras-related protein Rab-31; AltName: Full=Ras-related protein Rab-22B; - OS=Homo 
sapiens (Human). 
21.6 4 4 
1013 RAB5C_HUMAN 
RecName: Full=Ras-related protein Rab-5C; AltName: Full=L1880; AltName: Full=RAB5L; - 
OS=Homo sapiens (Human). 
23.5 4 4 
1014 RAB7A_HUMAN RecName: Full=Ras-related protein Rab-7a; - OS=Homo sapiens (Human). 23.5 9 9 
1015 RAB9A_HUMAN RecName: Full=Ras-related protein Rab-9A; - OS=Homo sapiens (Human). 22.8 1 1 
1016 RAC2_HUMAN 
RecName: Full=Ras-related C3 botulinum toxin substrate 2; AltName: Full=GX; AltName: Full=Small 
G protein; AltName: Full=p21-Rac2; Flags: Precursor; - OS=Homo sapiens (Human). 
21.4 4 3 
1017 RAN_HUMAN RecName: Full=GTP-binding nuclear protein Ran; AltName: Full=Androgen receptor-associated 24.4 3 3 
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protein 24; AltName: Full=GTPase Ran; AltName: Full=Ras-like protein TC4; AltName: Full=Ras-
related nuclear protein; - OS=Homo sapiens (Human). 
1018 RINI_HUMAN 
RecName: Full=Ribonuclease inhibitor; AltName: Full=Placental ribonuclease inhibitor; 
Short=Placental RNase inhibitor; AltName: Full=Ribonuclease/angiogenin inhibitor 1; Short=RAI; - 
OS=Homo sapiens (Human). 
49.9 12 12 
1019 RISC_HUMAN 
RecName: Full=Retinoid-inducible serine carboxypeptidase; EC=3.4.16.-; AltName: Full=Serine 
carboxypeptidase 1; Flags: Precursor; - OS=Homo sapiens (Human). 
50.8 7 7 
1020 RL12_HUMAN RecName: Full=60S ribosomal protein L12; - OS=Homo sapiens (Human). 17.8 3 3 
1021 RL7_HUMAN RecName: Full=60S ribosomal protein L7; - OS=Homo sapiens (Human). 29.2 3 3 
1022 RLA2_HUMAN 
RecName: Full=60S acidic ribosomal protein P2; AltName: Full=Renal carcinoma antigen NY-REN-
44; - OS=Homo sapiens (Human). 
11.7 2 2 
1023 RMD3_HUMAN 
RecName: Full=Regulator of microtubule dynamics protein 3; Short=RMD-3; Short=hRMD-3; 
AltName: Full=Cerebral protein 10; AltName: Full=Protein FAM82A2; AltName: Full=Protein 
FAM82C; AltName: Full=Protein tyrosine phosphatase-interacting protein 51; AltName: Full=TCPTP-
interacting protein 51; - OS=Homo sapiens (Human). 
52.1 6 6 
1024 ROA0_HUMAN 
RecName: Full=Heterogeneous nuclear ribonucleoprotein A0; Short=hnRNP A0; - OS=Homo sapiens 
(Human). 
30.8 1 1 
1025 ROA2_HUMAN 
RecName: Full=Heterogeneous nuclear ribonucleoproteins A2/B1; Short=hnRNP A2/B1; - OS=Homo 
sapiens (Human). 
37.4 4 4 
1026 RS10_HUMAN RecName: Full=40S ribosomal protein S10; - OS=Homo sapiens (Human). 18.9 1 1 
1027 RS12_HUMAN RecName: Full=40S ribosomal protein S12; - OS=Homo sapiens (Human). 14.5 2 2 
1028 RS14_HUMAN RecName: Full=40S ribosomal protein S14; - OS=Homo sapiens (Human). 16.3 1 1 
1029 RS16_HUMAN RecName: Full=40S ribosomal protein S16; - OS=Homo sapiens (Human). 16.4 1 1 
1030 RS18_HUMAN 
RecName: Full=40S ribosomal protein S18; AltName: Full=Ke-3; Short=Ke3; - OS=Homo sapiens 
(Human). 
17.7 1 1 
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1031 RS19_HUMAN RecName: Full=40S ribosomal protein S19; - OS=Homo sapiens (Human). 16.1 1 1 
1032 RS25_HUMAN RecName: Full=40S ribosomal protein S25; - OS=Homo sapiens (Human). 13.7 1 1 
1033 RS28_HUMAN RecName: Full=40S ribosomal protein S28; - OS=Homo sapiens (Human). 7.8 1 1 
1034 RT36_HUMAN 
RecName: Full=28S ribosomal protein S36, mitochondrial; Short=MRP-S36; Short=S36mt; - 
OS=Homo sapiens (Human). 
11.5 1 1 
1035 S10A4_HUMAN 
RecName: Full=Protein S100-A4; AltName: Full=Calvasculin; AltName: Full=Metastasin; AltName: 
Full=Placental calcium-binding protein; AltName: Full=Protein Mts1; AltName: Full=S100 calcium-
binding protein A4; - OS=Homo sapiens (Human). 
11.7 2 2 
1036 S10A8_HUMAN 
RecName: Full=Protein S100-A8; AltName: Full=Calgranulin-A; AltName: Full=Calprotectin L1L 
subunit; AltName: Full=Cystic fibrosis antigen; Short=CFAG; AltName: Full=Leukocyte L1 complex 
light chain; AltName: Full=Migration inhibitory factor-related protein 8; Short=MRP-8; Short=p8; 
AltName: Full=S100 calcium-binding protein A8; AltName: Full=Urinary stone protein band A; - 
OS=Homo sapiens (Human). 
10.8 4 4 
1037 S10AB_HUMAN 
RecName: Full=Protein S100-A11; AltName: Full=Calgizzarin; AltName: Full=Metastatic lymph 
node gene 70 protein; Short=MLN 70; AltName: Full=Protein S100-C; AltName: Full=S100 calcium-
binding protein A11; - OS=Homo sapiens (Human). 
11.7 3 3 
1038 S15A3_HUMAN 
RecName: Full=Solute carrier family 15 member 3; AltName: Full=Osteoclast transporter; AltName: 
Full=Peptide transporter 3; AltName: Full=Peptide/histidine transporter 2; - OS=Homo sapiens 
(Human). 
63.5 2 2 
1039 S27A3_HUMAN 
RecName: Full=Long-chain fatty acid transport protein 3; Short=FATP-3; Short=Fatty acid transport 
protein 3; EC=6.2.1.-; AltName: Full=Solute carrier family 27 member 3; AltName: Full=Very long-
chain acyl-CoA synthetase homolog 3; Short=VLCS-3; - OS=Homo sapiens (Human). 
78.6 3 3 
1040 SAMH1_HUMAN 
RecName: Full=SAM domain and HD domain-containing protein 1; EC=3.1.4.-; AltName: 
Full=Dendritic cell-derived IFNG-induced protein; Short=DCIP; AltName: Full=Monocyte protein 5; 
Short=MOP-5; - OS=Homo sapiens (Human). 
72.2 10 10 
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1041 SAP3_HUMAN 
RecName: Full=Ganglioside GM2 activator; AltName: Full=Cerebroside sulfate activator protein; 
AltName: Full=GM2-AP; AltName: Full=Shingolipid activator protein 3; Short=SAP-3; Contains: 
RecName: Full=Ganglioside GM2 activator isoform short; Flags: Precursor; - OS=Homo sapiens 
(Human). 
20.8 4 4 
1042 SBP1_HUMAN 
RecName: Full=Selenium-binding protein 1; AltName: Full=56 kDa selenium-binding protein; 
Short=SBP56; Short=SP56; - OS=Homo sapiens (Human). 
52.4 10 10 
1043 SCPDL_HUMAN 
RecName: Full=Saccharopine dehydrogenase-like oxidoreductase; EC=1.-.-.-; - OS=Homo sapiens 
(Human). 
47.1 2 2 
1044 SCRB2_HUMAN 
RecName: Full=Lysosome membrane protein 2; AltName: Full=85 kDa lysosomal membrane 
sialoglycoprotein; Short=LGP85; AltName: Full=CD36 antigen-like 2; AltName: Full=Lysosome 
membrane protein II; Short=LIMP II; AltName: Full=Scavenger receptor class B member 2; AltName: 
CD_antigen=CD36; - OS=Homo sapiens (Human). 
54.3 2 2 
1045 SEP15_HUMAN RecName: Full=15 kDa selenoprotein; Flags: Precursor; - OS=Homo sapiens (Human). 17.8 1 1 
1046 SEPT9_HUMAN 
RecName: Full=Septin-9; AltName: Full=MLL septin-like fusion protein MSF-A; Short=MLL septin-
like fusion protein; AltName: Full=Ovarian/Breast septin; Short=Ov/Br septin; AltName: Full=Septin 
D1; - OS=Homo sapiens (Human). 
65.4 2 2 
1047 SF3B1_HUMAN 
RecName: Full=Splicing factor 3B subunit 1; AltName: Full=Pre-mRNA-splicing factor SF3b 155 
kDa subunit; Short=SF3b155; AltName: Full=Spliceosome-associated protein 155; Short=SAP 155; - 
OS=Homo sapiens (Human). 
145.7 1 1 
1048 SFXN3_HUMAN RecName: Full=Sideroflexin-3; - OS=Homo sapiens (Human). 36.0 4 4 
1049 SG3A1_HUMAN 
RecName: Full=Secretoglobin family 3A member 1; AltName: Full=Cytokine HIN-1; AltName: 
Full=High in normal 1; AltName: Full=Pneumo secretory protein 2; Short=PnSP-2; AltName: 
Full=Uteroglobin-related protein 2; Flags: Precursor; - OS=Homo sapiens (Human). 
10.1 1 1 
1050 SH3L1_HUMAN RecName: Full=SH3 domain-binding glutamic acid-rich-like protein; - OS=Homo sapiens (Human). 12.8 3 3 
1051 SIAE_HUMAN RecName: Full=Sialate O-acetylesterase; EC=3.1.1.53; AltName: Full=H-Lse; AltName: Full=Sialic 58.3 2 2 
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acid-specific 9-O-acetylesterase; Flags: Precursor; - OS=Homo sapiens (Human). 
1052 SIAS_HUMAN 
RecName: Full=Sialic acid synthase; AltName: Full=N-acetylneuraminate synthase; EC=2.5.1.56; 
AltName: Full=N-acetylneuraminate-9-phosphate synthase; EC=2.5.1.57; AltName: Full=N-
acetylneuraminic acid phosphate synthase; AltName: Full=N-acetylneuraminic acid synthase; - 
OS=Homo sapiens (Human). 
40.3 2 2 
1053 SNG2_HUMAN RecName: Full=Synaptogyrin-2; AltName: Full=Cellugyrin; - OS=Homo sapiens (Human). 24.8 1 1 
1054 SNX3_HUMAN RecName: Full=Sorting nexin-3; AltName: Full=Protein SDP3; - OS=Homo sapiens (Human). 18.8 2 2 
1055 SODC_HUMAN 
RecName: Full=Superoxide dismutase [Cu-Zn]; EC=1.15.1.1; AltName: Full=Superoxide dismutase 1; 
Short=hSod1; - OS=Homo sapiens (Human). 
15.9 3 3 
1056 SPTA1_HUMAN 
RecName: Full=Spectrin alpha chain, erythrocytic 1; AltName: Full=Erythroid alpha-spectrin; - 
OS=Homo sapiens (Human). 
279.8 18 18 
1057 SPTB1_HUMAN 
RecName: Full=Spectrin beta chain, erythrocytic; AltName: Full=Beta-I spectrin; - OS=Homo sapiens 
(Human). 
246.3 18 18 
1058 STX11_HUMAN RecName: Full=Syntaxin-11; - OS=Homo sapiens (Human). 33.2 2 2 
1059 STX7_HUMAN RecName: Full=Syntaxin-7; - OS=Homo sapiens (Human). 29.8 2 2 
1060 SYWC_HUMAN 
RecName: Full=Tryptophan--tRNA ligase, cytoplasmic; EC=6.1.1.2; AltName: Full=Interferon-
induced protein 53; Short=IFP53; AltName: Full=Tryptophanyl-tRNA synthetase; Short=TrpRS; 
Short=hWRS; Contains: RecName: Full=T1-TrpRS; Contains: RecName: Full=T2-TrpRS; - 
OS=Homo sapiens (Human). 
53.1 4 4 
1061 TAGL2_HUMAN 
RecName: Full=Transgelin-2; AltName: Full=Epididymis tissue protein Li 7e; AltName: Full=SM22-
alpha homolog; - OS=Homo sapiens (Human). 
22.4 9 9 
1062 TALDO_HUMAN RecName: Full=Transaldolase; EC=2.2.1.2; - OS=Homo sapiens (Human). 37.5 7 7 
1063 TECTA_HUMAN RecName: Full=Alpha-tectorin; Flags: Precursor; - OS=Homo sapiens (Human). 239.4 1 1 
1064 TERA_HUMAN 
RecName: Full=Transitional endoplasmic reticulum ATPase; Short=TER ATPase; AltName: Full=15S 
Mg(2+)-ATPase p97 subunit; AltName: Full=Valosin-containing protein; Short=VCP; - OS=Homo 
89.3 13 13 
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sapiens (Human). 
1065 TFR1_HUMAN 
RecName: Full=Transferrin receptor protein 1; Short=TR; Short=TfR; Short=TfR1; Short=Trfr; 
AltName: Full=T9; AltName: Full=p90; AltName: CD_antigen=CD71; Contains: RecName: 
Full=Transferrin receptor protein 1, serum form; Short=sTfR; - OS=Homo sapiens (Human). 
84.8 17 17 
1066 THIL_HUMAN 
RecName: Full=Acetyl-CoA acetyltransferase, mitochondrial; EC=2.3.1.9; AltName: 
Full=Acetoacetyl-CoA thiolase; AltName: Full=T2; Flags: Precursor; - OS=Homo sapiens (Human). 
45.2 5 5 
1067 TIGAR_HUMAN 
RecName: Full=Fructose-2,6-bisphosphatase TIGAR; EC=3.1.3.46; AltName: Full=TP53-induced 
glycolysis and apoptosis regulator; - OS=Homo sapiens (Human). 
30.0 1 1 
1068 TIM13_HUMAN 
RecName: Full=Mitochondrial import inner membrane translocase subunit Tim13; - OS=Homo 
sapiens (Human). 
10.5 1 1 
1069 TIM8A_HUMAN 
RecName: Full=Mitochondrial import inner membrane translocase subunit Tim8 A; AltName: 
Full=Deafness dystonia protein 1; AltName: Full=X-linked deafness dystonia protein; - OS=Homo 
sapiens (Human). 
11.0 1 1 
1070 TIM9_HUMAN 
RecName: Full=Mitochondrial import inner membrane translocase subunit Tim9; - OS=Homo sapiens 
(Human). 
10.4 1 1 
1071 TM173_HUMAN 
RecName: Full=Transmembrane protein 173; AltName: Full=Endoplasmic reticulum interferon 
stimulator; Short=ERIS; AltName: Full=Mediator of IRF3 activation; Short=hMITA; AltName: 
Full=Stimulator of interferon genes protein; Short=hSTING; - OS=Homo sapiens (Human). 
42.2 1 1 
1072 TMM43_HUMAN 
RecName: Full=Transmembrane protein 43; AltName: Full=Protein LUMA; - OS=Homo sapiens 
(Human). 
44.8 3 3 
1073 TMX1_HUMAN 
RecName: Full=Thioredoxin-related transmembrane protein 1; AltName: Full=Thioredoxin domain-
containing protein 1; AltName: Full=Transmembrane Trx-related protein; Flags: Precursor; - 
OS=Homo sapiens (Human). 
31.8 1 1 
1074 TOM40_HUMAN 
RecName: Full=Mitochondrial import receptor subunit TOM40 homolog; AltName: Full=Protein 
Haymaker; AltName: Full=Translocase of outer membrane 40 kDa subunit homolog; AltName: 
37.9 2 2 
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Full=p38.5; - OS=Homo sapiens (Human). 
1075 TOM5_HUMAN 
RecName: Full=Mitochondrial import receptor subunit TOM5 homolog; - OS=Homo sapiens 
(Human). 
6.0 1 1 
1076 TPIS_HUMAN 
RecName: Full=Triosephosphate isomerase; Short=TIM; EC=5.3.1.1; AltName: Full=Triose-
phosphate isomerase; - OS=Homo sapiens (Human). 
30.8 11 11 
1077 TRI25_HUMAN 
RecName: Full=E3 ubiquitin/ISG15 ligase TRIM25; EC=6.3.2.19; EC=6.3.2.n3; AltName: 
Full=Estrogen-responsive finger protein; AltName: Full=RING finger protein 147; AltName: 
Full=Tripartite motif-containing protein 25; AltName: Full=Ubiquitin/ISG15-conjugating enzyme 
TRIM25; AltName: Full=Zinc finger protein 147; - OS=Homo sapiens (Human). 
70.9 2 2 
1078 TWF2_HUMAN 
RecName: Full=Twinfilin-2; AltName: Full=A6-related protein; Short=hA6RP; AltName: 
Full=Protein tyrosine kinase 9-like; AltName: Full=Twinfilin-1-like protein; - OS=Homo sapiens 
(Human). 
39.5 3 3 
1079 TXD12_HUMAN 
RecName: Full=Thioredoxin domain-containing protein 12; EC=1.8.4.2; AltName: Full=Endoplasmic 
reticulum resident protein 18; Short=ER protein 18; Short=ERp18; AltName: Full=Endoplasmic 
reticulum resident protein 19; Short=ER protein 19; Short=ERp19; AltName: Full=Thioredoxin-like 
protein p19; AltName: Full=hTLP19; Flags: Precursor; - OS=Homo sapiens (Human). 
19.2 1 1 
1080 TXD17_HUMAN 
RecName: Full=Thioredoxin domain-containing protein 17; AltName: Full=14 kDa thioredoxin-
related protein; Short=TRP14; AltName: Full=Protein 42-9-9; AltName: Full=Thioredoxin-like protein 
5; - OS=Homo sapiens (Human). 
13.9 2 2 
1081 TXTP_HUMAN 
RecName: Full=Tricarboxylate transport protein, mitochondrial; AltName: Full=Citrate transport 
protein; Short=CTP; AltName: Full=Solute carrier family 25 member 1; AltName: Full=Tricarboxylate 
carrier protein; Flags: Precursor; - OS=Homo sapiens (Human). 
34.0 2 2 
1082 UBA1_HUMAN 
RecName: Full=Ubiquitin-like modifier-activating enzyme 1; AltName: Full=Protein A1S9; AltName: 
Full=Ubiquitin-activating enzyme E1; - OS=Homo sapiens (Human). 
117.8 9 9 
1083 UBP5_HUMAN RecName: Full=Ubiquitin carboxyl-terminal hydrolase 5; EC=3.4.19.12; AltName: 95.7 1 1 
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Full=Deubiquitinating enzyme 5; AltName: Full=Isopeptidase T; AltName: Full=Ubiquitin 
thioesterase 5; AltName: Full=Ubiquitin-specific-processing protease 5; - OS=Homo sapiens (Human). 
1084 UFC1_HUMAN 
RecName: Full=Ubiquitin-fold modifier-conjugating enzyme 1; Short=Ufm1-conjugating enzyme 1; - 
OS=Homo sapiens (Human). 
19.4 1 1 
1085 URP2_HUMAN 
RecName: Full=Fermitin family homolog 3; AltName: Full=Kindlin-3; AltName: Full=MIG2-like 
protein; AltName: Full=Unc-112-related protein 2; - OS=Homo sapiens (Human). 
75.9 4 4 
1086 USMG5_HUMAN 
RecName: Full=Up-regulated during skeletal muscle growth protein 5; AltName: Full=Diabetes-
associated protein in insulin-sensitive tissues; AltName: Full=HCV F-transactivated protein 2; - 
OS=Homo sapiens (Human). 
6.5 1 1 
1087 VASP_HUMAN RecName: Full=Vasodilator-stimulated phosphoprotein; Short=VASP; - OS=Homo sapiens (Human). 39.8 1 1 
1088 VAT1_HUMAN 
RecName: Full=Synaptic vesicle membrane protein VAT-1 homolog; EC=1.-.-.-; - OS=Homo sapiens 
(Human). 
41.9 7 7 
1089 VATB2_HUMAN 
RecName: Full=V-type proton ATPase subunit B, brain isoform; Short=V-ATPase subunit B 2; 
AltName: Full=Endomembrane proton pump 58 kDa subunit; AltName: Full=HO57; AltName: 
Full=Vacuolar proton pump subunit B 2; - OS=Homo sapiens (Human). 
56.5 10 10 
1090 VATC1_HUMAN 
RecName: Full=V-type proton ATPase subunit C 1; Short=V-ATPase subunit C 1; AltName: 
Full=Vacuolar proton pump subunit C 1; - OS=Homo sapiens (Human). 
43.9 3 3 
1091 VATF_HUMAN 
RecName: Full=V-type proton ATPase subunit F; Short=V-ATPase subunit F; AltName: Full=V-
ATPase 14 kDa subunit; AltName: Full=Vacuolar proton pump subunit F; - OS=Homo sapiens 
(Human). 
13.4 2 2 
1092 VATG1_HUMAN 
RecName: Full=V-type proton ATPase subunit G 1; Short=V-ATPase subunit G 1; AltName: Full=V-
ATPase 13 kDa subunit 1; AltName: Full=Vacuolar proton pump subunit G 1; AltName: 
Full=Vacuolar proton pump subunit M16; - OS=Homo sapiens (Human). 
13.7 1 1 
1093 VDAC1_HUMAN 
RecName: Full=Voltage-dependent anion-selective channel protein 1; Short=VDAC-1; 
Short=hVDAC1; AltName: Full=Outer mitochondrial membrane protein porin 1; AltName: 
30.8 8 7 
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Full=Plasmalemmal porin; AltName: Full=Porin 31HL; AltName: Full=Porin 31HM; - OS=Homo 
sapiens (Human). 
1094 VDAC2_HUMAN 
RecName: Full=Voltage-dependent anion-selective channel protein 2; Short=VDAC-2; 
Short=hVDAC2; AltName: Full=Outer mitochondrial membrane protein porin 2; - OS=Homo sapiens 
(Human). 
31.5 7 7 
1095 VDAC3_HUMAN 
RecName: Full=Voltage-dependent anion-selective channel protein 3; Short=VDAC-3; 
Short=hVDAC3; AltName: Full=Outer mitochondrial membrane protein porin 3; - OS=Homo sapiens 
(Human). 
30.6 4 3 
1096 VIME_HUMAN RecName: Full=Vimentin; - OS=Homo sapiens (Human). 53.6 21 21 
1097 VP13C_HUMAN RecName: Full=Vacuolar protein sorting-associated protein 13C; - OS=Homo sapiens (Human). 422.1 1 1 
1098 VPP3_HUMAN 
RecName: Full=V-type proton ATPase 116 kDa subunit a isoform 3; Short=V-ATPase 116 kDa 
isoform a3; AltName: Full=Osteoclastic proton pump 116 kDa subunit; Short=OC-116 kDa; 
Short=OC116; AltName: Full=T-cell immune regulator 1; AltName: Full=T-cell immune response 
cDNA7 protein; Short=TIRC7; AltName: Full=Vacuolar proton translocating ATPase 116 kDa subunit 
a isoform 3; - OS=Homo sapiens (Human). 
92.9 11 11 
1099 VPS18_HUMAN 
RecName: Full=Vacuolar protein sorting-associated protein 18 homolog; Short=hVPS18; - OS=Homo 
sapiens (Human). 
110.1 1 1 
1100 ZNF90_HUMAN RecName: Full=Zinc finger protein 90; AltName: Full=Zinc finger protein HTF9; - OS=Homo sapiens (Human). 69.0 1 1 
MW: molecular weight; #peptides count: sum of peptide count;  #unique peptide: sum of unique peptide 
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